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Foreword
The skin is a complex organ comprising distinct cell populations with specific func-
tions. The importance of this organ can truly be appreciated when one recognizes the 
great impact of skin loss in patients affected by large ulcers or extended wounds such 
as burns. This critical clinical need has been a major incentive for the development of 
the first therapies based on the expansion of epidermal cells in culture. Thanks to the 
progress in tissue engineering and regenerative medicine, various models of skin sub-
stitutes have now been developed through the years by several teams around the world. 
The power of cells to create living substitutes for wound healing and burn treatment 
holds not only great promises but also daunting challenges. In addition to the clinical 
goal of enabling wound repair, the human nature of these in vitro models provides 
excellent tools to study skin physiology, physiopathology, and pharmacotoxicology. 
Moreover, the well-characterized culture conditions of skin cells allow the amplifica-
tion of human pathological cells in vitro and the production of three-dimensional (3D) 
models to investigate mechanisms of disease.
This book, “Skin Tissue Models,” offers an overview of available cutaneous mod-
els and their applications. The eighteen chapters summarize the efforts of leading 
centers toward continued improvement of skin tissue models. The content of this vol-
ume is enhanced by the experience and opinions of experts with diverse backgrounds: 
burn surgeons, biologists, chemists, and engineers. The first section comprises two 
chapters on industrial and clinical applications: the cosmetic industry requirements 
(Chapter 1) and the clinical importance of skin models (Chapter 2). The second sec-
tion focuses on 3D human models for skin diseases, which could favor the investi-
gation of various pathophysiologies and therapies. Each of the five chapters of this 
section focuses on a specific disease: melanoma (Chapter 3), genodermatoses that 
comprise several rare inherited diseases (Chapter 4), psoriasis (Chapter 5), vitiligo 
(Chapter 6), and squamous cell carcinoma (Chapter 7). The third section encom-
passes four chapters addressing important parameters to consider for clinical appli-
cations: promoting angiogenesis and tissue vascularization (Chapter 8), minimizing 
scar formation (Chapter 9), promoting wound healing (Chapter 10), and targeting 
inflammation (Chapter 11). The fourth section regroups four chapters describing 
more complex models as platform to study skin biology: hair follicle generation 
(Chapter 12), skin innervation (Chapter 13), white adipose tissue impact on skin 
healing (Chapter 14), and response of immunocompetent cells (Chapter 15). The last 
section describes emerging technologies for the production of innovative 3D skin 
models: bioprinting (Chapter 16), induced pluripotent stem cells (Chapter 17), and 
high-throughput screening (Chapter 18).
xx Foreword 
The variety of skin models gathered in this book highlight all the progress made 
toward the development of human models reflecting the native normal or pathological 
skin. These substitutes and accompanying enabling technologies offer exciting pos-
sibilities for new discoveries in skin biology and improved testing of the safety and 
efficacy of drugs or cosmetic ingredients. Finally, these substitutes provide hope of 
new treatments for patients suffering from various types of skin wounds or diseases.
Professor Lucie Germain
Scientific Director, Centre de recherche en organogénèse 
expérimentale de l’Université Laval (LOEX), 
Canada
Section A
Therapeutic molecules and 
cosmetics testing
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1Cosmetic industry requirements regarding skin models for cosmetic 
testing
Christian Pellevoisin*, Charbel Bouez†, José Cotovio‡
*EPISKIN Academy, Lyon, France, †L'Oréal Research and Innovation, Clark, NJ, United 
States, ‡L'Oréal Research and Innovation, Aulnay-sous-Bois, France
1.  Introduction
Scientific models are a simpler representation of reality, which help to explain and 
predict the behavior of real complex systems. Models of tissues or organs such as 
the skin, reconstructed by tissue engineering, are of central importance in many sci-
entific contexts and especially in cosmetics. In order to innovate, cosmetics research 
and development rely on reproductive, quantitative, and predictive methods, to assess 
the efficiency and safety of ingredients and cosmetic finished products at the earliest 
stages of development. In order to predict the response in human beings as accurately 
as possible, in vitro test systems rely more and more on cells of human origin, with a 
3D organization that mimics the in vivo situation more closely. Since the 1980s, when 
the first reconstructed human epidermis (RHE) was produced, several models of the 
human epidermis and skin have been developed. Based on these models, numerous 
protocols are widely used in cosmetics research, making skin engineering a power-
ful and highly versatile technology used at all stages of development of a cosmetic 
 product (Fig. 1).
2.  Principles of skin engineering
Tissue and skin engineering have proved to be a very valuable tool in different fields 
such as research (biomedical research, skin pathology, skin grafting, etc.) and evalua-
tion (safety and efficacy). Regardless of the application, successful tissue engineering 
projects always rely on the following key components:
●	 Access to cells (isolation, amplification, storage, and handling)
●	 Use of the proper culture media to control the balance between cell proliferation and 
differentiation
●	 Use of a scaffold that mimics the in vivo extracellular matrix (ECM) to support the growth 
of the model
●	 Designing and implementing the proper industrial setup to produce quality at all levels of 
production
4 Skin Tissue Models
2.1  The reconstructed skin adventure: Key developments
The pioneers of tissue culture are the American biologist Ross Harrison and the French 
Nobel Prize winner Alexis Carrel [1,2]. In addition to medium and culture conditions, 
the limiting factor was access to a sufficient number of cells. Thanks to the findings 
of Theodore Puck, who demonstrated that a layer of lethally irradiated epithelial cells 
could be used as a source of mitogens allowing a second population of cells to prolifer-
ate [3], keratinocytes were first cultured at the laboratory level about 35 years ago. The 
reconstructed skin adventure began when James Rheinwald and Howard Green [4,5] 
at Harvard cultivated keratinocytes on top of a feeder layer of fibroblasts (irradiated 
Swiss 3T3 mouse fibroblasts) and succeeded in obtaining small sheets of epithelium 
two to three layers thick (cultured epithelial autographs) used to treat burns patients [6]. 
However, these first epidermal substitutes composed of a few layers of human keratino-
cytes did not present a functional horny layer and were far from resembling the in vivo 
tissue. The first reconstructed epidermis model topped with a horny layer was perfected 
by Michel Pruniéras in 1979 [7]. Mimicking the in vivo situation, the reconstructed 
epidermis consisted of seeded human keratinocytes (extracted from human skin biop-
sies) on the top of a cell-free dermal substitute for about 2 weeks at the air-liquid in-
terface [8]. Simple dermal substitutes containing fibroblasts are also of importance for 
clinical use in the case of severe burns and wounds [9]. Today, skin equivalents can be 
divided into three categories: (i) epidermal substitutes, (ii) dermal substitutes, and (iii) 
full-thickness models containing both epidermal and dermal components.
2.2  Main steps in the reconstruction of the epidermis
Over the last few years, in vitro skin models have been perfected by adding different 
cell types, allowing various skin functions to be replicated. Epidermal reconstruction 
usually follows similar key steps: Primary keratinocytes are isolated from the epider-
mis of skin biopsies or from the external sheath of a hair follicle and further cultured 
Finished products
Formulation optimization (tuning parameters 
i.e., biodisponibility, synergies between active
ingredients, etc.); Safety and efficacy of finished  products
Ingredients & active principles
Screening of new ingredients and active principles for
safety (penetration, skin corrosion/irritation, genotoxicity, 
phototoxicity, sensitization, etc.) and efficacy (antiaging 
activities, photo-protection, modulation of pigmentation, etc.)
Basic research
Understanding and characterizing healthy skin (cornification, pigmentation,
immune function, etc.); Aging process; Environmental effects (Pollution, UV, etc.)
Skin-microbiota interaction; Imbalance of homeostasis that cosmetics can treat
(dry skin, oily skin,  sensitive skin, etc.)
Fig. 1 Application of reconstructed human epidermis and skin at different stages of the 
cosmetic product development process.
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as monolayers [8] in order to amplify the number of cells and to set up easy-to-use 
cell banks. In a second step, keratinocytes are “seeded” and allowed to proliferate onto 
the surface of a support, which can be either a deepidermized dermis (DED, a dermis 
whose cells have been eliminated by successive freezing and thawing) or a biomaterial 
often based on collagen. This second step in the culture process consists of obtaining a 
monolayer of keratinocytes by placing the cells and the dermal substitute immersed in 
the culture medium. During this step, other types of epidermal cells (e.g., melanocytes 
and Langerhans cell (LC) precursors) may be added to keratinocytes depending on the 
model to be produced. In a third step, keratinocytes are brought into contact with air 
(the air-exposed period) and then differentiated and stratified spontaneously to form 
all the layers of a fully differentiated epidermis, including the horny layer, which per-
forms a barrier function for the reconstructed epidermis.
Furthermore, a dermal equivalent can be produced by mixing native collagen type I 
and living fibroblasts according to the conditions that lead to the formation of a dermal 
tissue. Thus, an important additional step is taken when this living dermal compart-
ment containing fibroblasts is used during the epidermal reconstruction process, end-
ing with a full-thickness skin equivalent incorporating the skin’s two major cell types 
(keratinocytes and fibroblasts) [10].
Important developments in culture media composition and skin cell biology have 
allowed other important cells such as melanocytes and LC precursors to be incor-
porated, together with keratinocytes in the epidermal compartment generating more 
complex models and opening the way to new fields of research and applications 
[11,12]. Several specific substrates have been used to create the dermal structure 
in vitro, including DED [8,13,14] collagen lattices [15], collagen- glycosaminoglycan 
matrices [16,17], chitosan cross-linked collagen-glycosaminoglycan matrices [18], 
and biodegradable matrices [19] (Fig. 2).
In the future, new technologies could revolutionize the way we reconstruct skin 
equivalents. Bioprinting is a new area of research and engineering that involves printing 
devices and computer-aided design (CAD) technology to print 3D tissues or organs [20]. 
In this additive manufacturing approach, cells embedded in a gel are deposited onto a 
surface, layer by layer until the desired tissue has been reproduced. Bioprinting has the 
advantage of enabling a predefined arrangement of living cells, biomaterials, and growth 
factors to fabricate customizable constructs with a high degree of flexibility and repeat-
ability. Applied to skin reconstruction, this technology could make it possible to repro-
duce the complex architecture and multicellular organization of the living skin [21]. The 
primary application would be medical, for wound management, but reconstructed skins 
could also be used in different applications such as predictive evaluation tools. Recently, 
an American team conducted a proof-of-concept study showing that this technology 
could be used to build a full-thickness skin with keratinocytes and fibroblasts [22].
2.3  Industrial standardized production of 3D skin models
The regular use of 3D skin models in anticipated and well-planned studies requires the 
availability of standardized reproducible tissues and easy access to them. Some biotech-
nology companies are devoted to developing and producing robust models  aiming at 
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Fig. 2 Different types of reconstructed models depending on the support and the population of cells incorporated. Standard models consist of either 
an epidermis with keratinocytes or an epidermis and a living dermis with fibroblasts. However, it is possible to introduce other cells types such as 
melanocytes or Langerhans cells. Langerhans cells that reside in the skin, however, have a low survival and amplifying capacity in a culture, which 
is why it is more efficient to use blood circulating precursors from adult or cord blood. (A) Reconstructed epidermis on an acellular deepidermized 
dermis (DED). Keratinocytes are seeded directly onto a human dermis from which the resident cells have been eliminated. (B) Industrial models 
with keratinocytes seeded in plastic inserts on an artificial support (collagen sheets, polycarbonate, etc.). The inserts can be easily packed and 
shipped in 6, 12, 24, or even 96 well plates. (C) Full-thickness model or skin equivalent. A gel of collagen is reticulated by inserting living fibroblasts 
to form a solid lattice. Then, the keratinocytes are seeded onto this lattice to form a living epidermis on a living dermis. (D) The lattice of collagen 
can be replaced by an artificial porous scaffold made of different biomaterials such as collagen, chitosan, or synthetic polymer.
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providing tools for efficacy and safety screening of ingredients and/or finished cosmetic, 
pharmaceutical, and industrial products or medical devices. A specific cell culture pro-
cess allows human tissues with well-characterized histology, functionality, and ultra-
structure features to be produced on a large scale. The latter are mainly based on a RHE, 
using a biological or nonbiological support, possibly containing human melanocytes 
with different pigment levels (phototypes II–VI). Standardized large-scale manufactur-
ing processes are certified by the ISO 9001 standard. Batch reproducibility and quality 
control are generally evaluated by histological scoring and response to a reference test 
chemical. Such models are well designed for industrial application. They are produced 
in different formats and 6, 12, 24, or 96 well plate (Fig. 3) sizes. They are robust and easy 
to handle and can be used for high-throughput screening (HTS) applications.
3.  Skin models for research
In  vitro skin models improve the understanding of the skin in several ways. In it-
self, the process of “building” the model generates knowledge by: (1) understand-
ing the mechanism to being modeled; (2) identifying the cellular components; and 
(A)
(B) (C)
Fig. 3 Examples of industrial reconstructed 3D models in their container plates and specific 
inserts. (A) SkinEthic™ RHE small (0.5 cm2) × 24 tissues, (B) EpiSkin™ large (1 cm2) × 12 
tissues, and (C) SkinEthic™ RHE large (4 cm2) × 6 tissues.
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(3)  finding the proper culture conditions to promote their proliferation and differentia-
tion, etc. It is often a cross-disciplinary process that promotes exchanges and transfers 
of skills between different experts. In the same way, characterization of the model 
compared with the human skin increases the scientific knowledge that we have about 
this organ. Knowledge is still generated when the model does not respond as expected. 
Successfully incorporating melanocytes, LCs, or stem cells into the epidermis requires 
a high level of understanding of these cell types and their interactions. Verifying their 
presence and functionality leads to greater knowledge of the regulating mechanisms 
that govern their interactions and their survival and functionalities. Once constructed 
and characterized, the model is an exceptional tool for the researcher. The availability, 
reproducibility, and access to numerous parameters (proteomic and genomic analyses, 
assays, morphology, etc.) pave the way for innumerable fields of experimentation. 
The contributions of reconstructed skin models are significant in many areas of re-
search, for example, UV sensitivity, specific ethnic characteristics, skin sensitization 
and allergy, chronological aging, and skin microbiome. The examples in the following 
paragraphs illustrate some of the contributions of reconstructed skin engineering to the 
general understanding of skin physiology.
3.1  Studying skin aging
Chronological aging is a complex biological phenomenon that affects all organs to 
a different extent. In the skin, it is accompanied by specific clinical signs, the most 
prominent of which are wrinkles, slackening of tissues, and pigmentation disorders. 
Studies have shown that aging induces significant changes in all skin layers: decline in 
epidermal turnover, thinning of the epidermal layers, and flattening and delamination 
of the dermal-epidermal junction (DEJ). The dermis is also affected by a decrease in 
ECM glycosaminoglycans (GAGs), in the number of fibroblasts and their activity, and 
a degradation of the ECM [23]. Actinic aging induced by exposure to ultraviolet (UV) 
increases and accelerates these changes and is accompanied by specific signs, such as 
solar elastosis (Fig. 4).
Reconstructed skins are tools of choice for understanding the biological mecha-
nisms that accompany and induce the appearance of the clinical signs related to aging. 
Two regions are distinguished in the dermis: the papillary dermis, a region lying be-
neath the epidermis and the reticular dermis that lies below the papillary dermis. The 
influence of the origin, papillary or reticular, and the age of the fibroblasts (donors 
from 19 to 74 years of age) on the morphogenesis of the epidermis were evaluated in 
reconstructed skin models [24]. It was shown that dermal equivalents containing pap-
illary fibroblasts were more potent in promoting morphogenesis of a correctly strati-
fied and differentiated epidermis than those containing fibroblasts from the reticular 
dermis (Fig. 5).
These differences decline as donors increase in age. Matrix metalloproteinase 
(MMP)-1 and vascular endothelial growth factor (VEGF) secretion levels were in-
creased in the presence of papillary fibroblasts, whereas MMP-3 and keratinocyte 
growth factor (KGF) levels were higher in the presence of reticular fibroblasts [25]. 
These models revealed that papillary and reticular fibroblasts exert distinct functions 
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and activities in the skin. These functional differences may have strong implications 
in wound healing and skin-aging processes.
Skin aging is also characterized in the dermal compartment by cross-linking of 
fibrillar proteins that occurs by glycation. Glycation (i.e., sugars reacting with the free 
amine moiety of lysine and arginine in proteins) is a nonenzymatic slow process with 
the formation of covalent cross-linking between collagen fibers, making the collagen 
network more rigid. A dermal equivalent made of collagen fibers preglycated by ribose 
was developed, providing new insights into the role played by advanced glycation end 
products (AGEs) in the skin. This work highlights the influence of collagen glycation 
not only at the dermal level but also on the quality of the epidermis through fibroblast 
regulation [26–29]. Treatment of human dermal fibroblasts by mitomycin C (MMC) 
induced an accelerated senescence through DNA damage and generation of reactive 
oxygen species (ROS), two main aspects of in vivo aging [30,31]. This property has 
been used to developed aged 3D skin models by coculturing skin fibroblasts exposed 
to MMC and keratinocytes on a collagen-glycosaminoglycan-chitosan scaffold. In this 
in vitro aged model, filaggrin expression is reduced in the epidermis, and the amount 
of elastin and collagen is lowered in the dermis [32].
(A) (B)
(C) (D)
Fig. 4 Skin biopsies from a young (A) and a photoaged donor (B). Immunohistology shows 
epidermal alteration. Accumulation of elastin in the dermis of a photoaged skin (D) as 
compared with the skin of a younger donor (C).
From L’Oréal R&I.
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Apart from the eyes, the human skin is the only organ directly exposed to so-
lar (sun) UV rays, a well-recognized environmental damaging factor responsible for 
photoaging [33,34]. Acute overexposure of the human skin to UV rays causes sun-
burn, altered pigmentation, inflammation, immunosuppression, and damage to der-
mal connective tissue. Chronic UV exposure can induce a disruption in the normal 
architecture of the skin and ultimately cause premature photoaging. In worse cases, 
it may also cause skin cancer. Historically, UVB rays were thought to be the only 
UV rays detrimental to the skin because of their involvement in sunburn (apoptotic 
cells) and direct DNA damage in epidermal cells. Biologists have observed that UVA 
rays, which penetrate deeper into the skin, are also harmful as they directly alter the 
dermal compartment. Through an oxidative stress process (ROS generation), they 
damage the fibroblasts and promote the synthesis of proteins responsible for collagen 
Fig. 5 Age-related impact of Fp and Fr on the epidermal compartment in three-dimensional 
reconstructed skin. Keratinocytes from the same batch were seeded onto dermal equivalents 
containing papillary fibroblasts (Fp) or reticular fibroblasts (Fr) from young or old donors. 
Typical histological sections (HES blue coloration) and filaggrin immunolabeling (green 
labeling) of reconstructed skin samples made with collagen constructed lattices containing (A) 
young papillary fibroblasts, (B) young reticular fibroblasts, (C) old papillary fibroblasts, and 
(D) old reticular fibroblasts. The histologies and the filaggrin immunolabeling show that only 
reconstructed skin with papillary fibroblasts from young donors (A) induces morphogenesis of 
a well-stratified and well-differentiated epidermis.
Data from Mine S, Fortunel NO, Pageon H, Asselineau D. Aging alters functionally human 
dermal papillary fibroblasts: a new view of skin morphogenesis and aging. PLoS One 
2008;3(12):e4066.
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breakdown. The effects of UV rays (UVB and UVA) have been investigated using 
models of reconstructed full-thickness skin. It was shown that keratinocytes indi-
rectly participate in the photoaging process [35]. Under the influence of UVB, they 
release soluble factors, which cause dermal fibroblasts to synthesize MMP proteo-
lytic enzymes that degrade collagen and other ECM proteins of the dermal connective 
tissue. The effects of cumulative exposure to each type of UV radiation and their 
possible synergy can be studied using full-thickness skin models and combining fine 
adjustments of simulated exposure and specific treatments [36,37]. Likewise, signif-
icant advances in the knowledge of chronological aging/photoaging are anticipated 
through the use of “aging”/UV-exposed skin models, thus providing new strategies 
in antiaging research.
Pigmentary disorders are also associated with photoaging. To test the hypothesis 
of a dermal fibroblasts modulation of skin pigmentation, Bernerd et al. developed 
and characterized a functional pigmented reconstructed skin model composed of 
a melanocyte-containing epidermis grown on a dermal equivalent with living fi-
broblasts [38]. Using the same pool of keratinocytes and melanocytes, different 
models have been reconstructed with and without fibroblasts of different origins: 
fetal, adult, and photoaged [39]. Compared with the model with fibroblasts, the 
model without fibroblasts shows a 10-fold higher melanin content assessed by 
quantifying Fontana-Masson staining (Fig. 6A), suggesting that fibroblasts down 
control melanocyte activity. To analyze the effect of the origin of fibroblasts on 
pigmentation, fibroblasts of fetal or adult origin have been used for reconstruction. 
An intense pigmentation appeared, macroscopically and on histological sections, 
in the epidermis reconstructed on the dermal equivalent with fetal fibroblasts. The 
hyperpigmentation of the samples prepared with fetal fibroblasts was quantified 
and found to be associated with a 6.6-fold increase in melanin content (Fig. 6B). To 
investigate the influence of chronically photoexposed fibroblasts on pigmentation, 
the epidermis reconstructed on dermal equivalents containing fibroblasts from a 
photoaged skin (three different strains, donors aged over 70 years of age) was com-
pared with reconstructed skin models containing fibroblasts from a young, unex-
posed skin (16–21 years old, three strains). The data demonstrate that the presence 
within the dermal equivalent of natural photoaged fibroblasts, as compared with 
young unexposed fibroblasts, stimulates epidermal pigmentation as revealed by 
an increase in melanin content (Fig. 6C). These results clearly suggest that fibro-
blasts from a chronically sun-exposed skin may contribute to hyperpigmentation 
observed during photoaging.
The impressive variation in skin pigmentation at the macroscopic level, supported 
by quantitative measurement, demonstrates that the presence, origin, and, more impor-
tantly, the history and acquired characteristics of dermal fibroblasts are indeed modu-
lators of the level of pigmentation. Although the precise action mechanisms have not 
been identified, the tools employed here allow further investigations on ECM proteins 
and soluble factors to being considered to unravel the underlying molecular mecha-
nisms. This work underlines the importance and power of reconstructed human skin 
to model different biological systems for deciphering complex mechanisms and chal-
lenging different hypotheses.
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Fig. 6 Different reconstructed human skin with the same keratinocyte and melanocyte strains and fibroblasts from different origins. (A) Macroscopic 
pictures of reconstructed skin illustrate the drastic difference in pigmentation between the model with fibroblasts (from an adult 21-year-old 
donor) and the one without. This is confirmed by Fontana-Masson (FM) staining of melanin granules used and melanin content quantification. 
The CD13 staining (green) of cross sections confirmed the presence or absence of fibroblasts in the dermal equivalent. (B) Reconstructed skin 
models were reconstructed with either fetal fibroblasts (GM10) or adult (21-year-old donor) fibroblasts. A drastic increase in pigmentation of the 
model and activation of melanocytes in the presence of fetal fibroblasts compared with adult fibroblasts were noted macroscopically (macro) and 
on histological sections stained with Fontana-Masson (FM). (C) Pigmentation in the skin reconstructed with either natural photoaged fibroblasts 
or young fibroblasts was analyzed macroscopically and on histological sections stained with Fontana-Masson and melanin quantification. A 
significant increase in pigmentation was observed as shown by an increase in the concentration of melanin granules measured by image analysis on 
histological sections and the darkening of the skin samples. Values are expressed as a mean +/− SD calculated for three samples in three independent 
experiments.
Adapted from Duval C, Cohen C, Chagnoleau C, Flouret V, Bourreau E, Bernerd F. Key regulatory role of dermal fibroblasts in pigmentation as 
demonstrated using a reconstructed skin model: impact of photo-aging. PLoS One 2014;9(12):e114182. doi:10.1371/journal.pone.0114182.
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3.2  Studying skin-microbiota crosstalks
Skin is not only a complex organ that performs several of the body’s vital functions, 
but also with a surface area of nearly 2 m2 providing humidity, nutrients (sweat, sebum, 
and stratum corneum), and controlled temperature, it is an ecosystem hosting microbial 
communities of up to 106 microorganisms per square centimeter. The diversity and com-
plexity of this microbiota can begin to be unraveled using direct sequencing approaches 
for all microbial DNA (shotgun metagenomics), giving a detailed map of the biogeog-
raphy of bacterial and fungal populations living in different areas of this skin ecosystem 
[40]. Characterizing the skin microbiome opens the way to a new understanding of the 
interactions between the human skin and the foreign organisms inhabiting its ecosystem. 
The classical pathogen versus commensal strains classification is challenged by a more 
complex system, where the cross talks between different actors modulate the homeosta-
sis of the system. Currently, the skin microbiome is a major research focus in dermatol-
ogy laboratories across the globe, and its role is well recognized as a major player in skin 
homeostasis, opening new opportunities in predictive evaluation of cosmetic products.
Disturbance of the equilibrium between microbiota and its host is associated with 
several disorders or diseases [41] such as acne, atopic dermatitis (AD) [42,43], dan-
druff, and psoriasis. The cross talk between the skin microbiota and the host’s immune 
system is an important phenomenon in maintaining a healthy skin: it is clear that cuta-
neous innate and adaptive immune responses modulate the skin microbiota, while the 
microbiota also functions in educating the immune system [44]. RHE epidermis of-
fers a unique experimental support for modeling skin-microbiota interactions, to help 
decipher the system’s elementary mechanisms. Although simpler than the situation 
in vivo, reconstructed skin equivalents offer key advantages for building experimental 
systems that allow control of both the skin tissue and added microorganisms (bacteria 
and fungi) throughout the process of skin colonization and interactions.
The skin barrier is an important element of the innate immune function. Using 
RHE seeded with Propionibacterium acnes, Staphylococcus aureus (S. aureus), 
and S. epidermis, it has been shown that protection against bacteria disappears as 
soon as the barrier is impaired, leading to a strong inflammatory response from 
keratinocytes [45]. Some strains of S. aureus have developed resistance to antibi-
otics and are implicated in several nosocomial pathologies. Thanks to an experi-
mental system using an RHE model, several markers of virulence of these strains 
have been identified, such as gene coding for surface adhesion molecules, which 
are important for host-pathogen interaction, and gene coding for bacterial surface 
proteins, which participate in biofilm formation [46]. Acinetobacter species are 
other opportunistic pathogens associated with nosocomial infections. Two different 
strains, Acinetobacter baumannii and A. junii, are able to colonize an RHE model, 
but only A. baumannii forms large biofilms on the stratum corneum [47]. The abil-
ity of A. baumannii to form a biofilm on the human skin could play an important 
role in its persistence on the skin. With the emergence of antibiotic resistance, such 
in vitro models may be advantageous for identifying and evaluating new targets for 
disinfection and antimicrobial strategies.
AD is a type of chronic inflammation of the skin characterized by erythema, pru-
ritus, and severe impairment of the barrier function [48]. The lesioned skin in patients 
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exhibits infiltration by lymphocytes T helper cells type 2 (Th2) and a predisposition to 
colonization by S. aureus [49,50]. Recently, a cocultured model of RHE (Vitroscreen, 
Italy) has been able to reproduce a specific keratinocyte response observed in the le-
sioned skin of AD patients [51]. The experimental system comprises an RHE topically 
colonized by S. aureus and, underneath in the culture medium, a population of THP-1 
cells (Fig. 7). THP-1 is a human monocytic cell line derived from an acute monocytic 
leukemia patient. The response of the reconstructed epidermis evaluated by qRT-PCR 
reveals features close to the in vivo situation: overexpression of defensin beta 2, inte-
grin alpha 6, integrin beta 1, and keratin 19. Other genes are downregulated, such as 
claudin 1, filaggrin, kallikrein 5, and TRLP2.
These results show that this experimental system, which mimics the features of 
AD lesion, takes into account the keratinocyte innate and inflammatory response 
and the adaptive immunomediated response (coculture with monocytes). After thor-
ough characterization, this model was further used to assess the efficiency of two 
cosmetic formulations to restore normal homeostasis (barrier function) and to stim-
ulate natural defenses (antimicrobial response and downregulation of adhesion mol-
ecules) of the skin.
The development of such in vitro models of skin-microbiota cross talk and coregu-
lation will undoubtedly increase in the coming years and will allow innovative indirect 
strategies to be developed for addressing classical cosmetic end points (hygiene, anti-
aging, dandruff, sensitive skin, etc.).
4.  Skin models and methods for hazard and risk 
assessment of cosmetics
The ability to reproduce several functions of the human skin in  vitro broadens 
the scope for industrial applications. Thanks to in  vitro skin models, it is now 
possible to predict, early in their development process, the effects, positive or 
(A) (B)
Fig. 7 (A) Experimental system comprising a reconstructed human epidermis (SkinEthic 
RHE™), THP-1 cells in the culture medium, and S. aureus seeded topically on the surface of 
the RHE model. (B) SEM image of S. aureus on the surface of the RHE model.
Data from De Servi B, Semenzato A, Baratto G, Meloni M. Modeling atopic dermatitis in 
reconstructed human epidermis. Paris: SFC-Journées Jean Paul Marty; 2015.
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negative, of new compounds, drugs, chemicals, cosmetics, medical devices, etc. 
The development of new cosmetics requires a precise assessment of their safety 
and activity. A number of in vitro methods have been developed and proposed for 
this purpose. Methods using reconstructed epidermis or full-thickness skin models 
have been introduced and are today commonly used to assess both the efficacy and 
safety of cosmetic ingredients and formulations. These 3D skin models offer many 
advantages:
●	 Their architecture is close to that of the native skin.
●	 The presence of a stratum corneum forms a barrier to exogenous substances, although it is 
less efficient than that of the skin in vivo.
●	 They can be used to measure a large variety of parameters related to the efficacy or safety of 
ingredients.
●	 The air-exposed surface allows ingredients/products with various physicochemical proper-
ties to be applied topically, thus mimicking in vivo use.
●	 Compared with traditional in vitro 2D cell cultures, 3D models reproduce the complexity 
and richness of in vivo cell-cell and cell-ECM interactions.
Reproducing this microenvironment is important, since cellular interactions reg-
ulate several mechanisms, such as viability, proliferation, differentiation, morphol-
ogy, protein synthesis, and genome expression [52,53]. It has been shown that the 
gene expression profiles of keratinocytes from in  vitro 3D reconstructed skin is 
much closer to the in  vivo human skin than keratinocytes cultivated in 2D [54]. 
In 2D models, cells are immersed in an aqueous culture medium, which limits the 
testing to hydrosoluble substances. The use of in vitro skin models overcomes this 
limitation and makes it possible to apply ingredients or compounds, whatever their 
physicochemical forms (liquid, powder, or gel) directly onto the stratum corneum. 
The way the tested products are applied and the resulting exposure of the cells (bar-
rier function and gradient of concentration) are closer to the in vivo conditions, as 
compared with 2D protocols. Over the last 20 years, substantial work and invest-
ments have been devoted to the development of both in  vitro and ex  vivo meth-
ods. As a result, several validation studies based on test methods using organotypic 
models, reconstructed human tissues, simple cell assays, physicochemical assays, 
or a combination of tests have been conducted. However, despite huge progress 
in the models used, numerous questions have been raised regarding action mech-
anisms, classification, the scope of applications and, finally, the need to identify 
testing strategies able to strengthen final predictions. Today, in vitro reconstructed 
skin models are widely used in both safety and efficacy prescreening tests [55,56]. 
Increased interest in them was followed in the last decade by several validations and 
acceptance for regulatory purposes.
4.1  New paradigm in toxicology
Any novel substance used in the composition of consumer products has to undergo a 
preliminary comprehensive toxicological evaluation process. The use of animal test-
ing remains strongly questioned and rightly criticized for both ethical and scientific 
reasons, that is, methods with more or less subjective scoring, low interlaboratory 
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reproducibility, and known differences in sensitivity with humans [57–59]. In Europe, 
the seventh amendment (2003/15/EC) [60] to the Cosmetics Directive (76/768/EEC) 
introduced the regulatory framework for the phasing out of animal testing for cos-
metics purposes. Since 2009, this testing and marketing ban has covered “acute” tox-
icological end points, including those linked to adverse effects on the skin and eyes. 
In March 2013, it was extended to other tests requiring repeated applications, for 
example, repeat-dose toxicity, sensitization, reproductive toxicity, carcinogenicity, 
and toxicokinetics. This total ban on animal testing concerns not only products de-
veloped in Europe but also any cosmetic products intended to be marketed in Europe. 
In line with the movement initiated in Europe, we can see a strong trend worldwide 
toward a progressive shift to nonanimal methods for assessing the safety of ingredi-
ents and cosmetic products. In 2013, Israel banned imports of cosmetics tested on 
animals. This regulation supplemented a 2007 ban on animal testing for domestic 
cosmetics. In June 2013, India became the first country in South Asia to decide on 
a ban on animal testing for domestic manufacturing of cosmetics. In May 2014, the 
ban was extended to all imported cosmetics. For the ban to enter fully into force, the 
Bureau of Indian Standards (BIS) intends to set down standards to allow the Drugs 
Controller General of India (DCGI) to make relevant amendments to acts and laws. 
China’s position on animal testing is also changing rapidly. A new policy passed in 
December 2013 authorizes certain categories of cosmetics (such as soap, shampoo, 
and some skin products) developed locally to be marketed without the need for ani-
mal testing from June 2014. In January 2014, the state of São Paulo in Brazil released 
a bill prohibiting cosmetics testing on animals. In October 2016, Taiwan approved 
a regulation that comes into effect in 2019 and will amend Taiwan’s Control for 
Cosmetic Hygiene Act and ban cosmetic animal testing for both finished products 
and cosmetic ingredients. Cosmetics developed outside the country will not fall un-
der the new regulation.
In light of the changes in the regulations, toxicology is undergoing a profound 
revolution, with a shift from toxicology based on the observation of effects in animals 
to mechanistic approaches based on in  vitro and in silico tests to predict potential 
adverse effects in humans. In 2007, the US National Research Council proposed in 
its report “Toxicity testing in the 21st century” a road map for building a mechanistic 
understanding of biological action and exploiting an array of new technologies (i.e., 
high-throughput assays, −omics, bioinformatics, systems biology, and computational 
toxicology). The success of these mechanistic approaches relies on progress in fun-
damental knowledge of AOP to identify the cascade of events, from the molecular 
level up to the organism, which may ultimately produce an adverse effect. Advances 
in basic knowledge pave the way to the development of in silico, in chemico, and 
in vitro assays that can provide information about one or more key events of an AOP 
for a specific toxicological end point. This paradigm shift is accompanied by an as-
tonishing scientific and technological revolution, in which the academic community 
and the cosmetics industry have been engaged for more than 30 years. The cosmetics 
industry is at the forefront of this new paradigm in toxicology, but it will undoubtedly 
and increasingly concern other industries, such as chemicals, medical devices, or drug 
development.
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4.2  Validated versus valid methods
The diversity of existing in vitro models including reconstructed epidermis and skin tis-
sues, together with their variety, represents a potential strong driver for the application 
of adapted and integrated in vitro methods. To date, several in vitro methods have been 
developed based on skin models to assess different toxicological end points (skin pen-
etration [61,62], skin corrosion/irritation [63,64], phototoxicity [65–70], genotoxicity 
[71], and skin sensitization [72–74]). However, an in vitro alternative method must 
be validated before being recognized by the regulatory bodies concerned. Validation 
is the process whereby the reliability and relevance of a particular approach, method, 
procedure, or assessment is established for a defined purpose [75]. In Europe, the 
European Center for Validation of Alternative Methods (EURL-ECVAM) is devoted 
to the validation of alternative methods. EURL-ECVAM publishes a yearly report pro-
viding updates on the development, validation, and regulatory acceptance of alterna-
tive methods [76] and maintains the Tracking System on Alternative Methods (TSAR), 
which provides a view on the status of alternative methods from submitted scientific 
protocols up to their validation and acceptance within a regulatory context. Since the 
creation of ECVAM in 1991, four regional organizations have been created on the 
same principle in different countries (Table 1). Today, two alternative methods based 
on in vitro skin models have been validated as full replacement methods to animal test-
ing. These methods have been integrated into the test guidelines of the Organization 
for Economic Cooperation and Development (OECD): TG 431 for in vitro skin cor-
rosion and TG 439 for in vitro skin irritation potential of chemicals. Moreover, two 
other methods based on reconstructed human epidermis and full-thickness models 
have been submitted for validation in the field of sensitization and genotoxicity.
Country Name Acronym and website Created
Europe European Union Reference 
Laboratory for alternatives to 
animal testing
EURL-ECVAM (formerly 
ECVAM)
http://ihcp.jrc.ec.europa.eu/
our_labs/eurl-ecvam
1991
The United 
States
Interagency Coordinating 
Committee on the Validation 
of Alternative Methods
ICCVAM
http://ntp.niehs.nih.gov/go/
iccvam
1994
Japan Japanese Center for the 
Validation of Alternative 
Methods
JacVAM
http://www.jacvam.jp/
2005
Korea Korean Center for the 
Validation of Alternative 
Methods
KocVAM
http://www.nifds.go.kr/en/
inter/kocvam.jsp
2009
Brazil 
 
Brazilian Centre for the 
Validation of Alternative 
Methods
BraCVAM 
 
2011 
 
Table 1 List of validation centers of alternative methods 
worldwide
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4.3  Skin penetration & metabolism
In order to better evaluate and understand the needs for safety evaluation and the role of 
the tissue compartments, studies using infinite doses versus finite doses have been con-
ducted according to a validation-like format with several manufactured and “in-house” 
reconstructed human skin models [61]. A suitable in vivo/in vitro correlation has been 
demonstrated with regard to the test chemicals’ ranking with EpiSkin™, EpiDerm™, 
and SkinEthic™ RHE, even though permeation of in vitro models still generally ex-
ceeds that of the human excised skin. Because of this higher penetration profile, 3D 
models are preferentially used as screening tools to study relative penetration of chem-
icals and mixtures [77] rather than as regulatory validated assay where absolute quanti-
fication is required. The extracellular lipids of the stratum corneum form a continuous 
separation between living layers and outside and are therefore important in the func-
tionality of the skin barrier. All major classes of human skin lipids are expressed in the 
stratum corneum of RHE models [78], but deviation in some lipid profile composition 
could lead to differences in the spatial organization of the lamellar lipids that seems 
an important parameter for skin barrier function [79]. Different approaches have been 
tested to increase barrier function such as cytokines treatments [80], decrease of at-
mosphere humidity [81,82], or, more recently, by using specific dermal matrix [83]. 
These strategies showed mitigated success, and this subject is always of main concern 
to produce next generation of models with barrier function closer to in vivo situation.
Routine protocols for penetration studies have been developed to screen new chem-
icals and mixtures. Using the EpiSkin™ model, it has been demonstrated that percuta-
neous assays could be easily performed without a specific or complex device, such as 
Franz cell [62]. This system simplifies the development of screening tests for the eval-
uation of skin penetration of compounds with a high reliability and a high throughput. 
The permeation of essential oils was evaluated using SkinEthic™ RHE to establish 
the kinetics of release of active principles from cosmetic formulations. Diffusion and 
quantification of selected terpenes proved the method was sensitive, simple, and re-
producible, thus providing a convenient model for safety/quality assessment of for-
mulations [84]. Similarly, EpiSkin™ tissues were used to evaluate the absorption of 
vitamins C and E from topical microemulsions and to select the best formulation able 
to enhance penetration of the tested vitamins in the tissue [85]. Investigating the bio-
transformation of oxygen-sensitive aromatic diamines (ADA) (used in oxidative hair 
coloring) during penetration after topical application onto the EpiSkin™ model, it 
was shown, interestingly, that the reconstructed epidermis had a clear capacity to acti-
vate N-acetylation, glucuronidation, and sulfation enzymes, that is, to metabolize and 
detoxify these ADA derivatives. The data support the growing evidence that ADAs 
are transformed in the human skin and suggest that current practices for assessing 
the safety of ADAs should take these essential findings into account [86]. The latter 
results evidenced the role of the barrier function, together with the expression of meta-
bolic capacities in 3D models and thus supported their use as simple and cost-effective 
tools suited to efficacy/safety studies, overcoming the availability problems usually 
encountered with human skin explants, but with care needed when extrapolating re-
sults to clinical levels [61]. Other approaches using noninvasive imaging technology, 
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such as confocal Raman spectroscopy or two-photon imaging, provided new insights 
for studying the permeation process and development of local toxicity [87,88].
The skin plays an important role in the detoxification and metabolism of xenobiot-
ics for purposeful (i.e., drugs and cosmetics) or environmental substances and pollut-
ants in contact with the epidermis. The phase I metabolism of xenobiotics is catalyzed 
by cytochrome P450 and other oxidoreductases (esterases, epoxide hydrolases, alco-
hol, aldehyde dehydrogenases, etc.) that transform hydrophobic chemicals into more 
polar hydrophilic compounds. Phase 2 metabolism is catalyzed by transferases (UDP-
glucuronosyl transferases, glutathione-S-transferases, sulfotransferases, etc.), which 
add conjugated groups to increase hydrophilicity and clearance, thus avoiding bioac-
cumulation and potential intracellular toxicity. The skin’s role as a first-pass organ has 
been studied in detail through gene expression, protein level, or enzymatic activities 
and compared with reconstructed models. For example, gene expression profiles of 
61 phases of I and II metabolizing enzymes in the reconstructed epidermis EpiSkin™ 
model and in a reconstructed full-thickness tissue showed strong similarity to those 
in the skin in vivo [89]. The study of protein expression profiles has confirmed the 
similarity observed at the mRNA level between reconstructed models and whole skin 
[90]. Recently, the enzymatic activities of xenobiotic enzymes have been measured 
and compared between different reconstructed epidermis models, reconstructed skin 
model, and whole skin [91,92]. Weak cytochrome P450-dependent monooxygenase 
(phase I enzymes) and high transferase (phase II enzymes) activities have confirmed 
that the normal human skin and reconstructed skin models are well provided with 
the main detoxifying drug-metabolizing enzymes and present similar basal levels of 
activity. This xenobiotic metabolism is characterized by a limited functionalization ca-
pacity and a much greater detoxification (hydrolytic and conjugating) capacity. These 
results demonstrate that skin models are similar to the in vivo skin, in terms of meta-
bolic functionality toward the investigated xenobiotics [93].
4.4  Skin corrosion/irritation
Skin corrosion or dermal corrosion tests assess the potential of a substance to cause ir-
reversible damage to the skin, namely, visible necrosis through the epidermis and into 
the dermis, following the application of a test substance for a period of between 3 min 
and 4 h. The historical Draize test, developed in the 1940s, causes severe discomfort 
and pain to the animal (rabbit) and was one of the animal tests banned by the 2013 
deadline. Many attempts have been made to replace the in vivo Draize skin corrosion 
test. To date, six methods have been validated between 1999 and 2006 and officially 
quoted in EU statements from the ECVAM advisory committee (ESAC) (Table 2). 
Among these, two validated methods were not based on reconstructed tissues: the 
Corrositex (artificial biobarrier), a corrosion test peer-reviewed by ICCVAM (report 
1999), quoted in the ESAC 2000 statement and in the OECD guideline TG435, and 
the rat skin transepidermal electrical resistance—TEER test—validated by ECVAM, 
quoted in the ESAC 1998 statement and in the OECD guideline TG430. Four vali-
dated test methods using in vitro reconstructed epidermis were validated by ECVAM 
and subsequently endorsed by ESAC: the EpiSkin™ model [94], the EpiDerm™ 
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End point Method name Endorsement of scientific validity Regulatory acceptance
Skin corrosion In vitro skin corrosion: RHE 
test method: Episkin™ SCT, 
Epiderm™ SCT, SkinEthic™ 
RHE SCT, epiCS® SCT 
(formerly EST-1000); 
Vitrolife-Skin™
ESAC (1998, 2000, 2006, 
2009)
ICCVAM 
2002
OECD TG 431 
(2004, updated 
2015, updated 
2016)13a
REACH regulation
Skin irritation Reconstructed human 
epidermis test method: 
Episkin™ SIT, Epiderm™ 
SIT, SkinEthic™ RHE SIT, 
LabCyte EPI-MODEL24 SIT
ESAC (2007, 2008, 2009) JaCVAM 
(2010, 2012)
OECD TG 439 
(2010, updated 
2015)13b
REACH regulation
Dermal absorption/
penetration
In vitro skin absorption 
methods
No  No  
Genotoxicity Micronucleus test and comet 
assay in reconstructed skin
Models for genotoxicity 
testing
Submitted at EURL-
ECVAM for micronucleus
 No  
Skin sensitization SENS-IS method (Episkin™ 
model)
Submitted at 
EURL-ECVAM
 Submitted  
Phototoxicity EPISKIN phototoxicity 
assay (EPA) and Epiderm 
phototoxicity protocol
No  No  
Eye irritation 
 
 
 
 
Reconstructed human cornea-
like epithelium (RhCE) test 
for identifying chemicals not 
requiring classification and 
labeling for eye irritation or 
serious eye damage 22
EURL-ECVAM 
 
 
 
 
  
 
 
 
 
OECD TG 492 
(2015) 
 
 
 
REACH regulation 
 
 
 
 
Table 2 List of assays for safety evaluation of chemicals using reconstructed human epidermis
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model [94], the SkinEthic™ RHE model [95], and the EST-1000 model [64]. All these 
in vitro methods based on reconstructed epidermis were implemented in the EU test-
ing methods for dangerous substances and included in the OECD test guideline 431 
(dedicated to human in vitro skin model testing methods). Test Guideline 431 defines 
some general and functional rules and conditions that must be evaluated before us-
ing the models for routine purposes. The last revision of TG 431, released in July 
2016, allows noncorrosive and corrosive substances and mixtures to be identified in 
accordance with the UN GHS. It further supports the subcategorization of corrosive 
substances and mixtures into optional subcategory 1A, versus 1B1C versus noncor-
rosive [96,97]. A limitation of this test guideline is that it does not allow skin corrosive 
subcategory 1B to being discriminated from subcategory 1C due to the limited set of 
well-known in vivo corrosive subcategory 1C chemicals.
Skin irritation or dermal irritation is defined as reversible damage of the skin fol-
lowing the application of a test substance for up to 4 h. Evaluation of the potential to 
irritate the human skin of any chemical or product used in the pharmaceutical or cos-
metics industry is a requirement. The assessment of acute skin irritation was usually 
performed on a rabbit skin (Draize rabbit skin irritation test) [98] according to the 
test guideline 404 [99] and involved determining clinical signs, such as erythema and 
edema, after a single application to the skin. Animal data could be very questionable 
and are subject to regulatory issues [60] regarding potential misclassification [100] 
and ethical considerations. Consequently, alternatives to these animal testing proce-
dures have been developed in different fields. EpiSkin™ and EpiDerm™ test methods 
were evaluated for their ability to predict skin irritation [101] throughout an ECVAM 
formal validation study. On the basis of this study, ESAC (2007) [63] concluded that 
the EpiSkin™ skin irritation test (SIT) showed evidence of being a reliable and rele-
vant stand-alone test for predicting skin irritation as a replacement for the Draize skin 
irritation test. The test method is able to distinguish between skin irritant and no-label 
test substances. In 2008, ESAC endorsed two additional skin model test methods for 
skin irritation testing: the EpiDerm™ skin irritation test method and the SkinEthic™ 
RHE skin irritation test method. Both showed results similar to the validated refer-
ence method (VRM) EpiSkin™ test method and are considered as valid replacement 
methods. Validated models—EpiSkin™, EpiDerm™, SkinEthic™ RHE, and LabCyte 
EPI-MODEL24 SIT—are included in the last version of the test guideline TG439 
(July 2015). The VRM (EpiSkin™) was based on a short treatment time (15 min) 
followed by an extended 42 h posttreatment incubation period. The prediction model 
mainly based on the formally validated viability measurement (MTT test) and appro-
priate cutoff values (prediction model) allowed two chemical classes to be drawn up 
in accordance with the EU’s new classification labeling and packaging (CLP) regula-
tion: irritants (=Globally Harmonized System class 2) and nonclassified substances. 
Applied to a set of 184 substances, including references and industrial chemicals 
covering diverse physical-chemical categories, the performance of the EpiSkin™ test 
method were well balanced, with 85% sensitivity, 86% specificity, and 86% accuracy 
[102]. Assessing the performance of test methods on a large number of chemicals 
and products relevant to industrial needs will help to concretely determine and adjust 
(industry-specific) areas of applicability while identifying the remaining gaps. These 
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validated tools are part of the necessary and useful battery of alternative methods al-
lowing industrial nonanimal testing strategies to be used. In 2014, the OECD released 
a document on integrated approaches to testing and assessment (IATA) for skin corro-
sion and irritation [103]. It proposes pragmatic, science-based approaches to chemical 
hazard characterization that rely on an integrated analysis of existing information, 
coupled with testing strategies based on validated methods using reconstructed skin 
models.
4.5  Phototoxicity
Phototoxicity is an adverse acute, inflammatory and nonimmunologically mediated 
skin reaction that occurs after a single contact with a photoreactive chemical, under 
sun exposure. Since 2000, the in vitro 3T3 NRU phototoxicity test has been the only 
in vitro test validated for evaluating the acute phototoxicity of a chemical. However, 
this monolayer culture of fibroblasts is a simple basic system lacking connections and 
interactions between different cell types and ECM [66]. To overcome these limitations, 
some methods using reconstructed skin models (Epiderm™ and EPISKIN™) have 
been developed. In 1999, ECVAM funded a prevalidation study on the EpiDerm™ 
phototoxicity test, with promising results. More recently, the EpiSkin™ phototoxicity 
assay’s performance (on 17 reference chemicals) showed a very good overall accuracy 
of 94% [69]. Interestingly, the EPA takes into account the influence of the adminis-
tration route (topical treatment vs a systemic-like administration) in the prediction of 
phototoxic potency. Similar protocols based on viability assessment were applied to 
different skin and epidermis reconstructed models [104,67]. The promising perfor-
mance of EPA showed that the EpiSkin™ model is an interesting tool that is able to 
integrate decision-making processes to address the question of phototoxicity linked 
to the administration route. Using the industrial epidermis, SkinEthic™ RHE model 
showed that exposure to solar-simulated radiation (SSR) induced phototoxic features, 
such as the formation of sunburn cells and DNA damage (fragmentation) with the 
activation of caspase-3 protease in keratinocyte basal layers, which opens possibilities 
for evaluating the photoprotective capacity of cosmetic formulations [105].
4.6  Skin sensitization
An epidemiological study based on data collected on all age groups and all countries 
between 1966 and 2007 showed that prevalence of contact allergy to at least one al-
lergen is around 20% [106]. This underlines the importance of this health end point 
in hazard and risk assessments of chemicals. The need for nonanimal data to assess 
the skin sensitization properties of chemicals, especially cosmetics ingredients, has 
driven the development of many in vitro methods [107]. It is now widely accepted 
that for this end point, no single alternative can provide a solution to replace animal 
methods. In 2012, the OECD described the first AOP (Fig. 8) for this adverse effect 
[108]. According to this document “an AOP is the sequence of events from the chemi-
cal structure of a target chemical or group of similar chemicals through the molecular 
initiating event to an in vivo outcome of interest.” The first key event of the AOP for 
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skin sensitization is the molecular interaction with skin proteins, the site of action. 
Specifically, the target chemical or a metabolite or abiotic transformation product of 
the target chemical covalently binds to cysteine and/or lysine residues. The second key 
event takes place in the keratinocyte. This includes inflammatory responses and gene 
expression associated with particular cell signaling pathways (e.g., antioxidant/elec-
trophile response element-dependent pathways). The third key event is activation of 
dendritic cells, which is typically assessed by expression of specific cell surface mark-
ers, chemokines and cytokines. The final key intermediate event is T-cell proliferation.
This AOP provides a framework to develop, validate, and gain regulatory accep-
tance of various alternative approaches. For each key event, especially the first three, 
several alternative methods have been developed, and some are validated and OECD 
test guidelines released. Recent efforts have focused on the development of the inte-
grated approach to testing and assessment (IATA) and on using the data generated with 
these methods for hazard and potency assessment [109-111], but the situation is much 
more complex than for skin corrosion/irritation.
Among the alternative methods developed and under evaluation, some are based 
on the use of RHE as test systems [107,76]. The SENS-IS assay is an in vitro method 
developed based on the EPISKIN™ model and the analyses of the expression of three 
groups of genes by the transcriptomics approach (qRT-PCR) measuring fold increases 
in the expression levels of genes [73]. Statistical analyses of data on 150 chemicals 
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Fig. 8 Flow diagram of the pathways associated with skin sensitization adapted from 
“Adverse Outcome Pathway for Skin Sensitization Initiated by Covalent Binding to Proteins 
Part 1: Scientific Evidence,” OECD document (2012). Representation of the key events in the 
human skin compared with reconstructed human model that mimics the bioavailability of the 
chemical, metabolism and penetration, and key events 1 and 2.
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give an accuracy higher than 96% for a yes/no answer and 92% for potency prediction 
[74]. The results of a recent multicentric study on 19 blinded chemicals with this assay 
have been submitted to EURL-ECVAM and OECD for validation.
The epidermal equivalent (EE) potency assay is another assay that aims at classify-
ing sensitizer potency using RHE. This test requires prior identification with another 
assay if the substance is a sensitizer. Then, the reconstructed epidermis is exposed to 
different concentrations of the chemical, and the potency of the allergen is calculated 
from the concentration inducing 50% of cell viability (EE-EC50) measured by MTT 
[112,72,113]. In response to allergens, keratinocytes are capable of producing a wide 
range of pro-inflammatory cytokines. The release of the inflammatory cytokine IL-18 
has been shown to be specific to keratinocytes’ exposure to contact allergens [114]. 
This property is also exploited to develop an assay with reconstructed human epider-
mis to predict the sensitization potential and its potency of an allergen by quantifying 
secreted IL-18 into the reconstructed tissue culture medium [115,116].
Whatever the strategy chosen, methods using RHE as a test system benefit from the 
capacity of the human epidermis to reproduce four steps of the skin sensitization AOP 
in vitro, including two key events: penetration, metabolization, covalent interaction 
with proteins and keratinocyte activation.
4.7  Genotoxicity
Genotoxicity refers to processes that alter the structure, information content, or segre-
gation of DNA and that are not necessarily associated with mutagenicity. Thus, tests for 
genotoxicity include tests that assess induced damage to DNA (without direct evidence 
of mutation). Evaluation of genotoxicity and mutagenicity evaluations are important 
and early steps in the safety assessment of chemicals for industrial development and 
regulatory purposes. Although many in vitro tests are routinely used and accepted by 
regulatory agencies, their accuracy in predicting mutagenic/genotoxic potential in hu-
mans is frequently questioned [117]. In 2007, a workshop of experts underlined the 
fact that genotoxicity tests in 2D culture of mammalian cells in vitro produced a re-
markably high and unacceptable occurrence of irrelevant positive results. The only way 
to confirm such results would imply an in  vivo rodent carcinogenicity test. Among 
the proposals made to overcome this limitation, the experts concluded that the use of 
3D in vitro skin models was a promising option. These do present clear advantages 
(organ structure, functionality, standardized production, availability, etc.) as in  vitro 
screening tools for genotoxicity. Specific protocols to perform the comet assay (geno-
toxicity test) on EpiSkin™ were developed both with UV exposure and/or reference 
chemicals (lomefloxacin, 4-nitroquinoline-N-oxide) as stress agents. Pretreatment with 
the sunscreen Mexoryl SX® was able to clearly reduce the extent of UV-induced DNA 
damage assessed by the comet signal [118]. A second approach was developed, taking 
advantage of the barrier function and metabolic capacities of the EpiSkin™ model, to 
drive the response to a topically applied test chemical and its possible metabolites. A 
specific coculture system using a target lymphoma cell line (L5178Y) underneath the 
epidermis was carried out for evaluating micronucleus induction after topical appli-
cation of the test substance. This approach aims to improve the relevance of exposure 
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conditions for testing further products to be applied to the skin [118]. This could im-
prove the predictive value of a genotoxicity assessment as compared with those af-
forded by existing in vitro tests and, therefore, could be used as follow-up tests in the 
event of positive results from the standard in vitro genotoxicity testing battery. Another 
approach, currently being validated, is to conduct the micronucleus test and the comet 
assay directly on 3D reconstructed human skin models [119]. Validation studies of the 
reconstructed skin micronucleus assay (RSMN) using the Epiderm™ model are coor-
dinated and funded by the Cosmetics Europe Genotoxicity Task Force [120]. The 3D 
skin comet assay in full-thickness skin models, such as EpidermFT [71] or Phenion® 
FT, is being developed as a joint venture between the Cosmetics Europe Genotoxicity 
Task Force and a German consortium funded by the Federal Ministry of Education 
and Research (BMBF). The reproducibility and predictive capacity of this comet assay 
between laboratories is still being assessed.
These different projects on reconstructed epidermis and skin have helped improve 
the predictive capacity of in vitro assays. Optimization of the protocols has resulted in 
improved specificity of the micronucleus test, such that over 60% of irrelevant positive 
findings could be prevented by using the optimized methods. Both the micronucleus 
and the comet assay in reconstructed skin models will not be considered as stand-
alone assays, but they will be ideal in genotoxicity animal-free testing strategies to 
address positive in vitro genotoxicity test results [76] as part of a second tier.
5.  Skin models and methods for assessing the efficiency 
of new active ingredients and finished products
Objective evidence of the final efficacy of a cosmetic product should always be confirmed 
by clinical studies. At earlier stages of development, however, reconstructed human skin 
is an unbeatable tool for screening and assessing the efficacy of new active ingredients, 
deciphering their action mechanism, and finally, optimizing the composition of formula-
tions to maximize in vivo benefits. Extrapolating the results obtained in vitro on recon-
structed skins models to the in vivo situation in humans is an important line of research.
5.1  In skin aging
Skin aging induces dramatic changes in the extracellular dermal matrix (ECM) and 
in the DEJ. Reversing or slowing down these phenomena could reduce these visible 
signs of aging. It has been shown that topical application of a C-xylopyranoside 
derivative (C-beta-d-xylopyranoside-2-hydroxy-propane) onto a reconstructed 
full-thickness skin induced neosynthesis of some matrix proteins such as glycos-
aminoglycans (GAG) and heparan sulfate proteoglycans, as well as an improvement 
in DEJ morphogenesis together with increased collagen VII expression, thus sug-
gesting beneficial effects on an aged skin [121]. GAGs are major components of 
dermal ECM and participate in tissue cohesiveness and hydration. Through their 
ability to bind to and modulate the activity of a number of growth factors, GAGs 
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are also involved in cell adhesion and migration, as well as skin organogenesis and 
wound healing. The structure and integrity of GAGs is therefore essential for skin 
homeostasis and regeneration. Some research suggests that age-related alterations 
of the dermal connective tissue may involve a remodeling of GAG expression and 
structure [122,123]. Further studies with in vitro skin models have confirmed that 
C-xyloside strongly not only enhances synthesis of GAG chains but also induces 
significant changes in their size and structure. C-xyloside primed GAGs were exclu-
sively chondroitin/dermatan sulfate with reduced chain size, increased O-sulfation, 
and changed in iduronate content and distribution [124]. This gives new insights into 
the effect of C-xyloside on GAG structure and activities, which opens up prospects 
and applications for such compounds in skin repair/regeneration.
The differentiation/proliferation balance in keratinocytes strongly influences skin ho-
meostasis. Topical application of the antiaging gold standard retinol on an in vitro skin 
model has been shown to modulate differentiation. A combination of retinol and adenos-
ine applied to the 3D skin model showed the ability of adenosine to potentiate retinol 
effects in accordance with results from a clinical application of a skin care product con-
taining these active ingredients [125]. A derivative of jasmonic acid (LR2412), a signal 
molecule synthesized by plants under stress, was studied on EpiSkin™ models to evaluate 
its effect on their regenerative potential. Morphological studies, immunohistochemical 
measurements, and transcriptomic analyses were conducted. Preliminary results on thick-
ness and proliferation markers (Ki67 markers) showed an increase in the regenerative 
potential of treated in vitro epidermis compared with a control (Fig. 9). Transcriptomics 
and immunohistochemistry studies showed that this activity was mediated by a stimula-
tion of the hyaluronasome, a complex of proteins involved in the synthesis (hyaluronate 
synthetase HAS3 and HAS2), maturation (hyaluronidase) and fixation of hyaluronic acid 
on specific receptors (CD44). However, this increase of the epidermal hyaluronic content 
and of keratinocytic proliferation does not disrupt or alter the normal differentiation of the 
epidermis, unlike retinol, which tends to inhibit this process [126].
Further tests in a full-thickness model (Fig. 9) showed an increased synthesis of 
collagens IV and VII and laminin 5, essential components of the DEJ. The clinical 
studies that have followed confirmed the activity of this active and its antiaging po-
tential in vivo [127].
5.2  In photoprotection
Despite the beneficial effects of sunlight, excessive or repeated exposure is known to 
induce oxidative stress resulting from ROS production in the skin, a major contribu-
tor to the harmful effects that follow UVA exposure. Among the mechanisms known 
to be involved, iron plays a central role [128] and can act as a catalyst of uncon-
trolled oxidation reactions with cell components [129]. Applying iron chelators to the 
EpiSkin™ model in vitro potentially offers an effective way to protect the skin against 
UVA damage, but it is usually difficult to achieve it without disturbing iron homeo-
stasis. Recently, a novel compound (Sideroxyl), developed to avoid these potentially 
harmful side effects, has been evaluated in reconstructed human skin model. Designed 
to acquire its strong chelating capacity only during oxidative stress  following an 
Fig. 9 Coloration of a RHE model (EPISKIN™) and immunohistochemistry of a full-thickness model (TSKIN™) after 5 days’ exposure to 
10 μmol/L dehydrojasmonic acid. HES coloration shows an increased thickness of the epidermis after treatment versus control. We observe 
also an increase in the labeling of the hyaluronic acid receptor CD44 in the treated epidermis. In the dermal-epidermal junction the treatment 
induces elevation of some markers such as Coll VII (and laminin 5, data not showed) and procollagen I in the upper dermis.
Adapted from Tran C, Michelet JF, Simonetti L, Fiat F, Garrigues A, Potter A, et al. In vitro and in vivo studies with tetra-hydro-jasmonic 
acid (LR2412) reveal its potential to correct signs of skin ageing. J Eur Acad Dermatol Venereol 2014;28(4): 415–23.
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 intramolecular hydroxylation process, this active ingredient demonstrated protective 
efficiency against the harmful effects of UVA at the molecular, cellular, and tissue 
levels. The use of in vitro reconstructed tissue allowed several end points to be mea-
sured including carbonyl increase, intracellular ROS, DNA damage (comet assay), 
and MMP-1 synthesis and release, altogether suggesting that such an active ingredient 
may prevent UVA-induced damage in the human skin alongside sunscreens, especially 
in the long-wavelength UVA range [130].
The structure of the 3D models and the presence of an air-exposed stratum cor-
neum make them tools of choice for the topical application of finished products. 
Application of a product containing Mexoryl SX® sunscreen before solar-simulated 
sunlight exposure (conditions mimicking in  vivo use) revealed the ability of the 
sunscreen to inhibit UV-induced pigmentation [131] almost completely. The in vi-
tro evaluation of sunscreens after topical application allows their protective effects 
against UV to be investigated and proper selection of absorbers to be made and 
tested based on their absorption spectrum. Recent definition of a standard “daily 
UV radiation” (DUVR) allowed nonzenithal sun exposure conditions to be repro-
duced on in vitro models. Two commercial sunscreen products with a similar sun 
protection factor (SPF) but different absorption profiles over the UVA range were 
evaluated on reconstructed human skin. Using vimentin immunostaining for der-
mal fibroblasts and matrix metalloprotease (MMP)-1 secretion, it was shown that 
to ensure efficient daily photoprotection from DUVR, the filtration profile of the 
product should be well balanced over the UV range with a sufficient level of UVA 
absorption [132].
5.3  In the modulation of pigmentation
N-Acetyl glucosamine (NAG) is an amino sugar precursor in the human skin of the 
high molecular weight, water-binding polymer hyaluronic acid. It has been shown to be 
effective in reducing the appearance of hyperpigmented spots [133] through inhibiting 
the glycosylation of tyrosinase, a key enzyme in the production of melanin. To identify 
additional mechanisms by which NAG might affect melanin production, a transcrip-
tomics study of the effect of NAG has been conducted on the SkinEthic™ model of 
reconstructed human pigmented epidermis (RHPE). The results showed several changes 
in gene expression (upregulation and downregulation) with some of them related to syn-
thesis and regulation of intracellular cytoskeletal proteins that are involved in melano-
some transport within the cell [134]. Thus, several mechanisms may be operative in the 
observed effects of NAG on pigmentation. Produced on an industrial scale, these in vitro 
pigmented skin models are able to reproduce different phototypes. They are powerful 
tools to screen the pro- or depigmentation efficacy of new ingredients or compounds 
[135,136]. A model of this kind has been also used to develop RNA silencing (siRNA) 
strategies to modulate skin pigmentation. After selection of a potent siRNA compound 
that targets the tyrosinase gene, its efficacy was assessed during reconstruction of an 
RHPE model. Melanocytes derived from the highly pigmented phototype VI skin were 
used for the reconstruction of a phenotypically silenced epidermis. A visible and a long-
term pigmentation interference effect (lasting more than 30 days) were observed in the 
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SkinEthic RHPE model [137]. This knockdown of tyrosinase expression was transient 
since the reconstructed epidermis started recovering pigmentation at day 39 and thus did 
not irreversibly affect melanocyte differentiation. The use of a pigmented reconstructed 
epidermis is thus becoming a precious tool, allowing the action of different topical appli-
cations and vectors to be studied and new dermatological interventions, tools, and targets 
to be selected, evaluated, and designed.
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1.  Introduction
The human skin is a complex organ in both anatomy and physiology. It is the largest 
organ by weight in the human body, playing important functions from the production 
of vitamin D to providing a protective barrier against the outside environment and 
pathogens [1]. Diseases affecting the skin are a common ailment, and their effective 
treatment requires a better understanding of their underlying pathophysiology.
Skin models are valuable to study skin development and its diseases. These models 
range from in vivo animal models to in vitro models created using primary cells or cell 
lines. Considering the evolutionary principle that all organisms share most of the ge-
netic codes and somehow related due to common ancestry, well-designed animal mod-
els can recapitulate most of the disease characteristic. They are advantageous because 
studying skin disorders in the clinic is limited and in-depth investigation is only possi-
ble after biopsy of live tissue or postmortem analysis [2]. There is also limited access 
to normal and diseased human tissue, and therefore, there is a need for human tissue 
equivalents to be used in studying the underlying disease mechanisms in further detail. 
Various skin injuries can be mimicked in animal models that provide an easier way of 
studying the process of wound healing to find the main culprits of deficient healing 
versus excessive scar formation. Humanized mouse models are developed by growing 
human tissues transplanted into mice with severe combined immunodeficiency [3,4]. 
These models can be used to study diseased human cells or tissues as they continue to 
grow in the animal model, providing an exceptional opportunity to identify differential 
gene expression and response to drugs.
The use of animal models has been responsible for major advances in crucial in the 
understanding of human biology and disease in the last century. As noted, animal spe-
cies share similar physiological characteristics with humans; therefore, it is possible 
to produce a condition artificially in animals that resembles human disease or injury. 
As a result, animal models have been employed in all fields of biomedical research 
including skin diseases. This has led to the development and testing of drugs, vaccines, 
and other biologicals that have improved and advanced human health. Historically, a 
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variety of animal models has been utilized to develop treatments that revolutionize 
how physicians practice medicine. Most notably, in 1921, Drs. Banting and Best at the 
University of Toronto discovered the hormone insulin through the use of dogs. This 
discovery transformed the way physicians managed diabetic patients and provided 
relief for sufferers. Improving the quality of life became the main concern rather than 
how to prevent death in diabetic patients. The above example illustrates the substan-
tive contributions of animal models in the investigation of human disease. The limita-
tions of animal models should be acknowledged, however. Researchers should keep in 
mind that there is no “perfect” comprehensive animal model for every specific human 
disease. Rather, disease models need to focus on specific components of human ill-
ness to eventually develop a comprehensive understanding. For example, one model 
may be used to identify targets for compounds that treat acute tissue damage, whereas 
another may seek to find targets relevant to long-term recovery. The transferability 
and predictability of data obtained from animals is also a major concern [5]. This is 
because animals may not share all the properties necessary to completely recapitulate 
human conditions, particularly in the skin [6]. This requirement is not essential to 
creating an effective model, however, and animal models are required to discover new 
indications that may eventually be used in the clinic.
Interventional research studies play a fundamental role in understanding whether 
newly discovered drugs could be of clinical use. Long before these drugs are entered 
into clinical trials, the first step is to use surrogate models of the skin with closely 
matching physiology and anatomy. The relevant safety and efficacy of newly devel-
oped chemicals by drug discovery efforts can be tested extensively to ensure minimal 
risk and less number of failed attempts at finding the best remedy. Computational and 
mathematical models of skin bioprocesses are cost-effective ways of generating hy-
potheses that can later be tested in vitro or on animals.
Here, we will discuss the role of skin models in understanding the pathophysiology 
of skin diseases, drug discovery and treatment, and cell therapy. Various skin diseases 
ranging from skin cancer, trauma, and developmental disorders, and a wide variety 
of approaches with different levels of sophistication will be covered. We will address 
how these skin models are generated, their strengths and limitations, and finally their 
translation into the clinic.
2.  Skin models for understanding the pathophysiology  
of diseases associated with skin
Skin models are useful tools for better understanding the pathophysiology of skin 
diseases. Understanding the process of skin development is essential for a better un-
derstanding of skin diseases and the process of wound healing. As such, models for 
skin development are important since they provide insight into the complex features 
observed during skin diseases. To develop better clinical treatments of skin diseases, 
there is a need to better understand the pathobiology of skin diseases through skin 
models. Several models have been developed to recapitulate the features of specific 
skin diseases, and such models have provided valuable insight into the pathobiology of 
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these diseases. Moreover, the pathobiology differs greatly between skin diseases, and 
as such, understanding these differences is important to creating a useful skin model. 
These models need to encompass developmental and/or acquired skin diseases, skin 
cancer, and lastly wound healing in response to trauma such as burn injury.
3.  Developmental and acquired skin diseases
An ideal model should recapitulate most of the characteristics of the organ or target dis-
ease. The search for the perfect animal model to study developmental skin diseases such 
as systematic sclerosis (SSc) continues to elude scientists. For instance, numerous in vi-
tro and in vivo studies have shown that targeting tyrosine kinase inhibitors (TKI) such as 
nilotinib and imatinib can be used to target skin fibrosis [7–9]. In vitro data suggest that 
targeting TKI influences TGF-β and PDGF signaling leading to antifibrotic effects [7]. 
Moreover, in vivo studies utilizing bleomycin-treated mice (an experimental model of 
fibrosis) demonstrated the effect of nilotinib and imatinib in preventing fibrosis in sev-
eral different organs, including the skin [9]. Despite these promising in vitro and in vivo 
studies, the use of these drugs in open-labeled and controlled clinical trials has led to 
poor results in SSc patients [10]. This illustrates the importance of properly developing 
a skin model that can be translated to the clinic. An ideal skin model should recapitu-
late most of the pathophysiological changes observed in a specific disease. To further 
complicate matters, the drug response depends heavily on the animal model used that 
has significant implications for clinical trials. Bleomycin-treated mice exhibit a drastic 
reduction in PDGFRB-positive cells, skin thickness, and myofibroblast activation in re-
sponse to TKI treatment [11]. A newly developed animal model for SSc, called Fra2, 
however, has a completely different response. Like bleomycin-treated mice, Fra2 mice 
show decreased levels of PDGFRB in response to TKI treatment [11]. On the contrary, 
Fra2 mice do not show any phenotypic improvements as skin thickness was the same in 
treated and untreated mice [11]. It is clear that inconsistent results of the aforementioned 
clinical trials can be partially explained by the inaccuracies of these animal models in 
recapitulating SSc. This is especially important considering the heterogeneity observed 
in SSc and other skin diseases like skin cancer. Animal models, particularly mouse mod-
els, allow genetic manipulations of a gene throughout the body or in a specific cell type. 
For instance, labeling specific cells with a fluorescence reporter allows researchers to 
study the behavior of those specific cells in response to the disease [12] (Fig. 1). Animal 
models should be interpreted more cautiously when predicting treatment outcomes in 
humans. Another aspect that is often ignored when creating an animal model is whether 
the particular skin disease is observed in any other animal. As mentioned earlier, creating 
an accurate skin model for SSc has been difficult. SSc is a human-specific condition, and 
this key fact likely accounts for the difficulties scientists have encountered in creating a 
suitable model for this disease. Recently, in order to study skin diseases with an immu-
nologic component such as allergic dermatitis, immunocompetent 3-D models includ-
ing dendritic cells in addition to fibroblast and keratinocytes have been developed [13]. 
Overall, differences in the inflammatory response, immune system, or the metabolism 
of xenobiotics are only some of the issues limiting the applicability of animal models.
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In vitro models that attempt to reconstruct the skin are important in studying skin 
diseases, particularly in increasing the speed and success rate of drug development. 
Monolayer (2-D)-based assays are not suitable for drug development as they do not 
mimic interactions of different cell types present in multilayer tissue [14]. 3-D con-
structs are needed to accurately recapitulate the human skin and mimic the biotrans-
formation of drugs in such an environment. 3-D models are particularly important in 
diseases that arise from cell-cell interactions such as skin cancer. In 3-D skin models, 
a scaffold fosters cell adhesion to help guide tissue growth and development and sup-
ports the use of advanced coculture systems [14].
Several academic and industrial bodies have produced commercial in vitro human 
skin models composed of human keratinocytes cocultured with human fibroblasts 
(EpiSkin, EpiDerm, epiCS, and Labcyte) [15]. Interestingly, these skin models form 
multilayered epithelium and express markers of epidermal differentiation. The practi-
cality of in vitro skin models lies in their utility in studying the toxicity, pharmacology, 
and transport ability of new drugs and their ability to be reproduced in large quantities 
[14]. While convenient, there are several limitations to these skin models. They are 
not exact replicas of the human skin in vivo; thus, assessing tissue response is prob-
lematic. Moreover, the biggest limitation is their weak barrier function that leads to 
false-positive results when assessing dermal penetration.
NativeSkin, an ex  vivo skin model, attempts to address these limitations and 
improve upon currently available products (Fig.  2). To create NativeSkin, skin 
Fig. 1 Lineage-tracing experiment illustrating the role and contribution of myeloid cells in 
repairing the dermal compartment of the skin in mice.
Taken from Vorhagen S, Jackow J, Mohor SG, Tanghe G, Tanrikulu L, Skazik-Vogt C, 
Tellkamp F. Lineage tracing mediated by cre-recombinase activity. J Invest Dermatol 
2015;135(1):1–4. https://doi.org/10.1038/jid.2014.472.
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 biopsies are first obtained from patients undergoing surgery. The skin samples are 
then cultivated in multiwall transport plates surrounded by a proprietary matrix 
that nourishes the dermal of the skin using serum- and hydrocortisone-free culture 
medium. The tissue integrity, viability, and barrier properties are maintained for at 
least 7 days in culture allowing for studies to be conducted. NativeSkin has become 
a standardized ex  vivo model of the human skin for final testing prior to clini-
cal testing in humans due to its superior physiological barrier function and robust 
stratum corneum making it ideal for absorption studies. The major limitation of 
NativeSkin model is that one cannot replicate pathological conditions like SSc or 
skin cancer. Using a skin biopsy of these patients and developing an ex vivo skin 
model of the disease is another way to create disease models. However, the latter is 
deprived of the systemic microenvironment of the body. In summary, developing a 
skin model that recapitulates most of the hallmark features of the disease can be a 
useful tool to understand the accompanying pathophysiological features. For exam-
ple, studying the signaling pathways that are activated (or inactivated) or cells that 
are recruited to the skin of a disease model will shed light on the pathophysiology 
of the disease.
4.  Skin cancer
Several models have been developed for studying skin cancers. Developing skin 
models of nonmelanoma cancer is imperative as cutaneous squamous cell carcinoma 
(SCC) is one of the most common cancers in the Caucasian population causing sig-
nificant morbidity and mortality [16]. Because most SCCs are caused by excessive 
exposure to UV radiation [17], some skin models have utilized immunocompetent 
SKH-1 mice that lack a dense, UV-impenetrable hair coat found in wild-type mice. 
UV exposure in this model has been shown to induce SCC in a time and dose and 
exposure time-dependent manner [18]. The use of this model has been questioned, 
however, as the hairless gene plays an important role in skin metabolism [19] and 
might serve as a major confounding factor. Therefore, its knockout may inadver-
tently influence tumor development. The classic and more accurate animal model of 
studying skin cancers is two-stage chemical carcinogenesis. First, there is a topical 
Fig. 2 NativeSkin, an ex vivo skin model created from human skin biopsies, can be used to 
test treatments prior to use in clinical trials.
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 application of the carcinogen dimethylbenzanthracene (DMBA) that causes mutations 
in certain cells [20]. Next, there is repeated administration of the pro-inflammatory 
ester 12-O-tetradecanoylphorbol-1-acetate (TPA) that promotes the mutated cells into 
benign tumors that eventually develop into malignant ones [20]. The strength of this 
model is the ability to track the biological sequence of tumor formation, changes in 
signaling pathways, and the role of inflammation. The breadth of information acquired 
from the two-stage carcinogenesis model informs future approaches to treatment and 
chemoprevention in SCC. Skin models like this can enlighten further the signaling 
pathways and (ab)normal cells that have been recruited to the skin and therefore pro-
vide a valuable model for studying the pathophysiology of disease. Lastly, models of 
skin carcinogenesis caused by UVB rays have been created in vitro using human cells 
[21]. Even though in vitro models are deprived of the systemic and local microenvi-
ronment, these models are advantageous since human cells have been used, harboring 
the genetic and transcriptional machinery of human cells. One method of studying the 
pathophysiology of skin diseases is to culture patient-derived cells in vitro and study-
ing disease mechanisms at the molecular and cellular levels. While animal models 
are useful for studying skin cancer, tumor cells can be readily isolated from patients 
allowing for in-depth experiments. It is also possible to model the genetic abnormali-
ties in skin cancer by utilizing patient-derived cell lines isolated from tumor biopsies. 
Moreover, cell lines carrying a genetic defect of interest to model specific diseases can 
be accomplished [22]. This is advantageous because researchers can model a disease 
phenotype in undifferentiated or differentiated cells to elucidate disease etiology and 
develop novel therapies through drug screening.
5.  Trauma and wound healing
The development of reconstructed skin to replace damaged or lost skin such as in burns 
is important. The engineering of the skin not only is useful for the treatment of the pa-
tients but also can be used for studying the process of skin healing in vivo and in vitro. 
Wound healing is a highly complex, well-orchestrated process that involves a series of 
coordinated and overlapping processes. Skin models provide a new platform to better 
understand these cellular and molecular mechanisms underlying skin regeneration in 
mammals, ultimately leading to better treatments in clinical settings. To study wound 
healing, in vitro assays are commonly used as they are inexpensive, fast, and excellent 
for examining the effect of certain agents on particular cell types (e.g., fibroblasts 
and keratinocytes). This allows for researchers to determine the effectiveness of vari-
ous treatments, particularly healing-enhancing agents. For instance, 3-D skin models 
have been produced where keratinocytes are grown on a layer of fibroblasts within 
a collagen gel, mimicking basic skin layers [15]. This 3-D “skin equivalent” can be 
wounded, and interactions between these two different cell types during wound repair 
can be examined. Moreover, it is possible to evaluate the signaling pathways that are 
activated in each of these cell types after wounding and during different stages of 
healing. The strength of in vitro models of wound healing is the ability to easily con-
trol variables such as pH, salinity, and temperature. As previously mentioned, these 
models are incapable of recapitulating the in vivo wound  environment nor capable 
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of revealing the adverse effects of candidate therapeutic compounds since they are 
lacking the systemic and local microenvironment. Therefore, studying factors such as 
the inflammatory response or angiogenesis become difficult resulting in an inability to 
predict patient response to treatment.
Rodent and small mammal models of wound healing have become the model of 
choice for most researchers because they are inexpensive, easily obtainable, and un-
dergo accelerated healing compared with humans [6]. For instance, rodent models are 
commonly used to study full-thickness wounds. Fig. 3 illustrates one such model in 
which a full-thickness scald burn is used to study skin healing after burn [6]. The main 
strength of small animal models is the ability to implement genetic manipulations. 
These genetic alterations can approximate human conditions such as diabetes and al-
lows researchers to study the cellular and molecular intricacies involved in wound 
healing. As such, it is possible to map out the role of specific cells in skin healing that 
results in a better understanding of skin pathogenesis. The best in vivo animal model 
to study wound healing is the porcine model [6]. While most wound healing studies 
use the rodent system, the skin structure of pigs is most similar to humans as opposed 
to “loose-skinned” rodents. Both humans and pigs share similar epidermal thickness, 
similar patterns of hair follicles and blood vessels, and similar dermal collagen con-
tent. Pigs and humans also have similar molecular responses to various growth fac-
tors. Partial- or full-thickness surgical excisions can be performed on the dorsal trunk 
skin of the pig to accurately mimic a clinical situation tissue damage, and tissue loss 
occurs. Moreover, variations in the experimental design can be employed depending 
on which aspect of wound healing is being focused on. For instance, the method of 
anesthesia and pain control varies from study to study when porcine models are uti-
lized. While the porcine model is an indispensable skin model in wound healing, the 
Fig. 3 An example of a full-thickness burn model used to study wound healing.
Taken from Abdullahi A, Amini-Nik S, Jeschke MG. Animal models in burn research. Cell 
Mol Life Sci 2014;71(17):3241–55.
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significant cost disadvantage and difficulty in handling make this a difficult model to 
carry out [6]. Overall, pig skin most closely resembles human skin, but due to the size 
of pigs, implementing a porcine model is quite challenging to execute and can pose a 
risk to the researcher despite.
The development of hypertrophic scarring and keloids (also known as fibrosis) 
due to the excess accumulation of extracellular matrix during wound healing is a ma-
jor challenge in the clinic. Because of the complex nature of wound healing, in vivo 
models are best suited to study fibrosis. To evaluate potential antifibrotic therapeutics, 
bleomycin-induced skin fibrosis mouse model is commonly used. Repetitive subcu-
taneous injections of bleomycin cause dermal thickening and collagen accumulation 
that mimics fibrosis [23]. Histological analysis can subsequently be utilized to gain 
new insights into the mechanism of fibrosis. The complexity of the fibrotic process 
makes is quite difficult to mimic the process in vitro. Regardless, assays that evalu-
ate key processes such as proliferation, migration, myofibroblast differentiation, and 
collagen production are well suited to evaluate the effectiveness of antifibrotic agents 
[24]. In burn clinics across the world, hypertrophic scarring is still a major challenge. 
There is a tremendous need to improve outcomes and quality of life of patients [25]. 
This can be accomplished by further elucidating the molecular mechanisms involved 
in fibrosis so that scar development can be attenuated or prevented by using new ther-
apeutic strategies. Table 1 summarizes skin models used in understanding the patho-
physiology of skin diseases and their clinical translation.
6.  Skin models in drug discovery
Human diseases or injuries can be mimicked in animal models and then treated with 
experimental drugs to identify the ones with lowest complications and highest effi-
cacy. Before drugs are tested on animals, high-throughput screening (HTS) can be 
performed on millions of drugs simultaneously using cells or small model organisms 
using robotic technology and computational analysis that show a high level of predict-
ability for in vivo efficacy [26,27]. Many experiments can be conducted with more 
ease using in vitro model systems, such as assessment of repeated dosing effects [28]. 
In silico computational models are being used for drug discovery in skin cancers such 
as melanoma [29]. In silico models utilize computational models and/or computer 
simulation to screen and design drugs. Thus, these computational models are involved 
in all stages of drug development from the preclinical stage to the clinical trials them-
selves. Drug discovery and development is a lengthy and intensive venture; hence, in 
silico drug design is cost-effective in research and development of drugs. For example, 
in silico models have been used to study the mechanical stabilities of different cell 
types and keratinocyte migration during wound healing [30]. The use of skin models 
in HTS is cost-effective because it reduces the need for costly repeated trial and error 
experiments on animals. However, it should be noted that without animal experiments, 
results of HTS experiments do not initiate clinical trials. Furthermore, the translation 
of drug discovery to clinical trials is difficult. Many skin models used for drug discov-
ery have yet to translate their discoveries in to the clinic (Table 2).
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Skin disease 
model In vitro In vivo Description Clinical translation References
Systemic 
sclerosis
✓ (Mouse) ✓ Antifibrotic effects by targeting 
PDGFRB and TGF-β1 via tyrosine 
kinase inhibitors (TKI)
TKI inhibitors had poor results in SSc 
patients
[7,10]
Systemic 
sclerosis
 ✓ (Mouse) Fra2 knockout mice show reduced 
fibrotic response (PDFGBR)
N/A [11]
Squamous 
cell carcinoma 
(SCC)
 ✓ (Mouse) Two-stage chemical carcinogenesis 
in mice unravels pathophysiology 
and informs future treatments
N/A [19]
Wound healing ✓ (Human 
and 
mouse)
 3-D skin models where keratinocytes 
are grown on a layer of fibroblasts 
within a collagen gel, mimicking 
basic skin layers. Allows researchers 
to test the effectiveness of treatments
N/A [14] [54,55]
Hypertrophic 
scarring 
 
  
 
 
✓ (Mouse) 
 
 
Bleomycin-induced fibrosis in 
rodents has led to the targeting of 
specific cytokines such as TGF-β3 
Avotermin (recombinant, active, human 
TGF-β3) reduced total scar scores 
compared with placebo in phase I/II 
studies. Phase III trials failed, however
[22,56] 
 
 
Table 1 Skin models used in understanding the pathophysiology of skin diseases
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Skin disease model In vitro In vivo Description
Clinical 
translation References
Melanoma ✓ (Human)  Three-dimensional full-thickness melanoma spheroids 
that respond to treatment. Cisplatin identified as 
potential treatment
N/A [35]
Reconstructed human 
epidermis
✓ (Human)  Models such as EpiDerm, EpiSkin, and NativeSkin 
have been validated. Useful for testing drug toxicity, 
metabolization, and drug delivery
N/A [57–59]
Explant ✓ (Human)   Explants of diseased skin used to study epithelial 
migration and compound screening
N/A [60–63] 
Table 2 Skin models used in drug discovery
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Since the discovery of induced pluripotent stem cells (iPSCs), are human pluripo-
tent stem cells that are capable of self-renewal and have the potential to differentiate 
into almost any cell type. These cells can be used to help overcome the limitations 
of animal models for certain skin disorders leading to the establishment of new skin 
models that can be used for drug discovery. Recently, there has been a big boost in 
drug discovery using bioengineered human tissue such as the skin [31,32]. Skin mod-
els generated by iPSCs can be used to identify individual differences in treatment 
response for use in personalized medicine [33]. To illustrate this, organ-on-a-chip is a 
microfluidic device where cells can be cultured in chambers with continuous flow of 
media [34]. This is arranged on a microchip and allows for in vitro HTS of millions 
of drugs on live cells. Although most in vitro skin models are in a two-dimensional 
monolayer, 3-D models of the skin have been developed as better biomimetic to be 
used for HTS [35]. Better recapitulation of skin microenvironment provides a platform 
to study the response of skin cells to cosmetics and experimental drugs.
Three-dimensional full-thickness organotypic skin model of melanoma is being 
used to test for the most effective chemotherapy regimen [36]. Skin models can be 
used to evaluate the degree of topical drug penetration in vitro. By reducing skin bar-
rier using chemicals, studies are able to model skin diseases with reduced barrier func-
tion to be tested for penetration of drugs [37]. Other proposed skin models for studying 
drug penetration include isolated flaps of the human skin maintained by continuous 
perfusion ex vivo [38]. They showed that these flaps can be maintained metabolically 
active for up to 6 h and can provide a close-to-in vivo model of drug penetration in the 
human skin. The use of iPSCs to model specific skin disorders is limited by the ability 
to develop efficient and robust differentiation protocols [22]. Obtaining mature and 
functional cells for some cell types remains a challenge for some [22]. The greatest 
strength of iPSCs lies in the ability to screen new drugs, epically therapies relaying on 
nucleic acid-based and amino acid-based drugs [22]. iPSCs also become more useful 
when a skin disease lacks appropriate animal models. It is likely that many clinical tri-
als will bypass animal models and begin due to new drugs being discovered in culture.
7.  Skin models in cell therapy
Extensive skin injuries such as burn are associated with minimal viable cells includ-
ing stem cells to repopulate the wound area. Tissue-engineered skin substitutes are a 
special type of 3-D skin model that are created in vitro using different cell types and 
biomaterials to replace the loss of skin with cells [39,40]. These models serve two 
purposes: (1) provide epidermal barrier to prevent further contamination of the wound 
and to prevent fluid and heat loss from the injured skin and (2) to introduce mature fi-
broblast and keratinocytes and/or stem cells to promote healing. These substitutes are 
in turn initially tested on animal models of skin injury to evaluate their safety and ef-
ficacy [41]. To date, decellularized human dermis has been the most effective scaffold 
clinically and is superior to the available artificially engineered cross-linked scaffolds 
[42]. These dermal matrices are usually isolated from a cadaveric skin and then pro-
cessed with detergents to remove cells and antigenic material. Cells in a  cellularized 
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artificial skin substitute can be comprising of adult mesenchymal stem cells derived 
from multiple sources [43] or fully mature skin cells such as keratinocytes and fibro-
blasts. Bioprinting of engineered skin in 3-D is being developed as the next step in the 
advancement of skin substitutes and could potentially allow for a quick and efficient 
way of covering extensive skin loss in the operating room [44,45]. Another benefit 
would be their use in remote locations with limited availability of skilled plastic sur-
geons [45]. A crucial determinant of successful use of engineered skin substitutes is 
their engraftment and integration into the host skin. Vascularizing the scaffold can 
greatly improve its integration and viability at the graft site, and efforts are underway 
to create scaffolds that contain vascular networks derived from iPSCs [46].
Wounds caused by nonburn injuries are also a good candidate for the use of skin 
models. Skin healing post radiation therapy in mice has shown to be improved by 
bilayer tissue-engineered skin substitutes [47]. Any type of skin defect including de-
velopmental defects of the skin can be a good candidate for use of skin substitute. It 
has been used successfully in the treatment of abdominal wall defects such as giant 
exomphalos [48]. An artificial bilayer skin substitute derived from porcine tendon was 
clinically effective at covering wounds caused by necrotizing fasciitis in human with 
a low incidence of infection [49]. Table 3 summarizes skin models used in therapy 
and their clinical impact. Chronic nonhealing wounds are another major group of skin 
disorders that can benefit from skin substitutes. Venous leg ulcers are difficult to treat 
Skin 
disease 
model In vitro In vivo Description
Clinical 
translation References
Burn injury ✓ (Mouse)  Tissue-
engineered 
skin substitutes 
are a 3-D skin 
model created 
from different 
cell types and 
biomaterials. 
Can introduce 
different cell 
types like 
fibroblasts and 
keratinocytes
Several 
clinical 
trials have 
shown that 
Integra 
dermal 
regenerative 
template 
is safe and 
effective 
in treating 
burn 
wounds
[38,39], 
[64–67]
Wound 
healing 
 
 
 
 
✓ (Porcine) 
 
 
 
 
 
  
 
 
 
 
 
Artificial 
bilayer skin 
substitute 
developed from 
the porcine 
tendon 
Clinically 
effective at 
covering 
wound 
area in 
necrotizing 
fasciitis
[48] 
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clinically, and current treatment strategies are minimally effective. Randomized con-
trolled trials show that bilayer tissue-engineered skin is better at healing these wounds 
than simple dressing [50]. In addition to cellularized versions, acellular biopolymers 
are also proving to be highly effective treatment strategies to treat skin wounds [51]. 
Another use of skin models for treatment discovery is for gene therapy [52]. In vitro 
and in  vivo models of skin diseases can be subjected to gene-editing technologies 
such as CRISPR to remove known mutations in disease pathophysiology. Gene-edited 
iPSCs can potentially be used to generate gene-corrected tissue to be transplanted 
back into the patients [53].
8.  Conclusion
The heterogeneity and complexity of human skin diseases make it so that no single 
skin model is capable of fully recapitulating each clinical scenario. The mechanisms 
of skin diseases have yet to be fully elucidated; however, the use of skin models is a 
promising avenue for clinical translation. The benefits and limitations of each skin 
model such as reproducibility, cost, and accuracy must be considered when choosing 
the optimal model for each study. Many of the models discussed thus far can be further 
improved to enable better represent the challenges facing the clinic. By optimizing 
skin models so that they better represent the clinical manifestations of skin diseases, 
we can use these models to more precisely understand the associated pathological 
mechanisms. Consequently, we can identify therapeutic targets and develop more ap-
propriate treatments for patients in the clinic.
There has been a strong push recently in the scientific community to emphasize the 
importance of moving basic science into the clinic. Skin models provide a powerful 
tool for the discovery and development of new drugs and therapies for skin diseases. 
Clinical trials are expensive and time-consuming as they can require millions of dol-
lars and many years to implement and are associated with ethical issues. Fully explor-
ing potential therapeutics via skin models dramatically increases the chance of success 
in clinical trials. While the models described here are far from ideal, they are the best 
available presently and have provided new insights. The development of more robust 
models for evaluating new therapies for the treatment of skin diseases is of utmost 
importance. Despite imperfectness, skin models will continue to play an important 
role in the clinic.
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1. Introduction
Malignant transformation of melanocytes, the pigment cells of the human skin, causes 
formation of malignant melanoma that is a highly aggressive cancer with increased 
metastatic potential. Despite remarkable efforts, metastatic melanoma still presents 
with significant mortality.
Recently, monochemotherapies are increasingly replenished by more cancer- 
specific combination therapies involving targeted kinase inhibitors and immunotherapy 
regimens. Still, metastatic melanoma remains a life-threatening disease because tumors 
exhibit primary resistance or develop resistance to novel therapies, thereby regaining 
tumorigenic capacity. In order to improve the therapeutic success of malignant mela-
noma, novel treatment options need to be explored. Therefore, determination of mo-
lecular mechanisms conferring resistance against conventional treatment approaches 
requires innovative cellular in vitro models. Since malignant melanoma presents with 
high heterogeneity, the need of predictive tools that specify dysregulation within can-
cer cells and focus on individual molecular targets is demanded to identify respond-
ers to selected combination therapies while sparing unnecessary treatment burden for 
 nonresponders. It therefore appears that a more thorough and reliable preclinical eval-
uation of novel drugs and therapeutic combination will be essential to reduce attrition 
rates in clinical trials and improve the benefit from therapeutic interventions. The fol-
lowing chapter aims to introduce and discuss different 3D in vitro melanoma models 
that might be suitable to portray the in vivo architecture of malignant melanoma and 
may warrant new insights into intratumoral and tumor-host interactions.
2.  Development and treatment of malignant melanoma
2.1  The role of melanocytes in human skin
The human skin is composed of two distinct layers that serve different functions in 
protecting the body from adverse environmental effects [1]. The lower dermal com-
partment consists of a fibroelastic connective tissue, being composed of loosely con-
nected collagen and elastin fibers synthesized by fibroblasts, serving a mechanic 
barrier function. In addition, supplying nerves, vessels, and capillary and hair follicles 
and sweat glands are located in the dermis to further protect the body by regulating 
the temperature and itching [2]. The dermis is separated from the upper epidermal 
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layer by basal lamina that is produced as an extracellular matrix due to a constant 
communication between both skin layers. In contrast to the dermis, the epidermis is a 
squamous epithelium that mainly consists of keratinocytes that can be differentiated 
into four sublayers. The stratum basale consists of undifferentiated basal keratino-
cytes that constantly derive from skin progenitor cells stratifying through the stages of 
the stratum spinosum and stratum granulosum into the stratum corneum to protect the 
body from dehydration and infection by microorganisms [3]. Immunologic protection 
is furthermore provided by epidermal Langerhans cells that as the first immunologic 
barrier recognize pathogens for elimination.
Melanocytes are aligned at the basal membrane and communicate through den-
dritic extensions with multiple keratinocytes to form an epidermal melanin unit. 
Melanocytes produce the pigment melanin which, when distributed to the surround-
ing keratinocytes, protects them from UV-induced DNA damage by quenching the 
radiation intensity. Accordingly, such melanin units serve the function to protect the 
body from the adverse effects of UV radiation like skin aging, immunosuppression, in-
flammation, and formation of nonmelanoma skin cancer (NMSC). UV-induced DNA 
damage concomitant with UV-induced immunosuppression are the key inducers of 
malignant transformation of epidermal keratinocytes into squamous cell carcinoma 
(SSC) and basal cell carcinoma (BCC); their contribution to transformation of mela-
nocytes to malignant melanoma (MM), however, is still under debate [4].
2.2  Development of malignant melanoma
The source and/or risk factors for the development of malignant melanoma are multi-
factorial comprising environmental influences and genetic factors [5]. According to the 
traditional model postulated by Clark et al., melanoma development can be differen-
tiated into different tumor progression stages, being characterized by certain genetic, 
morphological, and histological changes [6]. In this model, melanoma originates from 
either innate or acquired nevi due to a local increase of melanocyte proliferation caus-
ing benign neoplasia. This benign precursor lesion may convert into structurally mod-
ified dysplastic nevi containing atypic cells, which may continue to the first malignant 
stage, the radial growth phase (RGP). This early tumor progression phase is character-
ized by cells radially proliferating within the epidermis, showing few locally invasive 
cells within the papillary dermis. During the subsequent vertical growth phase (VGP), 
melanoma cells already show a metastatic and invasive phenotype by breaking through 
the basal lamina to infiltrate the deeper parts of the dermis and the subcutaneous tissue 
[7]. Finally, the metastatic melanoma (MM) represents the most aggressive progression 
stage with metastatic cells systemically spreading throughout the blood and lymph sys-
tem to invade far organs like the liver, lung, and brain [8] (Fig. 1).
More recent melanoma models, however, could show that only 26% of all mel-
anoma originate from nevi of which only 43% went through the stage of a dysplas-
tic nevus [9]. Just like in any other neoplastic diseases, individual tumor progression 
steps may be omitted, or the tumor may develop from progenitor cells [10] or tumor- 
initiating stem cells [11].
While malignant melanoma represents only 5% of all skin cancers developed, it 
exhibits the highest mortality due to its very aggressive character, presenting with a 
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sevenfold increase in incidences within the last four decades (Robert Koch Institute). 
Already since 2008, this type of cancer represents the fifth highest tumor entity for 
women and the eighth highest for men [12]. Worldwide, about 160,000 new inci-
dences are being diagnosed per year (World Cancer Report).
2.3  Treatment options for malignant melanoma
2.3.1  Chemotherapy
To date, early diagnosis followed by surgery of malignant melanoma still remains the most 
effective therapy. While 90% of all melanoma are being diagnosed as primary tumors 
without metastatic indications, the 10-year survival rate adds up to 75%–85% [13]. The 
prognosis for patients with distant metastasis is particularly poor with 1-year survival rates 
ranging from 33% to 62% [14], with classical chemotherapy regimens found to confer 
little survival benefit. Until 2011, treatment with the alkylating agent dacarbazine (DTIC) 
was regarded as standard treatment for patients with inoperable metastatic melanoma. 
Up to that point, alternatives had been limited [15]. In several phase III studies, DTIC 
showed objective response rates between 5% and 14%, with a tolerable side effect profile 
but without a clinically significant impact on overall survival. The efficacy and toxicity of 
the alkylating agent temozolomide are comparable with those of DTIC [16]. Various com-
bined chemotherapy regimens have failed to show any survival benefit compared to DTIC 
monochemotherapy [17]. Given their high toxicity and associated impairment of quality 
of life, they may be considered for patients with a high-tumor load or rapid progression 
after failure of other systemic therapies [15,17]. In view of the treatment options currently 
available, it is safe to assume that chemotherapy is to be considered a “last-line therapy.” 
However, after decades of stagnation, recent advances in targeted therapies and immuno-
therapy have considerably improved the prognosis of stage IV melanoma.
2.3.2  Targeted therapy
Doubtlessly, dysregulation of two major mitogen-activated pathways, namely, the 
RAS-RAF-MEK-ERK and the PI3K-AKT-PTEN signaling pathways, presents key 
drivers of melanoma progression, especially when constitutively activating point mu-
tations of the protooncogenes BRAFV600 and NRAS are present [18]. Accordingly, 
the invention of targeted kinase inhibitors promised therapeutic benefit for patients 
suffering from metastatic melanoma. A multitude of clinical trials conducted to this 
point has not achieved significant benefit for patients with metastatic melanoma. In this 
Melanocyte Benign
nevus
Dysplastic
nevus
Melanoma
(RGP)
Melanoma
(VGP)
Metastatic
melanoma
(MM)
Fig. 1 Scheme of melanoma progression. Malignant transformation of primary melanocytes 
from benign or dysplastic nevi is a stepwise process involving the radial growth phase 
(RGP), followed by the vertical growth phase (VGP) finally leading to malignant/metastatic 
melanoma (MM).
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context, a phase III study showed that the BRAFV600E kinase inhibitor vemurafenib 
(Zelboraf) induces major tumor regression in 48% of patients with BRAFV600E-
mutated metastatic melanoma compared with 5% of patients treated with the classical 
chemotherapeutic drug dacarbazine [19]. However, nearly all responses are partial 
with a subpopulation of patients showing primary resistance. Moreover, the acqui-
sition of secondary resistance leading to relapse was observed in the majority of pa-
tients, with a median duration of response of ~7 months [20]. Administration of an 
alternative inhibitor of mutated BRAF, dabrafenib, showed comparable results in a 
phase III study [21].
Occurring in the majority of patients over the course of treatment, development of 
resistance poses a limitation to monotherapy with one of the aforementioned BRAF 
inhibitors. Most resistance mechanisms described to date result in reactivation of the 
MAP kinase signaling pathway [22]. By combining a BRAF and a MEK inhibitor, 
one may expect a delay in the development of resistance and a prolongation of the 
therapeutic response. Indeed, in a recent phase III study, the combined therapy with 
the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib was superior to dab-
rafenib alone, with a response rate of 69% versus 53% and a median overall survival 
of 25.1 months versus 18.7 months [23]. Similar data were obtained with the BRAF 
inhibitor vemurafenib in combination with the MEK inhibitor cobimetinib [24].
2.3.3  Immunotherapy
Immunotherapy strategies for the treatment of melanoma have been used or investi-
gated since a long time (e.g., interferon alpha and interleukin-2). They are based on the 
knowledge that, under certain conditions, the immune system is capable not only of 
controlling and combating tumor cells but also of “accepting” them [25]. Ipilimumab, 
a fully human IgG1 monoclonal antibody, blocks cytotoxic T-lymphocyte-associated 
antigen-4 (CTLA-4), a negative regulator of T-cells, thereby augmenting T-cell ac-
tivation and proliferation. Ipilimumab is the first therapeutic agent that in phase III 
clinical trials has been shown to lead to a significantly longer survival time than in 
control groups when given as a monotherapy or in combination with dacarbazine 
[26,27]. However, the rate of best overall response was only 15.2% in the ipilimumab- 
dacarbazine group and 10.3% in the dacarbazine group. In the analysis of pooled sur-
vival data from phase II and III studies, a plateau in the survival curve was observed 
after 3 years, with a 3-year survival rate of at least 20%–26% [28]. Still, the plateau 
that started at 3 years continued through to 10 years.
Another relevant immune checkpoint involves the programmed death-1 (PD-1) 
signaling pathway. This PD-1 receptor inhibits T-cell activity by interaction with its 
ligands PD-L1 on tumor cells and antigen-presenting cells, resulting in an immunosup-
pressive tumor environment [29]. Therapeutic use of blocking antiPD-1 (nivolumab 
or pembrolizumab) antibodies interrupts this immunosuppression and increases the 
antitumor T-cell response.
In a phase III study, nivolumab versus chemotherapy achieved a response rate of 
40% versus 13.9% and a 1-year survival rate of 72.9% versus 42.1% in patients with 
BRAF wild-type melanoma [27].
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Combined inhibition of PD-1 and CTLA-4 allows inactivated tumor-specific T-cells 
to proliferate and exert their effector functions again. In a phase III trial investigating 
nivolumab and ipilimumab versus nivolumab or ipilimumab alone in patients with 
metastatic melanoma, both response rates and the median progression-free survival 
could significantly be improved in the combination therapy compared to the respec-
tive monotherapies [30]. The combination of nivolumab and ipilimumab is expected 
to achieve a long-lasting response; however, the benefit of this combination strategy 
comes at the expense of a high-level toxicity that results from overall increased im-
mune activity [31,32], and a full cure of the disease is not yet tangible.
It becomes obvious that analysis of the mutation status alone is not sufficient to 
develop the most beneficial therapeutic strategy. In contrast, new fast and reliable 
diagnostic tools are demanded to systematically record and analyze responsiveness 
of individual cancer cells. The vast majority of currently available data on human 
melanoma have been obtained from homogeneous two-dimensional (2D) cultures of 
melanoma cell lines. Tumor cells, however, grow in a three-dimensional (3D) envi-
ronment in which intercellular crosstalk exists between differentiated cancer cell sub-
populations as well as between cancer and nontransformed neighboring host cells. It 
would therefore be desirable to reproduce the 3D context in which melanoma develops 
in a suitable preclinical model [33,34].
3.  In vitro models of melanoma
3.1  Sphere formation assay
Sphere-forming assays have been widely used to retrospectively identify (tumor) stem 
cells and their progeny based on their reported capacity to evaluate self-renewal and 
differentiation at the single-cell level in vitro [35]. The assay essentially tests every 
single cell in the population for its ability to undergo unlimited division thereby taking 
advantage of the fact that tumorigenic cells grow anchorage independently in soft 
agar. A colony is defined to consist of at least 50 cells forming solid microspheres with 
close cell-cell junctions [36]. Traditionally, these types of sphere-forming assay have 
been used since many years to study therapeutic responses, like ionizing radiation or 
chemotherapy survival curves of melanoma cells [37,38]. For this purpose, melanoma 
cells can be treated in vitro or alternatively be isolated from human melanoma xeno-
grafts or patients, and the clonogenic survival and tumorigenic potential can be as-
sessed by evaluating the number and size of colonies formed from an individual tumor 
cell in soft agar [37-40]. More recently, colony formation assays have also been used 
to study the effects of micro RNAs and expression of other tumor stem cell marker 
on melanoma stem cell potential in isolated tumor cells [41,42]. However, sphere for-
mation assays may not exclusively monitor stem cells but may also evaluate the po-
tential of a cell to behave as a stem cell when removed from its in vivo niche. Further 
limitations include medium composition and volume, surface area of the culture dish, 
duration in culture before quantification, and, most importantly, cell density—which 
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may lead to fusion of individual spheres [35]. Above this, sphere formation assays per 
definition focus on (tumor) stem cell behavior and do not capture the holistic compo-
sition of tumor metastasis, being composed of a heterogeneous cell population in vivo. 
Consequently, more accurate cellular 3D models have been developed that better re-
semble the architecture and cellular differentiation of metastasis.
3.2  In vitro homotypic melanoma spheroids
In contrast to cells in 2D, culture cells organized in tissues acquire a specific 3D 
architecture by being embedded into an extracellular matrix (e.g., collagen), which 
serves as a mechanic support and conveys biochemical signals and intracellular com-
munication [43]. This cellular organization influences the physiological properties of 
individual cells, like gene expression, adhesion, migration, invasion, and the therapeu-
tic outcome [44,45]. Multicellular tumor spheroids (MCTS) represent spherical and 
compact cell aggregates, which mimic avascularized tumor nodes, micrometastasis, or 
intercapillary microregions of a solid tumor in vitro [46]. Just like in a native tumor, 
the architecture of tumor spheroids represents with cellular heterogeneity due to a 
differential distribution of oxygen, nutrients, and cellular waste within the organoid 
[45,47]. Hence, a sufficient supply with oxygen and nutrients results in formation of a 
proliferating cell population at the outer rim of the spheroid corresponding to periph-
eral cells within the tumor tissue being located close the vascularization. With increas-
ing distance from the source of oxygen and nutrients and concomitant accumulation 
of cellular debris, a consecutive layer of quiescent cells is constituted, followed by a 
center being composed of necrotic and apoptotic cells, respectively (Fig. 2).
According to the pathophysiological gradient described, similar growth kinetics 
as in solid tumors occur in artificial tumor spheroids, starting with exponential cell 
proliferation in the periphery, followed by a layer of limited and linear proliferation, 
in which resting and dying cell are being generated to form the necrotic center [45,47]. 
Consequently, the size of the tumor spheroid critically determines the analogy to avas-
cularized tumor tissue. While spheroids up to a diameter of 150–200 μm will be suffi-
ciently supplied with nutrients and oxygen via diffusion, only spheroids of >500 μm 
in diameter will present with the diverse cellular layers and the typical necrotic center 
[45,48].
Conventionally, melanoma spheroids can be generated via different methods, while 
all of them require culture conditions under nonadhesive conditions. Different options 
include culturing under rotating conditions (e.g., spinner flasks) and static culturing 
on conic nonadhesive surfaces (e.g., on agarose-coated multiwell dishes) or within a 
“hanging drop” [46,48]. In all cases, gravitational forces cause aggregation of cells in 
regular culture medium, while the number of cells seeded plus the duration of cultur-
ing determines the size and complexity of individual melanoma spheroids in a very 
reproducible way [45]. Particularly for melanoma, an additional criterion determines 
the quality of spheroid formation, namely, the tumor progression stage melanoma 
cells were derived from. Accordingly, melanoma cells derived from the metastatic 
stage (MM) form more solid spheroids than melanoma cells derived from earlier ra-
dial growth phase, being indicative for genetic changes that must have occurred during 
tumor progression (Fig. 3).
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The generation of melanoma spheroids allows a thorough analysis of therapy re-
sponsiveness in vitro. For this purpose, spheroids can be stained for cell death (flu-
orescein isothiocyanate (FITC, green)-coupled annexinV and propidium iodide (PI, 
red)) and analyzed by imaging or flow cytometry. Alternatively, individual cells can 
be recollected by intense trypsinization for further biochemical analysis. Certainly, 
melanoma spheroids can be generated from genetically manipulated cells to specif-
ically study the influence of individual cellular components/molecules on spheroid 
formation, proliferation, and therapy susceptibility.
3.3  In vitro homotypic FUCCI melanoma spheroids
In order to study the specific impact of, for example, cytostatic drugs on melanoma pro-
liferation or the influence of targeted drugs on the cell cycle, FUCCI-melanoma cells 
have been generated that can be analyzed individually or within a spheroid structure, 
as described above [49]. FUCCI-melanoma cells are based on the protocol invented 
for the epithelial cell line HeLa to monitor progression of cells through the different 
cell cycle phases [50]. Cells express an mCherry-fused DNA replication  factor Cdt1 
Proliferating cells
Waste
Oxy
gen
N
utrients
Resting cells
Dying/necrotic cells
N
Fig. 2 Architecture of avascularized metastasis. Insufficient supply of nutrients and oxygen 
causes cell death in the center coinciding with an accumulation of cellular debris. As a 
consequence, only the cells of the periphery show high-proliferation rates, followed by a 
resting cell subpopulation and accordingly a necrotic/apoptotic center.
FDA
PI
Fig. 3 Melanoma spheroids generated via the “hanging drop method.” 250 cells per drop 
are being positioned on the lid of a cell culture dish supplied with PBS. After 10–14 days, 
melanoma spheroids of a diameter of about 500 μm can be harvested. Life/dead staining with 
fluorescein diacetate (FDA, green)/propidium iodide (PI, red) proofs that cells are well and 
alive within these spheroids.
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and mVenus-fused Geminin. These two chimeric proteins accumulate reciprocally 
during the cell cycle, labeling the nuclei of cells in G1 phase red and those of cells in 
S/G2/M phase green. Confocal live-cell imaging of FUCCI-melanoma spheroids can 
be utilized to document the relationship between the cell cycle and melanoma cell 
motility, invasion, and drug sensitivity [51].
3.4  In vitro heterotypic multi cellular melanoma spheroids
Since tumor nodes or micrometastasis in vivo do not exclusively exist of a homoge-
neous melanoma cell population but are surrounded or interspersed with stroma cells 
and endothelial cells [43], the development of heterotypic multicellular spheroids has 
become a particular challenge. On the one hand, a two-step process involves genera-
tion of melanoma microspheres first, which subsequently are exposed to fibroblasts 
or endothelial cells to surround or enclose the tumor (reviewed in [52]). On the other 
hand 2–3 cell types (melanoma cells, fibroblasts, and/or endothelial cells) might be 
incorporated at the same time into one single spheroid, probably reflecting best the 
heterogeneity of tumor metastasis in vivo [53]. Accordingly, melanoma cells, endo-
thelial cells, and/or skin fibroblasts can be mixed at different ratios to generate hetero-
typic multicellular spheroids, for example, in a “hanging drop.” Once the individual 
cell types included have been stained with different cell trackers before aggregation, 
multicolor heterotypic spheroids can be imaged by confocal microscopy (Fig. 4).
Above this, these heterotypic multicellular spheroids can be analyzed for drug sus-
ceptibility, by reisolating the different cell types and subjecting them to flow cytometry 
analysis after identification with selective antibodies. Consequently, heterotypic mul-
ticellular spheroids represent the smallest cellular unit to represent a  heterogeneous 
Endothelial cells
Fibroblasts
Melanoma cells
Fig. 4 Generation of multicellular spheroids. Fibroblasts (green), melanoma cells (blue), and 
endothelial cells (red) were stained with cell tracker and combined within a spheroid via the 
“hanging drop method.” Three days later, spheroids were analyzed by confocal fluorescence 
microscopy.
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tumor tissue including endothelial and stromal cells and may be supportive to under-
stand how infiltration with stroma and vessels may impact on the therapeutic outcome. 
If applicable, the composition of heterotypic spheroids may be altered by substituting 
skin fibroblasts with lung fibroblasts, liver stellate cells or astrocytes to mimic differ-
ent host tissues preferably targeted by melanoma metastasis. By these means, differ-
ences in growth behavior and drug susceptibility can be monitored dependent on the 
organ-specific tumor stroma. Still, these models have to deal with very small entities 
of cells, and an appropriate embedment of the tumor tissue into a respective microen-
vironment is not provided by these minimal models.
As an alternative, organotypic human skin models have been developed that harbor 
melanoma cells, melanoma nests, or melanoma spheroids to better mimic the in vivo 
setting of a primary tumor or primary metastasis embedded into the human skin.
3.5  Organotypic melanoma skin tissue models
Besides predictive tools and alternative treatment concepts, cellular models are man-
datory that best resemble the in vivo situation of human melanoma. Although genet-
ically engineered mouse models for metastatic melanoma have been developed [54], 
they provide only limited insight into mechanisms of development and therapy resis-
tance of the human disease, because mice fundamentally do not develop melanoma. 
This is probably due to the fact that murine melanocytes are located in the hair follicle 
rather than in the epidermal basal cell layer [55] and the skin is tightly populated with 
hair, by both means protecting melanocytes from the adverse effects of UV radiation. 
Accordingly, in vivo animal studies on melanoma are carried out in transgenic mice or 
using xenograft models [56]. Above this, the architecture and the physiology of mu-
rine and human skin differs significantly, comprising only three layers of  keratinocytes 
in the murine compared with 6–10 layers in the human epidermis [57,58]. Also for 
ethical reasons, the reputation of mice models decreases, while the impact of human 
organotypic skin reconstructs increases significantly.
Three-dimensional skin reconstructs (skin equivalents) have proved themselves to 
be very useful as test systems in the investigation of skin cancer, including  melanoma. 
These skin equivalents can close the gap between investigations in different in  vitro 
cell cultures and the in  vivo testing in animal models by reproducing the three- 
dimensional arrangement of epidermal and mesenchymal cells. While solely dermal 
and epidermal skin reconstruction models exist, organotypic full skin equivalents 
best recapitulate a differentiation status homologous to normal human skin [59]. In 
these skin equivalents, primary human keratinocytes, seeded on a dermal layer of 
primary human fibroblasts embedded into a collagen scaffold, stratify from undiffer-
entiated highly proliferative cells located at the base membrane to highly keratinized 
cells in the stratum corneum, thus forming distinct layers of the epidermis as seen 
in normal human skin. As shown in different studies, the close proximity of dermal 
fibroblasts and epidermal keratinocytes stimulates both cell types to form a basal 
membrane [60,61]. Due to cellular adhesion of molecules embedded in the basal 
membrane, the development of a mechanical resilient neodermis during the in  vitro 
culture is possible [62]. These organotypic full skin models can host melanoma cells 
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of different tumor progression stages and are therefore eminently suitable for in-
vestigating physiological and pathological processes of cutaneous melanoma under 
in vivo- mimicking conditions.
For this purpose, melanoma cells can be seeded into the epidermal or dermal part of 
the full skin reconstructs to mimic different stages of the disease, including migration, 
invasion, and tumor nest formation. Regarding the aggressiveness and the invasion 
potential, melanoma cells behave according to their tumor progression stage within 
this organotypic environment, thereby reflecting the clinical relevance of the model 
[58,63]. Cultured cells from RGP melanoma have characteristics of both malignant 
and nonmalignant cells: they are immortal but do not grow anchorage independently 
in soft agar nor are they tumorigenic in mice [64]. In a typical RGP lesion, mela-
noma cells predominantly reside in the epidermis, with little invasion into the dermis. 
RGP primary melanomas are considered metastasis-incompetent, implying that they 
do not invade lymphatics and capillaries [65]. Correspondingly, cells of the RGP re-
side in and distribute exclusively throughout the epidermal part of 3D organotypic 
skin reconstructs [45]. In contrast, melanoma cells from the biologically advanced 
VGP of primary lesions have an infinite lifespan [8] and an early metastatic poten-
tial. Accordingly, individual cells of the vertical growth phase penetrate through the 
basal lamina into the lower dermal part of the skin reconstruct. Finally, cells of the 
metastatic stage (MM) aggressively invade into the dermal part to spontaneously form 
melanoma nests [8] (Fig. 5).
By genetically manipulating melanoma cells prior to insertion, these types of mel-
anoma skin reconstructs offer an opportunity to identify molecular determinants for 
the development of the disease and at the same time support the target identification 
for the treatment of malignant melanoma [66]. Both, dermal and full skin models 
containing dermal nests of metastatic melanoma cells have significantly prompted and 
improved studies on monotherapy and combination therapy for melanoma in a more 
physiological context [67,68]. However, melanoma nests form randomly  showing 
huge variations in number and size, even if the same number of cells has been seeded 
into the skin reconstructs. Also it takes some days for melanoma nests to develop 
under these experimental conditions. Hence, due to the limited life span of skin re-
constructs (~20 days), most studies conducted start with an early treatment thereby 
rather interfering with tumor melanoma nest formation or outgrowth than inducing 
regression of existing tumor nests.
Above this, these metastatic melanoma nests typically consist of only a limited number 
of cells and therefore do not adequately recapitulate the complexity of human melanoma 
metastases. Melanoma nests lack the intratumoral cell heterogeneity and the existence of 
a necrotic center, which both might have an impact on the therapeutic outcome.
In order to improve the increasing requests on new therapeutic alternatives, ethically 
unproblematic yet highly reliable and reproducible ex vivo human-based  screening 
models are demanded that can be validated to translate the findings from basic cellular 
research into clinical applications. To narrow the gap between in vitro and in vivo 
studies, melanoma spheroids have been integrated into full skin reconstructs yielding 
an innovative organotypic skin-melanoma spheroid model that might be more suitable 
for translating new therapeutic approaches into the clinical setting [45].
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3.6  Organotypic melanoma-spheroid skin tissue models
Organotypic skin-melanoma spheroid models harbor precise numbers of mature and 
well-differentiated melanoma spheroids of defined size, which have previously been 
raised by the “hanging drop” method. Thereby the number of cells applied per drop 
plus the duration of culturing can precisely be determined to gain spheroids of highly 
reproducible accuracy and differentiation. Subsequently, the number of spheroids 
inserted into the dermal part of the organotypic skin reconstructs can individually 
be altered depending on the experimental setting yielding a highly reproducible 3D 
model suitable for proper validation. This cell-based model recapitulates both the 3D 
organization and multicellular complexity of an organ/tumor in vivo but at the same 
time accommodates systematic experimental intervention. These organotypic skin- 
melanoma spheroid models—once terminally differentiated—still have a life span 
of about 2–3 weeks that allows extended experimental procedures and therapeutic 
 interventions on existing metastasis-like melanoma spheroids. Embedded into organo-
typic 3D skin reconstructs, melanoma spheroids histologically show high similarity to 
w/o
MMVGP
RGP
Fig. 5 Melanoma progression in an organotypic environment. Melanoma cells derived from 
different tumor progression stages were inserted into organotypic 3D skin reconstructs and their 
characteristic studied in hematoxylin-eosin stained paraffin sections. According to the tumor 
progression stage, cells from RGB remained within the epidermis, individual VGP cells invaded into 
the dermis, while cells from MM formed metastasis-like cell nests in the deeper part of the dermis.
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primary cutaneous human melanoma metastases in vivo, including a similar degree of 
intratumoral melanoma cell differentiation and a necrotic center (Fig. 6).
Upon treatment with combination therapy, drug responsiveness can be evaluated 
immunohistochemically, by staining, for example, paraffin sections with antibod-
ies against selected activated kinases, proteins involved in execution of cell death 
or TUNEL staining for necrotic and apoptotic cell death, respectively. Moreover, all 
cell types can be reisolated from the tissue models following collagenase digestion, 
separated via subsequent cell sorting, and might be subjected to further biochemical 
analysis or quantification. Making use of such techniques at least allows for a semi-
quantitative prediction of therapeutic success.
In the context of melanoma therapy resistance, two molecules have moved into 
the focus of attention, because they had been shown to be upregulated in metastatic 
melanoma. On the one side, JARID1B represents a potential tumor suppressor that in 
normal cells exerts cell cycle control via maintenance of active retinoblastoma protein 
(Rb). Usually, JARID1B gets lost during melanoma development, but a subpopula-
tion of tumor cells regains JARID1B expression resulting in downregulation of the 
cell cycle activity thereby escaping therapeutic effects [69,70]. On the other side, the 
membrane-bound drug efflux transporter ABCB5 was shown to be coexpressed with 
the tumor stem cell marker CD133 [71,72] on a subpopulation of melanoma cells 
derived from patients with advanced melanoma that had acquired therapy resistance 
[73]. Analogous to cutaneous metastasis in vivo, a certain percentage of cells within 
the proliferating cell subpopulation of melanoma spheroids are embedded into skin 
Fig. 6 Organization of melanoma spheroids embedded into organotypic 3D skin reconstructs. 
Melanoma spheroids were embedded into the dermal compartment (collagen matrix 
containing primary human fibroblasts) of full 3D skin reconstructs. H&E stained paraffin 
section reveals the architecture of melanoma spheroids that is homologous to avascularized 
metastasis in vivo, that is, proliferating peripheral population and necrotic center.
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reconstructs, differentiated into JARID1B- and ABCB5-expressing cells [45]. Hence, 
melanoma spheroids may even represent the tumor stem cell subpopulation that is 
supposed to be present in metastasis in vivo and may hinder the therapeutic success. 
The degree of cellular differentiation observed is neither reflected in 2D cell culture 
nor sufficiently addressed in 3D models incorporating tumor nests or smaller spher-
oids. Moreover, melanoma spheroids generated from freshly isolated patient material 
can be generated, or small sections of tumor material can directly be inserted into the 
organotypic skin model for preclinical drug screening. Standardization of this model 
will allow to more reliably predict clinical effectiveness of novel therapeutic regimes 
to be taken to the clinical stage and may further allocate the basis for an individual 
preclinical drug screening tool to pave the way for personalized medicine.
4.  Conclusion
Despite the recent development of novel effective targeted drugs and immune check-
point inhibitors, metastatic melanoma remains a life-threatening disease because 
tumor cells show intrinsic resistance or acquire resistance to targeted therapy and 
immunotherapy, respectively, thereby regaining tumorigenic capacity. Yet, there is a 
high-unmet medical need for new treatment options for patients with metastatic BRAF 
wild-type and BRAF V600 mutant melanoma and for patients who developed resis-
tance to BRAF inhibitors. In addition, alternative treatment options for patients suffer-
ing from NRAS-mutated melanoma need to be identified to offer alternative treatment 
options for patients that fail immunotherapeutic approaches.
This chapter summarizes numerous elegant 3D models that have been developed 
within the last years that are able to better reflect the human disease in vitro (Table 1). 
These cell-based models warrant new insights for a deeper understanding of  intratumoral 
Tissue model type Application Limitations
(3.1) Sphere 
formation assay
– Generated from individual cells
– Tumor stem cell identification
– Melanoma growth and survival
– Studies on therapeutic responses
– Studies on miRNA
– Not limited to tumor stem 
cells
– Heterogeneous composition 
of tumor metastasis is not 
captured
– No microenvironment
– 50–100 cells only
(3.2) In vitro 
homotypic 
melanoma 
spheroids
– Generated from cell population
– Mimic avascularized tumors
– Architecture and physiology 
close to tumor nodes in vivo
– >500 μm in diameter possible
– Vascularization and 
microenvironment missing
– Size limited to <1 mm in 
diameter
Table 1 Summary of applications and limitations of different 
3D melanoma models
Continued
70 Skin Tissue Models
and tumor-host interaction; however, they are not able to satisfactorily  monitor im-
munotherapeutic approaches because insertion of immune cells faces problems with 
histocompatibility. Still, the different innovative 3D melanoma reconstruction models 
introduced here may provide better tools to study molecular mechanisms of tumor 
development and therapy resistance in the future. Each of them allows the in-depth 
Tissue model type Application Limitations
(3.3) In vitro 
homotypic 
FUCCI-melanoma 
spheroids
– Cell cycle-dependent analysis 
of melanoma motility, invasion, 
and drug sensitivity
– Vascularization and 
microenvironment missing
– Size limited to <1 mm in 
diameter
(3.4) In vitro 
heterotypic 
multicellular 
melanoma 
spheroids
– Contains melanoma cells, 
fibroblasts, and endothelial 
cells to better mimic the in vivo 
situation
– Study therapy resistance 
depending on microenvironment
– Separate analysis of drug 
susceptibility after cell sorting
– >500 μm in diameter possible
– Very small entities of 
individual cell types
– No embedment into 
microenvironmental 
scaffold (e.g., collagen)
(3.5) Organotypic 
melanoma skin 
tissue models
– Contains melanoma cells of 
different tumor progression 
stages within a full-thickness 
organotypic skin equivalent
– Mimics melanoma cell behavior 
(migration, invasion, tumor nest 
formation) under physiological 
conditions within the skin
– Drug testing/tumorselectivity
– Standardization as a 
screening model is 
problematic, since tumor 
nest numbers and sizes may 
vary significantly between 
different models
– Tumor nest formation 
takes time; therefore, 
drug application rather 
inhibits tumor formation 
than causing regression of 
existing tumor nodes
– Tumor nests do not reflect 
the complexity of metastasis 
in vivo
– No immune cells present
(3.6) Organotypic 
melanomaspheroid 
skin tissue models 
 
 
 
 
 
– Contains melanoma spheroids 
of defined number and size 
embedded within a full-
thickness organotypic skin 
equivalent
– Mimics avascularized metastasis 
under physiological conditions 
within the skin
– Drug testing/tumorselectivity
– No immune cells present
– Impossible to test drugs 
that interfere with immune 
checkpoints 
 
 
 
 
Table 1 Continued
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investigation of genetically modified melanoma cells to pinpoint genes and proteins 
that may be responsible for treatment failure and drug resistance, respectively. In vitro 
characterization of transcriptomes, proteomes, and miRNomes comparing 2D and 3D 
settings of melanoma cells may help to understand more general changes from 2D mel-
anoma cell culture to 3D in vivo-mimicking conditions, potentially helping to identify 
additional druggable targets. Moreover, utilizing melanoma cells that have previously 
been conditioned to specific drugs over months may be useful to investigate intratu-
moral changes under in vivo-mimicking conditions to study long-term survival of mel-
anoma metastasis in vitro. While the development of novel therapeutic strategies has 
been beneficial for patients suffering from early stage systemic metastatic melanoma, 
patients with stage IV and V metastatic melanoma still have a poor overall survival. 
At these late tumor progression stages, metastasis usually no longer exists exclusively 
within the skin but has spread to more distant parts of the body including the liver, 
lung, and brain [8]. Thus, cross talk with the respective tumor microenvironment—
different from the skin—may additionally alter the therapeutic outcome. Accordingly, 
development of dextran-based 3D matrices incorporating melanoma spheroids em-
bedded into human astrocytes, lung fibroblasts, or liver stellate cells is currently in 
progress and may help to address the influence of different tumor microenvironments. 
For direct preclinical drug screening, embedment of whole melanoma pieces into full 
skin equivalents generated—if possible from primary keratinocytes and fibroblasts 
from the same patient’s skin—would be most powerful and predictive. Conclusively, 
taking human cell-based models into the third dimension in the near future may foster 
the understanding of melanoma development, therapy resistance, tumor relapse, and 
metastatic outgrowth to pave the way to individualized medicine.
Abbreviations
2D two-dimensional
3D three-dimensional;
BCC basal cell carcinoma
CTLA-4 cytotoxic T-lymphocyte-associated antigen-4
DICT chemotherapeutic drug dacarbazine
FDA fluorescein diacetate
FUCCI fluorescence ubiquitin cell cycle indicator
MBM melanoma brain metastasis
MM malignant melanoma or metastatic melanoma
NMSC nonmelanoma skin cancer
PD-1 programmed death-1
PI propidium iodide
RGP radial growth phase
SCC squamous cell carcinoma
TUNEL terminal deoxynucleotidyl transferase dUTP nick end labeling
UV ultraviolet radiation
VGP vertical growth phase
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1. Introduction
1.1  Genodermatoses
The skin that covers and protects us is renewed throughout our lives thanks to complex 
processes of proliferation and differentiation or specialization of its cells, particularly 
those of the epidermis, whose main representative is the keratinocyte. These processes 
can be affected in many ways giving rise to a vastness of dermatologic diseases of 
lower or greater severity and degree of extension. Skin disorders like cancer or pso-
riasis are familiar to the public, but other entities are much less known, but not less 
important. They are infrequent or rare hereditary diseases of the skin, also known as 
genodermatoses. They constitute, as a whole, a relevant part of the pathology and 
dermatologic clinic, accounting for about 8%–10% of the total number of rare dis-
eases estimated in around 7000 [1]. Currently, the genetic basis of more than 500 
genodermatoses, mostly monogenic diseases, has been elucidated. This knowledge 
enables precise disease classification, molecular diagnosis, and, to a certain extent, the 
understanding of the pathogenic mechanism [2]. However, despite this knowledge, in 
the vast majority of cases, there is no curative treatment but essentially palliative. The 
genodermatoses can be broadly grouped in (a) skin fragility disorders, (b) keratini-
zation/cornification, (c) pigmentation disorders, (d) DNA repair, (e) ectodermal dys-
plasias, and (f) connective tissue disorders. Other more gene-oriented classification 
methods have been proposed [3]. Despite editorial-imposed text size limitations and 
the fact that not all genodermatoses have been modeled, this chapter intends to provide 
pertinent examples of studies using in vitro and in vivo models of the most relevant 
inherited skin disorders.
1.2  The importance of modeling genodermatoses
Ethical and practical constraints preclude in  vivo skin studies on human beings, 
more so in patients affected by genodermatoses, some of them devastating diseases. 
Establishing reliable models to address mechanistic matters and to test the efficacy of 
novel therapeutic approaches thus remains as a major research challenge. The  premise 
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of replacing animals (mostly mice) by in vitro and other skin-humanized in vivo mod-
els of disease not only concerns to important ethical issues but also, in the case of 
human skin diseases, pertains to the major differences between organisms. Current 
knowledge about disease mechanisms is mainly due from the use of murine models, 
including transgenic and knockouts. However, based on the significant differences 
existing between human and murine skin architecture and physiology, the question 
remains as to how far the results can be extrapolated to the human scenario. Skin 
organotypic cultures (OTCs) are widely used to examine epidermal gene expression, 
epidermal and dermal interactions, wound repair, and pharmacotoxicological in vitro 
studies [4–6]. However, rare skin disease modeling lags behind other applications. In 
this chapter, we review specific advantages and limitations of current in vitro organo-
typic and humanized models of genodermatoses, with regard to the particular features 
of the diseases modeled (Fig. 1).
Disease
cells
Dermal
matrix
Keratinocytes
Fibroblasts
St. Corneum
Basement
membrane
Extracellular
matrix
Genodermatosis
skin biopsy
Genodermatosis
organotypic culture
Genodermatosis
skin-humanized mouse
Fig. 1 Schematics of genodermatoses modeling through the production of OTCs and skin-
humanized mice. The process starts with the dissociation of a genodermatoses patient skin 
biopsy to obtain keratinocytes and fibroblasts. Cells are combined with the appropriate matrix 
biomaterial to produce a bioengineered 3-D skin, which upon culture at the air-liquid interface 
will be able to induce epidermal stratification. The bioengineered skin without epidermal 
stratification is orthotopically transplanted in the immunodeficient mouse and engraft to 
generate the genodermatoses skin-humanized mouse. The cartoon could well represent 
the modeling of an ichthyosis since the stratum corneum in the biopsy and in the OTC is 
exaggerated.
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2.  Modeling genodermatoses in vitro
Reproducing the normal physiology and architecture of the human skin in durable 
3-D systems remains challenging. This is the subject of other chapters in this book. 
The human skin is a stratified, multilayer epithelium possessing extensive capacity 
for self-renewal and repair. The original studies describing the ability to stratify and 
differentiate of human keratinocytes, when cultured in 3-D at the air-liquid interface, 
noticed that differentiation was highly dependent not only on the exposure to air but 
also on proper interactions of keratinocytes with mesenchymal fibroblasts, as well as 
the dermal matrix and culture media composition [7,8]. Thus, to authentically reca-
pitulate the disease phenotype in three-dimensional organotypic cultures, the specific 
process affected (e.g., epidermal differentiation) should be fully recreated. In other 
words, if for instance a keratinization disorder (e.g., ichthyosis) is to be modeled, it is 
common sense that the control OTC, established with healthy keratinocytes, should be 
able to achieve terminal differentiation including a well-developed stratum corneum 
and barrier function. Unfortunately, this is not always the case as it will be discussed 
along the chapter. Another critical factor for the accurate modeling of skin diseases is 
the composition of the dermal equivalents, which normally is composed of deepider-
malized dermis (DED), polycarbonate membranes, collagen hydrogels, fibrin gels, or 
commercial matrices. Efforts are now being put on the development of more authen-
tic matrices using smart combinations of biodegradable biomaterials and embedded 
fibroblasts. These dermal cells produce natural extracellular matrix components and 
soluble factor that helps to maintain the epidermal homeostasis and the stem-cell niche 
for enduring cultures [9–12]. In Table 1, we summarize some features of the OTCs 
described in this chapter.
2.1  Skin fragility disorders
Adhesion of the epidermis to the underlying dermis is critical for skin function 
and depends on the proper assembly of basement membrane (BM) proteins to 
form specialized interconnected “gluing” structures. The keratinocytes of the 
basal layer of the epidermis are anchored to the dermis through hemidesmosomes 
that together, with the anchoring filaments of the basal lamina and the anchoring 
fibrils of the dermis, form the dermoepidermal junction zone [33]. The hemides-
mosomes are multiprotein complexes that bind to the keratin filaments on their 
cytoplasmic face and to the basal lamina on their extracellular side through the 
anchoring filaments made of laminin 322 and type XVII collagen. The anchoring 
fibrils, composed almost exclusively of collagen type VII, anchor the basal lamina 
to type I collagen in the dermis. The different forms of inherited epidermolysis 
bullosa, that is, simplex, junctional, or dystrophic, are due to the faulty formation 
of these BM structures, in turn owing to a deficient or incorrect synthesis of their 
component proteins [33].
In the 3-D modeling of skin fragility disorders, the need to reconstruct a well- 
developed BM [34] with the proteins synthesized by the cellular components of the 
OTC equivalent is evident. Both epidermal and mesenchymal cells contribute in a 
Genodermatoses OTC composition Major achievements Major limitations Application Reference
Epidermolysis 
bullosa simplex 
(EBS)
KRT5-deficient immortalized 
human keratinocytes grown on 
DED or polycarbonate membrane
Cells stratified and 
differentiated into a 
multilayered epidermis
Did not reproduce a 
cytolytic phenotype
-  To test the therapeutic 
benefits of a chemical 
chaperone for EBS
[13]
KRT5- and KRT14-deficient 
immortalized human keratinocytes 
grown on a collagen-treated 
membrane
Generation of a 
multilayered epidermis
Did not reproduce a 
full EBS phenotype
-  To establish an 
in vitro model for 
EBS with expanded 
lifespan keratinocytes
[14]
Junctional 
epidermolysis 
bullosa (JEB)
LAMB3-transduced keratinocytes 
seeded on DED
Corrected cells showed 
normal assembly of 
hemidesmosomes
Short-term genetic 
correction evaluation
-  To test a gene therapy 
approach for JEB
[15]
Primary β4-integrin null 
keratinocytes grown on DED
Genetic and functional 
correction of β4-null 
keratinocytes
Short-term genetic 
correction evaluation
-  To test a gene therapy 
strategy for JEB
[16]
Recessive 
dystrophic 
epidermolysis 
bullosa (RDEB)
RDEB keratinocytes seeded on a 
normal fibroblast-derived dermal 
matrix
Restoration of Col 7 at the 
DEJ by normal fibroblasts
Anchoring fibril 
formation in OTCs 
requires long time
-  To study if C7 
produced by 
fibroblasts could be 
transported to the DEJ
[17]
COL7A1-transduced keratinocytes 
grown onto collagen-chitosan-
glycosaminoglycan matrices with 
fibroblasts
Corrected cells generated 
a stratified epidermis with 
deposition of C7 at the DEJ
Limited functional 
restoration of the 
dermal-epidermal 
adhesion
-  To test a gene therapy 
for RDEB
[18]
RDEB and non-RDEB cSCC 
keratinocytes grown on fibroblast-
dermal matrix, collagen-matrigel, 
or DED
Col7 deficiency promotes 
cSCC invasion and tumor 
progression
No major limitation 
for the raised objective
-  To study the effect 
of C7 deficiency on 
tumorigenesis and 
CAFs phenotype
[19,20]
Table 1 Review of in vitro OTCs skin models of genodermatoses
Continued
Ichthyosis 
vulgaris (IV)
FLG knockdown human 
keratinocytes grown on a collagen 
I matrix with wild-type fibroblasts
Barrier dysfunction and 
reduced keratohyalin 
granules
The use of healthy 
fibroblast may 
have attenuated the 
phenotype of the 
disease
-  To study the impact 
of filaggrin deficiency 
on the skin barrier 
function
[21]
FLG knockdown human 
keratinocytes grown on a 
polycarbonate membrane
Impaired keratinocytes 
differentiation and 
alterations on epidermal 
barrier function
The absence of a 
dermal matrix may 
precluded the fully 
recapitulation of the 
phenotype
-  To study the impact of 
filaggrin deficiency on 
the keratinocytes
[22]
Autosomal 
recessive 
congenital 
ichthyosis (ARCI)
ALOX12B and TGM1 knockdown 
rat keratinocytes grown on DED
Partial recapitulation of 
the ARCI phenotype with 
identification of common 
gene expression in ARCI
Differences between 
murine and human 
skin may be limited in 
its applicability
-  To identify common 
networks and 
mechanisms associated 
with hyperkeratosis
-  To test new therapy 
approaches
[23,24]
ALOX12B-null mouse 
keratinocytes grown on a collagen 
I matrix with fibroblasts
Abnormal barrier function 
and increased vesicular 
structures in the granular 
layer
The diseased OTC 
seems quite similar to 
the healthy skin and its 
stability declines along 
the first 2 weeks
-  To develop a murine 
OTC ARCI model
[25]
ALOX12B, TGM1, and ALOXE3 
knockdown and deficient human 
keratinocytes grown on a collagen 
I matrix with fibroblasts
Impaired barrier function 
and decrease in filaggrin 
expression
Did not recapitulate 
the thicker stratum 
corneum of ARCI
-  To develop a human 
OTC ARCI model
-  To test some 
penetration assays with 
different nanocarriers
[26,27]
Netherton 
syndrome (NS)
SPINK5 knockdown human 
keratinocytes grown on collagen 
matrix with fibroblasts
Detachment of the stratum 
corneum and the loss of 
corneodesmosomes
The diseased OTC did 
not recapitulate all 
features of NS
-  To test the therapeutic 
benefits of KLK5 and 
KLK7 inhibition in 
NS patients
[28]
Xeroderma 
pigmentosum 
(XP)
XPC keratinocytes grown on 
collagen matrix with XPC 
fibroblasts
Some proliferation and 
differentiation features 
consistent with XP
Abnormal expression 
of some epidermal 
differentiation markers
-  To study invasive 
phenotype of the XP 
cells
-  To test a gene therapy 
approach
[72–74]
Fanconi’s 
anemia(FA)
Immortalized keratinocytes with 
knockdown FA genes (FANCA or 
FANCD)
Recapitulation of DNA 
double-strand break 
sensitivity
Did not recapitulate 
the tumor progression 
phase
-  To study oncogenesis 
in FA patients and its 
relation with HPV in 
cSCC
[29,30]
Ehlers-Danlos 
syndrome (EDS) 
 
 
 
 
 
 
Primary human keratinocytes 
grown onto a 3-D decorin null 
mouse fibroblast matrix
OTC reveal new possible 
mechanisms involved in the 
wound healing of EDS
Abnormal and 
disorganized skin 
architecture
-  To study the impact of 
the decorin absence in 
the dermis
[31]
TNXB-deficient human 
keratinocytes and fibroblasts 
embedded in a collagen matrix 
 
 
The deposition of 
tenascin-X and elastic 
fibers occurs in a similar 
pattern than in normal skin 
 
No obvious phenotypic 
alterations were 
observed neither 
in vitro nor in vivo 
after grafting the OTC 
onto mice
-  To study the potential 
role of tenascin-X in 
extracellular matrix 
biology 
 
[32] 
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dynamic interactive way to the de novo synthesis of the BM protein components that 
need to localize and assemble properly. The majority of studies on the BM protein 
expression and assembly kinetics have been performed on organotypic cultures where 
type I collagen constitutes the dermal matrix (Table 1). In this setting, collagen IV 
and laminin-1 deposition occurred only in the presence of mesenchymal cells: patchy 
at day 4 and continuous after 1 week in after keratinocyte confluence. On the other 
hand, laminin 332 staining was first observed at day 4, in both mono- and cocultures. 
Although BM protein deposition was continuous at day 14, the ultrastructural orga-
nization was still fragmentary, eventually normalizing at 3 weeks [34]. These results 
indicate that the modeling of skin fragility disorders may not be considered valid with 
short-term OTCs. The presence of natural extracellular matrix components, properly 
synthesized by mesenchymal cells in the dermal equivalent, is guaranty of a healthy 
BM and dermoepidermal anchoring structures.
2.1.1  Epidermolysis bullosa simplex
Epidermolysis bullosa simplex (EBS), the first mechanobullous disease for which the 
underlying genetic lesion was characterized, is caused by dominant-negative mutations 
in the keratin 5 (KRT5) and keratin 14 (KRT14) genes [35]. Organotypic cultures were 
also used to study the behavior of immortalized dominant EBS [13,14]. Two immor-
talized cell lines from an EBS patient with a KRT5 mutation were established using 
human papillomavirus (HPV) E6/E7 protein expression and were assessed for growth 
characteristics and keratin expression profiles. Their ability to differentiate in OTCs on 
acellular dermis or polycarbonate membrane was demonstrated, with better results on 
DED. Although the OTCs did not reproduce a clear cytolytic phenotype, the cytoskel-
etal abnormalities, namely, keratin aggregates, were evident particularly in response 
to heat stress [13]. Moreover, these organotypic systems allowed testing the beneficial 
effects of a chemical chaperone [13]. EBS keratinocytes with greatly extended life span 
have also been obtained by ectopic human telomerase reverse transcriptase (hTERT) 
expression, and their differentiation features were studied in OTCs. Upon air-liquid 
interface exposure, hTERT-transduced EBS cells are differentiated into a multilayered 
tissue. However, a blistering phenotype was not described for these cells in OTCs [14]. 
A recessive form of EBS (REBS) has been described in which the keratin intermediate 
filaments are absent, because of homozygous null mutation in the KRT14 gene [36]. 
REBS is characterized by generalized cutaneous blistering in response to mechanical 
trauma, resulting from fragility of the basal keratinocytes. In addition, the program 
of epidermal differentiation is focally disturbed, resulting in exfoliative dyskeratotic 
plaques with histological appearance of epidermolytic hyperkeratosis (EHK) and su-
prabasal keratin clumping. El Ghalbzouri and coworkers developed a faithful OTC 
in vitro model for REBS, which reproduced basal cell vacuolization but not EHK. They 
focused on the role of fibroblasts to modulate the EBS phenotype using chimerical 
OTCs. To that end, fibroblasts from nondyskeratotic and dyskeratotic skin of a REBS 
patient were embedded into collagen matrices. Afterward, fresh biopsies from the non-
dyskeratotic and dyskeratotic skin of the patient were seeded on top and cultured at the 
air-liquid interface. In this case, the OTCs were instrumental to show that fibroblasts 
play a critical role in reproducing the REBS phenotype [37].
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2.1.2  Junctional epidermolysis bullosa
Junctional epidermolysis bullosa (JEB) is caused by deficiency of proteins Col17, 
Lam332, or integrins α6β4, located either in the lamina lucida or in the connecting 
structures of the basement membrane [38]. The severity of the different JEB forms 
ranges from mild to lethal. The only current therapeutic approach of the disease relies 
on gene and cell therapy. In fact, the first skin gene therapy clinical trial was carried out 
for the correction of a severe, not lethal, form of JEB due to a deficiency of Lam332 
using autologous grafts of genetically corrected cultured epidermal sheets [39]. The 
viability of the approach, however, had been tested and confirmed early on in vitro 
with corrected keratinocytes growing on different protein-coated plastic plates and, 
more significantly, with OTCs. In fact, the LAMB3-transduced  keratinocytes seeded 
on DED showed normal assembly of the dermal-epidermal attachment structures 
(hemidesmosomes), missing in uncorrected JEB cells [15]. Analogously, organotypic 
cultures (also on DED) were useful to evaluate the adherence of primary integrin-β4 
null keratinocytes, obtained from a newborn suffering from lethal JEB and stably 
transduced with a retroviral vector carrying a full-length β4 cDNA. The study demon-
strated that integrin α6β4 expression, localization, and structure of hemidesmosome 
components with β4-corrected keratinocytes were indistinguishable from organotypic 
cultures generated with normal keratinocytes, suggesting full genetic and functional 
correction of β4-null keratinocytes [16]. However, in contrast to LAMB3-corrected 
cells, β4-corrected keratinocytes have not been yet tested in the clinics. More recently, 
collagen OTCs were also used to test a protein replacement strategy for the restoration 
of the laminin 332 assembly and reversion of the JEB phenotype. In that study, trans-
fection of recombinant β3 chain in JEB keratinocytes (LAMB3 mutant) was shown to 
restore the formation and functional activity of the trimeric laminin 332. In fact, when 
β3-treated JEB keratinocytes were used in OTCs, laminin 332 was formed, secreted, 
and deposited, although in a patchy manner, into the basement membrane zone (BMZ) 
of the reconstructed skin [40].
In addition to their use as models for JEB therapies, OTCs (on collagen gels) pro-
vided mechanistic insight regarding the assembly of hemidesmosomal adhesion com-
plexes through inhibition of nidogen binding to laminin with a recombinant laminin γ1 
fragment [41]. Thus, using a simplified human skin model, a functional link between 
compound structures of the extra- and intracellular space at the junctional zone was 
demonstrated [41].
2.1.3  Dystrophic epidermolysis bullosa
Dystrophic epidermolysis bullosa (DEB), particularly the recessive form (RDEB), is 
among the most severe epidermolysis bullosa forms and the one that has prompted 
the lead developments with regard to strategies for therapeutic intervention. RDEB is 
due to a deficiency of the anchoring fibril-forming type VII collagen (C7) as a result 
of mutations in the COL7A1 gene [38]. Besides generalized mucocutaneous blis-
tering and scarring, RDEB presents a highly elevated risk of early-onset aggressive 
cutaneous squamous cell carcinoma (cSCC). The majority of advanced therapies 
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under scrutiny, which include protein replacement and several cellular and genetic 
strategies, aim at C7 replacement to restore the dermal- epidermal adhesion. Since 
the formation of ultrastructurally mature anchoring fibrils takes relatively long time, 
upon keratinocyte seeding on fibroblast-populated dermal matrices, standard OTCs 
may not be the best option to study full restoration of C7 functionality. With noncon-
ventional OTCs in which the dermal matrix is produced by fibroblasts growing on a 
nylon mesh [42], it was, however, possible to show that normal fibroblasts are capa-
ble to provide functional C7 to the BMZ of RDEB keratinocytes [17]. These results 
were also confirmed in an in vivo model with corrected RDEB fibroblasts and kera-
tinocytes [17,43]. Nonetheless, rather than showing bona fide established anchoring 
fibrils, skin OTCs have been useful to early detect C7 production and deposition at 
the BMZ by genetically corrected RDEB keratinocytes from different sources. In 
one of these studies, RDEB keratinocytes were transduced with a COL7A1 retroviral 
vector and cultured on  collagen-chitosan-glycosaminoglycan sponges [44] embed-
ded with RDEB fibroblasts [18]. In both cases, genetically corrected cells generated 
cohesive epidermal sheets. More recently, OTCs with keratinocytes derived from 
normal donor or RDEB patient iPSC have been used. Preliminary work had proved 
the feasibility of in vitro skin reconstruction using iPSC-derived fibroblasts and ke-
ratinocytes [45,46]. Later on, OTCs-based approaches were essential to functionally 
demonstrate the genetic correction in keratinocytes derived from RDEB and JEB 
iPSC cells [47,48]. In addition to gene transfer strategies, OTCs have also been in-
strumental to assess the effectiveness of experimental pharmacological approaches 
enabling C7 reexpression in cells carrying particular COL7A1 mutations [49]. In 
several cases, the therapeutic approaches mentioned in this section have already 
been translated to the in vivo preclinical and clinical stages. The robust and reliable 
results obtained with in vitro organotypic systems as testing platforms for therapeu-
tic intervention, mainly gene therapy, have been useful in the launching of in vivo 
studies and predicting clinical outcomes as it has been the case for JEB [39] and 
RDEB [50].
In addition to C7 restoration, other emerging therapeutic alternatives focus on the 
amelioration of the fibrotic and pro-inflammatory extracellular matrix (ECM), due to 
the aberrant behavior of RDEB fibroblast associated to an increased bioavailability 
of TGFβ among other causes not yet fully elucidated [51]. In fact, several studies 
have shown dramatic changes in the dermal microenvironment including increased 
expression of pro-inflammatory cytokines and derangement in expression and post-
translational modification of proteins secreted by RDEB fibroblasts [52,53]. It is thus 
tempting to speculate that OTCs, whose dermal equivalents are produced with RDEB 
fibroblasts secreting their own ECM, will soon become popular to test pharmacolog-
ical and cellular approaches capable to modulate fibrosis and matrix stiffness. While 
the latter application of RDEB OTCs remains potential, their use is increasingly wide-
spread to study carcinogenesis in RDEB. The trauma-exposed, fibrotic areas are prone 
to develop aggressive cSCC, the leading cause of premature death in RDEB [19,38]. 
Using different kinds of OTCs, it has been observed that C7-deficient keratinocytes 
became invasive, a behavior that unambiguously depends on the phenotypic changes 
in RDEB fibroblast and ECM [19,20,54].
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2.2  Keratinization disorders
The genodermatoses classified as disorders of keratinization/cornification (DOC) en-
compass a large heterogeneous group of skin diseases that share an abnormal barrier 
function, leading to increased transepidermal water loss with concomitant compensa-
tory hyperproliferation and epidermal acanthosis [55]. The general unifying term ich-
thyosis comes from the common feature of localized and/or generalized scaling of the 
diseases. Mutations in over 50 genes with very distinct functions have been reported to 
cause ichthyoses. However, despite the diversity in the pathogenesis pathways, all some-
how converge in disrupted barrier function [56]. In brief, epidermal barrier function is 
maintained by the differentiation of keratinocytes as they transit, in their permanent re-
newal cycle, from the innermost stratum basal to the outermost stratum corneum where 
they are ultimately sloughed off as squames. This complex  differentiation program is 
marked by site-specific expression of proteins such as cytoskeletal keratins and, in the 
suprabasal layers, by the expression of cross-linking enzymes like transglutaminase 
and others responsible for the synthesis of components necessary for the generation of 
the lipid barrier (phospholipids, cholesterol, sphingomyelin, and glucosylceramides). 
In 2009, the first ichthyosis consensus conference established an international consen-
sus classification for the DOCs based on pathophysiology, clinical manifestations, and 
mode of inheritance [56]. Several in vitro skin models have been developed for kerati-
nization disorders, including ichthyosis vulgaris [21], autosomal recessive congenital 
ichthyosis [23-27,57-59], epidermolytic ichthyosis [60], Netherton syndrome [28], and 
other forms [61,62]. Most of these models begin with the addition of fibroblasts to type 
I collagen matrix or DED, followed by seeding of keratinocytes and air-liquid interface 
differentiation. The difficult acquisition of biopsies from patients with rare diseases has 
led to the use of alternative ways to mimic the protein deficiency such as shRNA tech-
nology to knock down the expression of genes of interest in keratinocytes derived from 
human [21,26,28,57,62], mouse [25], and rat [23,24]. Other OTCs have used human 
cells from patients [27,61], and in some cases, keratinocytes have been immortalized to 
overcome the senescence of primary cells [60].
2.2.1  Ichthyosis vulgaris
The ichthyosis vulgaris (IV) is the most common form of DOC, related with loss-of-
function mutations in FLG gene. The profilaggrin/filaggrin protein encoded by this 
gene is a filament-associated protein that binds to keratin fibers and plays an important 
role as natural moisturizing factor in the formation of the stratum corneum, affecting 
the barrier function and the pH balance of the skin [63,64].
A filaggrin-deficient human organotypic skin model mimics some part of the de-
fects observed in IV patients, despite it does not recapitulate the thicker stratum cor-
neum seen in patients. The model presented barrier dysfunction, reduced keratohyalin 
granules, and decreased amounts of urocanic acid. Also the model showed increased 
UV sensitivity, evidencing the role of filaggrin in the UVB protection [21]. Similar 
results were observed in other OTCs, produced with filaggrin knockdown human ke-
ratinocytes grown on a polycarbonate membrane. In contrast to the one described by 
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Mildner and coworkers [21], this OTC displayed additional abnormalities in the epi-
dermal differentiation program [22]. The differences between these two models were 
attributed by the fact that one of the equivalents used normal fibroblast embedded 
in a collagen hydrogel as dermal matrix while the second did not include a dermal 
component. There is some evidence that the use of healthy fibroblast ameliorates the 
phenotype of diseased skin [17,65,66] and improves the regeneration and morphol-
ogy of epidermal tissue in 3-D cultures [10,12]. This and additional evidence from 
other models underscore the importance of using diseased-like fibroblast to create an 
equivalent that resembles the histogenesis of the skin and the disease phenotype. It 
is important to keep in mind that a useful organotypic model needs to be maintained 
for a long period and that the presence of an authentic dermal matrix is considered 
essential for this.
2.2.2  Autosomal recessive congenital ichthyosis
Autosomal recessive congenital ichthyosis (ARCI) is a group of nonsyndromic forms 
of ichthyosis, related to hyperkeratosis and skin barrier dysfunction. These disorders 
include harlequin ichthyosis (HI), lamellar ichthyosis (LI), congenital ichthyosiform 
erythroderma (CIE), and other minor variants. At least six genes have been associated 
with ARCI: ABCA12, TGM1, NIPAL4, ALOX12B, ALOXE3, and CYP4F22 [56]. The 
gene most commonly mutated in ARCI is TGM1, which encodes transglutaminase-1, an 
essential enzyme in the formation of the cornified envelope by cross-linking structural 
proteins such as involucrin, loricrin, and filaggrin [67]. Mutations in ALOX12B and 
ALOXE3, encoding the lipoxygenases, are the second most common cause of ARCI.
An in  vitro rat OTC containing knockdown TGM1 gene reproduced part of the 
disease and presented hyperkeratosis, hyperproliferation, and an increase in nonpolar 
lipids of the stratum corneum. Also, the model showed a defective cross-linking of 
loricrin and upregulation of interleukin-1 alpha (IL1A), as observed in LI patients. 
Treatment of these organotypic equivalents with an IL-receptor antagonist (IL1RA) 
prevented the hyperkeratosis showing improvement of the LI phenotype [23].
In addition, to identify common networks in ARCI disorders and to find new target 
drugs, another rat organotypic model was developed using shRNA knockdown for 
ALOX12B. The comparison of the common networks between altered genes of the 
TGM1 and ALOX12B models demonstrated a new critical pathway in hyperkeratosis 
leading to the repositioning of Mdm2 inhibitors, such as nutlin-3, as a new therapy 
approach for treating ARCI [24].
Another OTC for ARCI was developed from keratinocytes isolated from ALOX12B-
deficient newborn mice. The equivalent presented an epithelial architecture similar to that 
observed in vivo. The skin equivalents deficient in ALOX12B showed abnormal skin barrier 
function and increased vesicular structures in the granular layer. However, the phenotype 
of the diseased skin model rather resembled that of healthy skin and did not recapitulate 
hyperkeratosis, as the main feature of the disease. The epithelial architecture and stability 
of the OTCs declined when the cultures were prolonged for more than 2 weeks [25].
Human OTCs with keratinocytes were also developed for ALOX12B, TGM1, and 
ALOXE3 using gene expression knockdown with specific shRNAs. These models did 
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not recapitulate the thicker stratum corneum of ARCI, but showed an impaired barrier 
function and decrease in filaggrin expression [26]. These models were subsequently 
used to perform penetration and permeation assays of different nanocarriers, as a po-
tential approach for the topical treatment of ARCI. In this study, some OTCs were also 
developed with patient-derived primary cells [27]. We have recently developed a robust 
skin OTC for LI, containing TGM1-deficient human keratinocytes and fibroblasts. This 
model, which uses keratinocytes seeded onto a fibroblast-containing fibrin dermal ma-
trix, fairly recapitulates the major features of this ARCI, including a packed and faulty 
stratum corneum (Fig. 2) (Larcher and Chacón-Solano, unpublished results).
2.2.3  Netherton syndrome
Netherton syndrome (NS) is a syndromic form of inherited ichthyosis caused by loss-
of-function mutations in SPINK5 encoding lympho-epithelial Kazal-type  inhibitor 
(LEKTI), a serine protease inhibitor expressed in the epidermis and other stratified 
epithelia. Clinically, this genodermatosis presents severe skin inflammation and 
scaling, specific hair shaft defect, and constant allergic manifestations, although the 
symptoms and severity of NS can vary from one patient to another. Lethal variants of 
the disease have also been described [68]. LEKTI deficiency results in exacerbated 
activity of proteases such as kallikreins 5, 7, and 14 (KLK5, KLK7, and KLK14), 
which consequently produce increased corneodesmosomal degradation and desqua-
mation [69].
A SPINK5 knockdown organotypic human model recapitulated part of the NS 
phenotype, especially by the detachment of the parakeratotic stratum corneum and 
the loss of corneodesmosomes. Furthermore, the simultaneous silencing of KLK5 and 
KLK7 in this LEKTI-deficient model led to a partial improvement of the skin archi-
tecture. This OTC was therefore useful to confirm the potential therapeutic benefits of 
the inhibition of serine proteases in NS patients [28].
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Fig. 2 Recapitulation of skin disease phenotype in vitro and in vivo. The figure shows the 
modeling of lamellar ichthyosis (LI), characterized by a thick stratum corneum (SC). The 
OTC is cultured at air-liquid interface to induce differentiation or is orthotopically transplanted 
onto the immunodeficient mouse. Both models present normal skin architecture, with a fully 
stratified epidermis, and faithfully reproduce the hyperkeratotic disease phenotype.
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2.3  Disorders of pigmentation
The major inherited disorder characterized by the complete or partial absence of pig-
ment in the skin, hair, and eyes is albinism. In the majority of cases, this genodermatosis 
is due to a defect or an absence of tyrosinase, a critical enzyme expressed in melanocytes 
involved in the production of the human skin pigment melanin. The severe deficit of 
skin pigmentation in albinism makes individuals to be more susceptibility to sunburn 
and skin cancers. Although a careful review of the literature has not retrieved studies 
involving skin OTCs constructed with tyrosinase-deficient cells, there are several studies 
where OTCs are produced not only with keratinocytes but also with normal epidermal 
melanocytes in order to modulate the pigmentation and the concomitant responses to 
UV light [70].
2.4  DNA repair disorders
2.4.1  Xeroderma pigmentosum
The paradigm of genodermatoses involving of DNA repair disorders is xeroderma 
pigmentosum (XP), a rare autosomal recessive genetic disorder characterized by a 
deficient ability to repair DNA damage caused by UV light. Consequently, XP patients 
have an extremely high susceptibility to develop skin cancer. Skin malignancies occur 
at a young age, being metastatic malignant melanoma and cSCC, the two most com-
mon causes of death in XP patients. The absorption of the UV light leads to DNA dam-
age in the form of cyclobutane pyrimidine dimers and pyrimidine(6–4)pyrimidone 
photoproducts. In a healthy, normal human being, DNA damage is repaired by a pro-
cess known as nucleotide excision repair (NER). In XP, mutation in one of the repair 
enzyme genes (XPA-XPG and XPV) leads to a deficit of NER. If left unchecked, DNA 
damage caused by UV light causes mutations in cancer-relevant genes. Some forms 
of XP are associated with neurological abnormalities whose cause remains poorly 
understood, but are not connected with exposure to UV light [71]. Bernerd and co-
workers developed an OTC model of the disease through the culture of several strains 
of primary XP keratinocytes and XP fibroblasts embedded in a collagen matrix. In 
this setting, some proliferation and differentiation features consistent with XP disease 
were found [72]. This model system was also used to study the invasive phenotype of 
the XP cells related to their cancer predisposition [73] and also to assess the efficacy 
of a gene therapy strategy for xeroderma pigmentosum C (XPC) [74].
2.4.2  Fanconi anemia
Fanconi’s anemia (FA) is an inherited disease mainly characterized by congenital 
abnormalities, progressive bone marrow failure, and an increased predisposition to 
cancer. In FA patients, hematologic problems typically appear between ages of 5 
and 10 years with an actuarial risk of bone marrow failure above 90% by 40 years 
of age. FA patients also have a high risk of developing solid tumors, principally 
cSCCs. FA is due to a deficiency of enzymes involved in the recombinational repair 
of DNA double-strand damage. So far, 21 different genes have been implicated 
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in FA [75]. While studies of hematopoietic cells derived from FA patients have 
provided insight into bone marrow failure and leukemogenesis, oncogenic events 
in FA-deficient keratinocytes, the cell type of origin of cSCC, are much less under-
stood. Using skin OTCs containing HPV E6/E7-immortalized keratinocytes with 
knockdown FA genes FANCA or FANCD, Hoskins and coworkers showed the pre-
dicted but not previously described DNA repair defects and apoptosis in FA kerati-
nocytes upon mitomycin C treatment [29]. Also, hyperplasia due to increased basal 
and suprabasal cell proliferation was shown, although not observed in 2-D culture. 
The hyperplastic phenotype shown in the FA-reconstructed epithelium of the OTC 
model might thus represent a clinically relevant precursor of cSCC. Studies using 
a similar FA OTC setting showed that FA pathway downregulation increased HPV 
genome amplification in the epithelia, indicating that the HPV life cycle is attenu-
ated by the intact FA pathway [30], a relevant finding with regard to HPV-related 
cSCC development in FA patients.
2.5  Ectodermal dysplasias
The ectodermal dysplasias (ED) comprise a heterogeneous group of genodermato-
ses that affect the development of the ectoderm, the embryonic layer that forms the 
skin and its attachments (hair, nails, teeth, and sweat glands). The most frequent ED 
is hypohidrotic ectodermal dysplasia (HED), characterized by hypotrichosis, hypohi-
drosis, and hypodontia. Clinical manifestations in ED will depend on the involvement 
of different ectodermal derivatives. The most frequent HED is the X-linked recessive 
form due to mutations in the EDA gene, which encodes ectodysplasin, a member of 
the tumor necrosis factor (TNF) family. Mutations in the EDAR gene, encoding the 
EDA receptor, or in the EDARADD gene encoding the domain associated with EDAR, 
cause autosomal dominant and recessive forms of HED. Recently, HED patients with 
mutations in the WNT10A, TRAF6, and other genes have also been identified [76]. 
Another rare autosomal dominant ED is ectrodactyly-ectodermal dysplasia-cleft syn-
drome (EEC) characterized by the triad of ectrodactyly, ectodermal dysplasia, and 
facial clefts. EEC is caused by heterozygous mutations in the TP63 gene coding for 
transcription factor p63, a master gene for the commitment of ectodermal-derived 
tissues [76].
OTCs were used to study different aspects of EEC. By introducing various EEC-
causing TP63 mutations in human keratinocytes with retroviral vectors, Zarnegar 
and coworkers were able to disrupt epidermal differentiation and characterized a 
series of alterations in critical transcriptional activators of epidermal differentiation 
such as HOPX, GRHL3, KLF4, PRDM1, and ZNF750, shedding light on the mech-
anisms of these complex genodermatoses [77]. In another therapy-oriented study, 
naturally revertant oral mucosal epithelial stem cells from a patient with EEC, car-
rying a heterozygous R311K-p63 mutation, were isolated, and their capacity to 
differentiate was tested in OTC. The study showed that revertant EEC stem cells 
were able to generate a well-organized and stratified epithelium, lending support to 
a cell therapy strategy to counteract and resolve the progressive corneal degener-
ation due to a premature aging of limbal epithelial stem cells, the characteristic of 
this genodermatoses [78].
Organotypic and humanized animal models of genodermatoses 91
2.6  Connective tissue disorders
Connective tissue disorders comprise a large family of genodermatoses with genetic 
defects affecting any of the constitutive molecules of the connective tissue, including 
collagen, elastin, fibrillin, fibulin, and proteins that modify these component elements 
(e.g., metalloproteinases and lysyl hydroxylase 3). Collagen, the major connective 
tissue component, is not a single protein but a family of related proteins comprising at 
least 19 members identified to date, being dermal collagen type I the most abundant. 
The constituent strands of the known collagens are encoded by 30 different genes, dis-
persed in the human genome. Alterations in either specific collagen genes or enzymes 
involved in their synthesis give rise to various genetic diseases of collagen [79].
2.6.1  Ehlers-Danlos syndrome
Under this syndrome, various hereditary diseases exist, including some of  autosomal 
dominant or autosomal recessive inheritance, and others linked to the X chromosome, 
whose common pathogenic base is an alteration in collagen biosynthesis and whose 
clinical characteristics consist in hyperextensibility. Once divided into 11 different 
types defined by different clinical manifestations, inheritance patterns, and genetic 
loci, Ehlers-Danlos syndrome (EDS) is now classified into 6 types, with 3 types re-
ceiving the most attention in both research and clinical practice: classical EDS, hy-
permobile EDS, and vascular EDS [80]. The genes associated with EDS include 
collagen genes like COL1A1, COL1A2, COL3A1, COL5A1, and other genes including 
ADAMTS2, PLOD1, and TNXB, which code for proteins that process or interact with 
collagen [81]. There are also mutations described in genes coding for enzymes in-
volved in the posttranslational modifications of proteoglycans. For example, mutation 
in the gene B4GALT7, an enzyme involved in the synthesis of the linkage region of 
glycosaminoglycan (GAGs), leads to an EDS with skin fragility and wound healing 
deficiency. Notably, the fibroblasts from the affected patients display defective bio-
synthesis of decorin that in turn leads to abnormal fibrillar collagen [82,83].
Using an OTC system of keratinocytes grown on the top of fibroblasts embedded in 
their own matrix in the presence of abnormal GAGs, it has been shown that a decorin- 
deficient matrix caused a delay in epidermal differentiation. This provides an explana-
tion for the established defects in wound healing observed in some EDS patients [31]. 
The tenascin X-deficient form of EDS, due to TNXB mutation, was also investigated 
using OTC and in vivo after OTC grafting to immunodeficient mice. In this case, when 
the OTC dermal equivalent was made with tenascin-deficient fibroblasts embedded in 
a collagen matrix, no obvious phenotypic abnormalities were found in vitro or in vivo, 
although the system showed potential to study the role of tenascin-X in dermal matrix 
assembly and stability [32]. No studies have been reported, however, with OTCs popu-
lated by fibroblasts from patients with the most common forms of EDS.
3.  Modeling genodermatoses in vivo
Grafting of whole human skin to immunodeficient mice provides the ultimate and 
closer model to the patient/donor cutaneous situation. However, availability of the 
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human skin is very limited, particularly from rare skin diseases. Therefore, engraft-
ment of readily available bioengineered skin, which includes epidermal and dermal 
cells and authentic dermal matrices, represents an excellent alternative to skin bi-
opsy grafting. We review here, with some exceptions, the studies carried out by the 
authors.
3.1  The skin-humanized mouse model
Even though skin OTCs have been growing in complexity through the introduc-
tion of various cutaneous cell types, soluble mediators, and different matrix/scaffold 
materials, the in  vitro approaches are frequently insufficient to recreate complex 
dermatologic conditions. One of the major drawbacks of OTCs, related to the patho-
logical scenarios, is their inability to recapitulate regenerative processes involving 
repeated cycles of epidermal proliferation and differentiation. In other words, OTCs 
are not particularly suitable to assess the epidermal stem-cell performance during 
tissue  renewal. In fact, the majority of current skin OTCs do not even match a single 
native skin epidermal turnover cycle lasting at least 4 weeks. Other important short-
comings of OTCs relate to their isolation from environmental cues and the lack of 
interaction with the other tissues. Hence, modeling skin diseases such as genoder-
matoses, especially with the purpose of testing long-lasting therapeutic approaches, 
such as gene therapy, require accurate in vivo systems. As mentioned at the begin-
ning of the chapter, murine disease models often fail in the trustful recapitulation 
of the human condition. Thus, bioengineering-based skin-humanized mouse models 
seem to mirror the pathophysiological characteristics of human dermatologic dis-
orders. These platform models are based on the engraftment of human skin OTCs 
in immunodeficient mice. Our group has been working on a fibroblast-containing 
fibrin-based dermal matrix, where human keratinocytes are seeded [84]. In this sys-
tem, patient fibroblasts are embedded in a fibrinogen solution that is allowed to clot 
by the addition of thrombin or calcium ions, depending if fibrinogen is provided as 
a raw material or contained in plasma. The resulting fibrin hydrogel containing live 
fibroblasts is seeded with human keratinocytes that have been previously grown us-
ing the Rheinwald and green culture method [85]. When keratinocytes on top of the 
fibrin dermal equivalent reach confluence, the OTC is manually detached from the 
culture flask or plate and is ready for grafting (Fig. 2).
We have demonstrated that this fibrin-based dermal equivalent provides excel-
lent human keratinocyte growth support without the need of feeder layer cells [86]. 
Upon engraftment, a mature skin with human architecture was shown to persist for 
a large number of epidermal turnover cycles, as demonstrated during long-term 
follow-up periods in immunodeficient mice or in burn patients (autologous OTC) 
[84]. Experiments with single genetically marked epidermal stem-cell clones, as 
the keratinocyte component of the grafted fibrin-based OTCs, demonstrated endur-
ing regenerative properties of epidermal stem cells in vivo [87,88] including those 
from RDEB patients [89].
One of the main advantages of this method is the possibility to generate a large 
number of engrafted mice containing a significant area of homogeneous single 
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 donor-derived human skin, available in a relatively short period of time. Using skin 
cells isolated from patient biopsies, we and others have been able to reconstruct skin 
disorders including several rare human monogenic skin diseases (Table 2).
3.1.1  Epidermolysis bullosa
We and others have used graftable fibrin-based OTCs to generate RDEB skin- 
humanized mice, where it was possible to demonstrate the efficacy of an ex vivo gene 
therapy strategy that corrected RDEB keratinocytes [18,89] or both RDEB keratino-
cytes and fibroblasts [92]. The same kind of engrafted OTCs has been recently used to 
demonstrate the value of a COL7A1 exon skipping approach in vivo [93]. Using a JEB 
skin-humanized model, we demonstrated the accurate basal cell expression achieved 
with a lentiviral vector encoding LAMB3 cDNA under the control of the KRT14 gene 
regulatory sequences [90] for gene therapy. More recently, we could show that, upon 
engraftment, skin OTCs populated with COL17A1 revertant JEB human keratinocytes 
could regenerate a clinically normal skin, paving the way to a clinic application of 
natural ex vivo gene therapy strategies [91].
3.1.2  Keratinization disorders
Our skin-humanized mouse platform has been widely used for the modeling of 
genodermatoses with altered keratinization. Using sole keratinocytes from a patient 
with pachyonychia congenita (PC), a dominant inherited disease due to mutations in 
either KRT6, KRT16, or KRT17 coding genes, we were able to recapitulate in vivo 
the keratoderma and suprabasal blistering of this disease [94]. We could also show 
that the inclusion of PC fibroblasts in the graftable OTCs enhanced the disease 
phenotype upon engraftment (Larcher, unpublished results). Similarly, the engraft-
ment of OTCs prepared with NS keratinocytes allowed a faithful recreation of the 
disease and asserted the efficacy of a SPINK5 lentiviral gene therapy approach 
[95], now in the clinics [96]. Also, we established an ARCI (LI) skin- humanized 
model that mirrored the disease in humans with regard to defective barrier function 
and hyperkeratosis (Fig. 2), allowing a better characterization of the alterations in 
the expression of epidermal differentiation markers through a proteomic approach 
[97]. Using this LI model, we were able to preclinically assess a novel transgluta-
minase replacement approach that efficaciously restored barrier function and skin 
architecture [98].
3.1.3  DNA repair disorders: Xeroderma pigmentosum
In studies aimed to investigate the response to UV light under low and high sen-
sitivity skin settings, we developed a skin-humanized model for the cancer-prone 
disease XPC that fairly recapitulated the DNA-damage-induced skin responses 
seen in XPC patients [99]. The model was subsequently used to prove the value 
of a gene therapy approach based on the transfer of the XPC gene to human kera-
tinocytes [100].
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Table 2 Review of different skin-humanized mouse models of 
genodermatoses
Genodermatoses Characteristics Applications Reference
Junctional 
epidermolysis 
bullosa (JEB, 
LAMB3)
Unable to detect blistered 
regenerated JEB skin due 
to slough off of epidermis. 
Gene (LAMB3)-corrected 
keratinocytes were 
capable of normal skin 
regeneration
-  To test a lentiviral 
gene therapy 
approach that directs 
the expression of 
laminin β-3 to the 
basal cells of the 
epidermis
[90]
Junctional 
epidermolysis 
bullosa (JEB, 
COL17A1)
Revertant CO17A1 cells 
showed regeneration of a 
normal epidermis
-  To test a natural gene 
therapy approach 
using revertant 
COL17A1 human 
keratinocytes
[91]
Recessive 
dystrophic 
epidermolysis 
bullosa (RDEB)
Recapitulates general 
blistering caused by 
COL7A1 deficiency
-  To test different gene 
therapy strategies and 
establish translational 
research toward long-
term treatments of 
RDEB
[18,89,92,93]
Pachyonychia 
congenita (PC)
Full recapitulation of the 
PC phenotype: marked 
acanthosis and suprabasal 
epidermal blistering after 
minor trauma
-  To test novel 
pharmacological or 
gene-based therapies 
for PC
[94]
Netherton 
syndrome (NS)
Recapitulates NS features: 
marked hyperplasia, 
hypogranulation, and the 
loss of stratum corneum
-  To test different long-
term gene therapy 
approaches for NS
[95,96]
Lamellar 
ichthyosis (LI)
Recapitulates full LI 
phenotype: hyperkeratosis 
and severely decreased 
barrier function
-  To test novel protein 
(transglutaminase I) 
replacement strategies
[97,98]
Xeroderma 
pigmentosum 
(XPC)
Recapitulates XPC 
features: severe 
deficiency in DNA repair 
mechanisms. Maintenance 
of sunburn cells and 
pyrimidine dimers after 
UVB irradiation
-  To provide a UV 
hypersensitive skin 
model
-  To test gene therapy 
strategies
[99,100]
Cutaneous 
scleroderma 
(cSC) 
 
Marked fibrosis of 
the dermis induced by 
patient anti-PDGFR 
autoantibodies 
-  To study pathogenic 
mechanisms
-  To test the effect of 
cSC patient IgGs 
against PDGFR
[101] 
 
 
 
All the models summarized were generated using the methodology developed by the authors.
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3.1.4  Scleroderma
Although not cataloged as a connective tissue genodermatoses given its frequency 
and cause, cutaneous scleroderma is a rare disorder that results in hardening of the 
skin due to increased synthesis of collagen. Using a skin-humanized mouse model, 
we could demonstrate that anti-PDGF receptor (PDGFR) autoantibodies present in 
patients were able to induce a scleroderma-like phenotype in the human skin en-
grafted in the mouse, providing an explanation for the pathogenesis of this serious 
disease [101].
4.  Conclusions
Three-dimensional human OTCs and in vivo humanized skin mouse systems repre-
sent robust biological tools to mimic a wide range of cutaneous conditions, includ-
ing many inherited skin disorders. OTCs provide versatility with regard to cellular, 
matrix, and media components. Their value also lies in the fact that large quantities 
can be made suitable for multiassay settings without the ethical issues of animal 
experimentation. Major improvements have being achieved concerning duration, 
stability, and faithful recreation of certain skin pathology features with OTCs. The 
shortcomings of the in vitro 3-D cultures are evident, when the experimental ap-
proach (e.g., gene therapy) challenges epidermal stem-cell regenerative capability. 
Matrix and basement membrane remodeling are also long-term processes diffi-
cult to recreate using an in vitro setting. Therefore, enduring processes need to be 
addressed in  vivo. The skin- humanized mouse models thus represent a fantastic 
platform to cope with that challenge, in the intense search for curative treatments 
for genodermatoses. We greatly rely on these models as trustworthy predictors of 
clinical responses. In fact, the results obtained with these models have led to cur-
rent gene therapy trials on patients as in RDEB, JEB, and NS. With the advent of 
novel gene-editing strategies suitable for the treatment of many monogenic skin 
diseases, it is expected that the OTCs and skin-humanized mice herein introduced 
and many new ones will be pivotal to assess the efficacy and safety of these coming 
therapeutic approaches. Important advances may come from the new developments 
in the field of biomaterials and from the understanding of morphogenic interactions 
between epidermal and mesenchymal cells. It is foreseeable that, by including ad-
ditional cell types, perfected matrix components, and coadjuvant factors, OTCs 
will be ready to match current in vivo models.
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This chapter presents an overview of psoriasis, the latest developments in the multi-
disciplinary field of tissue engineering, and psoriatic in vitro models that have been 
developed. An emphasis is made on psoriatic substitutes produced according to a 
self-assembly approach, which maintained many characteristics of the disease includ-
ing the presence of a disorganized and thicker epidermis compared with normal skin 
substitutes. This self-assembly approach allows the understanding of pathological skin 
complexity through the possibility of [1] dissecting step by step the mechanisms of 
skin pathologies according to which kind of cells is present in the model at this time 
and/or [2] using various cell combinations. Unlike animal models, alternative in vitro 
models offer the opportunity to add, at the same time or successively, one or more 
components to assess their role in the disease. Section 4 of this chapter addresses the 
role of immune and endothelial cells in psoriasis. Moreover, lipidomic studies and 
transcriptomic characterization are also discussed. Finally, sections on the pharma-
ceutical screening of new antipsoriatic drugs and the metabolic capabilities of the 
model are presented. Reconstructed artificial skin substitutes mimic in the best way 
the native physiological context and represent sophisticated important tools for basic 
and applied skin research.
1.  Psoriasis
Psoriasis is an immune-mediated, genetic skin, and joint disorder affecting both men 
and women likewise [1,2]. An estimated 2%–3% of the world population suffers from 
this dermatosis, and of those, about 20 million are affected by the moderate or severe 
forms [3]. Therefore, psoriasis is probably the most prevalent immune-mediated skin 
disease in adults [4]. The specific pathogenesis of psoriasis is not yet fully under-
stood, but the underlying mechanism seems to involve an interplay between genetic, 
immunologic, and environmental factors, all playing important roles in the onset of 
psoriasis [5,6]. This pathology is characterized by the formation of sharply demar-
cated red raised plaques that may occasionally show a silvery white appearance and 
are further covered with thick scales [7,8]. Certain body regions are more likely to be 
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affected, as is the case for the elbows, knees, and scalp [9]. In fact, plaque formation 
occurs mainly at sites undergoing intensive mechanical stress [2]. Increased kerati-
nocyte proliferation leading to the thickening of the epidermis, an extensively altered 
differentiation process, the development of epidermal rete ridges forming long and 
thin downward projections into the dermis, and a greatly reduced or absent granular 
layer are all characteristics of psoriasis. All of these factors combine to yield a highly 
perturbed stratum corneum and, thus, impaired permeability function [4,10–12]. This 
break in the permeability barrier is also due to the psoriatic corneocytes’ failure to se-
crete extracellular lipids allowing these cells to adhere to one another [4,13]. Previous 
studies have also demonstrated alterations in lipid metabolism of psoriatic stratum 
corneum [14,15]. Other defining features of psoriasis include the presence of neu-
trophils within the stratum corneum, leukocytic infiltration into both the dermis and 
epidermis, along with marked angiogenesis and dilation of blood vessels causing the 
reddish aspect of psoriatic lesions [4]. This disorder may be found in several subtypes, 
such as guttate, pustular, inverse, erythrodermic, and plaque, the latter being the most 
common, accounting for about 90% of cases [2,16]. Psoriasis is currently incurable, 
although some treatments have shown worthwhile disease remission [17–22]. In fact, 
some treatments can revert back to symptomless or visibly healthy skin, with little or 
no trace of preexisting disease activity [23]. On the other hand, a large number of pa-
tients must live with consequently induced aftereffects, such as immunosuppression, 
since immunosuppressants still are widely prescribed for severe psoriasis cases, and 
secondly, some patients are simply unresponsive to current therapies [24].
2.  Tissue engineering
Tissue engineering is an interdisciplinary field that brings together cell knowledge and 
engineering coupled with biochemical cues toward the development of biological sub-
stitutes in order to repair, replace, or regenerate tissues and their function [25]. Cells 
and various artificial or natural matrices are combined in such a manner as to obtain 
tissue mimics for transplants up to pharmaceutical models [26]. It’s in the 1980s that 
the interest for tissue engineering and biomaterials really took off, thereby resolutely 
opening a new chapter in regenerative biomedicine [26]. First great efforts in this 
field have been made in skin research, and this was motivated by the acute need of 
solutions to help impaired burn patients in dire need of grafts. Indeed, this technique 
represents a pragmatic alternative where extensive wounds can neither pull through by 
themselves nor be satisfyingly cured or subdued using conventional techniques such 
as autografts or cadaveric transplantation. Assuredly, these approaches have saved and 
improved countless lives, but they remain imperfect solutions [25]. In addition, tissue 
engineering happens to be a thriving area in virtually every human tissue research for 
surgery-related application just as much as fundamental experiments or pharmaceuti-
cal assessments [27,28]. In this regard, tissue-engineered skin provides insights into 
the behavior of healthy and lesional skin cells [29]. It’s an inestimable addition for 
pharmaceutical research purposes, providing models where research is hindered by 
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the lack of naturally occurring disorders in laboratory animals that mimic the complex 
phenotype and pathogenesis of human diseases, as is the case for psoriasis [2]. Seizing 
this possibility to reconstruct human living tissues displaying distinctive lesional phe-
notypes, which could not have been envisioned not so long ago, has been achieved by 
several laboratories. They have contributed step by step to the understanding of psori-
asis by putting together in vitro psoriatic models. In order to do so, they used various 
approaches, which will be discussed just below, thus opening tremendous perspective 
to enhance the knowledge into the causes and treatments of psoriasis.
3.  In vitro models of psoriasis
The nonexistence of validated in vivo and in vitro models, or even the knowledge of a 
discriminating psoriasis biomarker, impede future findings and surely constitute one 
of the major challenges for antipsoriatic drug development. Better models are needed 
in order to dissect the interactions of many complex molecular pathways or networks 
in the skin [4]. Indeed, psoriasis consists of a complex disease involving the alter-
ation of over 1300 genes and the interaction of 30 or more upregulated cytokines and 
chemokines [11,30].
Firstly, no naturally occurring affected animal models mirroring both phenotype 
and immunopathogenesis of psoriasis are currently known, which has resulted in se-
verely hampered research efforts [31]. Consequently, several in vivo models have been 
developed to counterbalance this acute lack in psoriasis research and for preclinical 
drug development purposes. This category includes spontaneous mutations, xeno-
transplantation, knockout, and transgenic animal models [32]. Overall, rodent models 
are satisfyingly representative of the disease, but no one can fully mimic its particular 
genomic, histological, and inflammatory signature [31]. Indeed, dissimilar architec-
ture and metabolism between the mouse and human skin limit this approach [33]. 
Accordingly, we must not jump to early conclusions that results obtained from murine 
models are always predictive of the human condition and its response to treatments. 
Lastly, another issue is that in vivo models are exposed to increasing ethical concerns 
surrounding the use of laboratory animals.
On the other hand, following tissue-engineering development, in vitro psoriatic 
models have also been widely used as test systems in order to better understand 
its physiopathology and for pharmaceutical industry assessments. They represent 
suitable alternatives to in vivo models for numerous technical, practical, and ethical 
reasons. Besides being consequently more faithful models due to the direct use of 
human cells, they allow broad control over cellular composition and production as 
well as being assessment friendly [34]. However, we must again avoid making hasty 
conclusions on the fact that in vitro models are better than in vivo in all cases. Indeed, 
the lack of a surrounding living system and hence of certain cell types may lead us 
to believe that a number of results gathered from some psoriatic models are of ques-
tionable value. In this vein, considering that in vitro models have been developed in 
order to acutely reproduce key structural components and functional aspects of the 
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natural skin, the relevance of these models has undergone growing criticism in regard 
to their lack of an important component: immune cells [4,11]. However, it’s worth 
mentioning that a group has recently been able to populate their psoriatic equivalents 
with CD4+ T cells [35]. Seeing this opportunity, a focus of research manages to 
further improve the model we’re using by adding an immune component. Moreover, 
several teams, including our own, have previously tried to partially get around this 
immune cell addition through an induction of the equivalents with various cytokines 
in order to alter their gene expression patterns in a similar manner to what would be 
found in native psoriasis [36–40]. Subsequent sections will aim to introduce the dif-
ferent psoriatic in vitro models and provide detailed explanations necessary for their 
understanding.
3.1  Monolayer
Monolayer models enable researchers to consider only one cell type at a time. Either 
keratinocytes or fibroblasts can be separately cultured to test different conditions or 
to observe psoriatic skin features, such as keratinocyte hyperproliferation or abnor-
mal differentiation [32]. Thereby, this technique allows for the isolation of normal or 
pathological cell types, thus enabling the study of specifically involved mechanisms. 
Indeed, human skin cells grow within an organized three-dimensional environment, 
and monolayer cultures cannot capture this relevant complexity [41]. Yet, even if this 
monolayer culture does not allow this direct interaction, we can find in that same 
weakness all of its capability: through this application, it was possible to demonstrate 
the importance of this interaction between fibroblasts and keratinocytes and secondly 
that functional interactions between keratinocytes and T lymphocytes require direct 
cellular contact [42]. It has also been shown that psoriatic keratinocytes alter the func-
tion of normal T lymphocytes, which conversely modulates these keratinocytes, in a 
negative feedback loop [42]. Indeed, these models have led to a better understanding 
of the pathology [43]. For instance, Detmar et al. demonstrated that psoriasis involves 
a TGF-α regulation of vascular endothelial growth factor (VEGF) expression via an 
autocrine mechanism, which leads to vascular hyperpermeability and angiogenesis 
[44]. Also, monolayer cultures are still widely used to conduct toxicity assessments 
on each cell type independently [45]. Nonetheless, monoculture keratinocytes only 
generate thin epidermal layers, which anyhow, without any mesenchymal feeder layer, 
undergo fast apoptosis [46]. Furthermore, these kinds of artificial skin aren’t suitable 
for percutaneous absorption tests, which cannot be properly assessed without essential 
characteristics provided by three-dimensional organization [33].
As previously discussed, complex interactions occurring between skin cells and 
their microenvironment further call for three-dimensional skin models, which can 
capture in a more relevant way the complexity of in vivo situations. It’s undeniable 
that monolayers have played and still play an important role in the comprehension of 
psoriasis, but laboratories cannot be limited only to this type of model in order to fully 
understand the disease. Therefore, they have developed in  vitro three-dimensional 
models in order to overcome its inherent limitations. These psoriatic equivalents are 
intended to be introduced in hereafter sections.
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3.2  De-epidermized dermis
This approach has been first described by Pruniéras et al., as an attempt to achieve more 
physiological characteristics in the tissue-engineered skin [47]. By culturing epidermal 
cells on dead de-epidermized dermis (DED), an acellular structure, all morphological 
markers of differentiation were seen except for keratin patterns [47]. Using this same 
technique, Ponec further demonstrated that air-liquid interface cultures reproduce to a 
high extent the lipid composition of the native epidermis, except for higher triglyceride 
and lower glycosphingolipid content, as well as very low linoleic acid content [48]. 
Afterward, specialized research groups have introduced psoriatic skin equivalent mod-
els using various patterns arising from this approach. Some of them used explant cul-
tures [49], while others turned out seeding directly keratinocytes belonging to psoriasis 
patients [50,51] or instead simply using healthy cells paired with an induction of a 
psoriatic phenotype by inhibition of transglutaminase [52]. Finally, others introduce 
psoriatic skin equivalents through the addition of lymphocytes or cytokines [53,54].
3.2.1  Explant culture on de-epidermized dermis
From psoriatic skin biopsies cultured on deepidermized dermis, Mils et al. have been 
able to develop a reconstructed epidermal psoriatic model in an attempt to accurately 
reproduce its phenotype [49]. They began by depositing a 4 mm punch biopsy on the 
epidermal side of mortified de-epidermized human dermis, making contact with the 
remnant basement membrane components [55]. The DED was maintained at the air- 
liquid interface using a metallic support. Within 15 days, they were able to obtain a 
well- differentiated epidermis entirely covering the DED. Their results did not show any 
differences whatever using normal or psoriatic biopsy, thus yielding a unique in vitro 
phenotype, which is in dissimilarity with physiopathologic differences found between 
the normal and psoriatic skin in vivo. In fact, both conditions shared similar morphology 
with slight hyperacanthosis and orthokeratotic hyperkeratosis [49]. Those results seem 
to suggest a need for extracutaneous stimuli to maintain the psoriatic phenotype in vitro.
3.2.2  Keratinocytes on de-epidermized dermis
Using the same basic technique, another in vitro epidermal model has been devel-
oped, but rather using normal keratinocytes seeded directly on a DED [53]. DED 
were generated from surgery-discarded abdominal skin, where the epidermis has been 
dislodged from the dermis. Healthy keratinocytes are then seeded within a hollow 
metal ring placed on DED punches. Once keratinocytes were crammed on the dermis, 
they removed the ring and submerged the whole assembly in culture medium. To ob-
tain a well-differentiated epidermis, they also underwent an air-liquid phase using a 
metal grid as a shim [53]. Since they’re using nonpathological keratinocytes, they in-
duced psoriasis-associated features and gene expression by adding, at the last 4 days of 
the air-liquid interface culture, various combinations of pro-inflammatory cytokines, 
such as TNF-α, IL-lα, IL-6, and IL-22. The addition of this cytokine blend results 
in a strongly induced expression of hBD-2, SKALP/elafin, CK16, IL-8, and TNF-α, 
as well as keratinocyte hyperproliferation. Tjabringa et al. showed that retinoic acid 
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inhibits cytokine-induced gene expression at both the mRNA and protein levels, as 
found in the native form of psoriasis; different results were obtained using cyclosporin 
A. The model also demonstrated reduced expression of keratin 10, a differentiation 
marker [53]. In conclusion, this approach gathers major psoriatic model criteria and 
thereby attests promising potential in further pathology research efforts and pharma-
cological applications.
As introduced earlier, van den Bogaard et al. have been able, through this same tech-
nique, to produce psoriatic skin equivalents containing an immune component: CD4+ T 
cells [35]. They showed that the migration of those lymphocytes into the dermal equiv-
alent initiated keratinocyte activation within 2 days, with hallmarks of a psoriasiform 
inflammation after 4 days. They also observed upregulated expression of genes, which 
code for epidermal psoriasis markers along with various pro-inflammatory cytokines 
and chemokines. Furthermore, disturbed epidermal differentiation was established by 
downregulated filaggrin and involucrin expression in the spinous layer [35].
3.3  Collagen gels
The earliest dermal matrix used as tissue-engineered skin incorporated fibroblasts 
into exogenous collagen hydrated gels or lattices [56–58]. This path followed by 
tissue- engineering pioneers was sustained by the fact that collagen is the main matrix 
component of connective tissues and thus provides support for the whole cutaneous 
structure [59,60]. Once added, fibroblasts reorganized collagen fibers to form the der-
mis, and afterward, those fibroblast-populated matrices are overlayed with a suspen-
sion of keratinocytes or a full punch biopsy to recreate the epidermis [61]. Drawbacks 
of this method lie behind the use of exogenous material and weak mechanical resis-
tance along with the fact that this matrix undergoes severe contraction early in the cul-
ture process [62]. Nevertheless, this skin culture approach benefits from relatively fast 
production time and is well suited for chemical toxicity assessments [62]. Since then, 
collagen gels are used in many laboratories to produce healthy and lesional skin sub-
stitutes. As it will be presented below, slight technical particularities may be observed 
between different research groups in the production of psoriatic skin equivalents.
3.3.1  Explant culture
Saiag and coworkers used a technique that involved laying full-thickness punch biop-
sies on fibroblast-populated collagen gels in order to measure the effects of various 
combinations of keratinocytes and fibroblasts from the psoriatic skin, normal skin 
from psoriatic patients, and normal skin from nonpsoriatic controls on skin equivalent 
keratinocytes proliferation kinetics [63]. Results have convincingly showed that the 
basic defect in psoriasis appears to be related with both uninvolved and involved pso-
riatic fibroblasts and that psoriatic keratinocytes’ hyperproliferative growth was main-
tained even with the use of normal fibroblasts [43,63,64]. From these results, psoriatic 
fibroblasts prove to be key regulators of abnormal proliferation in psoriatic skin. Even 
so, it is still unproved whether they act autonomously or, more likely, under the direc-
tion of some local or distant stimuli that dictates its altered regulatory behavior [64].
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3.3.2  Models using multiple cellular types
Collagen gels have also been used as scaffolds in models composed from separately 
extracted healthy and pathological fibroblasts along with keratinocytes. Autologous 
fibroblasts are obtained through a biopsy, where they are removed from the dermis 
and expanded, as is the same for keratinocytes, which are, however, extracted from 
the epidermis and cultured on a 3 T3 fibroblasts feeder layer. As described above, fi-
broblasts are first embedded in the collagen matrix, and then, keratinocytes are seeded 
on top of the dermal equivalent [65]. Konstantinova et al. were first to introduce this 
technique, borrowed from field pioneers Bell et al., in order to produce psoriatic skin 
substitutes [58,60]. Their skin equivalents were thicker, lost filaggrin, showed more 
intense IL-8 staining when performing immunohistochemistry assays, and developed 
invaginations, all of which are factors found in psoriasis in vivo. These results led to 
the hypothesis that an IL-8 paracrine loop between fibroblasts and keratinocytes may 
play a key role in epidermal regeneration and, thus, in hyperproliferation [65]. Still, 
in order to be able to characterize the psoriasis in vitro, Barker et al. developed a pso-
riatic collagen gel skin model derived from normal involved psoriatic and uninvolved 
psoriatic cells. These psoriatic skin substitutes were well representative of the pathol-
ogy [51]. Results showed that classical keratinocyte differentiation markers exhibited 
similar patterns of distribution in psoriatic models to those derived from normal cells 
and generally reflected in vivo observations [51]. Moreover, their model retains many 
other psoriatic characteristics such as keratinocyte hyperproliferation and abnormal 
differentiation, as well as enhancement of IL-6 and IL-8 concentrations [51]. Models 
derived from uninvolved and involved psoriatic skin share the same gene expression 
profile and pathological characteristics as psoriatic human skin [43,51].
3.4  Commercially available model
MatTek corporation has developed an in vitro model of psoriasis in order to enable 
the screening of therapeutic candidates for safety and efficacy. The model is produced 
using collagen gels, exploiting, more specifically, the multiple cellular types approach 
described just above. They use normal human epidermal keratinocytes and psoriatic 
fibroblasts derived from psoriatic explants. Their skin substitutes exhibit and maintain 
a psoriatic phenotype as evidenced by increased basal cell proliferation; expression of 
psoriasis-specific markers; and enhanced release of psoriasis-specific cytokines, such 
as IL-6, IL-8, GM-CSF, and IP-10. Likewise, the model morphologically emulates 
lesional psoriatic human tissues. Finally, this in vitro psoriatic model is responsive to 
some marketed antipsoriatic therapeutics, thus representing a useful tool for pharma-
ceutical assessments [66–69].
3.5  The self-assembly method
The self-assembly method, developed by the LOEX group, allows the production of 
complete bilayered skin substitutes devoid of exogenous collagen or any other syn-
thetic materials [50]. The fundamental concept behind this method is to  reconstruct 
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an organ in a fashion closely emulating its formation in  vivo. Accordingly, this 
 tissue-engineering approach is based on the capacity of mesenchymal cells, such as 
fibroblasts, to create their own extracellular matrix in vitro. Thus, cells are grown 
in such a way that they literally embed themselves in their very own extracellular 
matrix [26].
Following the path of tissue-engineering pioneers, the development of this method 
was firstly motivated by the need of solutions to help impaired burn patients in dire 
need of grafts. Nowadays, the method is used for wound healing not only in the case 
of extensive burns but also in the case of chronic wounds (the lack of cadaver skin to 
protect burn patients and plasters for diabetic ulcers), not to mention cornea recon-
struction and various other research purposes [70,71]. Research upon these skin equiv-
alents has been motivated by the fact that they closely emulate many characteristics 
found in the normal human skin and avoid the possible bias caused by the contribution 
of exogenous materials [72,73].
From a dermopharmaceutical point of view, there is a need for skin models to 
test new formulations developed in vitro. The self-assembly method represents an 
alternative method to replace animal testing and, secondly, provides models where 
research efforts are impeded by the absence of naturally occurring disorders in lab-
oratory animals or validated in vitro models, as is the case for psoriasis [2]. Thus, 
facing the absence of exogenous material-free models, our group developed a patho-
logical skin model to study psoriasis in vitro, using this unique approach [72]. Indeed, 
the method can be adaptable to produce pathological skin substitutes from affected 
patients’ cells [43].
Foremost, it was shown that self-assembled equivalents partially maintained 
psoriasis- like features such as epidermis thickening and hyperproliferation, as well as 
abnormal keratinocyte differentiation [50]. We also demonstrated that our model posi-
tively reacts to treatments with an antipsoriatic molecule such as observed in psoriatic 
skin in vivo, thus providing a solid proof of principle [74]. It is clear that self- assembled 
skin substitutes emulate the normal human skin and psoriatic human skin much better 
than artificial membranes and thereby could become an effective and innovative dermo-
pharmaceutical tool for the screening of new treatments (Fig. 1) [43,75].
Healthy substitute Psoriatic substitutes
Fig. 1 Macroscopic aspect of substitutes produced according to the self-assembly method.  
(A) Healthy substitute and (B) psoriatic substitute.
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3.5.1  Skin cells source
Dermal fibroblasts and epidermal keratinocytes were obtained from healthy skin spec-
imens originating from surgical procedures, thereby serving as controls, and from 
6 mm punch biopsies belonging to patients with plaque psoriasis who were recruited 
from affiliated hospitals [76,77]. Psoriatic punches were taken either from uninvolved 
or involved skin portions depending on experimental purposes [43].
Keratinocytes were initially isolated with a thermolysin digestion, followed by a 
mechanical separation from the dermis with forceps [77,78]. Afterward, keratinocytes 
were dissociated from the epidermis using a trypsin-EDTA solution [78]. Cells were 
then amplified on a lethally irradiated 3 T3 feeder layer and finally banked. On the 
other hand, human fibroblasts were dissociated using collagenase and, alike, subse-
quently banked for ulterior use [77].
3.5.2  Cell culture media
Keratinocytes were cultured in complete DME-HAM, a combination of Dulbecco-
Vogt modification of Eagle’s medium (DME) with Ham’s F12 in a 3:1 proportion. 
The medium is supplemented with insulin, hydrocortisone, cholera toxin (which en-
hances growth factor uptake), 5% serum, epidermal growth factor, and antibiotics 
[79]. Fibroblasts, for their part, were cultured in DME supplemented with 10% serum 
and antibiotics [72]. In addition, fibroblasts were cultured in the presence of ascorbic 
acid. This additive increases procollagen mRNA synthesis in fibroblasts, thus allow-
ing the posttranslational hydroxylation of lysine and proline, which leads to efficient 
collagen helix formation and increases secretion of collagen in cultured cells [80–83]. 
In short, we are able to obtain manipulable fibroblast sheets through the addition of 
this latter compound. This represents the cornerstone of the self-assembly approach, 
allowing the production of skin equivalents devoid of any synthetic components or 
other exogenous materials.
3.5.3  Production of the self-assembled substitutes
In order to obtain psoriatic skin equivalents, normal and pathological fibroblasts are firstly 
thawed and cultured with ascorbic acid over a period of 4 weeks. During this period, der-
mal sheets are produced, and cohesive dermal tissues are obtained by stacking two of these 
fibroblasts sheets together upon which normal or pathological keratinocytes are seeded 
7 days later. After another 7 days of culture, the substitutes are raised to the air-liquid 
interface to promote cell differentiation and stratification. Finally, maturation ends after 
21 days of culture at the air-liquid interface, and samples are analyzed using histological, 
immunohistochemical, physicochemical, or permeability assays, as required [50].
One must admit that this approach, at the present time, is labor-intensive and 
time-consuming. Therefore, the development of new protocols and techniques and 
optimizing cell culture conditions in order to reduce production and maturation de-
lays remain relevant. This incessant development is likely worth it, considering, for 
now, that those skin equivalents are the purest form of in vitro models for various 
 physiological, pathophysiological, pharmaceutical, and toxicological studies [26].
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4.  Results from ongoing research projects and future 
insights
4.1  Understanding the role of immune cells in psoriasis through 
tissue engineering
Psoriasis is an organ-specific T-cell-driven autoimmune pathology that is engaged fol-
lowing T cells’ activity along with an array of other stimuli and subsequently main-
tained by the secretory activity of dendritic cells, macrophages, and again T cells 
[84,85]. Indeed, clinical and fundamental research observations have indicated that 
psoriasis involves an interplay between the innate and adaptive immune systems, in-
cluding complex feedback loops from antigen-presenting cells, neutrophilic granulo-
cytes, keratinocytes, vascular endothelial cells, and cutaneous nervous system [2,84]. 
These cells secrete cytokines such as IL-17, TNF-α, and IFN-γ, the first two being 
responsible for keratinocyte hyperproliferation, T-cell activation, and proliferation, as 
well as immune cell migration within both the dermis and epidermis [84,86].
Originally, there was a debate about whether the dominant process in psoriasis in-
volved hyperplasic keratinocytes or the immune system [87]. However, the remarkable 
efficacy of cyclosporine A, an immunosuppressive agent that inhibits T-cell prolif-
eration and cytokine production, essentially ended the controversy [84]. Nowadays, 
numerous other immunosuppressive therapies have been introduced for the therapeu-
tic armamentarium of psoriasis, thus confirming the immune system’s key role in its 
pathogenesis [88]. Even so, the further connection between immunologic, environmen-
tal, and genetic factors, all leading to this pathology, still remains somewhat puzzling.
Taking into account all the evidence showing the importance of underlying immune 
components in psoriasis, it becomes of prime importance to possess relevant models to 
investigate all of the involved mechanisms. Certainly, in vivo models could be used, but 
owing to human and animal immunologic differences, as well as price and ethical con-
siderations surrounding their use, they constitute a less appealing avenue [89]. Thus, 
these concerns made it necessary to develop new human immune-competent in vitro 
models in order to study the crucial and yet enigmatic interactions between skin and 
immune cells [41]. Moreover, besides being suitable for the understanding of this com-
plex pathology, immune-competent in vitro equivalents have the potential to serve as 
preclinical screening tools, where in vivo models often poorly predict the human im-
mune response, leading to potential new drugs not reaching clinical trials or clinical 
trial failures [35,89]. Accordingly, laboratories have investigated two types of psoriatic 
in vitro models, cocultures and three-dimensional models, as presented below.
Cocultures are very useful models to study psoriasis, even if they may seem ele-
mentary. Fibroblasts or keratinocytes are seeded and expanded on a plastic supportive 
material before adding a second cellular component to the culture. This way, as it 
will be presented in the following paragraph, many findings that all contribute to a 
greater understanding of the pathology have been possible. In counterpart, although 
they are and will remain invaluable tools, cocultures are bound to be transitional solu-
tions inasmuch as three-dimensional models containing immune components, which 
are currently rare due to technical challenges related to their production, are more 
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comprehensive models that should be preferentially used when they’ll become further 
available.
First, in the study of Schirmer et al., dendritic cells were cocultured with healthy 
fibroblasts, which allowed them to discover that dendritic cells secrete a greater 
amount of IL-23 and IL-6 when activated by fibroblast-derived TNF-α [90]. IL-23 
involvement in psoriasis occurs by stimulating T cells to secrete IL-17, a compound 
that acts as a pro-inflammatory cytokine, which further inducts TNF-α secretion from 
fibroblasts [90]. In another study, Wittman et al. added T cells to a culture of healthy 
keratinocytes [91]. This way, they observed that preactivated keratinocytes with IFN-γ 
secrete more CXCL10, which is responsible for the attraction of T cells to the lesion 
site [91]. Moreover, in Prinz et al. study, psoriatic keratinocytes were separately cul-
tured from T cells, and their supernatants were subsequently transferred to the kerati-
nocyte cultures in order to study their interaction with T-cell-secreted cytokines [92]. 
They showed that keratinocytes’ proliferation rate was higher in the presence of T-cell 
supernatants [92].
Our coculture models are unlike any other, this being due in part to the use of 
psoriatic epithelial cells. With this model, it appears that psoriatic keratinocytes low-
ered T cells’ apoptotic rate. Furthermore, this study demonstrated that inflammatory 
cytokines secreted by psoriatic keratinocytes, such as MCP-1, IL-8, and TNF-α, were 
significantly increased compared with cocultures using healthy keratinocytes [93]. 
Consecutive studies on the interaction between T cells and psoriatic keratinocytes 
showed that cell-to-cell contact increased cellular cytokine secretion [42].
On the other hand, studies on three-dimensional psoriatic in vitro skin equivalents, 
despite inherent difficulties in their production, are becoming more prevalent. It may 
be first mentioned the van den Bogaard et  al. model previously introduced, where 
preactivated and polarized T cells were inserted under an acellular dermis, over which 
are seeded healthy keratinocytes [35]. They demonstrated that preactivated T cells 
migrate in the acellular dermis and were able to activate keratinocytes and to induce 
their proliferation. After 2 days of migration, cytokines like IFN-γ, IL-17, IL-22, and 
TNF-α concentrations in the medium were at their peak. As priorly mentioned, this 
three-dimensional model is physiologically very accurate in regard to psoriatic le-
sions, because many proteins usually found in psoriatic skin are as well expressed 
in their equivalents. Furthermore, many genes normally expressed in psoriasis are 
alike expressed, and these include DEFB4, PI3, IL8, and S100A7 just to name a few 
[35]. In another study, Saalbach et  al. introduced monocyte-derived dendritic cells 
to a collagen 1 lattice over which were seeded healthy human fibroblasts [94]. They 
demonstrated that monocyte-derived dendritic cells preactivated with LPS migrate 
at higher rates in the presence of dermal fibroblasts than inactivated dendritic cells. 
These results suggest a possible interaction between these two cell types. Their model 
proved to be genetically representative of the pathology; indeed, several genes such as 
MMP-1, MMP-3, and cox-2, all involved in psoriasis inflammatory responses, were 
expressed by skin equivalents’ fibroblasts, as is observed in psoriatic lesions [94]. 
Conclusively, both models surely represent great achievements on a biological and 
technical basis and further allowed, in an unparalleled way, to gather precious evi-
dence that points us toward the right direction in the understanding of this pathology.
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4.2  Pharmaceutical screening of new antipsoriatic drugs
At the present moment, as was stated earlier, none of the available treatments has the 
potential to fully cure psoriasis; they only manage resulting symptoms. Despite their 
effectiveness in resolving psoriatic lesions, their use is limited because many of them 
have significant adverse effects on patients when used over extended periods of time 
or in large doses [95]. To address this problem, new therapeutic compounds are con-
stantly sought in order to, if curing is not feasible at the moment, be able to better and 
more efficiently control cutaneous lesions, in an attempt to improve patients’ quality 
of life. Developing such treatments for skin pathologies as psoriasis requires exten-
sive and fastidious assessments to evaluate the therapeutic potential of the imposing 
amount of substances. These tests are mainly conducted on in vitro models, which 
closely emulate normal skin reactions. Monolayers are well suited for primary tests 
but are superseded by three-dimensional models later in the characterization process. 
Thus, in pilot pharmacological screenings, tissue-engineered skin constructs, such as 
our own self-assembled, become opportunistic tools to measure cytotoxic drawbacks, 
allowing thereafter to select effective and harmless compounds.
To this end, our three-dimensional model is a valid and efficient experimental tool 
to develop potential treatments [50]. Several aspects of this model have been closely 
correlated to the native human skin, particularly in terms of pharmacological response, 
where equivalents positively react to retinoic acid and methotrexate, both commonly 
used systemic treatments [74]. Hence, the laboratory focuses on the screening of 
chemical compounds that may possess beneficial outcomes in psoriasis, in hope of 
resolving toxic aftermaths caused by current therapies. This interest is especially ori-
ented toward natural source molecules such as polyphenols, due to their antioxidant, 
antiproliferative, and anti-inflammatory potential [96]. This class of molecules could 
be of great interest for generating symptomatic treatments, which would be as effec-
tive as currently commercially available treatments, without related noxious effects, 
thus allowing extended use. The multiple phenol structural units, which consist of 
polyphenols, are responsible for its antioxidant potential by interrupting oxidation cas-
cades, thus protecting cells against oxidative stress [97]. Increasing oxidative stress or 
decreased antioxidant enzymatic activity leads to cellular damage and could partially 
explain the outbreak of various pathologies such as psoriasis [98]. As aforementioned, 
polyphenols also detain anti-inflammatory properties, which may be explained by the 
inhibition of two noteworthy cytokines involved in the complex inflammatory process 
in psoriasis: TNF-α and IL-6 [99,100].
Results gathered from studies, which were realized in this respect, further proved 
the toxicological and antiproliferative properties of polyphenolic extracts, more 
specifically those originating from Canadian bark species, and especially crude ex-
tracts from black spruce (Picea mariana) [101,102]. Purification of this promising 
extract yielded a fraction of enriched polyphenols, which allow for the identification 
and characterization of their effect on the NF-kB signaling pathway [103]. Results 
showed that this enriched fraction has the ability to inhibit cytokines, chemokines, 
nitric oxide, and prostaglandins produced by TNF-α-activated psoriatic keratinocytes 
following downregulation of the NF-kB pathway, thus potentially enabling their use 
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as anti-TNF-α [103]. Moreover, pharmacological screenings of diverse other poly-
phenolic molecules, extracted and purified from plant biomass, have been also carried 
out. These last analyses demonstrated that particular classes of phenols reduced the 
proliferation rate of lesional keratinocytes and improved their differentiation pattern, 
which is confirmed by a reduction of the living epidermis thickness, and the resto-
ration of various protein expression levels in the epidermis. Results also suggest that 
these polyphenolic compounds would be as efficient as methotrexate, but at concen-
trations about a hundredfold lower, demonstrating the effectiveness and potency of 
this kind of plant source molecules.
4.3  Lipodomics studies and epidermis lipids characterization
The uppermost layer of the epidermis, the stratum corneum, consists of nearly 20 
layers of corneocytes, completely keratinized dead cells, embedded in an extracellular 
lipid matrix [104]. The structure of this paper-thin layer has often been compared to 
a “brick-and-mortar” system [105]. Its main purpose consists of forming a semiper-
meable barrier, which prevents foreign matter from entering and protects underlying 
tissues from excessive water loss. Most of the lipids involved in its composition are 
ceramides, cholesterol, and various free fatty acids [106]. These lipids originate from 
a differentiation process occurring stepwise through maturation in the different epi-
dermal layers. One of these lipids is of particular interest: ceramide 1. This lipid binds 
to involucrin, a corneocyte membrane protein, thus creating a solid scaffold for the 
subsequent lipid matrix organization. Therefore, increased fatty acid and ceramide 
content, following the differentiation process occurring in epidermal layers, plays an 
important role in the skin barrier function onset [13,107]. Thus, knowing that psoriasis 
is marked by an abnormal epidermal lipid composition, it makes sense that psoriatic 
skin has proved to be more permeable than the normal human skin [2].
When producing skin equivalents, it’s essential to work on keeping the permea-
bility levels as close as what is found in healthy or lesional human skin in order for 
the model to be representative. This standardization is a prerequisite for the use of 
such models in pharmacological assessments. Thereby, in our specific case concerning 
psoriasis, there is an urgent need for reproducible alternative systems mimicking accu-
rately the barrier properties of human skin if one can hope to effectively find a way to 
cure psoriasis [108]. Although the self-assembly model is one of those that reproduces 
as faithfully the skin barrier function, absorption studies have shown that both healthy 
and psoriatic skin substitutes are more permeable than the normal human skin (Fig. 2) 
[72,109]. It has been shown that this increase could be correlated with an alteration of 
the skin substitutes’ lipid profile; as introduced earlier, lipids have a major role to play 
in the formation and maintenance of the skin barrier function [48]. Therefore, sev-
eral research groups, including our own, focus on restoring the lipid profile of tissue- 
engineered equivalents via supplementation in order to ameliorate their permeability, 
and this is usually achieved by directly adding lipids to the culture medium. Linoleic 
acid, given its direct role in the synthesis of the ceramide 1 and thus in staging of the 
lipid matrix, is one of the most commonly used fatty acid supplements, along with 
α-linolenic acid and palmitic acid [110–112].
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4.4  In vitro cutaneous vascularisation in psoriatic self-assembly 
skin substitutes
Angiogenesis is an important biological process through which new blood vessels 
are formed by sprouting or splitting from preexisting vasculature [113]. It involves 
the activation and expansion of endothelial cells, which are the constituents of the 
blood lining. It’s of utmost importance in development, reproduction, and wound 
repair throughout our whole life [114]. Under these circumstances, angiogenesis is 
tightly regulated by a balance of repressive and inductive mediators [115]. However, 
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Fig. 2 Percutaneous absorption of benzoic acid (A) and caffeine (B) through the normal skin 
substitute (NSS), psoriatic substitute 65 (PS65) and 46 (PS46), mouse skin (MS), and normal 
human skin (NHS) over 24 h. The number of each PS represents the age of the donor (N = 2, n = 3).
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it occurs not only under physiological conditions, where induced only transiently, 
but also in a variety of pathological conditions, including psoriasis. Once again, the 
establishment of new vessels represents a critical need for the disease development 
[115]. Indeed, capillaries grow and regress in healthy tissues according to functional 
demands, whereas increased metabolic needs and hypoxia of inflammatory and res-
ident cells in psoriasis require greater and ceaseless blood flow in order to meet the 
extensive needs of these cells [113]. This vascular alteration is alike required for the 
extracellular matrix modifications supporting the leukocyte extravasation [116–119]. 
In psoriasis, a key vascular alteration consists of the outgrowth of capillaries within 
the papillary dermis in early stages of the disease, which are further elongated, dilated, 
and abnormally orientated [116,120]. Moreover, disappearance of those previous 
changes is being observed with disease clearance [115]. These outcomes suggest that 
angiogenesis plays an important role in the onset and complex pathology of psoriasis. 
This brief introduction leads us to our problematic concerning this angiogenic process 
and production of in vitro psoriatic skin models.
The issue lies in the fact that some aspects of tissue engineering have lagged behind 
following the common endeavor to improve existing models, namely, vascularization 
and innervation [26]. These critical features have not received all the attention they de-
serve maybe due to the fact that there are occurrences, such as regenerative medicine, 
where clinically applicable skin grafts do not absolutely need preexisting vasculariza-
tion [26,121]. Nevertheless, these critical aspects must be addressed more efficiently 
in order to achieve sizeable skin substitutes [121].
This deficiency is particularly adverse in the case of psoriasis, where angiogenesis, 
as stated earlier, is one of its important histological hallmarks [2]. Indeed, the eluci-
dation of biochemical pathways leading to angioproliferation may reveal promising 
novel therapeutic targets, but in vitro models including vascular components, which 
could serve as vehicles to get to that end, are rare or simply nonexistent [122]. With a 
view to thwart this deficiency, an in vitro vascularized psoriatic equivalent that could 
be used for fundamental research and pharmaceutical purposes has been reconstructed 
[116,123].
Foremost, our team tested whether it was feasible to produce psoriatic skin 
equivalents using endothelial cells combined with the self-assembly method [116]. 
Histological analysis and immunofluorescence staining targeting specific endothelial 
cells and basal membrane component markers demonstrated that endothelial cells can 
penetrate and migrate within the matrix and then divide, lengthen, and break up this 
matrix via enzyme secretion. Thus, endothelial cells spontaneously organize capillary- 
like structures [116]. Moreover, the addition of these cells did not alter the macro-
scopic and histological aspects of the psoriatic equivalents. Among others, it was 
possible to observe a well-fused dermis, the presence of differentiation markers, such 
as filaggrin, loricrin, and keratin 10, whose expressions were farther decreased in pso-
riatic substitutes than proliferation marker Ki67 [116]. In the same way, the granular 
layer of psoriatic substitutes was greatly reduced and sometimes completely absent, in 
comparison with healthy skin, which is in accordance with the current knowledge of 
this dermatosis [4,116]. Three-dimensional whole-mount immunofluorescence stain-
ing showed that the quantity, complexity, density, and disorganization of capillary-like 
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structures were increased in psoriatic substitutes [116]. This chaotic vasculature or-
ganization in psoriatic equivalents, which includes various angiogenic provocation 
features and differential expression of cellular markers, provides a good proof of prin-
ciple concerning the self-assembled model, which was taken a step further by intro-
ducing these endothelial cells.
Subsequently, now that the relevance of this vascularized psoriatic model has been 
confirmed, the new focus is on investigating the behavior of endothelial cells within 
this in vitro environment [123]. Rochon et al. and Liu et al. previously studied the 
effect of epithelial cells on capillary-like structures and observed that keratinocytes 
were able to regulate their size and morphology [124,125]. Based on these results, 
it was important to establish whether such a phenomenon could be observed in the 
self-assembled model and looked at the consecutive steps of angiogenesis occurring 
in this kind of substitutes. In order to preliminarily determine if keratinocytes could 
enhance the formation of capillary-like structures, tests on endothelial monolayer 
cultures were conducted using conditioned media previously collected from kerati-
nocytes or fibroblast cultures. Results showed that keratinocyte-conditioned medium 
impacts the physiology of endothelial cells by inducing their reorganization in a cir-
cular pattern [123]. In the same course of events, endothelial cell proliferation ceased, 
and a sharp decline in viable cell count was observed. Fibroblast-conditioned medium 
have, however, shown to induce cell proliferation, and a mix of both conditioned me-
dia produced only few circular structures, which means branch formation was de-
layed. Additionally, specific endothelial cell medium EBM-2 alone did not induce 
the cells to form branches even with the addition of angiogenic growth factors and 
other supplements [123]. In order to further prove that the epidermis increased in vi-
tro angiogenesis, the expression of angiogenic mediators by the endothelial cells was 
analyzed. ELISA and IHC staining showed increased expression of two distinct an-
giogenic inducers, VEGF and angiopoietin-1 (Ang-1). However, the coculture with an 
epidermis did not affect the interleukin-8 (IL-8) release. This chemoattractant cyto-
kine being identified as having a pro-inflammatory function, it apparently means that 
the increasing capillary-like structure formation in psoriatic bilayered models is not 
due to inflammation process [123]. Lastly, matrix metalloproteinase activity and ma-
trix degradation are important processes in angiogenesis, allowing the establishment 
of new blood vessels by degrading and remodeling the extracellular matrix in order 
to allow endothelial cells to migrate and invade surrounding tissue [126]. Hence, it 
was not surprising to observe an increase MMP activity in this bilayered model [123]. 
Conclusively, our results showed that in  vitro microvascular network formation in 
tissue-engineered psoriatic skin models is predominantly managed by the epidermal 
components of substitutes [123].
4.5  Transcriptomic characterization of self-assembled psoriatic 
cutaneous model
The etiology and specific role of genetics in psoriasis, albeit its involvement is exten-
sively accepted, remains uncertain. Indeed, it has been shown that genetic background 
greatly increases the risk of being affected, although segregation does not occur in 
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accordance with Mendelian inheritance rules [125,127]. Genetic predisposition, on 
the other hand, cannot alone explain the dawn and sustaining of this pathology, since 
certain patients present no genetic influence [125]. Thus, these observations suggest 
a certain synergistic and imperative involvement of environmental, immunologic, 
and of course genetic factors. Among these factors, more than 30 putative susceptible 
loci have been identified as related to psoriasis, and these are named ##PSORS, an 
abbreviation of psoriasis susceptibility [128]. Genes contained within these regions 
are involved in inflammatory metabolic pathways, epidermal cell proliferation, and 
skin barrier function, all of which being impacted mechanisms in psoriasis [129]. Yet, 
the first and only consistently associated psoriasis susceptibility locus is PSORS1, a 
segment that spans a series of genes encoding for proteins such as class I MHC and 
further linked to early onset of chronic plaque, aberrant keratinocyte turnover rate, 
and corneocyte cohesion [4,11,130,131]. Genome-wide linkage scans also permitted 
to localize polymorphisms within or in the vicinity of cytokine-encoding genes, their 
receptors, or signal transduction pathway components, further implicating cytokines 
in the psoriasis pathomechanism [132]. Indeed, cytokines have been already linked 
to this pathology through their role in its initiation orchestration and afterward exac-
erbation of the cutaneous inflammatory response [4,133]. Among others, IL-17 and 
TNF, which promote the influx of inflammatory cells and onset of detrimental self- 
amplifying immunopathologic loops, were also linked to gene regulation and expres-
sion alterations in psoriasis [4]. Thus, a deeper knowledge of the multiple key roles of 
cytokines could suggest potential therapeutic targets or allow the development of more 
relevant and highly predictive tissue-engineered constructs.
As outlined earlier, human psoriatic skin being a rare commodity for laboratories, 
in vitro models are well-suited surrogates in order to study cytokines and their inter-
woven effects on genetic, angiogenesis, and cutaneous inflammatory response. Hence, 
our laboratory carried out a study consisting of two facets, either to investigate the 
effect of cytokines on skin cell transcriptomics or, secondly, if the addition of a cyto-
kine cocktail could consequently compensate the current lack of immune cells in our 
model [36]. The cocktail was composed of IL-1α, IL-6, IL-17A, and TNF-α and was 
added at the same moment that keratinocytes were overlayed on the dermal equiva-
lent. Microarray and scatter plot analysis revealed important gene pattern variations in 
subjected psoriatic equivalents. For instance, various late cornified envelope (LCE)-
related genes were downregulated, as well as KYNU, IL8, S100A12, and DEFB4A 
genes showing considerable increases in transcription levels, all of which being con-
sistent with the expression pattern found in psoriasis in vivo [36]. Along, many other 
strongly associated genes to psoriasis that further played important functions in an-
giogenesis, cell proliferation, and chemotaxis together with both immune cell acti-
vation and keratinocyte differentiation, such as CEACAM, CCL27, SERPINA12, and 
CX3CL1, were identified among deregulated genes [36].
Thus, our model is well representative of the pathology, as it appropriately repro-
duces the triggered repercussions owing to cytokines on the involved genetics in pso-
riasis. Cytokine cocktail addition also turned out to be a promising solution where 
in vitro skin models are not endowed with the capacity to retain gene expression levels 
near those found in native psoriasis, that being most likely due to the lack of immune 
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cells within the equivalents. Besides being meaningful models for transcriptomic anal-
ysis and everything that might ensue, future cytokine responsive in vitro models could 
promote studies focusing on the identification of autoantigen-triggering T cells and 
understanding, in minute detail, the potential role of CD4+ and CD8+ T cells in lesion 
development and how they maintain psoriasis [36].
4.6  Determining the ability of In Vitro psoriatic models to 
metabolize antipsoritatic drugs
The psoriatic self-assembled in vitro model has been greatly characterized and con-
sequently improved in recent years. However, drug metabolism assays were not yet 
attempted. Such studies could allow us to validate that this model is even more repre-
sentative of native psoriatic skin and, therefore, is a valuable pharmaceutical tool in 
psoriasis investigation.
Treatments administered to patients are biotransformed during their travel within 
skin to yield metabolites, which are often the pharmacologically active agents. 
Thereby, in order to ensure that a treatment has the desired therapeutic effects, it must 
be properly metabolized. This metabolism process is influenced by several skin factors 
including, among others, its permeability, moisture, structure, temperature, and the 
presence or absence of specific enzymes. In this sense, it is known that the organiza-
tion of psoriatic skin is impaired, which consequently leads to abnormal permeability 
barrier function, and furthermore that in vitro models are already more permeable than 
the native skin [72,109,134]. Thus, it would be interesting to observe if compounds 
are metabolized in the same manner even in these differential conditions, which is a 
prerequisite for the use of any model in pharmaceutical assessments.
Results have shown that self-assembled psoriatic skin equivalents possess a func-
tional metabolic capacity to what could be observed in native lesional skin. These 
experiments were conducted on the metabolism of tazarotene, an acetylenic retinoid, 
which is effective for topical treatment of plaque psoriasis [135,136]. Thereby, besides 
being a relevant model for metabolism assays and consequently a promising tool for 
the pharmaceutical industry, these results could pave the way to multiple other per-
spectives. Indeed, due to its autologous character, the self-assembly approach could 
allow for personalized treatments based on the patient’s very own cells’ response. It 
could be possible to carry out reliable and personalized therapeutic screening in a 
greatly reduced amount of time compared with similar in vivo analyses, where tests 
cannot be carried out simultaneously. As such, access to adequate medicine could be 
sped up, which would further improve patients’ quality of life. Moreover, one can see 
the potential to study the metabolism of antipsoriatic compounds in order to achieve 
effective formulations and concentration for the psoriasis treatment. It might also be 
interesting to avail the pairing of high-performance chromatography and percutaneous 
absorption in order to study the course of therapeutic compounds over an extended 
period of time, which is normally limited to 24 h. Thus, this merge could allow re-
searchers to retrieve the whole administered dose and, afterward, precisely determine 
where it was accumulated, used, or lost.
One can note that there are only very few studies concerning the metabolism 
among in vitro skin models. If other groups follow suit in this promising direction and 
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if already actively participating laboratories optimized their techniques, it might be 
possible in upcoming years to screen a phenomenal amount of auspicious compounds 
on a broad range of in vitro psoriatic models. Indeed, the metabolic capacity of in vitro 
models is a promising discovery for pharmaceutical development.
5.  Conclusion
Psoriasis has many yet unexplained mechanisms and even if there’s a spectrum of 
local and systemic therapeutic alternatives, none of them can do more than merely 
manage its repercussions. The absence of validated models or even the knowledge of a 
specific profile that defines the psoriatic phenotype surely constitutes one of the major 
challenges for antipsoriatic drug development and hinders research in this direction. 
Hence, both research and pharmaceutical laboratories resolutely need relevant and 
reliable psoriatic in vitro models to use as testing platforms in order to investigate the 
complex interplay between keratinocytes, fibroblasts, vascular endothelium, genetics, 
and the innate and adaptive immune systems. Indeed, in vitro tissue-engineered con-
structs represent suitable alternatives to in vivo models, which ever so often failed to 
faithfully mimic the human pathology and face, in addition, an increasingly strength-
ened ethical control. Existing psoriatic in vitro models use just as different as inno-
vative techniques for their production, of those, we can mention the monolayers, the 
DED and collagen gel-based methods and the self-assembly approach. While none 
of these previous models is foolproof, they allowed us to gather valuable information 
about the pathogenic interplay underlying psoriasis. Thus, the development of more 
relevant psoriasis models could pave the way for new and less harmful treatments and 
for personalized medicine, but most importantly, it would be an important step toward 
a cure for this disorder, affecting patients far beyond the skin.
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1.  Introduction
Vitiligo is an acquired chronic depigmenting disorder of the skin resulting from a se-
lective loss of melanocytes. The prevalence of vitiligo is often referred to as 0.5%–1% 
of the world's population [1,2]. Various theories have been suggested for the cause 
of melanocyte loss in vitiligo. Vitiligo can be considered as a multifactorial disease, 
with both genetic and environmental factors implicated in the initiation of the disease. 
Over the past years, several mechanisms of melanocyte loss in vitiligo have been pre-
sented. Researchers have shown the presence of melanocyte-intrinsic abnormalities in 
vitiligo leading to impaired melanocyte degeneration and/or proliferation, supporting 
the hypothesis that the disease could be due to a primary defect of melanocytes [3]. 
However, recent observations strongly support the role of the autoimmune system, 
particularly in chronic and progressive conditions [4–6]. Indeed, vitiligo is often as-
sociated with autoimmune diseases such as autoimmune thyroiditis, atopic dermatitis, 
and rheumatoid arthritis; genome-wide association studies and functional pathway 
analyses have shown that most vitiligo susceptibility loci encode components of the 
immune system [7–12]; and innate and adaptive immune cells are found in the per-
ilesional margin of the actively depigmenting skin of vitiligo patients [13,14]. Since 
none of these processes alone are sufficient to fully explain the pathomechanisms of 
the disease, there are to date ample evidences supporting an interplay between all 
hypotheses [15]. Vitiligo can result from a combination of biochemical, environmen-
tal, and immunologic factors, in genetically predisposed patients. Therefore, only a 
multidisciplinary approach may unveil the pathogenic puzzle of the disease. Actually, 
in vitro strategies to study vitiligo range from the analysis of different skin cell sub-
sets individually to the whole skin, using different techniques that will be described 
in this manuscript: primary cell cultures (melanocytes, keratinocytes, or fibroblasts), 
isolation of blood or skin-resident inflammatory cells to identify inflammatory cells 
* This chapter has no funding source.
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involved in disease development, and three-dimensional skin models to reproduce the 
in vivo network. These models allow the characterization of the phenotype and func-
tion of all cell subsets involved in vitiligo pathogenesis.
2.  Primary cell culture of skin cell subsets
Melanocytes and keratinocytes can be cultured from both the skin and hair follicle. 
Indeed, epidermal stem cells are present in the basal layer of the epidermis and within 
hair follicles; keratinocyte stem cells are situated in the bulge area, whereas those for 
melanocytes are found in the subbulge area [16].
2.1  Isolation and culture of skin melanocytes and keratinocytes
Vitiligo or healthy skin cells are obtained from the perilesional or nonlesional skin of 
vitiligo patients or healthy skin samples (e.g., the foreskin), respectively. The method 
for the isolation of primary melanocytes or keratinocytes is similar for both vitiligo 
and normal skin samples. Split-thickness skin samples are cut in small pieces and tryp-
sinized. Trypsin disrupts the epidermis above the basal layer and is neutralized with 
fetal calf serum or trypsin-soybean inhibitor. The epidermis is removed, and the basal 
layer is scraped to dissociate melanocytes and basal keratinocytes. Cells are seeded at 
a density of 200,000/cm2 for melanocytes and 100,000/cm2 for keratinocytes culture 
[17]. Usually, the culture media for melanocytes are M2 medium (PromoCell), M254 
(Gibco), or MCDB153 (Sigma), MGM4 BulletKit (Lonza), supplemented with specific 
growth factors. Several different handmade growth factors' cocktails for culture are used 
(Table 1). The specific composition of the growth factor cocktail will affect the pro-
liferative or differentiation signature and growth rate and the delay between isolation 
and standard growth [18]. Moreover, the presence of α-melanocyte-stimulating hormone 
(MSH) analogue or precursor could influence the effect of some in vitro treatments [19]. 
The culture media used for keratinocytes are CellnTechn-07 (Chemicon), MCDB153 
(Sigma), M154 (Gibco), KGM-2 (Promocell), or KSFM (Invitrogen), with the appro-
priate growth factors. Cells at passage 2–3 can be used to perform functional studies, 
reconstructed epidermis, or to start cocultures for studies investigating cellular network.
2.2  Isolation and culture of skin fibroblasts
After obtaining keratinocyte and melanocyte suspensions, the scraped dermis is cut in 
small pieces and incubated with collagenase, allowing the fibroblasts to exit from the 
extracellular matrix. Fibroblasts are cultured in DMEM supplemented with 10% fetal 
calf serum (FCS).
2.3  Genetic modification of cells
Since it is difficult to get enough cells from vitiligo patients to test all hypotheses, we 
can, according to genetic data, modulate susceptible genes using overexpressing or 
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A
Medium
bFGF
(ng/mL)
PMA
(nM)
Transferrin
(μg/mL)
a-Toc
(μg/mL)
Insulin
(μg/mL)
FCS
(%) hCS
BPE
(μg/mL)
M154 3 16 5  5 0.5 0.18 μg/mL 2
MCDB153 0.3  5 1 5 5 0.5 μg/mL 30
MCDB153 0.6 8  1 5 4  13
MCDB153 0.6 8 5 1 5 5 0.5 μg/mL 30*
MCDB153     20 3 1.75 μM 140
B
Medium
EGF
(ng/mL) Glutamine Adenine
Cholera
toxin Thyronine
Insulin
(μg/mL) FCS Hydrocortisone
BPE
(μg/mL)
Celln
Tech-07
         
MCDB
153
10     5  1.4 μM 70
DMEM:
HamF 12
(2:1)
10 
 
4 mmol/L 
 
0.18 mmol/L 
 
0.1 nM 
 
2 nM 
 
5 
 
10% 
 
0.4 μg/mL 
 
70 
 
In all culture media, penicillin and streptomycin are added, 10,000 U/mL and 10,000 ng/mL, respectively. a-Toc, tocopherol; hCS, hydrocortisone.
Ham F12 contains 1% ultracer, 2 mM Glu, 10 ng/mL PMA No, and 0.1 nM IBMX.
* Also contains 20 μg/mL catalase.
Table 1 Types of cell culture media used to culture (A) vitiligo melanocytes and (B) vitiligo keratinocytes
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silencing vectors such as nephroblastoma-overexpressed protein (NOV) also known as 
CCN3 (homeostasis of melanocyte), discoidin domain receptor 1 (DDR1) (adhesion 
of melanocyte to basal membrane), and cadherins (cell adhesion) [20,21]. Two types 
of vectors can be used in cells according to the time of the experiment or to the labo-
ratory agreement. For short time, studies on transient modification (transfection) are 
made using plasmid encoding the gene of interest or siRNA [20]. However, for long-
term studies, viral infection (transduction) using viral particles is necessary. Different 
types of virus coding the gene of interest or shRNA can be used. Viruses (retrovirus, 
lentivirus, adenovirus, or adeno-associated virus (AAV)) differ mostly by their ca-
pacity to infect proliferative or quiescent cells and to integrate or not host genome. 
To circumvent the fact that shRNA does not induce 100% inhibition, the CRISPR 
technology has been developed. Another key point especially for long-term studies is 
to decide if the gene has to be expressed or repressed permanently or at a precise time. 
For the last case, inducible promoter or Tet-on/Tet-off technologies are used.
After the first or the second passage, cells are incubated with viral particles at mul-
tiplicity of infection (MOI) 10 in a small volume of serum-free medium. After 6–16 h, 
fresh FCS-containing medium is added to complete the volume to usual one (e.g., in 
25 cm2 flasks, transduction is made in 0.5 mL serum-free medium, and then, 3 mL 
FCS-containing medium is added). Medium is changed after 48 h, and percentage of 
transduction using a fluorescent reporter gene (e.g., RFP, GFP, and YFP) present in the 
vector is estimated 72 h after transduction to avoid overestimation due to pseudotrans-
duction. To obtain 100% transduction, an antibiotic resistance gene such as puromycin 
resistance gene can be added in the vector construct. Otherwise, cells can be sorted by 
flow cytometry to obtain around 95% transduction.
3.  Isolation of immune cells
Besides the role of epidermal cells (melanocytes-keratinocytes) and/or dermal cells 
such as fibroblasts, vitiligo is often associated with an exaggerated response of both 
the innate and the adaptive immune system [4]. Indeed, infiltration of T cells is con-
sistently found in perilesional margin of the actively depigmenting skin of vitiligo 
patients and plays a crucial role in the loss of melanocytes. T cells expressing CXCR3 
infiltrate the vitiligo skin in response to chemokine ligands CXCL9/CXCL10 pro-
duced by keratinocytes [22,23]. Isolating these cells to analyze their precise pheno-
type, function, and their capacity to respond against melanocytes is critical in order to 
decipher the link between the response of the immune system and defect of melano-
cytes in vitiligo.
3.1  Isolation of peripheral blood mononuclear cells
First, the isolation of vitiligo peripheral blood mononuclear cells (PBMC) is per-
formed through the stratification onto a Ficoll density gradient (1.077), which allows 
the separation of mononuclear from polynuclear and red cells. PBMC localize at the 
interface between plasma and Ficoll, whereas polynuclear cells, after centrifugation, 
go to the bottom of the tube. After recovery, PBMC are washed twice with a saline 
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solution and used as planned. The procedure should be carefully performed (short 
time, <30 min, between blood withdrawal and PBMC isolation; gentle manipulation) 
in order to avoid any physical stress able to affect vitiligo PBMC independently of 
in vitro tests. Theoretically, vitiligo PBMC may be used even after freezing in DMSO/
serum mixture. Then, T cells can be isolated through positive or negative selection 
(MicroBeads) or using cell-sorting technology.
3.2  Isolation of skin antigen presenting cells  
(skin dendritic cells and Langerhans cells)
Antigen-presenting cells such as Langerhans cells (LC) or dermal dendritic cells (DC) 
play an important role in vitiligo by activating skin T cells. These cell subsets can be 
purified from the normal human skin [24]. Subcutaneous fat is excised, and the remain-
ing tissue is washed with phosphate-buffered saline (PBS). The dermal layer is heavily 
scored with a scalpel and incubated with 1 mg/mL type 1 collagenase (Invitrogen), 
1 mg/mL dispase (Invitrogen), and penicillin-streptomycin solution overnight at 37°C. 
Epidermal and dermal sheets are separated and placed in RPMI 1640 supplemented 
with 10% pooled human serum (Cellgro Mediatech), 0.1% gentamicin reagent solution 
(Invitrogen), and 1% 1 M HEPES buffer (Sigma-Aldrich). After 48 h at 37°C, cells are 
collected and filtered with 40 μm cell strainers (BD Biosciences) and then enriched 
with a Ficoll-diatrizoate gradient (GE Healthcare Bio-Sciences). LC are further puri-
fied by positive selection using anti-CD1a MACS (Miltenyi Biotec). Dermal DC are 
purified by positive selection using BDCA1+ isolation kit (Miltenyi Biotec).
3.3  Isolation of skin T cells
Various techniques have been described to extract skin T cells. First, full-thickness 
human skin samples are extensively minced and incubated for 2 h at 37°C in RPMI 
1640 containing 0.2% type I collagenase (Life Technologies) and deoxyribonuclease 
I (30 Kunitz units/mL, Sigma-Aldrich). Thereafter, cells are collected by filtering the 
 collagenase-treated tissue through a 40 mm cell strainer. Another method to extract T 
cells out of the skin uses three-dimensional matrices. A 4 mm-diameter punch biopsy 
taken from vitiligo patients or the normal skin obtained from plastic surgery can be 
used to extract skin T cells. First, subcutaneous fat is removed, and the tissue is minced 
into explants of approximately 2 × 2 × 2 mm in size. Skin explants are placed on the 
surface of Cellfoam matrices (grids, Cytomatrix Pty Ltd., Melbourne, Australia) 
coated with type I collagen and allowed to briefly air-dry to maintain adherence of the 
skin to the matrix. The matrices and skin are then placed in wells of a 12 mm-diameter, 
0.4 mm-pore-size polyester membrane transwells (Corning, Corning, NY), and the 
culture is maintained submerged in 2 mL of Iscove's modified medium (Mediatech, 
Herndon, VA) containing 20% heat-inactivated fetal bovine serum (Sigma, St Louis, 
MO), penicillin and streptomycin, and 3.5 mL/L β-mercaptoethanol with feeding three 
times per week. For feeding, 1 mL (of total 2 mL) is aspirated and replaced with fresh 
medium. The use of transwells was optional; T cells are then isolated by aspiration 
of medium in the wells and by thorough flushing of the matrices. To expand T cells 
without affecting their phenotype, interleukin (IL)-2 and/or IL-15 is added from the 
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initiation of culture until collection of T cells after up to 21 days. Human recombinant 
IL-2 is included at 100 U/mL. Human recombinant IL-15 is added at 20 ng/mL [25].
4.  Next generation cultures
Isolating primary cell subsets do not completely reflect the complexity of the skin 
microenvironment. Growing estimation is recently gained by the extracellular envi-
ronment role on cellular behavior. The network between mechanical, chemical, and 
structural aspects of the environment heavily affects the cell function. Considering 
that physiologically, the cells are not seeded on plastic or glass but grow in a 3-D 
space, biomaterials, including hydrogels, have been developed to investigate the com-
plex world of live cells. Most of functional data on cultured cells arise from 2-D sup-
port, such as flat stiff materials (polystyrene and glass), determining per se flattened 
shape, aberrant polarization, the loss of differentiation, and altered response to drugs. 
Hydrogels, that are water-swollen networks of polymers, have been developed to over-
come this problem by mirroring, more than standard stiff supports, the physiological 
extracellular matrix. Currently, several different types of hydrogels are commercially 
available, both natural and synthetic (or mixed), characterized by specific physical 
and chemical properties. The companies BD Biosciences, Baxter, Johnson & Johnson, 
Sigma, Pronova, and BioTime, Inc. are the major vendors of the different hydrogels 
for both 2-D and 3-D cultures. According to their different physical features, each hy-
drogel is more or less suitable, based on epitope accessibility or stability and protein/
RNA recovery, for microscopy, flow cytometry, or molecular studies [26].
5.  Three-dimensional models to study pigmentation
To better understand cell subsets behavior in their proper microenvironment and their 
relation between each other, three-dimensional models can be developed. As early 
as in 1979, Pruniéras et  al. have demonstrated that it is possible to obtain a fully 
differentiated epidermis in vitro by simply raising keratinocytes up to the air-liquid 
interface [27]. Apparently, the interface with air stimulates synthesis of profilaggrin 
by keratinocytes and thus the appearance of the granular phenotype when keratohy-
alin granules develop [28]. The epidermis can be reconstructed using various sup-
ports: dead deepidermized dermis (DDD) [27], gel of collagen (EpiSkin), lattices 
including fibroblasts and collagen [29], lattices including fibroblasts and collagen- 
glycosaminoglycan-chitosan [30], human fibrous sheet [31], and basal inert substrates 
such as porous filters [32]. Reconstructed epidermis models have been perfected by 
adding melanocytes [33]. These reconstructed epidermis containing both keratino-
cytes and melanocytes on DDD [34] and polycarbonate filters (BIOalternatives and 
SkinEthic RHPE) reproduce the epidermal melanin unit (EMU) and are suitable to 
study pigmentation. In addition, reconstructed models containing also immune cells, 
as LC [35] or T cells [36], or endothelial cells [37] have been developed; nonetheless, 
they have not been tested in vitiligo experiments.
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5.1  In vitro reconstructed pigmented epidermis using 
polycarbonate filters
Melanocytes and keratinocytes (from healthy skin or nonlesional vitiligo skin) at pas-
sage 2 or 3 are seeded at 5 × 105 cells/insert (melanocyte/keratinocyte ratio of 1:10) in 
a 12 mm-diameter polycarbonate Millicell inserts (Millipore) placed in six well plates, 
in complete EpiLife medium (Cascade Biologics) supplemented by 5 μg/mL insulin 
and 1.5 mM CaCl2. Twenty-four hours after seeding, the medium is renewed and com-
pleted with 50 μg/mL vitamin C and 3 ng/mL KGF, and the inserts are shifted to the 
air/liquid interface for 10 days before functional studies (Fig. 1).
(A)
(B)
Fig. 1 Reconstructed pigmented epidermis using polycarbonate filter: (A) Hematoxylin and 
eosin staining associated with ES staining associated with Warthin-Starry staining to visualize 
melanocytes at the basal layer of the epidermis. (B) Immunofluorescence using anti-TRP-1 
antibody (green, melanocytes); cell nuclei are labeled with DAPI (red); observation of the 
basal side by confocal microscopy.
136 Skin Tissue Models
5.2  In vitro reconstructed pigmented epidermis containing 
fibroblasts
This model uses the same method and media as described above, but epidermal cells 
(keratinocytes and melanocytes 10:1 ratio) are uploaded on a previously prepared col-
lagen gel containing fibroblasts (dermis equivalent). The dermis equivalent is pre-
pared by mixing a rat tail collagen solution to fibroblast suspension (1.3 mg/mL and 
0.5 × 106 cells/mL, final concentration/content, in a volume of 400 μL/insert). After 
2 h, polymerization/solidification, the epidermal cell suspension is added for 2 days. 
Inserts are then placed at the interface air medium on a sterile gauze with a medium 
change every 2 days (Fig. 2).
5.3  In vitro reconstructed pigmented epidermis using dead 
deepidermized dermis
5.3.1  Preparation of dead deepidermized dermis
Human dermis is obtained from plastic surgery specimen from normal adults, mostly 
breast reduction specimen. Skin samples are thinned, cut into very small pieces, and 
incubated at 37°C in Hank's balanced salt solution until epidermis can be removed 
without excessive scraping. After removal, the dermis is rinsed in 70° ethanol and 
submitted to two cycles of freezing and thawing and stored in Hank's balanced salt 
solution at −20°C until use.
5.3.2  Epidermal reconstruction
Melanocytes and keratinocytes (from healthy skin or nonlesional vitiligo skin) at pas-
sage 2 or 3 are seeded in an incubation chamber placed on the epidermal side of 
Fig. 2 Reconstructed pigmented epidermis containing fibroblasts. Melanocytes were stained 
for the PMEL17 protein (HMB45).
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DDD at 4 × 105 cells/cm2 at a melanocyte/keratinocyte ratio of 1:20 (5%) for normal 
melanocytes [34] and 1:20 or 1:10 (5%–10%) for vitiligo melanocytes since vitiligo 
melanocytes have a defective adhesion [38,39]. Twenty-four hours after seeding, the 
incubation chamber is removed, and the DDD is immersed for 3 days. Epidermal re-
construction is shifted to the air/liquid interface for 8 days before functional studies. 
The model can be improved by seeding fibroblasts in an incubation chamber placed on 
the dermal side of DDD 72 h before seeding keratinocytes and melanocytes (Figs. 3–5).
5.4  Inflammatory reconstructed skin model
To better understand the interplay between the immune system and melanocyte loss 
in vitiligo, T cells can be incorporated to the reconstructed skin. A human 3-D skin 
equivalent model containing keratinocytes and populated with CD4 T cells has been 
developed [36]. Blood or skin isolated T cells (0.25 × 106 to 2.5 × 106 T cells) could 
be introduced in the reconstructed skin to analyze the consequences of the presence 
of immune cells on keratinocytes. After 4 days of culture, T cells can be observed in 
the dermis or in the epidermis of the reconstructed skin. A similar model with recon-
structed pigmented epidermis (containing keratinocytes and melanocytes) where vit-
iligo T cells would be added is of interest to study the impact of T cells in melanocyte 
loss. The possibility to include antigen-presenting cells into the equivalent skin model, 
Colonization
Control or vitiligo keratinocytes
Control or vitiligo melanocytes
72 h
72 h
7 days
24 h
24 h
Adhesion
Adhesion
Proliferation
Differenciation
DDD
DDD
Normal or vitiligo fibroblasts
Fig. 3 Model of reconstructed pigmented epidermis using dead deepidermized dermis (DDD).
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as LC, has also been demonstrated [35]. Yet, models with either T cells or LC have 
not been tested in vitiligo experiments so far. Moreover, due to the difficulty to obtain 
from the same patient sufficient skin samples to isolate both epidermal and immune 
cells, an autologous model is often difficult to perform, introducing an important bias 
to consider in the analysis of the results obtained.
Pigmented epidermis can therefore be reconstructed on dead deepidermized der-
mis (DDD) or polycarbonate filters. The main difference between these two types of 
support is the formation of epidermis with rete ridges only possible on DDD. Thereby, 
this model allows testing molecules that modulate the dermoepidermal interaction 
[40]. However, due to biological origin of DDD, quality of pigmented reconstructs is 
variable, and standardization of reconstructs is not possible. On filter, all the processes 
(A)
(B)
Fig. 4 Reconstructed pigmented epidermis using DDD: double staining melanA (red)-
E-cadherin (green) on reconstructed epidermis using normal keratinocytes and normal 
melanocytes (A and B).
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are standardized, and since the quality of cells can be managed before reconstruction, 
this model ensures production of reconstructs of similar architecture.
To date, no pigmented reconstructions on collagen gel without fibroblasts are avail-
able. Introduction of fibroblasts in DDD or in collagen (lattice) allows testing the 
influence of fibroblasts on pigmentation and differentiation. However, on DDD, the 
real number of colonizing fibroblasts is difficult to manage; thus, this model is only 
suitable for basic research. Fibroblasts have to be used carefully since passages [41] 
and age impact the secretion of soluble factors by fibroblasts, which may influence 
the reconstructions.
Therefore, having introduced the different techniques to allow isolation the  different 
cell subsets involved in vitiligo pathogenesis and described methods for developing 
(A)
(B)
Fig. 5 Reconstructed pigmented epidermis using DDD: double staining melanA (red)-E-
cadherin (green) on reconstructed epidermis using vitiligo melanocytes (A) or keratinocytes 
and melanocytes from vitiligo patient (B).
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three-dimensional pigmented epidermis, these techniques can be used to better under-
stand the functional interplay between each cell subsets involved in the pathogenesis 
of the disease.
6.  Functional studies
6.1  Functional studies of vitiligo cells using monolayers: 
Melanocytes, keratinocytes, and fibroblasts
Cell cultures can be used to characterize the phenotype of vitiligo melanocytes as 
compared with control pigment cells under various treatments such as UV or pharma-
cological agents. The cells are usually seeded the day before to obtain 60%–70% con-
fluency on the day of treatment. Various techniques can be used to observe melanocyte 
behavior. Direct observation by microscopy on fixed and specifically stained mela-
nocytes (melan-A, DOPA, c-kit, S-100, and HMB-45) gives information on shape, 
dendricity, and pigmentation. DOPA staining is often used as alternative method to 
overcome the poor melanocyte number. Vitiligo melanocyte and keratinocyte cultures 
can be tested in  vitro in order to determine their specific susceptibility to noxious 
stimuli or to physiological growth factors. UVB, cumene hydroperoxide, and tert- 
butyl-phenol are the most used stimuli [33,42–49].
Moreover, these cells can be also tested in vitro with pro- or antiinflammatory sol-
uble factors. Recombinant cytokines identified as predominantly expressed in vitiligo, 
alone or in combination, could be added at various concentrations to stimulate vitiligo 
or normal melanocytes or keratinocytes [50]. Another way could be to test the culture 
supernatant of T cells isolated from vitiligo blood or skin following in vitro activation 
with anti-CD3/CD28.
Cell proliferation and mortality can be assessed through MTT test, manual cell 
count, annexin V/propidium staining, DNA ladder, or caspase profile [51]. In addition, 
the morphology and mode of melanosome transfer in vitro can be studied using atomic 
force microscopy, which allows to estimate and quantize the measure and the distri-
bution of the dendrites including internal melanosomes distribution and arrangement 
[48,49,52]. Culture on 3T3 feeder layer induces the formation of colonies of kerati-
nocytes that vary in size according to the state of cell proliferation, differentiation, or 
senescence. Lesional vitiligo keratinocytes are characterized by a lower proliferative 
potential, as indicated by a shorter in vitro life span. Moreover, the expression of p16, 
PCNA, p53, and p63 markers differs between lesional and nonlesional cells. Lesional 
keratinocytes show a lower level of the senescence marker p16 and a higher level of 
the melanocyte growth factor SCF [53].
Genetically modified cells in monolayer can be useful to verify if putative 
gene can reproduce some key features of diseased cells mostly adhesion and 
dendricity for melanocyte, but sometimes, in monolayer, cells do not express 
protein they express in tissue. For example, melanocytes in monolayer do not 
express E-cadherin, thus silencing of E-cadherin has no effect on their behavior 
in culture. Several genes are implicated in cell adhesion, but their silencing may 
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have various effect; silencing of DDR1 (collagen IV receptor) has no effect on 
plastic adhesion, whereas silencing of CCN3 (melanocyte's homeostasis) is lethal 
for melanocytes [8].
6.2  Functional studies of vitiligo cells by next generation 
approach
Cultures can be also used to perform functional studies based on epigenome editing. 
This branch of biology refers to directed alteration of chromatin marks at specific ge-
nomic loci by EpiEffectors aiming to durable gene regulation with application in basic 
research and clinics. Targeted deposition or removal of chromatin modifications is a 
powerful approach for functional studies. It includes histone posttranslational modi-
fications, DNA methylation, and hydroxymethylation, which in concert regulate the 
gene expression. The available profile of chromatin modifications yields thousands 
of global scale epigenomic maps. In preclinical studies, epigenome editing will give 
rise to a fine mapping of the regulatory mechanisms leading to health/disease process. 
It is an integrating part of interdisciplinary field of synthetic biology. It represents 
new and interesting avenues to treat metabolic diseases, possibly including vitiligo, 
characterized by aberrant signaling pathways through a causative therapy. However, 
some questions are still open: Which modifications have a causal role in governing 
processes such as transcription or alternative splicing? Which modifications lead to 
stable and heritable changes in chromatin status? Which chromatin behavior affects 
the maintenance of such modifications? Is the specificity per se able to provide clin-
ical applications? [54]. Recently, single-cell epigenomic approach was developed by 
combining several different high-throughput techniques allowing studies on cytosine 
modification, protein-DNA interaction, chromatin structure, and 3-D organization 
[55]. Single-cell epigenomic studies might complement single-cell transcriptome and 
genome analysis in defining for example vitiligo melanocytes. Therefore, targeted 
therapeutics can be designed to better improve melanocytes regeneration.
6.3  Functional studies using reconstructed epidermis
Monolayer cultures and cocultures [56] are useful to study vitiligo melanocytes and 
keratinocytes direct (cell-cell contact) or indirect interaction (soluble factors/culture 
insert), but they do not reproduce the tridimensional interactions of cells of the EMU. 
Epidermal reconstructs, which reproduce the EMU and basal membrane attachment, 
are thus a handful “in vivo-like” model. Indeed, reconstructions of different levels of 
complexity can be prepared (reconstructs with keratinocytes alone, keratinocytes and 
melanocytes, keratinocytes, melanocytes, and fibroblasts), including chimeric recon-
structs (normal vs pathological cells). According to the initial reflection, the analysis 
of the behavior of melanocytes and keratinocytes is done in a more physiological envi-
ronment than that of monolayer cultures and cocultures and allows to test conveniently 
compounds that are suspected to be implicated in vitiligo etiology or susceptible to im-
prove the attachment and survival of melanocytes upon the basal layer. An example of 
epidermal reconstructs tested with epinephrine, norepinephrine, dopamine, hydrogen 
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peroxide, or vitiligo sera is illustrated in Fig. 6. Our main results using this model [39] 
were the following: reconstructs made with melanocytes from nonlesional generalized 
vitiligo skin have a significantly reduced number of basal layer melanocytes, and the 
presence of vitiligo keratinocytes enhances this effect. Vitiligo sera may induce mela-
nocyte detachment independently of the disease activity or extent. Hydrogen peroxide 
induces melanocyte detachment in reconstructs containing vitiligo melanocytes and 
normal keratinocytes, but not in normal controls. Epinephrine, but not norepinephrine, 
allows melanocyte detachment. Lastly, the effect of T cells or soluble factors produced 
by these cells in reconstructed pigmented epidermis would be important to decipher 
their precise role in the process leading to melanocyte loss in vitiligo.
Epidermal reconstructs are useful to address several research questions regarding 
the pathomechanism involved in melanocyte loss in vitiligo: Is the melanocyte pri-
marily affected? Is the cellular environment important (keratinocytes and fibroblasts)? 
Are other (soluble) factors implicated in the development of vitiligo? However, this 
model has some limitation since we have not yet been able to introduce, for instance, 
LC or other immune cells to study their implication in vitiligo etiology; the study of 
topical molecules to improve vitiligo treatment is less easy than that of soluble fac-
tors and that long-term studies (>3 weeks) are not possible, since there is no renewal 
of the basal layer. Moreover, the analysis of intracellular signaling and membrane 
assessment per cell can be just on a single-cell-type culture, when cell sorting is not 
available.
Modelization of vitiligo by transgenesis has mostly to do with melanocyte. Since 
we supposed that genetic defect in vitiligo melanocyte does not induce per se detach-
ment of melanocytes, experiments are designed in two steps. The first step consists to 
analyze the behavior of genetically modified melanocytes in reconstructed epidermis 
in the absence of stressor. In a second step, vitiligo known stressors are used to induce 
melanocyte detachment if the tested modification alone has not induced a mislocal-
ization of melanocytes. Silencing of CCN3 in melanocyte induced a decrease in the 
number of melanocytes and the detachment of melanocyte according to the level of 
CCN3 inhibition [20]. On the other hand, hydrogen peroxide induces a detachment of 
E-cadherin silenced melanocyte as for vitiligo (Fig. 7) [21]. This model affords good 
Fig. 6 Model of melanocytes migration: Fontana-Masson staining of reconstructed epidermis 
with melanocytes. Detached melanocyte (white arrow) after incubation with vitiligo serum 
during 17 h.
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opportunities to study molecules on genetically altered cells; however, the effect of 
the molecules has to be fast enough to be seen in this model that can only be studied 
during 3 weeks.
7.  Analytic techniques
7.1  Fluorescence-based assays
Fluorochrome-conjugated monoclonal or polyclonal antibodies are widely applied to 
visualize and quantify the expression of some surface or internal melanocyte mark-
ers [35,57–59]. The first data were derived from immunohistochemistry methods on 
frozen and paraffin-embedded sections, followed by fluorescence and confocal mi-
croscopy on slide-cultured cells. Phenotypic characterization of cultured vitiligo mela-
nocytes with respect to control cells was carried out and revealed a reduced expression 
of c-Kit, endothelin 1 (ET-1) receptor, tyrosinase, and MITF in vitiligo melanocytes, 
with a pattern progressively varying from the edge of the white spot to the nonlesional 
area [58]. A flow cytometry approach permits both a qualitative and quantitative mul-
tiparametric and time-dependent analyses. Membrane and intracellular staining to-
gether with the analysis of the physical and biological parameters allows the structural 
and functional characterization of melanocytes and their sorting for further cultures. 
Beside the antibody-based approach, flow cytometry has been used to detect in vit-
iligo melanocytes levels of intracellular ROS production (DCFH-DA or dhRho123 
staining), membrane lipo-peroxidation [60] (BODIPY581/591 staining), and content 
and transmembrane cardiolipin distribution (NAO fluorescence pattern) [42]. Several 
new approaches, based on “fluo world,” are now available. Most of these innovative 
technologies have not yet been applied to the study of vitiligo, but they open promis-
ing perspectives. The laser scanning cytometer (LSC) permits slide-based cytometry 
(SBC) and the hyperchromatic approach. Its potential use in vitiligo study arises from 
its intrinsic features: nonconsumptive, iterative restaining, differential photobleaching 
Fig. 7 Epidermal reconstruction using transgenic cells: double staining melanA (red)/E-
cadherin (green) on reconstructed epidermis using normal keratinocytes and melanocytes 
inhibited for E-cadherin.
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(fluorochromes differentiated on the basis of their specific photostability), and pho-
toactivation (for nanoparticles or photocaged dyes). A single cell can be reanalyzed, 
whereas the information gained per specimen is only limited by the number of avail-
able antibodies and sterical hindrance [61].
7.2  Proteomic
Mass spectrometry in conjunction with free-flow electrophoresis of sucrose density 
gradient has allowed the identification of early-stage melanosome proteins [62]. Two-
dimensional differential image-gel electrophoresis (2D-DIGE) and liquid chromatog-
raphy tandem mass spectrometry (LC-MS/MS) allow the analysis and identification 
of the protein components of the organelles of melanocytes with melanosomes at 
different maturation stages [63]. Even if proteomic assays have been so far carried 
out on murine healthy melanocytes, the scenario possibly designed by this approach 
may be crucial for the maturation process leading from nonpigmented melanocytes to 
pigmented melanocytes in vitiligo. Starting from the consideration of vitiligo as met-
abolic multifactorial disease, an analysis of the systemic proteomic profile will sup-
port its characterization. Recently, proteomic approach was applied to formalin-fixed 
 paraffin-embedded tissue [64].
7.3  Metabolomic
Metabolomics is an emerging field of biological science and considers the high- throughput 
characterization of small compounds (<1500 Da) representing the final products of cellu-
lar metabolism that mirrors the chemical fingerprint of an organism at a precise point. It 
aims to identify and quantify the metabolites to correlate their changes with pathological 
conditions or with drug intake. Accordingly, metabolomics is one of the building blocks 
of biology systems. Metabolomic studies generate a complex set of data requiring spe-
cialized analyses based on cheminformatics, bioinformatics, and statistics expertise.
With regard to the specific vitiligo application, metabolomic research will provide 
a fingerprinting of the metabolic activities related to immune deregulation and degen-
erative process, possibly merging the vitiligo profile with those known and described 
in other diseases and health population. The separation techniques are based on gas 
chromatography, high-performance liquid chromatography, and capillary electropho-
resis; the detection techniques usually are done by mass spectrometry or nuclear mag-
netic resonance [65].
7.4  Transcriptomic
Recently, oligonucleotide-based microarrays have been used to explore the pattern 
of gene expression of vitiligo melanocytes. Interestingly, the most upregulated genes 
are related to the network of endosome and lysosome organelles. The next step is to 
analyze the various clusters of the differentially expressed genes. This approach can 
represent the basis for further in-depth analyses to better clarify the complex vitiligo 
pathomechanisms [66].
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The fields of genomics and transcriptomics have known a considerable progres-
sion with the next-generation sequencing (NGS) technology [67]. RNA-sequencing 
on samples or even on single cells represents an innovative approach for both mapping 
and quantifying a large number of transcribed RNA in a given sample. Such method is 
of interest to improve our understanding on vitiligo pathomechanisms through identi-
fication of genes important in depigmentation and melanocyte loss.
8.  Concluding remarks
Cell culture models are useful to investigate the differences between normal and vit-
iligo cells and to test potential treatment options in a cell-focusing approach. New 
analytic techniques using a limited amount of biological material are very promising. 
Beyond the study of vitiligo pathomechanisms or therapies using unmodified patient's 
cells, in vitro approaches can be also adapted to generate melanocyte-specific silencing 
or overexpression of putative target genes or, a further step, to design animal models 
using melanocyte-specific expression of modified genes. The study of various issues 
pertaining to vitiligo, including the role and regulation of transcription factors, organ-
elle genesis, intracellular transport, stem cell maintenance, and senescence, can be 
envisaged [68]. This step will allow the development of vitiligo models using normal 
cells bypassing the difficulty to culture vitiligo cells, which is currently the limiting 
factor for studying vitiligo in vitro. Combining these approaches with new generation 
tools (genomic and transcriptomic analyses and proteomic and/or metabolomic analy-
ses) could be of major interest to precisely define primary defect of cells in the context 
of vitiligo pathogenesis. Moreover, the thorough characterization of the phenotype 
and function of immune cells involved in human vitiligo skin could emphasize the 
role of specific cell subsets or inflammatory soluble factors that could be added in 
these models to go more in depth in the interplay between epidermal (keratinocytes- 
melanocytes) or dermal cells (fibroblasts) with innate or adaptive immune cells.
Finally, one limit of our manual technique of reconstruction is that it does not en-
sure a homogenous deposition of melanocytes on dermis. 3-D printing could address 
this point in the future; yet, nobody has printed melanocytes so far, and nobody has 
been able to print a single cell, which represents a better way to study molecules in 
a similar environment. Indeed, such technology would allow on the same reconstruct 
printing of both unmodified and modified cells.
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Nonmelanoma skin cancer is the most prevalent and steadily increasing cancer world-
wide. Cutaneous squamous cell carcinomas (cSCCs), the second most frequent tumor 
of that group, have gained strong metastatic potential and, in absolute numbers, are 
causing as many deaths as malignant melanoma. Immunosuppression of transplant 
recipients and novel cancer treatment modalities, such as the BRAF inhibitors, suc-
cessfully applied for treating malignant melanoma, further increases the incidence of 
cSCC. Thus, understanding the cSCC’s pheno- and genotype and mechanistic traits 
induced by the different compounds will be an absolute requirement to develop new 
treatment strategies. Therefore, the use of models that perfectly recapitulates this tu-
mor type can thereby help to further unravel fundamental biological questions and to 
function as preclinical models to test, for example, novel treatment strategies.
1.  Nonmelanoma skin cancers
Nonmelanoma skin cancer comprises several tumor types, with basal cell carcinoma 
(BCC) and cSCCs, the first and second most prevalent, respectively, representing 20% 
of all nonmelanoma skin cancers. While BCCs are locally destructive but rarely me-
tastasize, cSCCs are more aggressive with a metastasis rate of up to 5%. As metastasis 
still lacks successful treatment, cSCCs contribute to the high cancer mortality rate 
of the present. It is estimated that one in every six North American will develop skin 
cancer during his/her lifetime, and the incidence of cSCC in Europe has increased up 
to 3%–8% each year since the 1960s (reviewed by Leiter et al. [1] and Perez et al. [2]).
The reason for this continuous increase is in part due to an altered attitude to-
ward tanning, which has seen a rise in excessive sun exposure and use of tanning de-
vices. Indoor tanning was first introduced in Europe in 1906, by the German company 
Heraeus, as sunlight therapy for patients suffering from bone diseases like rickets to 
help them develop more vitamin D. In the 1920s, being tanned became a trend, which 
lead to the development of sunbeds, a method by which to simulate sun by controlled 
UV exposure, by the 1970s. Ever since, the production of tanning beds is an ever- 
growing industry. However, due to the strong correlation with skin  cancer,  tanning 
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salons and tanning bed manufacturers are now restricted by defined skin cancer pre-
vention guidelines (IARC Working Group, 2007; WHO Artificial tanning sunbeds: 
risk and guidance, 2003). As skin cancer development typically requires 2–3 decades 
or more between the period of sun exposure and tumor onset, the consequence of fre-
quent and/or regular use of sunbeds is already started to show and is likely to continue 
to increase the incidence of skin cancer in the future [3,4].
2.  Risk factors for the development of cSCCs
2.1  Immunosuppresion and cSCC
While skin cancer is largely a disease of old age, due to the required accumulation 
of genetic events and a possible contribution of the age-dependent increase in im-
paired immunity (e.g., [5]), the immunosuppression required by transplant recipients 
has been suggested to influence UV sensitivity and strongly accelerates skin cancer 
development at younger age. This is particularly true for cSCC development. While 
immunocompetent patients show a general prevalence for BCCs with a ratio of 4:1 
compared with cSCC, this ratio reverses in the immunosuppressed transplant recipi-
ents who bear a 100-fold risk for the development of cSCC (Scottish Intercollegiate 
Guidelines Network (SIGN). Edinburgh: SIGN, 2014). Further, these tumors that 
occur earlier in life are more aggressive, with a metastasis rate of up to 10%, and 
frequently occur as multiple cSCCs, also termed carcinomatous catastrophe. While 
this may support the notion that the immune system plays an important role in per-
mitting cSCC development and/or progression, there is evidence that the risk con-
ferred is dependent on the specific drug used and, thus, immune-independent factors 
may also play an important role [6]. Moreover, Abikhair and colleagues provided a 
link between the immunosuppressive agent cyclosporine A (CsA) and IL-22 in the 
tumors of the immunosuppressed cSCC patients. They found that “CsA drives T cell 
polarization toward IL-22-producing T22 cells, and CSA treatment increased IL-22 
receptor in SCC cells” [7]. Since inhibition of IL-22 action reduced the tumor burden 
in their mouse model, they proposed anti-IL-22 treatment as a potential therapy to 
antagonize cSCC development in immunosuppressed transplant recipients. As the 
number of transplant recipients is steadily growing, there is a clear demand for better 
understanding and improve treatment modalities to combat this devastating type of 
skin cancer.
2.2  Smoking and cSCCs
While it was still a matter of debate whether smoking is a risk factor for developing 
cSCCs (see [8], and references therein), a recent study of as many as 43,794 skin 
cancer patients suggested that former smoking, irrespective of time and dose, did 
not influence the risk for skin cancer. However, for current smokers, the risk for 
developing a cSCC was significantly increased while that of developing a BCC was 
reduced [9].
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2.3  Targeted therapy and cSCC
Upon targeted therapy, the skin is the tissue with the strongest adverse effects. As per-
fectly reviewed by Tang and Ratner [10], tyrosine kinase inhibitors frequently cause rash 
and perturb differentiation as particularly obvious for EGFRi (epidermal growth factor 
receptor inhibitor) and the tyrosine kinase inhibitor imatinib. For the multikinase inhibitor 
sorafenib, the adverse development of single or multiple keratoacanthomas (KAs) and 
cSCCs was reported. Also, the hedgehog pathway inhibitor vismodegib, applied for the 
treatment of BCCs, caused rapid appearance (within 4–12 weeks) of single or multiple 
cSCC at sites distant to the primary BCC. This is unexpected, since hedgehog/Gli1 sig-
naling was long thought to be relevant for the regulation of hair follicles and its aberrant 
expression to be a characteristic for BCCs. Furthermore, it was recently shown that an 
aberrant hedgehog/Gli1 signal pathway facilitates proliferation, invasion, and migration 
of cutaneous SCC through regulating VEGF [11,12], thus further questioning the mech-
anism underlying the adverse event of cSCC development upon vismodegib treatment.
Also therapies with PD-1 or PDL-1 (programmed cell death-1 receptor and ligand) 
give rise to skin phenotypes. These immune-based checkpoint inhibitor therapies have 
demonstrated a distinct toxicity profile compared with chemotherapy, with the skin 
belonging to the most common target organ and erythema (rash) to the most common 
appearance of adverse events (reviewed by Maughan et al. [13]). It should be expected 
that when these drugs are more commonly used, the overall magnitude of adverse 
events would further increase.
The most severe example of skin-related adverse events relates to the BRAF in-
hibitors (vemurafenib and dabrafenib) used for the treatment of malignant melanoma. 
Vemurafenib treatment causes rapid development of KAs and cSCCs in up to 30% of 
the patients (for reference, see, e.g., [14]). Having identified adverse hyperactivation 
of the RAF-MEK-ERK pathway in the melanoma cells, BRAF inhibitors were com-
bined with MEK inhibitors. Comparing monotherapy with combination therapy, Erfan 
et  al. concluded that “combined treatment of MAPK inhibitors may prevent some 
of the skin toxicities, including the rapid development of cSCCs.” Interestingly, the 
most frequent side effects, such as keratosis pilaris (KP)/hyperkeratinization of hair 
follicles; palmoplantar keratoderma (PPK)/hyperkeratosis, that is, perturbation of dif-
ferentiation; and photosensitivity, were not prevented [15]. Thus, targeted anticancer 
therapies can cause cutaneous adverse events different from classical chemotherapeu-
tic toxicities, which even include the rapid development of cSCCs.
3  What is known about the genetics of cSCCs
The etiology of cSCCs is multifactorial, and besides chemicals such as polycyclic 
aromatic hydrocarbons, UV radiation is believed to be the causal exogenous inductor. 
Accordingly, in 2009, the World Health Organization (WHO) accepted UV radiation 
into the group 1 of agents considered to be “carcinogenic in humans” [16]. In agree-
ment with that, cSCCs predominantly develop at sun-exposed sites of the skin that also 
show other signs of sun damage. Interestingly, even for sun-exposed sites, the specific 
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location of the primary tumor can be indicative of aggressiveness. It is suggested that 
cSCCs of the ear and lip are more prone to metastasize than cSCC from other sun- 
exposed sites [17]. In the guidelines of the National Comprehensive Cancer Network 
(NCCN), the list is extended to also other areas of the face including the eyelids, 
eyebrows, nose, and chin (NCCN, Guideline Version 1.2016, Squamous Cell Skin 
Cancer, 2016). In addition, the scalp was included as a high-risk site in the European 
guidelines [18]. Tumor diameter (>2 cm), tumor thickness, and anatomical depth have 
also been suggested as independent risk factor for tumor recurrence and metastasis; 
for example, invasion depths from 2 to 6 mm are correlated with an increase to 15% as 
summarized by Cheng et al. [19] and reviewed in a meta-analysis by Thompson and 
coworkers [20]. In addition, it has long been thought that histological grade and dif-
ferentiation are of prognostic value, suggesting that poorly differentiated cSCCs have 
a higher potential for local recurrence and distant metastasis [20]. However, many 
cSCCs are moderately well differentiated, including the more aggressive cSCCs in the 
immunosuppressed transplant recipients [21], thus arguing against the requirement for 
the loss of differentiation in order to gain metastatic potential.
A number of studies have indicated that UV light initiates cSCC development by 
causing inactivating mutations in the p53 tumor suppressor gene. Accordingly, UV-
indicative p53 mutations are still the most frequent recurrent aberrations found [22]. 
The loss of heterozygosity or loss-of-function mutations in CDKN2A are also reported 
as being frequent [23]. CDKN2A encodes two different, unrelated tumor suppressor 
proteins, p16INK4a and p14ARF. While p16INK4a contributes to the dysregulation of 
the Cdk4/6-cyclin-retinoblastoma (Rb) pathway and consequential loss of cell-cycle 
control, p14ARF mutations, although reported to be found in cSCC [24], are hardly 
followed up. This may be surprising as p14ARF is generally upregulated by oncogenic 
stimuli and serves as a critical regulator of p53 stability. The nucleolar localization of 
p14ARF may therefore be seen as a reserve to be able to cause rapid p53 induction or 
to coordinate effects on cell cycle, survival, and growth [25]. As CDKN2A mutations 
were already identified in actinic keratoses (AK), that is, precursor lesions of cSCC, 
it is suggested that they contribute to deregulating cell-cycle control but do not serve 
as tumorigenic drivers [26]. Similarly, NOTCH1, a gene involved in regulating differ-
entiation, proliferation, and apoptosis, is one of the most frequently mutated genes in 
cSCCs [27]. Depending on the cellular context, NOTCH1 has been shown to act either 
as a tumor suppressor or as an oncogene [28].
Interestingly and similar to p53 mutations, NOTCH1 loss or downregulation is 
often found in normal-looking skin, thereby supporting a role for NOTCH1—as 
it was already done earlier for p53—in cancer initiation rather than tumorigenic 
progression [27,29]. Leigh and coworkers suggested NOTCH1 “as a gatekeeper in 
human cSCC” [27].
The role of oncogenic ras, on the other hand, is still controversially discussed (for 
review, see [30]). Even in the most recent sequence analysis, the rate of HRAS mu-
tations was only 8%, a frequency similar to that listed in the COSMIC database (as 
discussed in [31]). However, the frequency of HRAS mutations may be enriched in 
cSCCs occurring in melanoma patients under BRAF-targeted therapy [32,33]. Under 
these specific conditions (vemurafenib-induced cellular and microenvironmental 
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changes), the ras oncogene may act as a driver mutation for the tumorigenic conver-
sion of human skin keratinocytes (Tham et al., in preparation).
To further increase the number of drug targets for the therapy of cSCC patients, 
a comprehensive genomic profiling was performed from 122 advanced-stage cSCCs 
[31]. This study further supported the strong mutational heterogeneity of cSCCs and, 
in addition, confirmed the presence of at least one clinically relevant (accessible for 
targeted therapy) genomic alteration in the majority of these cSCCs. Despite the ge-
netic heterogeneity, also in this study, the most frequent and recurrent aberrations 
included p53, CDKN2A, and NOTCH1, thus confirming the previous findings with 
the cohort of cSCC from immunosuppressed patients [27] and making them the most 
prevalent aberrations for cSCCs.
Noteworthy and for a long time demonstrated for p53, a high mutation load was 
identified already for normal human skin. By ultradeep sequencing of 74 cancer genes 
in small biopsies of eyelid epidermis, Campbell and colleagues reported on a bur-
den of somatic mutations as high as 2–6 mutations/megabase/cell, exhibiting charac-
teristic signatures of UV exposure [34]. Positively selected “driver” mutations were 
found in 18%–32% of the normal skin cells, and the most frequently mutated genes 
were NOTCH1, 2, and 3; p53; and FGFR3. This again demonstrates that many of the 
cancer-related genes are already existent in their mutant form in normal human skin 
where they may still contribute to tissue homeostasis. Only in combination with a 
set of aberrant regulations these mutant genes get active and become able to confer 
tumorigenicity. The genetic heterogeneity of the cSCCs further suggests that this dys-
regulation does not necessarily occur via one “well-defined pathway” but that diverse 
regulatory combinations can lead to the same result of tumorigenic conversion, thus 
being consistent with the genetic complexity required for skin cancer development 
and progression.
Specifically addressing cSCC metastases, targeted sequencing of 504 cancer- 
associated genes demonstrated that the genomes of the lymph node metastases were as 
heterogeneous as the primary cSCCs, with large variations in the number of genomic 
alterations [11]. Consistent with the primary tumors, mutations in p53, CDKN2A, and 
NOTCH1/2 predominated, with UV-indicative C to T transitions being the dominant 
substitutions in the mutation spectra. In addition, they identified mutations in genes 
affecting RAS/RTK/PI3K, squamous differentiation, cell cycle, and chromatin remod-
eling pathways. Collectively, these findings indicate a high similarity between the 
aberration profile of primary tumor and metastasis and thereby underline the relevance 
of the current skin cancer cell models as excellent tools for unraveling cSCC-specific 
functional and responsive consequences.
Inconspicuous in most of the mutation studies are EGFR (epidermal growth factor 
receptor) and c-Myc, which appear to be altered more frequently by amplification or 
gene rearrangement. Reports of EGFR amplification in cSCC have ranged from as 
low as 1% (COSMIC database) up to 20% [11]. Nevertheless, advanced tumors often 
show upregulated EGFR expression without exhibiting EGFR or RAS mutations [35], 
and overexpression of EGFR was shown to be associated with poor outcome in cSCC 
[36]. The importance of EGFR overexpression was also demonstrated in a phase II 
trial where the EGFR antagonist gefitinib caused a complete response rate in 18% of 
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the cSCC patients [37]. c-Myc aberrations were observed in 35% of AK lesions and 
63% of the cSCCs analyzed, and its relevance for skin cancer was demonstrated by the 
significant association between copy number gains and protein expression ([38] and 
references therein). In addition, changes in the micro-RNA (miR) expression profile 
are depicted between the human healthy skin and cSCC [39]. The possible change in 
regulatory competence suggests that miRNAs may be promising targets as biomarkers 
for diagnosis and prediction of prognosis and/or targeted therapies (for review, see 
[40]). In this context, it was shown that miRNA-203 targets and regulates c-myc and 
functions as a tumor suppressor in cSCC [41].
As extensively reviewed by Rudnick et al. [42], so far, most patients are treated 
with surgical means. Additionally, retinoic acid or synthetic retinoid analogues in 
combination with interferon alpha and cisplatin are administered aiming for their dif-
ferentiation, antiproliferative, and proapoptotic potential. Indeed, this combination has 
shown to produce objective response rated in locally advanced and metastatic cSCCs. 
In addition, an oral 5-FU off-label treatment for advanced cSCCs is used, and a pro-
drug of the inactive form of 5-FU is currently FAD approved. From the molecularly 
defined drugs, only the EGFR inhibitor has made it into clinical trials. Though not yet 
approved by the FDA for advanced cSCC failing standard treatment, they are aimed to 
stop proliferation and hinder EGF-dependent resistance to apoptosis. The inhibitory 
activity was proved by analyzing EGFR expression after a 14-day treatment, and for 
an observation time of 2 years, the disease-free survival rate was 60% and 73% of 
patients that remained recurrence-free [43]. Whether, for example, NOTCH1 and 2, 
as the most frequently mutated genes in cSCCs, will have the potential for targeted 
therapy remains to be seen.
4.  Role of the microenvironment
It is, however, not only the cancer cells that drive tumor initiation and progression. 
Increasing evidence has pointed to the microenvironment, with its neighboring stromal 
extracellular matrix (ECM) and soluble growth factors as major drivers of tumorigenic 
behavior (for review, see [44]). Apart from the epidermal keratinocytes, UV radia-
tion also causes genetic and epigenetic changes in the underlying dermal fibroblasts, 
thereby inducing changes that alter the interplay with the keratinocytes and allow pre-
malignant lesions to become invasive or even metastatic cSCCs. Accordingly, alter-
ations in the composition of basement membrane and dermal ECM are early events 
in cSCC progression. Proteases are required for matrix modulation and degradation 
with the consequence not only of altering tissue stiffness but also of releasing growth 
factors, cytokines, and chemokines that are preferentially stored in the ECM of the 
dermis, as perfectly reviewed by Nissinen et al. [45]. At present, the major focus re-
mains on inflammatory cells as the main source for protease production. However, the 
dermal fibroblasts are also induced to modify their growth factor and protease profile 
and even to drastically modify their ECM profile in response to chronic UV exposure 
(Bauer et al., in preparation). We further showed that upon exogenous Wnt stimula-
tion, it was not the keratinocytes but the stromal fibroblasts that became  activated 
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and expressed factors that, in a paracrine fashion, promoted keratinocyte growth and 
invasion [46].
Currently, the best documented example for a severe role of the microenvironment in 
cSCC development is provided by patients suffering from recessive dystrophic epider-
molysis bullosa (RDEB), a hereditary skin disorder based on a mutation in the collagen 
VII (COL7A1) gene responsible for causing epidermal blistering and chronic wounds. 
These patients are afflicted with an increased risk for developing aggressive and rapidly 
metastasizing cSCCs. So far, it is still elusive whether RDEB cSCCs and sporadic UV-
induced cSCCs are distinct tumor entities (for review, see [47]). However, as RDEB 
cSCCs preferentially arise in long-term skin wounds or cutaneous scars, it is suggested 
that the altered microenvironment may be of utmost importance and causally involved 
in the progression of these specific cSCCs. Bruckner-Tuderman and colleagues now 
suggest that the “inherent structural instability of the RDEB dermis, combined with 
repeated injury, increased the bioavailability of TGF-ß. TGF-ß, in turn, promotes ECM 
production, cross-linking, thickening of dermal fibrils, and tissue stiffening.” This trig-
gers myofibroblast activity in the modified dermis and consequently alters mechano-
signaling in the tumor cells, thus supporting tumor cell invasion in this “preexisting 
injury-driven microenvironment” [48]. Together, these examples accentuate the increas-
ing importance of the microenvironment in tumor progression of human cSCCs.
5.  How to study skin cancer?
Taking these findings—the genotypic and phenotypic aspects of cSCC—into consid-
eration, numerous approaches have been established to better understand their role in 
skin cancer development and progression and to allow for the establishment of models 
suitable to study these aspects and to evaluate for exogenous carcinogens and cancer 
treatment modalities.
5.1  Mouse models
For decades, the mouse has served as an important model to study skin carcinogene-
sis. Skin cancer is mostly induced by carcinogens—the two-stage skin carcinogenesis 
protocol—originating from the Berenblum/Mottram experiment [49]. In this model, 
skin cancer is based on the induction of ras mutations by the application of the carcin-
ogen Dimethylbenzanthracene (DMBA) followed by long-term promotion with the 
tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA). This skin cancer model 
is used to unravel the biological and genetic events and to determine factors that affect 
the process of skin carcinogenesis. Similarly, studies concerning the nature of the skin 
cancer-initiating cell, their malignant progression and metastasis, and the role of in-
flammation in this tumor type were successfully performed (for review, see [50]). As 
skin cancer risk is closely correlated with UV exposure, more recently, hairless mouse 
models have been utilized more frequently to induce skin carcinomas. Daily exposure 
to UVB radiation is predicted to provide a similar stimulus for tumor induction as UV 
does in human skin cancer (see, e.g., [51]).
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Undoubtedly, mouse and human differ significantly, and this is particularly relevant 
for the anatomy, physiology, and regulation of the skin and skin cancer; as best ex-
pressed by Khavari, “the skin is illustrative of these differences” [52]. One of the most 
important differences is tissue architecture. The epithelium in not only fur-coated but 
also largely furless nude mice is characterized by an extensive and dense distribution 
of hair follicles, even when being defective as in the case of nude mice. They undergo 
regular synchronized cycles, that is, are frequently activated and thereby are likely to 
contribute to the epithelial pool that is the target of skin cancer initiation. In the hu-
man skin, hair follicles are sparse and replicate asynchronously and infrequently, thus 
making the interfollicular epidermis (IFE) the major target of skin cancer initiation. 
With the differences in architecture and regeneration time of the IFE, important differ-
ences in regulatory networks also exist between the mouse and human skin, including 
the fact that the identity of the human IFE stem cells is still elusive [52–54]. Similar 
differences account for the connective tissue, the dermis, of the mouse and human 
skin. As the interaction of the tumor cells with their environment (epidermal-dermal 
interaction) is increasingly appreciated [55], these profound cross species differences 
strongly demand for experimental models that also recapitulate the stromal compo-
nent of the human skin more accurately.
Despite all differences/diversities, there is no question that genetic mouse models 
are invaluable and that, in its complexity, certain questions can yet still only be ad-
dressed in mouse models.
Accordingly, Kretzschmar and colleagues showed that the activation of β-catenin 
in different stem cells of the murine hair follicle (LGR5-, LRIG1-, and LGR6-positive 
epidermal stem cells) elicited different responses concerning the formation of ecto-
pic hair follicles and therefrom derived tumors. They also demonstrated that the dif-
ferent stem cells caused distinct changes in the underlying dermis, concluding that 
compartmentalization of epidermal stem is responsible for tumor heterogeneity [56]. 
Similarly, important is the question concerning the cell of origin for BCCs and SCCs. 
Utilizing inducible Cre drivers to delete Ptch1, the gene known as being causal for 
BCC development, in different cell compartments of the mouse skin, Peterson et al. 
demonstrated that different stem cell populations from the hair follicle rapidly develop 
BCC-like tumors, while this was not the case with stem cells from the IFE ([57] and 
references therein). By determining the role of Wnt regulation in the different murine 
epidermal stem cell populations, Kretzschmar et al. showed “that different stem cells 
are associated with different tumor types and stromal responses” and postulated that 
“compartmentalization of epidermal stem cells underlies tumor heterogeneity” [56].
Xenograft mouse models are similarly indispensable. Immunodeficient mice can 
host human tumor cells, thus enabling the identification and functional characteriza-
tion of genetic changes in the human skin cancer cells in a complex in vivo environ-
ment, thus allowing to dissect, for example, their role in angiogenic or inflammatory 
attraction. This said, we demonstrated that earlier unraveling overexpression of 
 thrombospondin-1 acts as an important tumor suppressive mechanism for human skin 
cancer by halting tumor vascularization [58]. Furthermore, new humanized mouse 
models were established in which murine recipients are engrafted with human hema-
topoietic stem cells that develop into a functional human immune system. As these 
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humanized mice can further be engrafted with other human tissues, including the skin 
and skin SCCs, they promise significant improvements in studying the role of immu-
nity and cancer (for review, see [59]).
5.2  Human models
5.2.1  2D models; tumor-derived and genetically modified cell 
lines
The aim of understanding and functionally characterizing human skin cancer was 
first explored by establishing cell lines derived from skin cSCCs [60–64]. Later, 
in vitro-derived models, such as the HaCaT in vitro skin carcinogenesis model, were 
developed through selective genetic modification to recapitulate the multistep genetic 
development of skin cancer [65–70]. Of extreme value for skin cancer research is 
also the “MET model,” comprising cell lines from the primary tumor, recurrence, 
and metastasis from the same patient [61,62]. These cells proved an excellent pen-
dant to the frequently used HaCaT model as the MET cells are wild type for the 
tumor suppressor p53 and thus allow the dissection of p53-dependent versus p53- 
independent circuits in skin cancer. Of note, the origin of A431 cells, often referred to 
and commercially distributed as a human cutaneous epidermoid carcinoma cell line 
(Sigma Aldrich), is likely of vulvar origin (squamous cell carcinoma, NCIt: C4052 
Cellosaurus) and thus may cause misleading interpretations when compared with and 
taken as a skin cancer cell.
5.2.2  3D models
Spheroids
While conventional 2D in vitro cultures have served as the basis for biological, bio-
chemical, and molecular genetic discoveries and will remain an important tool, it 
is apparent that the cultivation of cells in monolayer cultures remains restrictive. 
Tissue organization not only requires a very specific overall regulatory network but 
also moves individual cells into different regulatory states. This similarly accounts 
for normal and cancerous tissues, creating great recognition for the need of 3D 
 tissue-like models. The most frequent approach that particularly aims at recapitu-
lating in vivo growth conditions of cancer is the spheroid models. As reviewed by 
Ishiguro et al. [71], spheroid models include tumor-derived organoids, tumor-derived 
spheroids, organotypic multicellular spheroids, and multicellular tumor spheroids—
based on the source of the tumor cells, execution protocol, and timing. Hereby, the 
uniqueness of tumor-derived spheroids as perfect tools for the enrichment of cancer 
stem cells (CSCs) or cells with stem-cell-related characteristics is frequently empha-
sized. The hypothesis that CSCs are the basis for tumorigenicity and chemoresistance 
has quickened the use of tumor-derived spheroids for the research of many tumor 
entities, including cSCC [72], with the hope that they may prove instrumental for 
high-throughput screening approaches including the identification of regulatory cues 
that are drug targetable.
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Organotypic cultures
However, spheroids do not fully recapitulate the three-dimensional (3D) organization 
of cells in a given tissue or tumor and, in particular, are missing the proper environ-
ment with the cells and ECM characteristic for the tissues and organs. Consequently, 
there is still a large gap between our detailed knowledge of subcellular processes and 
the understanding of mammalian biology at the tissue and organ level.
For the skin, the development of organotypic models followed the important work of 
Bell et al., which introduced the dermal collagen model, with incorporated fibroblasts 
as a dermal equivalent and the keratinocytes forming an epidermis on top (Bell et al. 
[73] and more extensively reviewed by Parenteau et al. [74]). Thereafter, many groups 
have been able to develop and use these models to, for example, study the formation 
of the basal membrane [75,76]. These models permitted the further understanding of 
the role of fibroblasts in epidermal regeneration and contributed substantially to the 
understanding of the development of the skin barrier [77–80]. To avoid some of the 
problems with collagen-based gels, like short life span and shrinkage, approaches to 
reinforce the models with scaffolds that provide more stability and alternate gel forms 
that offer a better environment for the fibroblasts to produce their own ECM have been 
explored [54,81–84]. The aim was to make the models more authentic and long-lived.
Organotypic skin cancer models
Human organotypic cancer models are usually constructed with the same basis as 
nonpathological models. Some will only focus on one tissue, for example, epidermis, 
and others will be more advanced and include different cell types, that is, are comple-
mented with a stromal component. Thereby, the model’s mesenchymal compartment 
either is based on an acellular gel made from animal or synthetic ECM proteins, the 
most common one being collagen I, or will include fibroblasts embedded in the gel. 
Alternatively, the mesenchymal cells make their own ECM, the so-called “cell-derived 
or fibroblast-derived” matrix, in order to study the function of tissue-tissue interac-
tion in a more biologically accurate form [85-89]. One crucial aspect, particularly for 
cancer models, is to produce an oxygen gradient that resembles that seen in tumors, 
where the cycle of growth and vascularization is produced by the hypoxic center of the 
cancer mass. In scaffold-based systems, this can be achieved by increasing the density 
of collagen [90]. Here, the level of oxygen can easily be manipulated by changing 
the matrix density and/or cell amount. One could also reverse angiogenesis by means 
of perfusion by incorporating degradable phosphate-based glass fibers (PGFs) [91]. 
Another cancer model with a documented tumor hypoxia-like environment was made 
with a synthetic scaffold-based copolymers and oral squamous carcinoma cells [92].
Epithelia cancer models
Many organs in our body have similar tissue structures, one of them being epithelia, 
which means that the 3D in vitro model approaches that are used or developed for 
other epithelial tissues can be used or adapted to produce skin in vitro models and vice 
versa. The intestine is one of those organs. As for skin epithelia, the quest for finding 
an in vitro testing model and developing personalized cancer treatment approaches 
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has given researchers a broad spectrum of in vitro techniques to choose from, from the 
simplest “organoids” to more sophisticated alternatives like “organ-on-a-chip” [93].
In epithelial models of colon cancer, the aim has been to target the polarization 
of the cells. This was approached by using a microporous filter membrane that al-
lowed for an apical side, with a single polarized cell layer containing microvilli, and 
a basolateral side that either can be the source of nutrients and factors from media or, 
in the case of a 3D coculture, can “mimic” the living mucosa by including immune 
cells or myofibroblasts. By turning the polarized epithelial colon cells upside down 
and adding cells that are usually found in the loose connective tissue surrounding the 
epithelial tissue, researchers have improved the cell-cell interaction between different 
compartments, like immune cells, and have formed more in vivo-like models [94–97].
Another cancer type that has been modeled for quite some time is breast cancer. 
Starting in the 1970s, researchers have been investigating what we now take for granted 
in the field of in vitro modeling, like the use of different matrices as scaffolds and the 
effects of ECM components on the tumor or tumor cells [98,99]. Other important work 
showed the crucial role of stromal cells for cancer models [98,100–102], which ap-
plies for any model where the goal is to understand the tissue or organ-specific effects.
Skin cancer models
During the last decade, it has also become more common to utilize in vitro skin cancer 
models to answer questions regarding skin cancer biology, cancer progression, and 
treatment for cSCC. Following the footsteps of early cSCC in vitro models [60], other 
significant works were published at the beginning of this decade. In 2009, Commandeur 
and coworkers described and compared two existing skin-modeling techniques, an ex-
plant model and a skin equivalent model with SCC cell lines (SCC12B2 and SCC13) 
cocultured with a collagen scaffold populated with normal human fibroblasts [103]. 
Importantly, these models can be performed using defined skin model media con-
taining l-serine and lipid supplements, among other factors [78]. This work clearly 
pointed out how the protein expression pattern of these two models differed and, even 
more so, how they diverged from what was seen in skin SCC biopsies. Furthermore, 
this study clearly demonstrated that even the explant tissue changed its characteristics 
from in vivo. Another aspect that needs to be taken into consideration for an explant 
model is the fact that several biopsies would be needed, which may be a not only 
ethical but also practical problem. In 2015, Danso et al. reported on the establishment 
of second- and third-generation explants, and indeed, their concept worked. However, 
the further away the explants were made, the more the new-generation models differed 
from the original [104].
When it comes to cell-line-based models, one argument is that cell lines have gen-
erally been artificially selected and represent a more homogenous view of SCC. Thus, 
the aspect of tumor heterogeneity is poorly recapitulated. Therefore, if the aim is to 
understand the mechanisms of SCC, it is of importance to include not only one cell 
line model. In the study mentioned above, two distinct and individual patterns could 
be observed, one invasive with SCC12B2 cells and the other leading to the detachment 
of the epidermis from the dermis with SCC13 cells [103].
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A year later, Ridky and coworkers used the technique of deepidermized dermis 
(DED) from normal human skin. The key finding of this study was that the DED 
could maintain an intact basement membrane and being repopulated with foreskin 
fibroblasts produced a dermal equivalent, with a matrix similar to that seen during 
initiation of epithelial tumor cell invasion [105]. For this study, neoplastic tissues were 
generated from different kinds of normal epithelia, including the skin, by transforming 
the cells with the ras oncogene and cyclin-dependent kinase-4 (Cdk4). The neoplastic 
epithelial cells invaded into the stroma within 1 week. These models gave a rapid as-
sessment tool of anticancer drugs and showed the effect that gene expression signature 
had on neoplastic invasion.
The importance of stromal cancer-associated fibroblasts (CAF) was addressed by 
Commandeur et al. [106]. This study showed that a collagen-based dermal compart-
ment including CAFs indeed affected the way the epidermal cells (NHEK, SCC12B2, 
and SCC-13) behaved. By examining proliferation, differentiation, and invasion of the 
tumor cells and collagen fiber contraction in the stroma, they concluded that the CAFs 
in this collagen cancer model increased contractility of the dermal equivalent and, 
among others, contributed to a decreased proliferative activity of the epidermal cells, 
increased terminal differentiation, increased invasion of the SCC-12B2 cells, and in-
creased dermal-epidermal detachment of the SCC-13 cancer cell line. Using the same 
model, the authors studied overexpression (addition of EGF) or inhibition (addition 
of tyrosine kinase inhibitor, erlotinib) of EGFR [107]. They concluded that erlotinib 
treatment produced a thinner epidermal compartment in both models and additionally 
showed epidermal scaling in one of the models, something that is a common side ef-
fect of this drug in vivo in the form of xerosis, giving insight in how these models can 
be used to evaluate the effects of drugs.
Another aspect of in vitro skin model application is to evaluate phototoxicity and 
sunscreen properties [108], thereby giving the industry a tool for evaluating new pro-
tective substances. A lot of work has been focused on the effects of UV radiation on 
normal human skin [109–114], which is a relevant point when trying to find what 
causes the damage that will persist and with time develop into cancer. UV-exposed 
models have also been useful to understand the role of key protein components of 
UV protection. Accordingly, a knockdown in vitro model of filaggrin showed that this 
protein is crucial for UVB protection [115].
Immunosuppression in transplant patients is strongly associated with an increase in 
the development of cSCC (for review, see Mittal et al. 2017) [116]. Thus, organotypic 
cultures have beneficially been used (besides hairless mice) to address the immediate 
role of different immunosuppressive drugs and additionally determined the role of 
acute UVB radiation on epidermal regeneration, proliferation, and apoptosis under 
“physiological” conditions [117]. Thereby, the authors could show that the immu-
nosuppressive drug cyclosporin A inhibited apoptosis after UV and, on the contrary, 
rapamycin (m-TOR inhibitor) increased the apoptotic effect. Another key argument 
favoring work in organotypic models is that they give us an opportunity to manipulate 
and examine the role of different biological key players or discover new ones. By us-
ing this approach, it could, for instance, be shown that stromal Wnt activation caused 
the fibroblasts to express chemokines such as CCL2 and IL-8 and that these in turn act 
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on the keratinocytes and stimulated proliferation of the HaCaT cells [46]. SCC models 
have also been used to understand a relatively unknown proteins’ mode of action in the 
skin. A recent example is the protein flightless I (FLII), an actin remodeling protein. 
The authors showed its effect on cell adhesion, proliferation, and migration in the nor-
mal skin and its role in SCC progression by using the human MET-1 cell line cultured 
on a collagen: matrigel-based fibroblast-containing dermal equivalent [118].
All models that have been covered in this section have included a biological- or 
synthetic- based platform as the dermal compartment. However, these are limited in 
their sustainability due to either their composition or their short life span. Following 
the seminal work of Ahlfors and Billiar [119], many groups have used the approach of 
cell- derived matrix as the basis for a dermal equivalent [86–88,119–121]. Modifying the 
original protocol, we developed a fibroblast-derived matrix skin cancer model [85]. This 
model proved suitable to support normal epidermal regeneration for >20 weeks and, im-
portantly, recapitulated invasion of tumor cells in its best sense. Starting from a super-
ficial epithelium, the tumor cells rupture the BM, degrade the underlying collagen, and 
penetrate the dermal equivalent (Fig. 1). Moreover, each tumor cell line showed a unique 
and characteristic pattern of invasion, thus making this a relevant tool for studying early 
changes and mechanisms required for the initiation of tumor cell invasion and studying 
the role of tumor-stroma interaction in cancer progression. Due to its extended viability, 
this model also allows for chronic exposure of chemicals or UV radiation, thereby predes-
tining it not only for experimental approaches but also for the use as preclinical models.
5.2.3  The future of skin cancer models
The progress in the field of 3D biology and bioengineering and the need to find hu-
man disease models in translational medicine to better understand a disease or to find 
new treatments have made the public and pharmacological and biomedical companies 
more open to the possibility to expand their use of 3D model. And although the exist-
ing models already have given us a lot of insights into the biology and chemistry be-
hind tissues and disease, we still need to strive to make the models more biologically 
accurate and to include them in preclinical trials on a regular basis.
It should be the basis of any attempt to improve existing or design new mod-
els and modeling techniques to recapitulate the in  vivo situation. One step toward 
this goal is clearly the complementation of the existing models with additional cell 
types. Important aspects to further develop skin cancer models are immune-related 
 questions. The first approaches are promising. Based on collagen-glycosaminoglycan- 
chitosan dermal substrates, Dezutter-Dambuyant et al. were the first to present a liv-
ing dermal equivalent containing fibroblasts, endothelial cells, and dendritic cells to 
study the differentiation of interstitial DC in a dermal equivalent [122]. The same 
group now presents an immunocompetent reconstructed skin model maintained in a 
microfluidic-based cell culture system [123]. Macrophages were incorporated into a 
 collagen-based OTC model, which proved suitable to modulate macrophage activation 
toward a tumor-supporting phenotype [124]. Thus, incorporating the different kinds of 
immune cells into the different OTC models and determining their controlled distribu-
tion and participation in skin cancer progression will be the next challenge.
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(A)
(B)
(C)
(D)
Fig. 1 Characterization of the 3D in vitro skin cancer model. (A) 3D organotypic culture 
model: schematic representation of the 3D organotypic culture (left); H&E-stained histological 
section of the skin equivalent (middle), immunofluorescence staining demonstrating the 
desmosomal network in the epidermis (staining for desmocollin); and the integrity of the 
basement membrane (BM) (staining collagen type IV) (right). (B) 3D skin cancer invasion 
model: schematic representation of the OTC (left); H&E-stained histological section 
representing invasively growing keratinocytes (middle), immunofluorescence staining 
demonstrating maintenance of the desmosomal network in the epidermis (staining for 
plakoglobin); and the in part disrupted BM (staining for collagen type IV) (right). (C) 
Characterization of the invasion process of the skin cancer modes: immunofluorescence 
staining demonstrates the invasion of the epithelial cells (stained for E-cadherin) into the 
dermal equivalent (stained for collagen type III) (left). Picrosirius red staining (middle) 
with its corresponding polarization (right) demonstrates collagen organization in the dermal 
equivalent, showing the loss of collagen fibers around and accumulation of collagen fibers 
between the invasive epithelial strands. (D) Demonstration of tumor-cell-specific invasion. 
H&E staining of histological sections from two different tumor cell lines, each shows a unique 
and highly reproducible invasion phenotype, supporting the relevance of this 3D organotypic 
model as an in vitro skin cancer model.
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Vascularization is also an important trait that needs to be addressed in more depth. 
The first endothelialized skin model based on a chitosan cross-linked collagen- 
glycosaminoglycan scaffold has enabled the formation of capillary-like structures, which 
showed several morphological characteristics associated with the microvasculature 
in vivo [125]. Similarly, our approach of scaffold-based endothelialized OTCs allowed 
for the self-assembly and maturation of a microvasculature (Böhnke et al., in prepara-
tion). Based on a porcine vascular scaffold, a first bioreactor-based system has been de-
scribed [126]. Besides these promising approaches, no model has yet proved suitable as a 
tumor model, and we are still far away from connecting them to a dynamic flow.
The first skin-on-a-chip model has been described [127], thereby paving the way 
to overcome the fluidity problems of the normal skin organotypic culture  models. 
Furthermore, by improving the complexity, that is, by integrating this into the 
“ human-on-a-chip” model, a new era of interactive studies will become possible. As 
this will clearly be extended to cancer cells, models are to be expected that, despite 
their great complexity, will feature reproducibility and the potential to learn about 
tissue interactive regulatory loops.
Presently, the most rapidly evolving approach to improve complexity, reproducibil-
ity, and in particular the quantity of specimen is the technique of 3D bioprinting. An 
automated cell printing system was used to bioprint a 3D coculture model of ovarian 
cancer cells and normal fibroblasts in Matrigel, thereby allowing for a highly con-
trolled cell density and cell-cell distance [128]. First approaches for 3D bioprinted 
skin have also been described [129,130], though the quality of the epidermal tissue 
shown so far still leaves a lot to be desired. Furthermore, skin cancer models with 
their complex microenvironment (cells and ECM) have still to be shown. However, 
from the rapid advances in the field of bioprinting, we can expect that preclinical skin 
cancer models will be available soon (for review, see also [131]).
Independent on what the in vitro models will be used for, their future use and devel-
opment lie in their flexibility, reliability, and reproducibility. Particularly in the field of 
personalized medicine, that is, dermatooncology, modeling techniques can play an im-
portant role in establishing patient-specific therapies also including clinical manage-
ment methods and assessment, closing the gap between bench and clinic even more.
Finally, it should be mentioned that the question of biological authenticity in the 
models, be it tissue-specific, organ-specific, or organ-system-specific, will start to be-
come more and more relevant due to the increasing understanding of how important 
the human body interplay between microenvironments, tissues, and organs is in health 
and disease.
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1 Introduction
Ensuring adequate vascularization remains one challenge of foremost importance for 
the engineering of thick tissues. Nutrient and oxygen diffusion ensured by the micro-
vasculature remains a central issue for optimal tissue production in vitro and timely 
survival after in vivo transplantation. The importance of studying vascularization pro-
cesses (angiogenesis, vasculogenesis, and intussusceptive angiogenesis) and design-
ing appropriate vascularization strategies in the field of tissue engineering is reflected 
by the increased number of yearly publications on the topic (Fig. 1), which is also true 
for skin vascularization in particular, which represents up to 10% of the yearly publi-
cations in the last 5 years (Fig. 1).
Skin substitutes are among the first tissue-engineered constructs that have been 
grafted to patients and are still the focus of numerous clinical investigations. The 
well-defined hallmarks of healthy skin, including specific epithelial markers of kerat-
inocyte differentiation, combined with the ease of visually monitoring grafted tissues, 
undoubtedly contribute to the intense scientific activity observed in the field of wound 
repair and skin replacement products. Indeed, novel technologies, cell-editing tools, 
and proof-of-concept studies are often investigated using the skin as a model system, 
including various vascularization strategies.
While not mutually exclusive, methods employed to promote vascularization can 
be subdivided into proangiogenic approaches and in vitro cell-based prevasculariza-
tion techniques. Early achievements using the “angiogenic” approaches in the field 
of skin vascularization relied on gene transfer to stimulate the ingrowth of blood ves-
sels into the grafted reconstructed skin, for example, by overexpressing VEGF [1–3], 
PDGF [4,5], or bFGF [6] using modified viral vectors (reviewed in [7,8]). Currently, 
the creation of bioinductive scaffolds is actively investigated, including the functional-
ization of materials by the incorporation of these proangiogenic growth factors (EGF, 
bFGF, and PDGF). Scaffold-based promotion of vascularization has been addressed 
in recent reviews describing how structural and physicochemical modifications and 
biological activation of dermal scaffolds can stimulate healing processes [9–11].
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Indeed, an increasing number of studies focus on the development of connective 
tissue constructs, devoid of keratinocytes, acting as fillers or bandages to stimulate 
resident skin cells at the wound periphery. A wide array of constructs with various 
specifications have been produced, and their impact on regenerative processes in-
cludes accelerated wound closure due to increased reepithelialization and/or contrac-
tion, with improved neovascularization being the most common functional outcome 
observed [12,13]. However, for more extensive and deeper tissue defects such as se-
vere burn injuries, trauma, or tumor resection, stimulating peripheral keratinocyte mi-
gration, granulation tissue formation, and therapeutic angiogenesis is not sufficient. 
Rapid coverage with a substitute already featuring a dermis and an epidermis (referred 
here as reconstructed skin and bilamellar or bilayer skin) is required. Novel models 
incorporating an adipose compartment (hypodermis) to generate a trilayer skin sub-
stitute have also been developed. For all these types of constructs, a widely studied 
strategy to promote vascularization consists in incorporating vessel-forming cells that 
will reorganize to generate a preformed vascular network of capillary vessels in vitro. 
Upon grafting, inosculation between the host recipient bed and the substitute’s net-
work is therefore favored, resulting in timely blood perfusion [14–16].
This chapter will focus on recent cell-based vascularization strategies for the de-
velopment of tissue-engineered constructs designed for skin replacement. Considering 
the diversity of the in vitro models available, we will procure an overview describing 
how the choice of scaffolding elements and the origin of the cell source (including pro-
genitor cells and adult microvascular endothelial cells) can impact vascularized skin 
reconstruction. Particular emphasis will be given to studies that assessed functional 
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Fig. 1 Increase in the number of publications associated with vascularization in the field 
of tissue engineering. Consultation of the PubMed search engine with the keywords “tissue 
AND engineering AND vascularization” and “skin AND engineering AND vascularization.” 
Performed December 12, 2016, 6:30 pm.
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parameters of the preendothelialized reconstructed tissues in vitro and their outcome 
after in vivo implantation. Lastly, recent investigations of lymphatic microvasculature, 
an important complement of blood microvasculature, will be briefly discussed.
2  Cell-based vascularization strategies
2.1  Promoting vascularization of dermal substitutes
The epidermis is an avascular compartment that is nourished from the underlying der-
mis. The active role of the dermis in supporting keratinocyte adhesion, migration, and 
differentiation is also essential during the reepithelialization phase and thus is key to 
wound healing. Therefore, many studies focused on dermal template vascularization 
as a first step toward bilayer skin reconstruction and assessed efficacy using various 
wound healing models. Most methods used to engineer prevascularized dermis have 
focused on synthetic or animal-derived matrices or the cell’s ability to produce their 
own extracellular matrix. Some of these studies are listed in Table 1, which details the 
matrix and cell origin and the functional tests performed to assess these constructs 
(in vitro and in vivo).
Hydrogels based on collagen or fibrin materials are often used in combination 
with stromal cells and endothelial cells (EC) or endothelial progenitors to generate a 
vascularized dermis. For example, Kuo et al. extracted murine collagen to develop a 
hydrogel containing human blood-derived endothelial colony-forming cells (ECFC) 
or human bone-marrow-derived mesenchymal stem cells (BM-MSC), which can be 
injected into a full-thickness wound to form a dermal template [17]. A similar ap-
proach based on a hyaluronic acid-containing hydrogel and using human ECFC has 
shown that the human capillary network is remodeled but still present after 2 weeks 
of transplantation to nude mice. Murine smooth muscle cells wrapped around human 
vessels were identified in the transplant after hydrogel degradation during the inflam-
mation period (day 3 after grafting) [18]. The vessels’ functionality was assessed by 
UEA-1 lectin injections after grafting, and at days 5–7 post implantation, the human 
and murine vessels were successfully anastomosed with the host vasculature, with 
the presence of chimeric vessels. The connections and chimeric vessel number were 
reported to increase over time (at day 11) [18].
With a structure between a sponge and a typical hydrogel, gellan gum-hyaluronic 
acid hydrogels have also been used to produce dermal substitutes comprising human 
adipose-derived stromal/stem cells (ASC) and human adipose-derived endothelial 
cells [19]. Endothelial cells were characterized by the expression of surface mark-
ers such as CD31 and von Willebrand factor and their ability to uptake acetylated 
low-density lipoprotein (Dil-Ac-LDL) and to form tubes in Matrigel® [19]. The 
addition of endothelial cells was reported to improve tissue vascularization after 
grafting compared with the use of hydrogel with ASC only (quantified by CD31 
staining).
Sponges are another type of biomaterials used for dermis reconstruction and  usually 
feature more rigid scaffolding elements that are also conducive to the development of 
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Scaffold/matrix Matrix origin Endothelial cells
Endothelial 
origin
Functionality 
assay
Animal 
model References
Collagen gel Murine ECFC h – Nude mice [17]
HA hydrogel Microbial 
fermentation
ECFC h UEA-1 lectin Nude mice [18]
Gellan gum-HA 
hydrogel
Microbial 
fermentation
AT-derived EC h Dil-AC-LDL 
uptake
Nude mice [19]
Collagen-chitosan 
sponge
 HMVEC h Pericyte 
recruitment
Nude mice [20,22,43]
Integra® Bovine and shark AT-derived microvascular 
fragments
m – Nude mice [24]
Endothelial progenitors r – Nude mice [26]
Cell sheet 
nanofilms
Human, bovine, and 
porcine components
HUVEC h UEA-1 lectin Nude mice, 
nude rats
[23]
Cell sheet/self-
assembly 
 
Human 
 
 
HUVEC h CM-DiI staining – [30,35]
HMVEC h CM-DiI staining – [30,35]
HMVEC h Ang-2 secretion – [33]
HBOEC h Ac-LDL uptake – [36]
Table 1 Examples of vascularized dermal substitutes
h, human; m, murine; r, rat.
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an in vitro preformed EC network [20,21]. In collagen-chitosan sponges, human mi-
crovascular endothelial cells (HMVEC) can form microvessels that have the capacity 
to recruit pericyte-like cells [22]. These α-smooth muscle actin-positive cells were 
identified around CD31-positive tubules when HMVEC were cocultured with human 
fibroblasts, but this was not observed with fibroblasts only. This illustrates the ability 
of in vitro preformed capillaries to be attractive to cell types involved in capillary sta-
bility such as pericytes [22,23].
The dermal substitute Integra® (Integra LifeSciences, Plainsboro, NJ), which is a 
Food and Drug Administration (FDA)-approved product, was used by different groups 
to study the effect of prevascularization [24,25]. It consists of a matrix made of cross-
linked bovine collagen and shark glycosaminoglycan combined with a silicone layer 
mimicking a pseudoepidermis to protect the implant after grafting. This acellular off-
the-shelf dermal substitute can be preseeded with endothelial cells (and stromal cells 
if desired) to facilitate its rapid integration and reduce the usual time required for 
vascularization (up to 3 weeks). For example, vascular resident endothelial progenitor 
cells extracted from rat hearts were differentiated toward endothelial cells and were 
then able to form tubes in a gel. These cells were then seeded in the Integra® matrix 
and grafted onto nude mice. When preseeded with EC, the implant showed a higher 
density of vessels 2 weeks after transplantation (analyzed by tissue transillumination 
and digital segmentation) [26]. Furthermore, the added endothelial progenitor cells 
displayed a proangiogenic secretory profile combined with chemoattractant secretion 
(such as MCP-1).
Using the same Integra® matrix, Frueh et al. studied the effect of prevascularization 
by incorporating adipose-tissue-derived microvascular fragments [24]. For this study, 
they used cells extracted from epididymal fat pads of GFP-expressing transgenic mice, 
and the implant was grafted on nude mice. This leads to the formation of a dense 
GFP+ microvascular network in the tissue, primarily at its periphery. This network 
rapidly connected with the host vasculature and allowed quick perfusion (in 3–6 days), 
whereas nonprevascularized implants did not show perfusion after 14 days (only par-
tial infiltration of the host vessels at the border periphery). During the first 2 weeks 
after transplantation, the preformed vessels showed signs of remodeling as assessed by 
microhemodynamic analyses [24].
Another approach to generate vascularized dermal substitutes is to create cell 
sheets, which slightly differs from methods based on cell seeding on or within a pre-
formed scaffold. Different kinds of cell sheets can be produced, ranging from thin 
keratinocyte layers to cell sheets made of mesenchymal cells that are able to produce 
abundant extracellular matrix (ECM) (Fig. 2). Indeed, methods that reproduce with 
higher fidelity the native microenvironment are based on the ability of stromal cells 
to produce and assemble their own human extracellular matrix. Most of the recent 
 developments we will describe relate to such cell sheets produced using either ther-
moresponsive culture substrates, the self-assembly approach (vitamin C supplemen-
tation) or a combination thereof. Cell sheets can be produced from a wide range of 
stromal cells using thermoresponsive plates [27]. These connective sheets can then 
be seeded with human umbilical vein endothelial cells (HUVEC) or HMVEC to 
coculture both cell types. This results in the formation of tube-like structures. For 
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example, Sasagawa et al. showed that HUVEC could also form tube-like structures 
when cocultured with myoblasts [28]. They produced prevascularized tissues by using 
temperature-responsive culture dishes to form cell sheets. Myoblasts were cultured 
to confluence in a dish; the temperature was then brought to 20°C to detach the cell 
sheet. Cell sheets were manipulated using a hydrogel-coated plunger designed for this 
purpose. To add endothelial cells, a cell sheet was applied on a HUVEC monolayer, 
which was then detached using a lower temperature. Once transferred on the sheet, the 
HUVEC were sandwiched with another cell sheet [28]. This allows to produce thicker 
implants (about 100 μm thick) able to connect to the host vessels after transplantation, 
as observed with five-layer myoblasts and HUVEC sheets implanted in nude rats [28].
Another variation of a sheet method is the use of cell coating with fibronectin and 
gelatin to build up extracellular matrix nanofilms that can then be stacked [23]. Using 
this method, a dermal multilayered tissue (thickness of 30–50 μm but can go up to 
100 μm with 20 layers of dermal fibroblasts) was reconstructed and prevascularized by 
seeding HUVEC on different layers [23].
Cell sheet formation based on ascorbic acid stimulation of ECM by the stromal 
cells is also an approach used to generate connective tissue constructs that can be 
Fig. 2 Schematic summarizing common methods of tissue-engineered skin prevascularization 
using different cell sources. Endothelial cells can be extracted from different tissues to obtain 
either HUVEC, HMVEC, SVF, or progenitors (shown in dark red, BEC), as well as lymphatic 
endothelial cells (green, LEC). Stromal cells can also be isolated (skin fibroblasts or ASC, 
in pink). These primary cells can be incorporated into various scaffoldings or hydrogels or 
seeded on thermoresponsive plates (cell sheets) and/or for long-term culture in the presence 
of ascorbic acid (self-assembly approach) to produce prevascularized skin substitutes. 
Keratinocytes (in beige) are then isolated from skin biopsies and seeded at the surface of the 
dermal templates.
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further vascularized in vitro. Dermal extracellular matrix is composed of a complex 
combination of structural proteins and small molecules. This complexity is often not 
fully reproduced by hydrogels or sponges. At the LOEX center, the self-assembly 
approach of tissue engineering is the core technology for the reconstruction of mul-
tiple tissues. These types of cell sheets can be obtained when dermal fibroblasts (or 
other stromal cells) are cultured with ascorbic acid over many days, leading to tissues 
stable for many weeks in vitro (up to 3 months) [29,30]. Ascorbic acid is a cofactor 
of the prolyl 4-hydroxylase, an enzyme involved in the assembly of the triple helix of 
procollagen. This allows the formation of cell sheets enriched in ECM, on the surface 
of which endothelial cells are generally seeded, although endothelial cells can also 
be incorporated directly earlier in the process [31]. The cell and matrix sheets are 
then manipulated with forceps and stacked to produce a tissue of the desired thick-
ness featuring human extracellular matrix favorable to endothelial cell reorganization 
into a capillary-like network. Using human cells, the extracellular matrix is therefore 
fully human and not altered by subsequent chemical or physical treatment, allowing to 
mimic more adequately the native microenvironment. With this method, HUVEC and 
HMVEC have been used to produce vascularized connective tissue substitutes com-
prising BM-MSC sheets [32], ASC sheets [33,34], and vascularized dermal substitutes 
using fibroblasts [30,35].
The self-assembly method can also be combined with endothelial progenitors such 
as human blood outgrowth endothelial cells (HBOEC) [36]. HBOEC can be extracted 
from peripheral blood and thus are easy to obtain. The expression of genes facilitating 
wound healing and implant vascularization was compared with those of HUVEC and 
early endothelial progenitor cells. HBOEC expressed higher levels of genes involved 
in the cross talk with cells from the wound bed such as resident endothelial cells, im-
mune cells (e.g., through VEGF, MCP-1, and angiopoietin-2) and keratinocytes [36]. 
Like HUVEC, these cells could form tubes in vitro, and their functionality was as-
sessed by Ac-LDL uptake and the binding of UEA-lectin. This reconstructed dermis 
featuring endothelial progenitor cells is another example of constructs that could be 
used in the future to treat wounds associated with impaired healing such as ulcers, 
using autologous cells displaying a therapeutic secretome.
2.2  Considerations for the choice of an endothelial cell source
The diversity of dermal substitutes shows that many different scaffolds and cells can 
be combined to generate a microvascularized tissue (Table 1), but the endothelial cell 
source is of uttermost importance for clinical translation. Existing methods investi-
gating tissue prevascularization have used different types of endothelial cells: from 
HUVEC to HMVEC extracted from different tissues (adult skin and adipose tissue) or 
progenitors. Functional and transcriptomic studies have revealed differences between 
endothelial cells from different origins when maintained and assessed in culture. The 
first distinctions involve two subtypes: endothelial cells from large vessels (HUVEC, 
aortic endothelial cells, and vein endothelial cells) and microvascular endothelial cells. 
These cells can reorganize into vessels of various sizes when seeded into tissue con-
structs, but they also differ by their gene expression profile. Many variations  between 
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these cells are seen for genes involved in production and interaction with ECM. For 
example, HMVEC express genes linked to the production of basement membrane 
(laminin and collagen type IV), whereas macrovascular endothelial cells do not have 
this direct contact with ECM and basement membrane [37]. Microvascular endothe-
lial cells are also characterized by genes associated with a phenotype more closely 
adapted to angiogenesis, with the expression of factors such as angiopoietin-2, LMO2, 
and transforming growth factor α. Even if this seems to correspond to their in vivo lo-
calization and function, it is particularly interesting for tissue engineering to consider 
these parameters, as they are maintained by cells in an in vitro context [37].
While more similar compared with macrovascular endothelial cells, differences were 
also observed between HMVEC originating from different tissues, reflecting the varia-
tions between vascular beds from different tissues. HMVEC have tissue-specific gene ex-
pression variations. For example, skin HMVEC were found to express bFGF and different 
genes involved in cholesterol biosynthesis. Molecules involved in immune trafficking and 
immune responses have also been reported to differ depending on the cell origin [37].
The choice of endothelial cells can be particularly important for clinical applica-
tions and needs to be further characterized. Endothelial cells are immunogenic and 
thus should be autologous. HMVEC are obtained in small quantities from skin ex-
traction procedures and need to be expanded. HMVEC are obtained in small quantities 
from skin extractions and need to be expanded in vitro before tissue production.
This is why alternative sources such as adipose-tissue-derived cells and other progeni-
tors are investigated [38–41]. A study recently compared the use of adipose-tissue- derived 
EC and dermal EC for their in vitro vascularization potency and found that even if some 
differences existed between these cells, they had a similar response and angiogenic poten-
tial. It confirmed that EC from an abundant and accessible source as subcutaneous adipose 
tissue can be an alternative to the expansion of dermal microvascular endothelial cells 
[38]. Further progress in these characterizations will likely improve autologous-based 
vascularization strategies.
2.3  Bilayer skin reconstruction models featuring vascular-like 
networks
To achieve optimal wound healing and skin regeneration, reestablishing the skin’s 
essential roles is of the uttermost importance. Reepithelialization needs to occur early 
in the healing process to prevent infections and restore the barrier function. To en-
sure proper reepithelialization, different bilayer skin substitutes presenting an epider-
mis and a vascularized dermis are now being developed. Keratinocytes can be added 
to the different vascularized dermis described in Section 2.1 to produce bilamellar 
substitutes. Therefore, the main techniques used for skin reconstruction also include 
cell seeding in hydrogels, on decellularized matrix, or the use of the cell sheet/self- 
assembly methods (Fig. 2). Vascularized bilamellar skin reconstructed with hydrogels 
is often based on the use of animal-derived material such as bovine or rat collagen 
and combined with either allogenic or autologous cells [9]. Table 2 summarizes key 
studies including the ones that evaluated the reconstructed microvascularized skin in 
animal models.
Strategies to promote the vascularization of skin substitutes after transplantation 185
Historically, the first vascularized bilamellar skin substitutes were produced 
using chitosan and bovine collagen biopolymers in which fibroblasts, HUVEC, 
and keratinocytes were cultured [42,43]. In these reconstructed tissues, HUVEC 
formed tubes with lumens featuring a basement membrane but only when grown 
in  coculture with fibroblasts, thus demonstrating the critical role of stromal cells in 
skin vascularization. Another pioneering study developed a bilamellar skin substi-
tute based on a collagen-glycosaminoglycan substrate [44]. They seeded fibroblasts 
and HMVEC in the substrate and then layered keratinocytes on the surface. In vitro, 
HMVEC seemed to affect keratinocyte stratification and alter their differentiation. 
HMVEC were also aggregated in the dermis near the dermoepidermal junction. No 
network developed or was observed in vitro compared with the previous work in 
collagen-chitosan sponges [45], but once grafted into athymic mice, the HMVEC 
in the substitute were reorganized to form vascular analogs and secreted collagen 
type IV, indicative of a basement membrane deposition, between 2 and 4 weeks after 
implantation [44].
More recently, rat collagen type I or bovine fibrin hydrogels were used to pro-
duce bilamellar skin featuring blood capillaries [46,47]. These skin substitutes are 
composed of exogenous matrix and human keratinocytes, fibroblasts, and HMVEC. 
This allows the production of vascularized skin substitutes in 3 weeks, and grafting 
on nu/nu rats showed improved wound healing and anastomosis with the host vas-
culature [46]. Of note, the extraction of sufficient quantities of HMVEC can repre-
sent a challenge, especially when autologous treatment of large skin surface areas 
is required. One alternative that has been proposed is to replace the HMVEC by 
white adipose-tissue-derived endothelial cells [47]. Using the same model based on 
bovine fibrin hydrogels, the authors reported that upon coculture in hydrogel with 
white adipose-tissue-derived stromal cells (ASC), the adipose-derived endothelial 
cells formed capillaries in the skin substitutes that were able to accelerate tissue 
Scaffold/matrix
Matrix 
origin
Endothelial 
cells
Endothelial 
origin
Animal 
model References
Collagen-chitosan 
sponge
Bovine HUVEC h – [42]
Collagen-
glycosaminoglycan
 HMVEC h Nude mice [44]
Collagen gel Rat HMVEC h Nude mice [46]
Fibrin hydrogel Bovine AT-derived EC m Nude rat [47]
Self-assembled 
generated ECM 
 
Human 
 
 
HMVEC h Nude mice [30,48-50]
HUVEC h Nude mice [30,50] 
Table 2 Examples of vascularized skin substitutes
h, human; m, murine.
186 Skin Tissue Models
 perfusion after grafting (rat erythrocytes were observed in human capillaries at day 
4 post  implantation). A recent comparison of endothelial cells extracted from the 
dermis and adipose tissue also supports the use of adipose tissue endothelial cells 
for tissue engineering considering their availability and similarities with dermal 
HMVEC [38].
Similarly to dermal substitutes, vascularized skin can be produced by the self- 
assembly approach [30,48,49]. Using this method, the crucial role of cross talk be-
tween different cell types was shown by the effect of keratinocytes on HMVEC and 
HUVEC [30]. In this study, vascularized substitutes were produced using human 
dermal fibroblasts. The reconstructed tissues contained either HMVEC or HUVEC. 
Keratinocytes were seeded on top of the dermal compartment or not, and the forma-
tion of vascular network was assessed by time-lapse imaging using GFP-HUVEC or 
by subsequent immunostaining. Keratinocytes maintained a network of small diame-
ter capillaries and were able to reduce the size of bigger capillaries seen in the stromal 
constructs devoid of keratinocytes. This effect was found to rely on a paracrine effect 
(in part VEGF-driven) and not dependent of direct contact between the keratinocytes 
and the endothelialized stroma. This model of self-assembled skin was later produced 
using GFP-transduced HMVEC and HUVEC to follow the substitutes after grafting 
in nude mice. HMVEC- and HUVEC-formed capillaries in the skin substitute in vitro, 
and those capillaries were remodeled within 4 days in mice [50]. At the same time, 
anastomosis between the human GFP+ endothelial cells and the murine capillary net-
work showed the functionality of the human preformed capillaries.
2.4  Achieving the production of a trilayer skin substitute: 
Vascularization of reconstructed adipose tissue to recreate 
the hypodermis
While thinner skin substitutes can lead to effective wound coverage and graft take 
without the presence of a preformed capillary network [51–54], thicker skin substi-
tutes will likely require more than proangiogenic cues from their cellular and scaffold-
ing components in order to promote graft survival and integration without necrosis. 
Full-thickness skin constructs including the deepest layer of subcutaneous fat, also 
called hypodermis, represent emerging skin models. The precise contribution of the 
hypodermis to skin homeostasis is still unclear; however, adipose tissue is well vas-
cularized, and both adipocytes and stromal vascular cells possess a secretome highly 
relevant for skin repair, including proproliferative, proangiogenic, and antiapoptotic 
actions [55–58]. Few studies investigated the direct role of adipocytes in wound heal-
ing [57,59], but Schmidt et al. reported an important functional role of adipocytes in 
recruiting fibroblasts to the wound bed during the proliferative phase of healing [60].
A limited number of studies addressed the technical engineering challenge of de-
veloping a human trilayer skin [61–64]. The first all-human trilayer skin was pro-
duced using the self-assembly approach of tissue engineering, resulting in a skin 
featuring a well-differentiated epidermis directly interacting with a stromal compart-
ment made of either dermal fibroblasts or undifferentiated ASC, which itself was in 
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contact with an hypodermal compartment [64,65]. This hypodermis was produced by 
differentiating ASC into adipocytes while stimulating matrix production and assem-
bly, leading to the presence of rounded adipocytes embedded in a rich matrix made of 
human structural collagens and basement membrane components (laminin-1 and col-
lagen type IV) present around the newly developed adipocytes [64,65]. This model 
features the advantage of being readily scalable for the production of large surface 
areas (at least 90 cm2) that can be easily manipulated by the surgeons. Other models 
compared BM-MSC and ASC for the production of a plasma-based hydrogel hypo-
dermis and reported that both cell types have the capacity to contribute to the epider-
mal differentiation program [61]. Silk scaffolds have also been used for the creation 
of the hypodermis based on in vitro differentiation of ASC within a reconstructed 
skin featuring a dermis made of fibroblasts and type I collagen [63]. Depending on 
the exogenous scaffolding components used, adipocyte-like cells can be difficult to 
identify on histological sections, but leptin and other secreted products usually sup-
port the presence of adipogenic cells in the reconstructed skin constructs. The most 
recent model used freshly isolated human adipocytes seeded into a rat collagen type 
I hydrogel to produce the hypodermis compartment of the trilayer skin constructs 
[62]. Different media formulations were tested to determine culture conditions opti-
mal for these mixed cell types [62]. Indeed, for all models, the challenge of trilayer 
skin reconstruction is to find out culture conditions favorable to the differentiation/
maintenance of mature adipocytes since supplements present in either keratinocyte or 
endothelial cell media contain molecules known to influence the metabolic functions 
of adipocytes (adipogenesis and lipolysis) and able to trigger adipocyte dedifferen-
tiation [33,66].
In the context of skin substitute production, the use of a trilayer skin could be 
beneficial for the treatment of deep lesions, especially at anatomical sites prone 
to scarring. The clinical application of such substitutes will likely depend on the 
prevascularization of both the dermal and hypodermal compartments to ensure effi-
cient graft take and survival. To date, the production of a reconstructed skin featur-
ing an epidermis supported by a collagen-gel-based dermis (prevascularized or not) 
under which a silk-based vascularized hypodermis was placed has been reported 
[63]. Investigating the fate of the network upon grafting will provide interesting 
insights into the potential benefits on skin quality of implanting such a construct 
in vivo.
Independently of skin reconstruction, numerous studies assessed the production of 
vascularized adipose tissue featuring mature adipocytes, using various reconstruction 
strategies [67]. Indeed, the characterization of the structural features and functionality 
of AT constructs before their incorporation into a skin construct comprising a dermis 
and an epidermis is an important step. Creating and maintaining a developed network 
of capillaries in vitro while differentiating cells into mature adipocytes require that 
special consideration is given to the culture protocol to determine the best sequence 
for cell seeding, induction of adipogenesis, and use of specialized culture media (such 
as EGM2 endothelial cell medium) to ensure an optimal composition supporting all 
cell types [33,66,68–70].
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Among adipose tissue models described since 2010, constructs engineered from 
naturally-derived scaffolding elements and featuring adipocytes cocultured with en-
dothelial cells are summarized in Table 3.
Self-assembled adipose sheets and thicker adipose tissues have been produced, 
and they efficiently supported EC reorganization into capillary-like networks into 
that highly natural microenvironment [33,34]. Our experience with in vivo implan-
tation of such self-assembled adipose tissues [65] is that inosculation with vessels 
of the recipient site (muscular bed) is occurring as fast as reported for reconstructed 
dermis (within 3–4 days). Indeed, the preformed network in vitro within these ad-
ipose constructs (Fig.  3) rapidly connected with the murine vasculature, as sup-
ported by the presence of red blood cells within human CD31-expressing capillaries 
(Fig. 4).
Silk fibroin is a prominent material in this field of research [71,72], and cocul-
ture with endothelial cells has led to the formation of capillary-like networks in vi-
tro [73,74]. Microtissues formed by collagen/alginate microspheres or microparticles 
[75–77] and from spheroids/fibrin [78,79] have also been investigated in combination 
with HUVEC, both in vitro and after implantation into nude mice (Table 3). Most 
studies demonstrated in vivo angiogenesis within the constructs.
Scaffold/matrix
Endothelial 
cells
EC assembly 
in vitro Animal model References
Silk fibroin HUVEC ns – [71,72]
Silk fibroin coated with 
VEGF and/or laminin
HMVEC Yes (lumen) – [73]
ASC spheroids 
induced or not toward 
adipocytes
HUVEC EC alignment Nude mice [78]
Fibrin gel or spheroids HUVEC ns Nude 
mice/1 week
[79]
Collagen 
microparticles with 
or without fibrin and 
growth factors
HUVEC ns NOD SCID 
mice/12 days, 
4 weeks, or 
4 months
[75]
Collagen/alginate 
microspheres
HUVEC Limited – [76]
Collagen/alginate 
microspheres coated 
with collagen fibrils
HUVEC Limited Injected in 
BALB/c-nu 
mice/4, 8, and 
12 weeks
[77]
Self-assembly HUVEC Yes – [34]
HMVEC Yes Nude mice [65] [33]
Table 3 In vitro-engineered adipose constructs featuring 
endothelial cells, natural scaffolding elements, and adipocytes 
differentiated from ASCa
a Since 2010; ns, not shown.
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2.5  Considerations for vascularization assessment after grafting
Neovascularization is classically assessed following immunolabeling for blood ves-
sel components on histological sections, a useful but time-consuming method that 
does not allow to easily distinguish nonperfused from functional vessels. Confocal and 
two-photon microscopy can reveal the architecture of the capillary networks, and a 
detailed characterization (e.g., network extent and branching) can be performed when 
used in conjunction with specialized software [80,81].
Systems suitable for the in vivo evaluation of angiogenesis are needed. Color-coded 
or crossover murine models have been developed to enable in situ imaging of anas-
tomosis and to determine the origin of skin graft vasculature [82–84]. In preclinical 
models, these approaches in combination with dorsal skinfold chambers can establish 
the dynamics of the neovascularization process quite precisely [24,83,85]. The use of 
transillumination and computerized digital segmentation has also been reported as a 
simple, low-cost method allowing to visualize large tissue areas and to quantify the vas-
culature with better resolution than radioangiographic studies [86]. However, the need 
to excise the tissues to perform ex vivo analyses using transillumination methods is a 
limitation. Nonmicroscopic methods such as magnetic resonance imaging (MRI) with 
contrast agents [87,88], computerized tomography (CT), positron emission  tomography 
(PET), and ultrasonography can determine tissue perfusion noninvasively, and new re-
search designed at improving their limits in spatial resolution will likely result in more 
widespread applications in the clinical practice (reviewed in [81]). The development 
of a low-cost, accessible, reliable, and noninvasive procedure for the characterization 
and quantitative analysis of angiogenesis using methods directly applicable to human 
patients is still needed. The skin’s easy access for such investigation will likely lead 
Fig. 3 Capillary network development in vitro. Confocal imaging reveals that HMVEC 
organize into CD-31+ capillary-like structures (green) when seeded into a reconstructed 
adipose tissue produced from in vitro-differentiated ASC according to the self-assembly 
approach of tissue engineering [33]. HMVEC were cultured for a total of 13 days after seeding 
between two adipose sheets (adipogenically induced for 29 days) that were superposed for 
6 days. Hoechst-labeled nuclei appear in blue (20×).
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to new technologies and broader applicability of already existing  methods such as la-
ser Doppler flowmetry, transcutaneous oxygen tension measurements, and capillary 
microscopy. For example, capillary microscopy (also called videocapillaroscopy or 
intravital capillaroscopy) is a method typically used and validated to examine the mor-
phological and functional changes in microcirculation in the skin affected by patholog-
ical conditions such as psoriasis and systemic sclerosis [89,90]. The noninvasive nature 
of the device for direct observation of the architecture of the local microcirculation 
is an advantage. This tool can determine capillary morphology including size, shape, 
and tortuosity in addition to capillary density; skin percentage occupied by capillaries 
(volume fraction); and changes in the velocity of the red blood cells within capillaries. 
This technique allows the assessment of the nutritive capillary bed, distinct from the 
(A) (D)
(B) (E)
(C) (F)
Fig. 4 Vascularization of adipose tissue constructs. Human capillaries within the 
microvascularized adipose tissues are stable and functional 14 days after grafting. 
Immunolabelings on cryosections reveal that human CD31-expressing capillary structures 
(A and D in red) are filled with murine red blood cells (B and E in green) indicating that 
functional inosculation occurred upon grafting. C and F are image superposition of A and D, 
with B and E images, respectively (40× magnification).
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thermoregulatory vascular bed, which contributes 85% of the total blood flow, usually 
evaluated using transcutaneous oxygen tension and Doppler laser. When capillaroscopy 
is performed in combination with the use of intravenous fluorescent dyes such as so-
dium fluorescein, the imaged capillaries allow the determination of perfusion indexes 
[90]. It would be interesting in the future to use similar approaches for the monitoring 
of prevascularized reconstructed skin after grafting to evaluate the evolution of neo-
vascularization in comparison with normal skin. Recent state-of-the-art advancements 
achieved using multimodal imaging to evaluate blood flow will undoubtedly benefit the 
field of microcirculation and lead to a more widespread use of these modalities in the 
clinical realm (extensively reviewed in [91]).
2.6  Beyond blood vessel vasculature: Lymphatic-like networks 
revealed in vitro
As described in the previous sections, the need for nutrients and gas exchanges has 
driven extensive research on vascularization strategies with a focus on blood micro-
vascularization. However, it is now recognized that lymphatic vascularization is also 
a key aspect to consider while performing tissue reconstruction, particularly for the 
clinical application of skin substitutes. The lymphatic capillaries are part of a unidirec-
tional system and are characterized by blind ends and button-like junctions allowing 
fluid and cells to easily enter the capillaries [92].
The lymphatic vasculature allows to transport debris from the wound site and to 
drain interstitial fluid, but it also plays a major role in the immune response by allow-
ing immune cells to access and leave an inflammation site. A quick drainage of the 
grafted site, for example, for burn or venous ulcer patients, is key to the successful 
integration of skin substitutes.
A small number of teams addressed the lack of lymphatic capillaries in skin substi-
tutes generated by tissue engineering [41,46,47,50,93]. Lymphatic engineering mainly 
stems from the thorough characterization of human microvascular endothelial cells 
performed in recent years. Typical extraction methods for microvascular endothelial 
cells are based on cell extrusion and generate cell populations widely used to gener-
ate blood capillaries. These cells also include a subpopulation of lymphatic endothe-
lial cells (LEC), which can form new dermal initial lymphatics [94–96]. LEC can be 
purified by flow cytometry or using immunomagnetic beads directed at podoplanin, 
lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1), and CD34 and then be 
incorporated into substitutes [94,97]. For example, purified human LEC seeded on top 
of fibroblast-derived cell sheets generated by the self-assembly approach, which were 
later stacked, produced a reconstructed dermis featuring a lymphatic capillary network 
[97]. This network displayed blind-ended lymphatic capillaries expressing prospero 
homeobox protein 1 (PROX1), LYVE-1, and podoplanin. Anchoring filaments were 
also present. Moreover, in vitro lymphangiogenesis could be modulated by VEGF-C 
and hepatocyte growth factor (HGF), which are able to induce lymphangiogenesis via 
VEGFR-3 and c-Met, respectively. In addition, this study demonstrated that when sup-
plemented together, the impact of VEGF-C and HGF was more potent than for each 
molecule separately [97].
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The first demonstration of the ability of lymphatic capillaries to be translated 
in  vivo was reported in a bilayer skin substitute featuring blood and lymphatic 
capillaries produced in a rat collagen hydrogel, which was grafted to nu/nu rats 
[46]. In this study, it was shown that, as with blood capillaries, lymphatic vessels 
anastomosed with rat vessels by either direct or wrapping connection [46]. Direct 
connections happened at blunt ends, whereas wrapping connections formed hy-
brid vessels with rat and human cells. Rat capillaries were also often found in the 
proximity of human lymphatic vessels. The subsequent addition of melanocytes to 
the skin substitutes did not influence the formation and development of lymphatic 
vessels after grafting [98].
Skin equivalents comprising blood and lymphatic microvessels have also been 
generated by the use of fibronectin and gelatin cell coating with a mixture of 
HUVEC and human dermal lymphatic microvascular endothelial cells [93,99,100]. 
It will be interesting to determine the fate of the lymphatic microvessels in vivo, 
considering that similar dermal substitutes with blood vascularization only, gener-
ated by this method were grafted and have shown the persistence of the network in 
nude mice [23].
Similarly than for blood vascularization studies, other cell sources could provide an 
easier way to scale up autologous vascularized skin production by extracting more endo-
thelial cells or progenitors than with classical skin biopsies. One alternative is the use of 
adipose-tissue-derived cells. The extraction can be done following a minimally invasive 
liposuction procedure. Human endothelial cells isolated from adipose tissue can form 
microvessels when seeded in a collagen type I hydrogel [41,47]. In addition, in order 
to assess the ability of microvascular fragments to produce lymphatic vascularization, 
murine GFP+ cells were seeded in a cross-linked bovine collagen and shark glycosami-
noglycan matrix (Integra®) and then applied on murine dorsal full- thickness skin defects 
[24]. After 14 days, all implants (with or without microvascular fragments) presented 
lymphatic vessels, but in the group enriched with fragments, the lymphatic network had 
a higher density, and more than 60% of the lymphatic vessels were GFP+, indicating that 
they originated from the transplanted microvascular fragments. GFP+ lymphatic vessels 
were also shown to invade the surrounding host tissue. A dense network of GFP+ blood 
vessels was also obtained by preseeding of fragment-derived cells in Integra®, indicating 
the plasticity of these cells. This study demonstrated the implication of microvascular 
fragment-derived cells in a prevascularized implant for the development of new lym-
phatic vessels, expected to facilitate the graft vascularization and drainage.
Finally, in the future, skin tissue engineering could also benefit from the use of 
LEC derived from induced pluripotent stem cells. Lee et al. generated LEC from plu-
ripotent stem cells and characterized them [101]. After different processes of differen-
tiation, a mixed population of LEC and lymphatic progenitor cells was obtained. They 
expressed LYVE-1, VEGFR-3, and podoplanin. These cells are able to form lymphatic 
capillaries and can be produced on a large scale from the same population of fibro-
blasts that would be used to produce dermal substitutes. They also displayed a higher 
secretion of prolymphangiogenic and proangiogenic factors such as angiopoietins and 
VEGF-C compared with human normal LEC, making these cells a valuable tool to 
promote skin wound healing.
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3.  Conclusion
The field of skin tissue engineering has been progressing at great strides. The variety 
of reconstructed skin models being currently investigated in an experimental or clinical 
setting is very promising for the development of optimal skin replacement adapted to 
specific wound types (e.g., diabetic ulcers and severe burns). In addition to the advances 
mentioned for the reconstruction of a more complete reconstructed skin (the trilayer 
skin and lymphangiogenesis), robust but uncomplicated imaging platforms allowing 
vascularization assessment will be needed to further the field. Vascularization strategies 
will continue to evolve along with the more widespread use of new technologies such 
as bioprinting, microfluidics, nanotechnologies, and the production of microstructured 
templates [102–104]. These exciting technologies have the potential to generate per-
fusable microchannels or networks featuring predetermined organization and pattern-
ing resulting in improved spatial control of vessel distribution. We can speculate that 
thicker and customized skin substitutes could be designed in vitro in the future, with 
tissues optimized for distinct anatomical sites submitted to various mechanical loads, 
for example. In this regard, system-based approaches [105] and mathematical and in 
silico modelization [106,107] are also likely to gain more attention in the future in 
the design of new strategies. Finally, the emergence of cell-editing tools will likely 
result in a broader range of applications of tissue-engineering strategies, ranging from 
genetic skin diseases such as epidermolysis bullosa, to the manipulation of cutaneous 
and immune cells in order to generate a “universal” skin substitute. Altogether, the nu-
merous applications of tissue-engineered skin substitutes for cosmetic and reconstruc-
tive surgery prompt continued efforts toward successful translation for broad clinical 
implementation.
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1 Introduction
Wound healing is a multifactorial process, which commences after any form of cuta-
neous injury resulting in immediate vasoconstriction and coagulation [1]. The subse-
quent release of cytokines by keratinocytes and platelets leads to initial inflammation, 
with various immune cells, including neutrophils and monocytes, migrating into the 
wound bed [1]. Release of growth factors by macrophages stimulates angiogenesis, 
resident epithelial cells to proliferate, and fibroblast infiltration to occur, ultimately 
assisting with wound closure [2]. The final visual appearance of the wound-healing 
process is of upmost importance to both patients and physicians alike, with adverse 
scarring being a cause for concern. A major challenge currently facing researchers 
investigating this area is creating an ideal model to study this complex process, evalu-
ate candidate therapies, and ultimately improve aesthetic and functional outcomes for 
patients with abnormal wounds and scars [3]. Many models currently exist, investigat-
ing all stages of wound healing including reepithelialization and scar remodeling [4].
Animal models have been widely used in attempts to replicate the human skin 
[5]. Pig skin is currently thought to be the most accurate animal model; however, no 
animal skin is an exact replica of the human skin, leading to significant differences 
in the wound-healing mechanisms between them [6,7]. Additionally, ethical issues 
surrounding their use also need to be taken into consideration [8].
Numerous human scar and wound-healing models have been developed, including 
in silico, in vitro, ex vivo, and in vivo. The aim of this review is to summarize and eval-
uate each of the above models including their advantages and limitations (Table 1).
2  In silico
The large variety of interactions that influence wound healing requires the need for com-
putational models in order to accurately understand and investigate this complex process 
#Authors contributed equally to the chapter and are joint first authors.
202 
Skin T
issue M
odels
Model Description/features Application Advantages Disadvantages
In silico
Differential 
equations
Agent-based models
- The use of mathematical 
equations based on known 
cellular behaviors to simulate 
wound healing
- A computational modeling 
technique that can simulate 
interactions between cells and 
their environment. Classically 
consist of three components: 
agent, region, and patch
- Investigation of all 
stages of wound 
healing, along 
with the impact 
that various cells, 
cytokines, and 
growth factors have 
on this process
- Can be used as an 
initial screening 
tool to help plan 
clinical trials/
research
- Can involve complex 
mathematical equations
- The lack of standardized 
outcome measures
- Remain experimental unless 
validated
In vitro
Single cell
Coculture
Organ culture
- A defect simulating a wound 
is created in cells cultured in 
monolayer
- Coculture of more than 
one cell type. The use of 
the Transwell system has 
classically been described for 
this purpose
- Cells cultured on a three-
dimensional (3-D) scaffold 
or grown in a 3-D format 
in order to create a skin 
“equivalent”
- Studying rates of 
cell migration and 
proliferation in 
a wound setting, 
for example, 
keratinocytes and 
fibroblasts
- Investigation of 
specific cellular 
interactions and 
subsequent effects
- Investigation of 
scar pathogenesis
- Single-cell models 
are relatively quick 
and inexpensive to 
conduct and allow 
the investigation 
of one specific cell 
type
- Ability to include 
more than one 
cell type more 
accurately reflects 
the wound 
environment, 
particularly with 
organotypic models
- Models cannot accurately reflect 
cellular interactions in the 
wound environment, particularly 
single-cell and coculture models
- Many models use serum, which 
is inflammatory when compared 
with plasma and interstitial fluid. 
Can therefore be difficult to 
translate findings into the in vivo 
setting
- The lack of validated biomarkers
- Dependence on excised tissue
Table 1 Human wound models
W
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ex vivo
Scars
Skin with the 
epidermis intact
The skin with 
artificially created 
wounds
- The use of harvested 
cutaneous tissue
- Common scar tissue used 
includes that from keloids and 
striae albae
- Wounds created can be full 
thickness or partial thickness 
and include burns
- Investigation of 
scar pathogenesis 
and physiology of 
wound healing
- Testing of potential 
therapeutic agents
- Genotoxicity 
testing
- Provides a safe 
environment for 
the assessment 
of potential 
treatments
- Creates an 
environment that 
more closely 
resembles normal 
skin
- Short investigative opportunity
- Not subject to the same 
environmental factors that would 
be present in a patient
- The lack of standardization in 
study design
In vivo
Scars
Wounds 
 
 
- The use of live subjects. 
These can be either patients 
with wounds or scars already 
present or volunteers in which 
a wound is created
- Validation of 
wound and scar 
therapies 
 
- Physiology of 
healing is identical 
to that in patients 
 
- The lack of standardization in 
study design
- Difficulties with recruitment 
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(Fig. 1) [9]. Numerous work has been conducted into designing such models for various 
stages of the wound-healing processes [9]. These can then subsequently be validated 
experimentally and used to assist in various areas of tissue engineering research.
Differential equations have been widely used to investigate the differing phases of 
wound healing [9]. Models specifically looking at the inflammatory phase of healing 
have used ordinary differential equations to outline the effects of variability between 
patients in growth factors and structural proteins, along with macrophages and fibro-
blasts [10,11]. Equations have also been used to model wound closure [12,13]. Arciero 
et al. investigated the mechanisms that coordinate cell migration during wound heal-
ing by deriving a two-dimensional continuum model [12]. Evolution equations were 
then solved numerically using a level set method. Mathematical models were also 
utilized by Wearing et al. who looked into the effects of keratinocyte growth factor on 
reepithelialization [13]. The final stage of the wound-healing process, tissue remodel-
ing, was investigated by McDougall et al. [14]. They applied mathematical models to 
demonstrate the influences that constituents of the extracellular matrix (ECM) have on 
the trajectories of fibroblasts and direction of collagen deposition.
Agent-based modeling is a computational modeling technique that can simulate 
complex behaviors and interactions between agents and their environment while tak-
ing into consideration the stochastic nature of biological processes [15]. Agent-based 
models (ABMs) typically consist of three components: agent, region, and patch [15]. 
The agent represents cells or molecules that move in the region, which consists of 
individual patches. The simulated behaviors of agents in their virtual environment are 
based on current knowledge regarding their known behavior [16]. They have several 
advantages including being easier to use for nonmathematicians while also simplify-
ing the representation of tissue structure [16]. Adra et al. derived an ABM to assess the 
regulatory actions transforming growth factor-beta 1 (TGF-β1) has in tissue regener-
ation [17]. They subsequently validated the model by using it to create a virtual piece 
of epidermis and comparing keratinocyte behavior and the actions of TGF-β1 with 
the existing literature. Similarly, Li et al. used a three-dimensional (3-D) ABM of the 
epidermis to investigate epithelial renewal and basal keratinocyte regeneration [18].
Fig. 1 Diagram illustrating examples of in silico human models of scar formation and wound 
healing.
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ABMs have also been used to provide a framework for the creation of multiscale mod-
els for wound healing. Along with investigating the effects of interactions between kera-
tinocytes and fibroblasts [19], such models have also been used to study the biological 
influences that regulate human keratinocyte organization [20]. Anderson et al. advanced 
this type of model to create a hybrid continuous-discrete model for deterministic systems 
[21], which has been utilized to study fluid flow through vascular networks [22,23].
3  In vitro
In vitro models have been widely used in the investigation of wound healing and scar 
pathogenesis [3]. They are generally inexpensive and require less ethical consider-
ations when compared with their in vivo counterparts [24]. They vary in complexity 
ranging from single-cell and coculture (two different cell types) models to organotypic 
multicellular-layered constructs (Fig. 2) [24].
Single-cell models commonly involve culturing cells in monolayer directly on the sur-
face of the culture dish itself or on substrates including collagen and fibrin [24]. A defect, 
simulating a wound, is then created in the cell monolayer through mechanical [25,26] or 
chemical methods [27]. The defect is then gradually repopulated by the surrounding cells 
[28]. Using microscopy, the rates at which this proliferation and migration occur can then 
be determined. Such models classically involve keratinocytes [29] or fibroblasts [28,30].
Although they are relatively quick and inexpensive to conduct, single-cell mod-
els do not accurately reflect the wound environment [3]. In order to overcome this, 
several other models have been created. Cocultures of fibroblasts and keratinocytes 
using Transwell systems (Corning Costar, MA) have been conducted, allowing the 
Fig. 2 Diagram illustrating examples of in vitro human models of scar formation and wound 
healing.
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investigation of the interactions between these two cell types and the subsequent ef-
fects [31,32]. The Transwell assay is composed of two separate mediums divided by a 
porous membrane and can be used for various cell types including epithelial [33] and 
mesenchymal cells [34].
In vitro 3-D models have also been used in attempts to construct and mimic the 
ECM while also more accurately reflecting normal wound physiology [35]. It has al-
ready been shown that both collagen and collagenase production by fibroblasts varies 
when they are cultured in two and 3-D, presumably due to the action of integrins [36]. 
Nayak et al. utilized a construct of sericin to assess the proliferation and viability of 
cocultures of keratinocytes and fibroblasts, which were located on the upper and lower 
surfaces, respectively [37]. Similarly, collagen and fibrin have been used to create a 
3-D environment, with both promoting fibroblasts to differentiate toward the scar phe-
notype when combined with a mechanical load [38]. Additionally, Karamichos et al. 
created a 3-D collagen matrix to study the effects of different culture conditions on 
matrix remodeling and fibroblast migration [39].
The knowledge that extensive interaction between keratinocytes and fibroblasts reg-
ulates the production of dermal ECM, led to the development and use of organotypic 
skin equivalents in scar research [40]. Bellemare et al. isolated keratinocytes from hy-
pertrophic scars on a dermal matrix and created a fully differentiated epidermis [41]. 
This subsequently exhibited characteristics of adverse scarring and highlighted the 
contribution that keratinocytes have in hypertrophic scar formation. Likewise, Chiu 
et al. investigated the effects of photodynamic therapy on keloid scars through the use 
of an organotypic skin equivalent with keratinocytes and keloid fibroblasts [42]. The 
use of such models to investigate potential therapeutics is, however, limited due to the 
need for excised scar tissue along with a lack of validated biomarkers [3]. This led to 
the development of a hypertrophic scar model created from adipose-derived mesen-
chymal stem cells [43]. This model exhibited many similar characteristics to that of 
hypertrophic scars (e.g., increased collagen I secretion) while also allowing for the 
identification of measurable scar parameters that were subsequently validated using 
various treatments. The authors did, however, conclude that this model is only relevant 
for hypertrophic scars caused from injury where the adipose tissue is exposed.
4  Ex vivo
Ex  vivo models initially involve the harvesting of cutaneous tissue from informed 
volunteers and with appropriate research ethical approvals in place. These models are 
critical in evaluating the pathophysiology of scars and wounds and their response to 
treatment, especially in diseases, such as keloid, where no animal models exist. The 
three main categories of cutaneous ex vivo models published are scars [44–47], skin 
with the epidermis intact [48–53], and skin with various artificially created wounds 
[48,52,54–58] (Fig. 3).
Scar models include keloid [44–47], striae alba [46], hypertrophic [46], and fine-
line scars [46], with the site of scar harvest differing greatly between studies [46,47]. 
Biopsies of the scars used varied in shape and size; however, the majority were  created 
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using circular punch biopsies [44,46,47], although square-shaped explants have also 
been utilized [45]. The minimum diameter of biopsies used was 3 mm [44] with 
the largest reported at 6 mm [44,46]. Both Hanks buffer [44,45,47] and phosphate- 
buffered saline [46] have been used to wash the explants prior to embedding. Using 
multiple validation measures including histological assessment, cell proliferation and 
apoptotic assays, ELISA, and immunohistochemical and immunofluorescence stain-
ing, both Duong et al. [45] and Bagabir et al. [44] were able to preserve keloid ex vivo 
organ culture models for up to 6 weeks. Various media were used to support the ex-
plants (Table 2), with the use of supplemented William’s E medium changed every 
3 days, supporting superior proliferation with reduced cytotoxicity [44]. All explant 
models were embedded in collagen gel matrix with the epidermis either submerged 
in media [44,45] or air-exposed [44–47], with superior morphology being observed 
in the air-exposed explants [45]. Bagabir et  al. [44] supplemented the media with 
dexamethasone, which is employed in the clinical management of keloid disease, and 
found shrinkage compared with untreated controls at 4 weeks, whereas at 3 weeks, 
no such macroscopic changes were apparent, highlighting the need for keloid models 
with longevity in order to accurately determine treatment output. The same model has 
also been used to evaluate photodynamic [46] and antifibrotic therapies [47].
Skin explant models with the epidermis intact are employed as a control to wounded 
explant models. They are typically harvested from the breast [49–52] and abdomen 
of patients undergoing elective surgery [51,53]. The size of the explants described 
Fig. 3 Diagram illustrating examples of ex vivo human models of scar formation and wound 
healing.
 Model
Shape/
size
Embedding 
techniques Epidermis
Culture 
duration
Culture 
media
Validation 
techniques Site
Therapeutics 
investigated Disinfection
[44] -Scar -Circle
-3–6 mm
-RTCG -AE-S -6 weeks -DMEM
-WEM
- Changed 
every 
3 days
-LDH
-MTT
-TUNEL
-Ki67
- Col I–III 
ELISA
-Histology
-IHC-IF
-Sternum
-Arm
-Pubis
-Scalp
-Face
-Ear
-Abdomen
-DEX -HB
[45] -Scar -Square
-3–5 mm
-RTCG -AE
-S
-6 weeks -DMEM
-FBS
- Changed 
every 24
-72 h
-IHC
-TUNEL
-ISH
-NS -Nil -HB
[46] -Scar -Circle
-6 mm
-RTCG -AE -7 days -WEM -Histology
-IHC
-IF
-qRT
-PCR
-Abdomen
-Arm
-Breast
-Thorax
-Ear
-PDT -PBS
[47] -Scar -Circle
-4 mm
-RTCG -AE -4 weeks -WEM
- Changed 
every 
3 days
-LDH
-MTT
-TUNEL
-Ki67
- Col I–III 
ELISA
-Histology
-IHC
-qRT
-PCR
-Sternum
-Arm
-Pubis
-Scalp
-Face
-Ear
-Abdomen
-EGCG
-PAI-1
-DEX
-HB
Table 2 Ex vivo models
 Model
Shape/
size
Embedding 
techniques Epidermis
Culture 
duration
Culture 
media
Validation 
techniques Site
Therapeutics 
investigated Disinfection
[48] -Skin
-Wound
-Circle
-6 mm
-Circle
-6 mm
- 3 mm 
FTW
-RTCG
-RTCG
-AE
-AE
-3 weeks
-3 weeks
-DMEM
- Changed 
every 
48 h
-LDH
-Histology
-IHC
- VEGF 
ELISA
-NS -IL 10 -HB
-70% ethanol
[49] -Skin -Circle
-3 mm
-TF -AE -24 h -IMDM -IHC -Breast -Cytokines
-LPS
-NS
[50] -Skin -Square
-1.5 cm2
-TF -AE -15 days - EpiLife 
with 
EDGS
- Changed 
every 36 h
-Histology
-TUNEL
-Breast -Fixator pin
-Biomaterial
-PBS
[51] -Skin -Circle
-16 mm
-NI -AE -24 h -DMEM
- Changed 
every 24 h
- Comet 
assay
-MTT
-Breast
-Abdomen
-Toxins -HB
[52] -Skin
-Wound
-Square
-1 cm2
-Square
-1 cm2
-Circle
- 4 mm 
FTW
-NS -AE -6 days -KBM -Planimetry
-Histology
-Breast -Toxins -NS
[53] -Skin -NS -CS -AE -14 days -DMEM
- Changed 
every 
48 h
-Histology
-TUNEL
-Ki-67
-IF
-Abdomen -Nil -Betadine
-70% ethanol
[54] -Wound -Circle
-8 mm
- 4 mm 
FTW
-TF -AE -21 days -DMEM
- Changed 
NS
-Histology -Abdomen -Hyaluronan -NS
(Continued)
FTW, full-thickness wound; NS, not specified; PTW, partial-thickness wound; RTCG, rat tail collagen gel; TF, Transwell filter; NI, Netwell inserts; CS, cell strainer; AE, air-exposed; S, submerged; 
DMEM, Dulbecco’s modified eagle’s medium; WEM, William’s E medium; FBS, fetal bovine serum; IMDM, Iscove’s modified Dulbecco’s medium; EDGS, EpiLife defined growth supplement; 
KBM, keratinocyte basal medium; LDH, lactate dehydrogenase; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; Col, collagen; ELISA, enzyme-linked immunosorbent assay; 
IHC, immunohistochemistry; IF, immunofluorescence; ISH, in situ hybridization; qRT-PCR, quantitative reverse transcription-polymerase chain reaction; VEGF, vascular endothelial growth factor; 
DEX, dexamethasone; PDT, photodynamic therapy; EGCG, (−)-epigallocatechin-3-gallate; PAI-1, plasminogen activator inhibitor-1; IL, interleukin; LPS, lipopolysaccharides; HB, Hanks buffer; PBS, 
 phosphate-buffered saline.
Table 2 Continued
 Model
Shape/
size
Embedding 
techniques Epidermis
Culture 
duration
Culture 
media
Validation 
techniques Site
Therapeutics 
investigated Disinfection
[55] -Wound -Circle
-6 mm
- 3 mm 
FTW
-Square
- Burn 
wound
-Nil -S -14 days -DMEM
- Changed 
every 
48 h
-Histology
-Cell culture
-Breast -Nil -NS
[56] -Wound -Circle
-6 mm
- 3 mm 
PTW
-Culture disc -AE -7 days -DMEM
- Changed 
every 
48 h
-IHC
-ISH
-Trunk -Keratinocytes -NS
[57] -Wound -Circle
-8 mm
- 4 mm 
FTW
-RTCG -AE -16 days -DMEM
- Changed 
every 
48 h
-Histology
-IHC
-qRT-PCR
- Western 
blotting
-LDH
- Flow 
cytometry
-Abdomen - Electric 
stimulation
-PBS
[58] 
 
 
-Wound 
 
 
-Circle
-8 mm
- 2 mm 
FTW
-TF 
 
 
-S and AE 
 
 
-8 days 
 
 
-NS
- Changed 
NS 
-Histology
-IHC 
 
- Tissue-
engineered 
human 
skin
- Dermal 
substitutes 
 
-NS 
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varies in size and shape, ranging from 6 to 16 mm circular punches [48,49,51], uni-
form squares with a surface area of 1–1.5 cm2 [52] or being irregularly shaped [50]. 
Numerous solutions have been used to disinfect the explants including 70% ethanol 
[48,53], betadine [53], Hanks buffer with [51] or without antibiotic supplementation 
[48], and phosphate-buffered saline supplemented with gentamicin and amphotericin 
B [50]. Explant viability ranged from 24 h [49] to 3 weeks [48] with the epidermis be-
ing air-exposed in all models [48–53]. Balaji et al. [48] embedded the skin explants in 
rat tail collagen 1 gel matrix cultured in supplemented serum-free Dulbecco’s modified 
eagle’s medium with the epidermal surface air-exposed. With the media changed every 
other day for 21 days, they showed detachment and decreasing thickness of the epider-
mis at day 14; however, they showed the dermis was similar to day 0 skin and lactate 
dehydrogenase (LDH) activity declined from day 1 to day 21. Companjen et al. used 
a different embedding technique with the skin explants inserted into Transwell filters, 
with the dermis suspended in culture medium and the epidermis also air-exposed [49]. 
These biopsies, taken from healthy volunteers and those with psoriatic plaque-type 
skin lesions, were incubated for only 24 h in standard conditions (5% carbon dioxide 
and 37°C) or special conditions, where explants were placed into Tedlar culture bags 
with an artificial atmosphere of 5% carbon dioxide and 95% oxygen at 32°C. They 
found morphological deterioration of psoriatic lesions in standard conditions that were 
abolished under special conditions. No such deterioration of normal skin explants was 
noted. They concluded the model allowed maintenance of the normal skin architecture 
without spontaneous induction of regenerative maturation markers, through measure-
ment of cytokine release with ELISA and immunohistochemistry. However, they only 
cultured the model for a very short time period [49]. Xu et al. anchored a partial der-
mal thickness skin explant using sutures to a nylon mesh cell strainer and showed nor-
mal epidermal morphology, with keratinocyte proliferation up to 12 days and an intact 
basement membrane for up to 21 days. [53]. The epidermis was air-exposed, while the 
dermis was surrounded in media that was changed every other day. The skin explant 
models have been used to assess cytokine activity [48,49], glycosaminoglycans [50], 
and toxins [51,52].
Cutaneous explants with iatrogenic wounds were either harvested from the breast 
[52,55], the abdomen following abdominoplasty surgery [54,57], or the trunk [56]. 
All but one study used circular skin explants 6–8 mm in diameter [48,54–58]. Tomic-
Canic et al. used 1 cm2 explants with a 4 mm circular punch biopsy through the re-
ticular dermis [52]. All other studies have also utilized circular wounds within the 
explants ranging in depth from 1 mm [55], the upper dermis [56], to full thickness 
[48,54,57,58]. Kratz et al. also created a deep dermal burn wound model by applying 
a heated brass string to the epidermal surface for 1 s at a temperature of 150°C [55]. 
Disinfection, embedding, length of culture, type of media, and validation methods 
varied between the studies (Table  2). Balaji et  al. evaluated cytokine treatment on 
wound healing by embedding the wounded explants in rat tail collagen matrix, main-
taining the model for up to 3 weeks with media changed every other day and monitor-
ing viability using a LDH cytotoxicity assay and histological evaluation [48]. Kratz 
et al. found discrepancies in the wound-healing process between incisional and burn 
wounds, highlighting the vital role ex vivo models have in understanding the normal 
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healing process of different types of wounds, and thus potentially allowing the inves-
tigation of therapeutics that are wound type-specific [55]. These cutaneous wounded 
explant models have also been used to assess toxins [52], glycosaminoglycans [54], 
and keratinocyte transplantation [56]. Dermal substitutes have also been assessed by 
inserting them into the full-thickness wounds created in the tissue explants [54,58]. 
Sebastian et al. used the donut-shaped full-thickness wounded explants to investigate 
the effect of electric stimulation on wound closure and found enhanced epidermal 
proliferation [57].
The use of these diverse scar and wound models described above in assessing cyto-
kine activity, toxin effects, cell migration, and proliferation is extensively highlighted. 
These models have also allowed assessment of other features such as epidermal thick-
ness [44], epithelialization [57], and the role of immune components in healing and 
response to treatment [5]. Other features of wound healing where these models could 
be used to investigate include the study of dermal thickness, angiogenesis, hair folli-
cles, rete ridge formation, and ECM proteins.
5  In vivo
In vivo cutaneous scar and wound models are ideal for investigating the pathophysiol-
ogy of healing in live subjects (Fig. 4). In vivo models are used to either assess normal 
scarring or wound-healing processes or used to investigate the effect of candidate 
therapeutics [59,60].
To assess the normal scarring process, the creation of a scar in healthy volunteers 
is a model that has been utilized. Dunkin et al. hypothesized that there is a critical 
depth of wounding beyond which a fibrous scar develops [61]. They confirmed this 
by creating an incisional wound of varying depth with deep dermal at one end and 
superficial dermal at the other in 113 healthy volunteers along the lateral aspect of 
the hip. Using digital images and high-frequency ultrasound, they found no detectable 
scar at the shallow end of the wound at the study end point of 9 months, confirming 
their hypothesis [61].
The impact of treatments on scars has been assessed in clinical studies. Ud-din et al. 
conducted a case series of 65 patients with keloid disease to assess steroid-sensitive 
responders using mostly subjective parameters [59]. Over a 3-month period, they found 
keloid scar steroid sensitivity was associated with anatomical location and frequency 
of injections. However, the lack of objective measures of response and short follow-up 
period are limitations to be considered. The same group conducted a similar case series 
on patients with keloid disease undergoing photodynamic therapy over a longer follow- 
up period of 9 months; however, on this occasion, they also included quantifiable non-
invasive objective measures of response including spectrophotometric intracutaneous 
analysis and full-field laser perfusion imagery [60]. Human in  vivo scars have also 
been used to assess less conventional treatments such as electric stimulation [62]. 
The application of electric stimulation on raised dermal scars found reduced pain and 
pruritus over a 2-month study period in 19 patients [62]. Although, objective mea-
surements of scar melanin, collagen, hemoglobin, and blood flow were measured, the 
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 primary  significant findings were subjective outcomes. As well as noninvasive objec-
tive  measures, invasive biopsies of scars following treatment have also been done to 
assess morphological and immunohistochemical changes post treatment [63].
Various cutaneous wound models in patients and healthy volunteers have been in-
vestigated with regards to the healing process and the effect of various treatment mo-
dalities. These models include superficial [64–69], burn [70,71], incisional [72], and 
excisional wounds [73–77].
Superficial wounds include the blister model [64–66], tape-stripping method [67], 
and skin graft donor sites [68,69]. The blister model allows the creation of a standard-
ized superficial wound that can be monitored for epidermal regeneration. This is cre-
ated using various suction devices, and these models can be used to assess drug effects 
and drug absorption [65,66]. They are easily replicated; however, they are limited to 
only providing a useful tool for the investigation of superficial rather than deep dermal 
wounds. Less detrimental to the epidermis is the tape-stripping method. This involves 
the noninvasive application of adhesive tape to the skin with repeated stripping of the 
epidermis that leads to skin barrier loss [67]. Although offering the least side effects 
and proving useful in assessing treatment penetration, these advantages are limited to 
Fig. 4 Diagram illustrating examples of in vivo human models of scar formation and wound 
healing.
214 Skin Tissue Models
the stratum corneum. Skin graft donor sites are a further model of superficial wound-
ing [68,69]. These are advantageous as they are easily made and duplicate wounds 
can be created in the same individual that allows the investigation of treatments with 
optimum control comparisons. They do, however, heal rapidly making a significant 
detectable difference difficult.
The creation of a burn wound in healthy volunteers is another option. Mattsson 
et al. produced a superficial burn injury on the flexor surface of the forearm using an 
electrically heated aluminum rod at 51°C and assessed the impact of intravenous lido-
caine infusion on the inflammatory phase of healing [71]. They found a significantly 
faster restitution of residual erythema in the active group compared with placebo at 
12 h post burn. Another method of creating a burn wound is the use of ultraviolet 
radiation [70]. The application of this appears a safe model, with the only long-term 
consequence being tanning at the irradiated site. With the application of three times 
the minimal erythema dose, Bishop et al. found no blistering and no loss of skin bar-
rier function [70].
Other in vivo models of wound healing include incisional and excisional wounds. 
Incisional cutaneous wound models involve the immediate primary closure of the 
wound following its creation and can be used to assess wound healing and comparison 
of standard versus investigative treatments. Conde-Green et  al. assessed the use of 
negative-pressure wound therapy in patients who underwent primary abdominal wall 
closure and found a significant reduction in wound complications and dehiscence rates 
compared with conventional dry gauze dressings [72]. The use of a biopsy punch of 
various sizes to create a full-thickness excisional wound in healthy individuals allows, 
with the use of invasive and noninvasive techniques, the profiling of normal healing 
and the impact of treatments. Biopsies are typically taken at multiple time points usu-
ally from the inner aspect of the upper arms under local anesthetic [73,77]. This makes 
the process convenient for the subjects and the location being relatively well hidden. 
Ud-din et al. used objective noninvasive devices such as spectrophotometric intracuta-
neous analysis, full-field laser perfusion, and 3-D imaging to ascertain melanin, hemo-
globin, collagen, blood flow, and wound size up to 14 days post wounding [74]. They 
found corroboration of these findings with immunohistochemical techniques, thus 
supporting the use of these noninvasive devices in wound theranostics. The excisional 
punch biopsy model has also been used to assess treatments such as skin substitutes 
[75,76] and also less common treatments such as electric stimulation [73,77]. Greaves 
et al. assessed the use of skin substitutes including Decellularised Dermis (NHSBT, 
Watford, the United Kingdom), Integra Matrix Wound Dressing (Integra LifeSciences 
Inc., Plainsboro, NJ), and autografting of the skin and found enhanced angiogenesis 
[75] with acute wounds treated with Decellularised Dermis and reduced dermal fibro-
sis compared with control wounds [76]. Ud-din et al. identified increased blood flow 
in this excisional wound model following electric stimulation of the wound using non-
invasive objective devices [77] and later confirmed this using immunohistochemistry 
and western blotting [73]. They also found increased angiogenic marker response in 
electrically stimulated wounds [73].
In vivo models using animals have also been widely described in the investiga-
tion of wound healing. Perhaps the most economical of these is the murine model. 
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Numerous studies have used mice, with wounds being created on the head, ear, tail, 
and back [78,79]. Mice also have the additional benefit of being amenable to genetic 
manipulation [80]. These genetically modified mice allow for specific genes and their 
function to be investigated during the wound-healing process [80]. Despite their ben-
efits, wound healing in mice primarily occurs through contraction and is therefore 
significantly different from that in humans [79,80]. Attempts have been made to try 
and overcome this limitation, however, through the use of back splints to limit the 
degree of wound contraction [81]. The animal model that currently offers the most 
accurate replication of human wound healing is that of the pig [82]. They have a 
thick dermis, which is structurally similar to that in humans [83], and have sparse hair 
and skin that is adherent to underlying structures, which is also observed in humans 
[84]. The porcine model has been used to study various wound-healing pathologies 
including chronic ischemic wounds [84] and burns [85]. They have also been instru-
mental in the development of epidermal and dermal skin substitutes during preclinical 
studies [86,87]. However, despite their benefits, there are several limitations to their 
use. Despite being similar to the human skin, there are significant structural differ-
ences observed in porcine skin, such as a less vascular dermis [88]. Pigs are also more 
expensive and difficult to manage when compared with their murine counterparts. 
Additionally, as with all animal models, there are numerous ethical considerations that 
must also be taken into account before their use.
6  Conclusion
Human cutaneous scar and wound models are vital in helping researchers better 
understand the physiological and pathological processes of normal and abnormal 
 healing, and in certain scenarios can be considered to be superior to animal models 
in the absence of an exact replica. In silico, in vitro, ex vivo, and in vivo models also 
provide relevant and realistic models to assess the therapeutic effects of experimental 
treatments aimed at improving the wound-healing processes.
The use of in silico models are currently limited by the absence of standardiza-
tion and the lack of validation and therefore remain in the experimental phase [89]. 
The need for transferability of methods across different laboratories and inter- and 
intralaboratory reproducibility are crucial before such models are deemed reliable [8]. 
In vitro models are beneficial as they are relatively less expensive and their complex-
ity is broad ranging from single-cell models to organ cultures. However, translation 
of findings into an in vivo model is challenging given the multiple confounding fac-
tors encountered in clinical situations. To some extent, ex vivo human models aim 
to solve these difficulties in clinical translatability. They provide an excellent means 
of assessing the complex wound-healing processes and providing a platform to as-
sess the impact of treatments in a safe environment. However, certain environmental 
factors patients with wounds would be subjected to are not reproducible, and these 
models only provide a short investigative opportunity into a process that continues for 
several months to years [90]. In vivo models of scarring and wound healing are ideal 
for investigative purposes as they provide the closest resemblance, if not the same, 
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to patients. However, limitations include difficulties in recruitment and current stud-
ies lacking consistency in study design, assessment techniques, and follow-up [82]. 
Tissue-engineered models are emerging to closely resemble the in vivo environment 
through regulation of environmental factors that would help resolve limitations with 
current wound-healing models [91,92].
Human cutaneous scar and wound models are critical in improving our understand-
ing of the pathophysiology of cutaneous healing and scarring. They are additionally 
vital to aiding with the safe assessment of current and emerging wound therapeutics, 
with the ultimate aim of creating a scarring-free environment leading to optimal skin 
regeneration.
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1. Introduction
Wound healing is an evolutionarily conserved process aimed to efficiently restore cutane-
ous barrier upon injury. It consists of the sequential yet overlapping phases of hemostasis, 
inflammation, proliferation, and tissue remodeling [1]. Previous basic and preclinical re-
search utilizing in vitro and in vivo wound models has greatly advanced understanding of 
distinct molecular and cellular processes involved in wound healing. However, attempts 
to translate these findings into the clinical setting had only limited success. Here, we 
outline the most commonly utilized in vitro, ex vivo, and in vivo wound-healing models, 
highlighting their applications in both mechanistic and preclinical studies.
Preclinical research remains the gold standard to evaluate safety, toxicology, and 
efficacy in a dose-response fashion. In addition, it provides great advantage to study 
specific mechanism(s) that contribute to the healing process. In vitro wound-healing 
assays such as wound scratch or transwell migration assays are useful when inves-
tigating the effect of a novel therapeutic agent on particular cell types or a specific 
factor that could be important during tissue repair [2–4]. However, two-dimensional 
in vitro assays are unable to completely reproduce biological conditions such as im-
mune response, cell-cell, and cell-matrix interaction and pathology of wound-healing 
disorders. Therefore, organotypic cultures that recreate dermal layer and the stratified 
epidermis have been developed and successfully utilized to evaluate keratinocyte- 
fibroblast cross talk during wound healing and repose to topical treatments in three 
dimensions [5,6]. Similar human ex vivo wound model has been utilized successfully 
to study mechanism of wound epithelialization under a wide variety of experimen-
tal conditions [7]. In vivo animal wound models are the next step in the preclinical 
testing. Both small and large animal models are widely used in the wound-healing 
field as they illuminate the mechanisms of cutaneous wound repair under systemic 
conditions [8–11]. Importantly, in vivo wound models mimicking complex conditions 
such as diabetes, infection, or ischemia have been established and extensively utilized 
[2,12–18]. In vitro, ex vivo, and in vivo models have greatly advanced our understand-
ing of the wound-healing process and molecular mechanisms; however, they often fail 
to completely reproduce human condition, particularly the complexity of nonhealing 
chronic wounds.
Skin Tissue Models. https://doi.org/10.1016/B978-0-12-810545-0.00010-3
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Chronic wounds are the result of a dysregulated tissue repair process to restore a 
structurally and functionally intact skin barrier. They are frequently associated with 
underlying conditions that include vascular disease, diabetes, and aging [1]. This mul-
tiple, variable systemic contributing factors along with local tissue impairments make 
it challenging to model and replicate. Yet, estimates are that up to 2% of the world 
population will develop chronic wound, with the United States alone accounting for 6.5 
million patients [1,19]. Treatment of chronic wounds has become a tremendous eco-
nomic burden with costs estimated up to $25 billion a year in the United States alone 
[19]. Despite the high mortality rate and severe morbidities, mechanisms that result in 
the development of chronic wounds remain poorly understood, which, together with 
limitations in experimental models of these diseases, resulted in fewer effective thera-
pies [1]. In addition, current treatment options are often not fully efficacious in restor-
ing healing. The complexity of heterogeneous patient population with multifactorial 
etiology and lack of animal models that recapitulate the human condition hindered the 
research on chronic wounds and the development of new therapies [1]. Although exper-
imental chronic wound models equivalent to human in laboratory animals do not exist, 
some animals develop nonhealing or slow healing wounds [20] with a low incidence.
Here, we describe the most current in vitro and in vivo models for wound-healing 
studies referring to their advantages and disadvantages. Recent advances in “micro-
engineered” models of the functional human skin, known as organs-on-chip [21], that 
could provide the basis for preclinical assays with greater predictive power are also 
discussed. Although well-controlled, randomized clinical trials are the final testimo-
nial of product efficacy, in vitro and in vivo models remain essential for the evaluation 
of wound-healing therapeutics.
2.  In vitro wound healing models
In vitro models are important tools for preclinical wound-healing research. They not 
only aid in understanding the mechanisms of cellular response to wound-initiated mi-
gration and cell-cell interactions but also provide a tool to evaluate the effects of novel 
therapeutic agents at the cellular level in a controlled environment. These easily im-
plemented, affordable assays can be employed to assess migratory capacity of primary 
cells (keratinocytes and fibroblasts) grown from patients’ healthy or diseased skin 
specimens or from genetically manipulated animals. In the light of high-throughput 
and high-content imaging systems, these models provide an effective platform for 
drug discovery and screening.
2.1  In vitro two-dimensional wound assays
2.1.1  In vitro wound scratch assay
The scratch assay is typically utilized to quantify cellular migration on two- 
dimensional (2-D) surfaces over time upon different treatments. It is one of the 
most commonly used in vitro wound-healing assays, allowing determination of the 
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optimal dose of the agents being tested. Cells are grown to confluency in a mono-
layer, and a scratch is made with a pipette tip to create an incision-like gap. The 
“wounded” area is photographed immediately after wounding and at defined time 
points thereafter, and cell migration is quantified and expressed as average percentage 
of closure of the scratch area [2,3]. Alternatively, laser ablation or hydrogel-coated 
dishes can be used in order to create a well-defined gap for the cells to move across 
[22,23]. For longer-term wound-healing assays (>24 h), mitosis inhibitors such as 
mitomycin C treatment are required to eliminate the contribution of cell prolifera-
tion to gap closure, allowing the assay to specifically assess migration of the given 
cell population. Scratch assay is compatible with time-lapse microscopy including 
live cell imaging, imaging specific patterns of cell migration behavior, and more-
over a single-cell movement [24]. Live cell imaging also allows mechanistic studies 
during cell migration including those focusing on intracellular signaling events, 
such as visualization of fluorescently tagged proteins and their subcellular localiza-
tion, or fluorescent resonance energy transfer (FRET) for protein-protein interac-
tions [3]. Multiple studies have utilized wound scratch assays to evaluate the effects 
of major wound-healing growth factors, chemokines, and cytokines on cell migra-
tion [25–27]. Major promotility factors within human serum have been identified 
to stimulate keratinocyte migration in the following order of potency: TGFα > in-
sulin > EGF > HB-EGF > IGF-1 > FGF > IL-8 > HGF > IL-1 > KGF > TGFβ [4]. 
These factors have been utilized as positive controls in in  vitro wound assays 
[27,28].
2.1.2  Transwell migration assay
Another commonly used in vitro wound-healing assay utilized for cell migration as-
sessment is the transwell assay, also known as the Boyden chamber assay. This method 
is ideal for quantitative analysis of single-cell migratory capacity toward certain che-
moattractants. It consists of two medium-containing chambers separated by a porous 
membrane that allows cells to migrate through. By adjusting the cell numbers and 
concentrations of chemoattractant in the upper and lower chambers, it allows studies 
focusing on wound healing, relevant chemotaxis, and chemokinesis [29]. Generally, 
cells are seeded in the upper compartment and cultured to allow migration. After non-
migratory cells are removed by a cotton swab from the upper side of the membrane, 
the membrane is stained for cells that have migrated through the pores to the bottom 
of the membrane. The number of migratory cells is quantified per imaging field [30]. 
Utilizing transwell migration assay, Kroeze and colleagues demonstrated that chemo-
taxis of human primary keratinocytes is attracted by an array of cytokines including 
CCL14, CCL22, CCL27, CXCL1, and CXCL10, whereas keratinocyte chemokinesis 
is stimulated by CXCL8 [31].
Although highly relevant for the initial preclinical screening, the physiological rele-
vance of in vitro migration assays is relatively low and cannot fully simulate the com-
plexity of the cutaneous wound-healing process (Table 1). Due to the limitations of 
2-D monolayer cell culture, these assays lack the cross talk between different cell types 
involved in the wound-healing process, such as keratinocyte-fibroblast interactions and 
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In vitro and ex vivo wound-healing models
Model Advantages Disadvantage Reference
In vitro—2-D cellular assays
Wound scratch 
assay
-  Scratching monolayer 
cell culture mimics 
“wounding” in vitro
-  Low-cost, high-
throughput, easily 
implemented assays to 
measure cell migration
-  The lack of cross 
talk with other cell 
types
-  The lack of ECM, 
low physiological 
relevance
[2-4,22-28]
Boyden chamber 
assay
-  Measures cell motility 
such as chemotaxis and 
chemokinesis
-  Assesses single-cell 
motility
[29-31]
In vitro—3-D skin equivalent
Human skin 
organotypic 
wound model
-  Standardized functional 
skin equivalent
-  Assesses reepithelialization 
and interaction between 
keratinocytes and 
fibroblasts; may include 
lymph and blood vessels
-  Ability to mimic chronic 
wound phenotype with 
primary or genetically 
modified cells
-  Simplified ECM
-  The lack of a 
functional dermal-
epidermal junction
[5,32-40]
Organ-on-a-chip 
skin model
-  Microfluidic chip system 
provides perfusion to skin 
culture
-  Compatible with ex vivo 
skin model
-  In development [21,45]
Ex vivo wound models
Human acute 
wound ex vivo 
model
-  Ex vivo skin culture 
obtained from reduction 
surgery that maintains 
healing capabilities in vitro
-  Human skin full-thickness 
epidermis and dermis; 
Langerhans cells, pigment 
cells and nerve endings
-  Absence of immune 
cells and blood 
supply
-  Variation in wound 
depth can affect 
healing outcome
[7,28,46, 
48-54,56,57]
Murine skin 
explant model
-  Assess keratinocytes 
migration from the full-
thickness murine skin
-  The lack of immune 
cells and blood 
supply
[59]
Table 1 Summary of the frequently used in vitro and ex vivo 
models for wound-healing studies
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interactions of resident cells with infiltrating immune cells, neurons, and other cell 
types. Therefore, it is often necessary to validate the results of in vitro assays with other 
preclinical tests that allow such interactions.
2.2  In vitro three-dimensional wound models
2.2.1  Organotypic human wound model
Organotypic cultures are in vitro systems that recreate rudimentary skin layers and 
the stratified epidermis and can assess keratinocyte response to topical treatments in 
three dimensions (3-D) before moving to in vivo studies. Similar to ex vivo wound 
models, this model can evaluate the effects of a wide variety of molecules and agents 
on keratinocyte migration and keratinocyte-fibroblast interaction during the process 
of wound healing. The organotypic culture model consists of human keratinocytes—
HaCaT (immortalized cell line) being commonly used—grown on a matrix of type I 
collagen with fibroblasts [5,32] or devitalized human dermis [33]. Wounding is per-
formed on this cellular bilayer using a biopsy punch, and after removal of the punched 
tissue, the remaining tissue is placed on top of a second premade type I collagen ma-
trix and allowed to reepithelialize (Fig. 1) [6]. Other wounding methods include CO2 
 laser-induced burns [34] and needle punctures [35]. Upon wounding, topical treat-
ments may be applied. Reepithelialization can be measured by histomorphometric 
analysis or keratin immunostaining. Organotypic cultures use primary human cells 
and provide a standardized platform to study the pathogenesis of wound healing and 
its related disorders and development of more efficacious therapeutics.
This model has several advantages compared with traditional primary cell culture. 
First, this biomimetic model allows for the study of cell behavior in a 3-D  environment 
Table 1 Continued
In vitro and ex vivo wound-healing models
Model Advantages Disadvantage Reference
Human pressure 
ulcer ex vivo 
model
-  Human skin full-thickness 
epidermis and dermis; 
Langerhans cells, pigment 
cells, and nerve endings
-  Utilizes mechanical 
explant test system to 
create chronic wounds
-  Variation in skin 
thickness may affect 
outcomes
-  The absence of 
immune cells
[58,60-62]
Porcine skin 
explant wound 
infection model 
 
 
 
-  Full-thickness porcine 
skin that maintains 
healing capability in vitro
-  Allows for evaluation of 
a variety of antimicrobial 
dressings and topical 
treatments
-  The lack of immune 
response and blood 
supply
-  Does not account 
for effects of host 
microbiome 
[63-66] 
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as opposed to the 2-D monolayer culture. The cells in organotypic cultures can main-
tain complex behaviors such as migration and even hair follicle formation that requires 
the interactions between different cell types in 3-D [5]. Of particular interest in the 
study of wound healing is that organotypic cell cultures have a basal keratinocyte pro-
liferation rate similar to that found in vivo, a well-differentiated epithelium, and com-
plete reepithelialization following wounding [6,36]. Second, this model allows for tight 
control of experimental conditions. Because well-defined lineages of cells are used, 
the keratinocytes in this model are without any interpatient or locational variability. 
Third, organotypic culture allows for genetic manipulations that are not possible or 
are unethical in vivo [5]. More importantly, 3-D organotypic model allows the incor-
poration of primary cells that are isolated from patient biopsy to study and compare a 
variety of  disease-like scenarios [37]. Furthermore, keratinocytes derived from induced 
pluripotent stem cell (iPSC) isolated from both the normal and patient skin have been 
successfully incorporated into 3-D cultures and were fully functional [38]. Recently, 
full-thickness human skin constructs equipped with functional lymph and blood capil-
laries have been developed and tested on animal models demonstrating their potential 
to improve the survival of engrafted tissue [39].
Despite these advantages, the organotypic culture system has its own limitations, 
including a simplified anatomy and cell types compared with that seen in  vivo. 
Therefore, it cannot replicate some complex cellular interactions that occur during 
the wound-healing process such as inflammation and angiogenesis [5]. Additionally, 
the lack of a functional dermal-epidermal junction leads to incomplete differentiation 
of cultured cells and affects their stability and the nature of their interactions [40]. 
Furthermore, organotypic cell behavior can be affected dramatically by the culture 
conditions, and thus proper media choice is paramount [5].
2.2.2  3D organotypic cultures mimicking wound healing 
disorders
Currently, there are chronic wound and hypertrophic scar organotypic models es-
tablished using diseased and/or healthy human keratinocytes and fibroblasts. Three-
dimensional organotypic cultures assembled with diabetic foot ulcer (DFU)-derived 
fibroblasts and healthy keratinocytes maintained pathological phenotype of DFUs, 
Fig. 1 Organotypic human wound model. H&E-stained section of the organotypic human 
model generated from HaCaT keratinocyte cell line and human fibroblasts grown on a matrix 
of type I collagen. Keratinocytes migrate over the matrix to fully reepithelialize wounding 
4 days upon wounding. Black arrows indicate the edges of the initial wound area, and red 
arrow indicates wound closure. E, epidermis; D, dermis; AD, acellular dermis.
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such as increased proliferation of basal keratinocytes, impaired reepithelialization, 
decreased extracellular matrix (ECM) production, and reduced neoangiogenesis [41].
The most advanced organotypic fibrosis model is the hypertrophic scar formation 
model with a reconstructed epidermis on a dermal matrix populated with adipose- 
derived mesenchymal stem cells (ASC). This organotypic model with ASC-populated 
matrices represents hypertrophic scar both macroscopically and microscopically and 
has been utilized for therapeutic evaluations. This organotypic model with ASC-
populated matrices can reproduce a number of epidermal and dermal scar characteris-
tics, mimics hypertrophic scar both macroscopically and microscopically, and has been 
validated with five known therapeutics [42]. For 3-D keloid models, either combina-
tions of keloid fibroblasts with normal skin-derived keratinocytes [43] or a fully differ-
entiated epidermis constructed from keratinocytes isolated from hypertrophic scars on 
a healthy fibroblast-populated dermal matrix was able to exhibit characteristics of an 
adverse scar (e.g., dermal thickness, epidermal thickness, and collagen I) suggesting 
the pathological changes in both cell types during hypertrophic scar formation [44]. 
In all, organotypic culture is a valuable model in the field of cutaneous wound healing 
because of its potential preclinical applications and assessment of novel therapeutics.
2.2.3  Organ-on-a-chip model
Organ-on-a-chip technologies that can mimic multilevel organ functions are being 
developed to screen drugs and treatments in a way that circumvents the need for live 
animals [45]. These biomimetic, microfluidic devices are generally small in size and 
are being developed with increased complexity. Organ-on-a-chip applications for 
skin-centered models have been developed and focus on accommodating a bioengi-
neered skin equivalent that is continuously perfused through a microvascular channel. 
Atac et  al. have shown that human skin equivalents, human ex vivo skin, and hair 
follicle cultures all had increased longevity in the organ-on-chip, as compared with 
static 3-D cultures [21]. Additionally, tissue disintegration was decreased in the chip 
cultures [21]. While there are several barriers to overcome before a full multilevel, 
organ-on-a-chip skin equivalent can be fully utilized for wound-healing studies, the 
power of this technology has already been made evident. What remains is to create and 
uphold the native skin’s three-layered architecture, with sensory organs, appendages 
including the hair follicles and sebaceous and sweat glands, and a full vascular net-
work, all on a single organ-on-a-chip. Once created, this can then be integrated onto 
multiorgan chips, mimicking a full organism’s native environment, thus opening doors 
to more powerful treatment screening methods for wound-healing disorders.
3.  Ex vivo wound models
3.1  Human ex vivo wound model
Ex vivo wound models are time- and cost-efficient to determine the effectiveness of 
topical or injected treatments before using in vivo models [7]. This model system can 
be used to assess a wide variety of molecules and agents on epithelialization. The skin 
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utilized in these models is typically acquired from reduction surgeries. The skin is 
cleaned from underlying fat to allow for adequate adherence of the dermis to the plate, 
and an excisional wound is created with a 3–4 mm punch. A larger, full-thickness 
8–10 mm biopsy punch around the wound is then used to separate the wound from the 
rest of the skin (Fig. 2). The donutlike wounds are placed at air-liquid interface with 
media [7]. Treatments can be applied directly to the wound and the media to mimic 
either topical or “systemic” effect. Reepithelialization can be measured and quantified 
using histomorphometric analysis and keratin immunostaining [2,7,28,46,47].
Advantages of this model are numerous (Table  1). Foremost, it allows for as-
sessment of reepithelialization in the human skin with uniform wound sizes under 
standardized conditions. A good amount of the skin can usually be obtained from re-
duction surgeries, allowing for multiple ex vivo wounds to be generated from a single 
patient source, allowing experimental replicates, and eliminating variability due to 
skin differences between individuals [7]. Furthermore, basement membrane integrity 
is preserved in the ex vivo culture, while it is not in the in vitro models such as organo-
typic culture [48]. However, whereas some resident inflammatory cells are retained, a 
major limitation of the ex vivo model is the lack of blood supply, thus limiting studies 
involving immune cell infiltrates.
To this date, the human ex vivo skin wound model has been successfully used to 
test the effects of growth factors like epidermal growth factor (EGF), microRNAs, 
and various pharmacological agents including glucocorticoids and beta-adrenergic 
antagonists [28,47,49-53]. A great amount of information can be obtained using this 
model including changes in gene expression pattern, protein levels, signaling events, 
and tissue morphology in order to comprehensively evaluate novel therapeutic agents. 
Importantly, the human ex vivo wound model has been shown to have comparable 
gene expression patterns to in vivo models, thus supporting its implementation in the 
functional assessment of human epidermal healing [54,55]. In all, this model has been 
implemented successfully in the literature to assess epithelialization under a wide vari-
ety of experimental conditions [52,56-58], and therefore, it is an extremely useful tool 
for the exploration of wound-healing epithelialization of the human skin and evalua-
tion of novel treatments.
Fig. 2 Human ex vivo wound-healing model. (A) Gross photo of human ex vivo wound. 
White dashed line indicates wound edge; red dashed line indicates visual signs of 
epithelialization 4 days after wounding. (B) Keratin 6-stained ex vivo wound edge. Red color 
depicts keratin 6, and blue color depicts nuclei. Scale bar = 50 μm.
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3.2  Murine skin explant model
In addition to human ex vivo wound model, murine skin explant culture can be used 
to evaluate keratinocyte migration. When fascia is removed from mouse skin samples, 
the skin is able to adhere to tissue culture plates while submerged in culture media. 
Keratinocyte migration out of skin explants can be observed over the course of up to 
7 days [59]. This model represents a useful tool to study collective cell migration in 
the transgenic or knockout mouse skin or in response to pharmacological treatments to 
determine the effects of the overexpressed or knocked out gene or the pharmacological 
treatments on keratinocyte migration [59].
3.3  Pressure ulcer ex vivo model
In addition to studying acute wound healing, the human ex vivo wound model can be 
applied to study chronic wounds such as pressure ulcers [58]. Stojadinovic et al. demon-
strated inflammasome induction in the ex vivo skin that was loaded with static stress at 
different time points using a well-described mechanical explant test system [58,60,61]. 
These specimens were analyzed for protein and RNA expression levels and morpho-
logical changes in response to mechanical load. A similar model has been developed 
in a porcine model. Yeung et al. applied pressure to porcine ex vivo wounds to assess 
the effectiveness of novel pressure-reducing devices [62]. These results demonstrate 
the flexibility of the ex vivo wound model to mimic both acute and chronic wound 
condition and its durability under various environmental and experimental influences. 
In summary, ex vivo models are useful to explore molecular mechanisms of epitheliali-
zation, as well as evaluation of novel pharmacological treatments and devices.
In vitro cell culture, ex vivo skin explants, skin-on-a-chip, and reconstituted organo-
typic cultures have their respective advantages in wound-healing studies. Single-cell 
type cultures, grown in vitro, allow individual repair processes—such as prolifera-
tion or cell migration—to be investigated at the lowest costs. Three-dimensional “skin 
equivalent” organotypic cultures generally use keratinocytes grown on a feeder layer 
of fibroblasts within a collagen matrix, thus recreating rudimentary skin layers and 
stratified epidermis. When wounded, this model allows studies pertaining to inter-
actions between keratinocytes and fibroblasts and matrix, even though important 
wound-healing processes such as the inflammatory response and angiogenesis are 
missing. Human skin explants cultured ex vivo, on the other hand, contain all the lo-
cal cell types including some resident inflammatory cells, thus mimicking the in vivo 
situation more closely. Taken together, all the in vitro and ex vivo models described 
represent powerful tools for wound-healing study, allowing us to gain insights in mo-
lecular events pertaining to this sophisticated process while also serving as valuable 
tools for preclinical testing.
3.4  Porcine ex vivo wound infection model
Porcine skin explants have been recently used as a model for wound infection and to 
evaluate novel antimicrobial therapies. Porcine skin was sterilized with chlorine gas 
in order to remove commensal bacteria while preserving histological properties of 
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epidermis and dermis [63,64]. Partial-thickness wounds can be generated with a der-
matome, which are then inoculated with the bacteria of interest [63-65]. Importantly, 
this ex vivo model simulated growth of Pseudomonas aeruginosa and Staphylococcus 
aureus biofilms on wounds, mimicking chronic wound environment [63-65]. After 
allowing time for a mature biofilm to form, the wound may be treated with a variety 
of dressings and other topical antimicrobial compounds to evaluate their efficacy [63-
66]. For example, this model has been used to evaluate iodine-containing dressings, 
silver-containing dressings, surfactant-based dressings, and honey ointments, among 
many others [64,65]. The similarity of cutaneous physiology of the porcine skin as 
compared with the human skin is an advantage of this model. Additionally, this tis-
sue can be easily obtained from meat processing facilities. Limitations of this model 
include a limited host immune response as would be seen in vivo and an absent com-
mensal microbiome due to sterilization.
4.  In vivo wound healing models
In vivo wound models help illuminate the mechanisms and pathophysiology of cu-
taneous wound repair under systemic conditions that allow paracrine and autocrine 
interactions between local cells and recruitment of immune cells through circulation. 
To this end, various in vivo wound models have been developed, and the animals most 
commonly used are mice, rats, rabbits, and swine (Table 2). Despite their vastly varied 
appearances, the mammalian skins share many common features in both anatomy and 
physiology. These models have been successfully used to delineate the basic mech-
anisms of wound healing and provide preclinical testing of novel interventions and 
optimizing treatment regimens.
All animal procedures need to be approved by institutional animal care and use 
committees prior to work and must be performed under aseptic conditions in anes-
thetized animals. Hair is often removed from the areas to be wounded by clipping or 
depilatory chemicals.
4.1  Rodent wound healing models
Mice and rats are the most frequently used animal models for wound-healing studies 
for several reasons. They are relatively inexpensive to acquire and maintain, develop 
rapidly, are of small body size that translates to small amounts of reagents needed, and 
have accelerated modes of healing (so that experiments usually last for days instead 
of weeks). The many inbred strains and large litters offer genetic homogeneity and al-
low for quantification and reproducibility, and the growing number of natural mutants 
and genetically modified strains (transgenic or various knockouts/knockins) facilitates 
studies of particular molecular pathways. The broad use of mice and rats in other bio-
logical and biomedical studies means that reagents (e.g., antibodies, ELISA, shRNA, 
and microRNAs) for a wide array of analyses are readily available. Additionally, mice 
and rats are easily manipulated to mimic specific wound conditions such as diabetes, 
infection, malnutrition, immunodeficiency, local tissue hypoxia, and ischemia [12]. 
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In vivo wound-healing models
Model Advantages Disadvantages References
Rodent wound-healing models
Murine 
incisional 
wound model
-  Allows studying the 
interactions and influences 
of different cell types
-  Elucidates biomechanics of 
wound healing and scarring
-  Use of wound splinting can 
minimize contraction
-  Uncomplicated standardization 
and multiple replicates, 
repeated sampling as well
-  Not optimal for 
assessment of 
epithelialization
-  Differences in 
skin anatomy and 
physiology in rodents 
versus humans
-  Influence of the hair 
follicle cycling on 
epithelialization
[8,67-69, 
71-76]
Murine 
excisional 
wound model
-  Allows studying the interactions 
and influences of different cell 
types on contraction
-  Can be used to evaluate 
treatment effects
-  Not optimal for 
assessment of 
epithelialization
[76,78]
Murine full-
thickness 
splinting 
model
-  Can attenuate the effect of 
contraction, thus modeling 
human epithelialization 
process more closely
-  More reproducible than 
nonsplinted wounds
-  Variation in skin 
anatomy and 
physiology in 
rodents versus 
humans
[11,84-87]
Parabiosis 
model
-  Effective for study of 
circulation and infiltration 
of cells and factors in the 
context of wound healing
-  Demonstrates involvement of 
factors and various cell types in 
models of delayed wounding
-  Not optimal for 
assessment of 
epithelialization
[10,88]
Dead space 
wound model
-  Connective tissue formation 
isolated from other events of 
wound healing
-  Interstitial fluid 
accumulation provides 
valuable information about 
the wound environment
-  Not useful for 
assessment of 
epithelialization
-  Variation in skin 
anatomy and 
physiology in rodents 
versus humans
[89-91]
Dorsal skinfold 
chamber model
-  Enables vasculature 
microscopic imaging in vivo
-  In combination with intravital 
fluorescence microscopy 
enables pathophysiological 
imaging in real time
-  Variation in skin 
anatomy and 
physiology in 
rodents versus 
humans
[10,92]
Table 2 Summary of the frequently used in vivo models for 
wound-healing studies
Continued
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Table 2 Continued
In vivo wound-healing models
Model Advantages Disadvantages References
Tape stripping -  Partial removal of epidermis
-  Several levels of barrier 
disruption can be induced
-  Variation in depth of 
barrier disruption
[94]
Diabetic wound-healing models
Diabetes type 2 
murine wound-
healing model
-  Not significantly influenced 
by other diabetes-related 
parameters
-  Permits application of 
bacterial biofilm to mimic 
chronic wound phenotype
-  Variation in skin 
anatomy and 
physiology in 
rodents versus 
humans
[13-15,95,96]
Streptozotocin-
induced 
diabetic wound 
model
-  Permits study of wound 
healing in the context of type 
1 diabetes
-  Nonspecific toxicity 
in other organs; no 
significant delay in 
wound closure
[95,97-101]
Porcine model of wound healing
Porcine partial/
full-thickness 
wound model
-  Greatest structural, 
biomechanical, immune, and 
most importantly wound-
healing process similarity to 
humans
-  Multiple replicates within 
single animal, repeated 
sampling, and multiple 
concomitant assessment 
treatments
-  Sweat gland locations 
dissimilar to humans
-  The lack of 
transgenic animals 
and reagents for 
analyses
-  High maintenance 
costs
[9,110]
Rabbit ear wound model
Rabbit ear 
wound model
-  Decreased blood flow
-  Absent wound contraction
-  Multiple replicates within 
single animal
-  Dermis firmly 
attached to 
underlying cartilage
-  Avascular wound base
[117,118]
Ischemic wound model
Ischemic 
wound models
-  Accurate and reproducible 
model to depict characteristics 
of ischemic tissue with  
age-dependent response
-  Labor-intensive and 
costly
[18,125]
Denervation wound model
Denervation 
wound models 
 
-  Can be used to test potential 
therapeutics to restore 
sensation and improve 
wound healing
-  The total lack of 
sensation does not fully 
mimic neuropathy in 
chronic wounds
[1,102,126] 
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Although contraction plays a major role in murine wound healing as compared with 
human skin wound-healing process, many molecular pathways involved in wound 
healing are well conserved between mice, rats, and humans.
The rat model is used less frequently than the mouse model largely due to the 
smaller number of genetically manipulated (transgenic and knockouts/knockins) rat 
strains, their larger size, and higher costs to maintain. However, the rat model also 
provides a variety of strains with different characteristics, and their larger size may 
allow comparison of different treatments in the same animal.
Murine hair follicles undergo cycles of growth and regression, and all the follicles 
on the dorsal skin are synchronized in their postnatal morphogenesis and the first post-
natal hair cycle (catagen/regression phase, telogen/resting phase, and anagen/growth 
phase) [67]. A wounded skin shows accelerated healing when the follicles are in the 
growth phase (anagen) because follicular keratinocytes migrate to the wound site to 
contribute to healing [68]. Therefore, the age of mice and rats has to be carefully 
planned in wound-healing experiments, and the hair growth is closely monitored. To 
minimize the contribution to wound healing by keratinocyte migration from the hair 
follicles to the wound sites, wounds are ideally induced during telogen. For C57BL/6, 
the most commonly used mouse strain in biomedical research, all the dorsal skin hair 
follicles are in telogen 7 weeks after birth. This is evidenced by the homogeneous 
pink/gray skin color. Because follicular melanogenesis is strictly coupled with hair 
follicle cycling [69], anagen is associated with characteristic increase in skin pigmen-
tation in C57BL/6 mice, with the skin turning dark gray at anagen entry, then com-
pletely black at the peak of anagen, and then turning gray at the follicles entry catagen. 
Additionally, synchronized anagen entry in mice results in profound increase in the 
thickness of almost all skin compartments [67], making anagen skin black and thick 
and “rubbery” compared with pink/gray and thin skin of telogen. Besides naturally 
occurring synchronized hair cycling in early postnatal life, synchronized anagen and 
subsequent spontaneous catagen/telogen can also be induced by depilation [70].
Samples collected at different time points and at the end of the wound-healing 
studies can be analyzed for the rate of wound closure by histology, breaking load 
and tensile strength, biochemistry (e.g., collagen deposition), and gene expression. 
Noninvasive methods such as bioluminescence in transgenic mice and laser Doppler 
imaging (to monitor blood flow) make it possible to monitor wound-healing progres-
sion in the same animals over time [71]. By comparing wound healing in experimen-
tal animals with that in control animals, one can determine the role of the mutated 
gene product, physiological condition, or therapeutic agent administered during acute 
wound healing. Here, we discuss incisional wound, full-thickness excisional wound 
including splinting, dead space wound, and tape-stripping murine models.
4.1.1  Incisional murine wounds
Cutting the skin with a sharp blade results in rapid disruption of tissue integrity with 
minimal collateral damage [61,62]. A fibrin clot quickly forms to bridge the injury 
margins. The size of the gape depends on the species, the size of the incision, the 
amount of subcutaneous fat, and the tensional forces on the wound site determined by 
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the location and orientation of the incision. The loose skin in mice and rats can slide 
and retract over the subcutaneous fascia and produce a relatively large gape initially. 
In “primary intention closure,” closure of incisional wounds by suture, staple, clip, or 
bandage reduces the tissue gap to allow rapid and efficient bridging of the wounded 
edges by granulation tissue and new epithelium and provides a useful model for bio-
mechanical studies of healing [63,72-74]. In “secondary intention closure,” an inci-
sional wound is intentionally left open, and a much more extensive fibrin clot in the 
wound space is eventually replaced by ample granulation tissue and the surface gap 
closed by epithelialization, as well as contraction [8,75]. This model is more useful 
for the study of scarring over long periods of time and is not suitable for the study of 
epithelialization [76].
4.1.2  Full-thickness excisional murine wounds
In mice and rats, excisional wounds are created by removal of the full-thickness dorsal 
skin using 5–8 mm biopsy punch (wound area of 20–50 mm2), and the entire wound is 
left open (Fig. 3). Alternatively, full-thickness excisional wounds can be generated on 
the mouse tail resulting in delayed healing [77]. Excisional wound model is used for 
the study of rate of contraction and epithelialization and factors that influence these 
processes. Agents that may accelerate or delay healing (including infectious agents) 
[78] may be applied topically to the wound bed before a scab is formed. When ex-
cisional wounds are covered with occlusive dressings, the exudate (wound fluid) is 
retained and can be used for assessing various soluble factors in the wound environ-
ment, such as cytokines, growth factors, nutrients, proteinases, and tissue degradation 
products. Both contraction and epithelialization contribute to wound closure in this 
model. Contrary to intuition, the size of the scab does not reflect the rate of epitheli-
alization, which is measured reliably only by histology. The excision sites including 
Fig. 3 Mouse excisional wound model. (A) Excisional wounds are created by removal of the 
full-thickness skin using biopsy punch, and the entire wound is left open. (B) Representative 
trichrome-Masson stained section of murine full-thickness wound at day 15 post wounding. 
Morphological features are indicated as E, epidermis; D, dermis; and G, granulation tissue.
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wound edge are harvested at different time points for the analysis of histology (e.g., 
granulation tissue, epithelialization, contraction, and leukocyte infiltration), biochem-
istry (e.g., exudate analysis), and gene expression (e.g., RNA, microRNA, or protein). 
This model is the most widely used in murine wound studies and has led to the 
 identification of important signaling pathways in wound healing, such as Wnt/β-
catenin, TGF-β, Notch, hedgehog, and BMPs [79-83].
It has been further shown that variability is substantially lower in histological mea-
surements of incisional and excisional wounds than planimetry [76]. Additionally, 
wound planimetry is less variable in excisional wounds than incisional wounds (sec-
ondary intention closure), but correlation between planimetric and histological mea-
surements is greater in incisional wounds than excisional wounds [76].
4.1.3  Full-thickness splinting murine wounds
In addition to epithelialization, contraction makes a significant contribution to 
full-thickness wound closure in the murine models. The murine skin has an exten-
sive layer of striated muscle just beneath the subcutaneous fat, called the panniculus 
carnosus, which is largely absent in humans. Upon wounding, the panniculus carno-
sus allows the skin to move independently from the deeper muscles and is largely 
responsible for the rapid skin contraction. To reduce the influence of contraction so 
that murine wound models can more closely mimic the human processes of epitheli-
alization and new tissue formation, a silicon splint can be applied to the full-thickness 
wound [11,84-86]. Wound healing is then dependent on epithelialization, cell prolif-
eration, and angiogenesis, which closely mirror the biological processes of human 
wound healing. Furthermore, splinted wounds were found to be more reproducible 
than nonsplinted ones [87].
4.1.4  Parabiosis model
The parabiosis model has been an effective model used to study circulation and infil-
tration of cells and factors in the context of wound healing. The model consists of two 
mice, a donor mouse (e.g., a wild-type mouse or a mouse carrying a genetic marker 
such as EGFP) and a recipient mouse (e.g., a mouse carrying a genetic mutation such 
as Lepr- or a wild-type mouse), surgically conjoined at their flank skin in which cross 
circulation is established between the joined mice several days post surgery through 
vascular anastomoses [10]. A wound can then be created on the recipient mouse, per-
mitting the study of circulating factors and systemically derived cells from the donor 
mouse important for wound healing [10]. The parabiosis model has been utilized to 
highlight the importance of systemic factors and cell types in delayed wounding in 
diabetic mice and inflammatory cells and mesenchymal derived cells that function in 
skin homeostasis and wound repair [10,88].
4.1.5  Dead space wound model
In this model, connective tissue formation is isolated from other events of wound 
healing, such as contraction and epithelialization. This is achieved by inserting  porous 
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implants into the subcutaneous space, into which plasma infuses. This infusion leads 
to the development of a fibrin clot and subsequent formation of granulation tissue. 
The implants are made of relatively inert and nonbiodegradable materials to mini-
mize inflammation. The implants allow interstitial fluid to accumulate, which can be 
extracted for analysis of metabolites, cytokines, growth factors, and nonadherent cell 
populations. Agents of interest can be orally administered or injected into the im-
plants (such as growth factors, chemoattractants, and neutralizing antibodies) [89,90]. 
Because the implants have defined dimensions, this model is ideal for biochemical 
analysis once the granulation tissue is removed. The most common analyses include 
the hydroxyproline assay to estimate collagen content and hexosamine assay to esti-
mate the stabilization of collagen and hence the strength of the repaired tissue [91].
4.1.6  Dorsal skin fold chamber model
The dorsal skinfold chamber utilizes an implanted chamber over exposed skin that 
allows for the microscopic imaging through an observation window embedded in the 
chamber [10]. It is a well-established model that permits the in vivo study of vascula-
ture physiology in the context of wound healing under normal and pathophysiological 
states [10]. In addition, the use of intravital fluorescence microscopy allows for the 
capture of high-resolution images in real time of cutaneous physiology that includes 
vessel growth, microvascular perfusion, vascular permeability, and cell interactions 
[92]. Combined with intravital fluorescence microscopy is then performed over a pe-
riod of time lasting up to 3 weeks allowing for the analyses of the early inflammatory 
response and angiogenic host response in real time after wounding.
4.1.7  Tape stripping wound model
The tape-stripping wound model involves the partial removal of the epidermis with 
adhesive tape. Depending on the adhesive used and the number of times it is applied, 
one can disrupt the epidermal barrier by removing the stratum corneum and stratum 
granulosum. Although the basement membrane is left intact and there is no blood loss, 
the epidermal permeability barrier is disrupted and leads to increased transepidermal 
water loss and activates epidermal repair [93,94]. This model is the least invasive type 
of all murine wound models discussed here and is useful to study genes and pathways 
involved in epidermal barrier differentiation and function.
4.2  Diabetic wound healing models
4.2.1  Diabetes type 2 murine wound healing model
Since it is expected that the incidence of chronic wounds in human population will in-
crease due to a rise in diabetes prevalence [1], significant research effort has been em-
ployed to develop diabetic models of wound healing. Diabetic db/db mice are the most 
commonly used model for type 2 diabetes and wound-healing studies. A deletion mu-
tation renders the leptin receptor (LepR, db/db) in the hypothalamus defective, caus-
ing the mouse to lose control of satiation, overeat, and develop hyperphagia, obesity, 
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hyperlipidemia, hyperinsulinemia, and insulin resistance, thus closely resembling type 
2 diabetes mellitus in humans [13,95]. Diabetic db/db mice exhibit significantly im-
paired wound healing, for both excisional and incisional wounds [13-15]. Furthermore, 
synergism of advanced age and db/db genotype can further delay wound healing [96]. 
One benefit of using the db/db mouse model is that the wound-healing process is not 
significantly influenced by other diabetes-related parameters. Variability in the rate 
of wound closure among individual animals does not correlate with the severity of 
obesity, hyperglycemia, hyperinsulinemia, or insulin resistance, helping to rule out 
possible confounding variables in the study [14]. A variation of the db/db model in-
volves application of bacterial biofilm, such as P. aeruginosa, on excisional wounds. 
Introduction of the bacterial biofilm with the goal to mimic chronic wound phenotype 
results in extensive inflammatory cell infiltration, tissue necrosis, epidermal hyper-
plasia adjacent to the challenged wounds, and a severe delay in wound healing [13].
4.2.2  Streptozotocin-induced diabetic rodent wound healing 
models
Streptozotocin-induced diabetic murine models develop type 1 diabetes, due to the 
cytotoxic glucose analogue streptozotocin (STZ) that is toxic to pancreatic β-cells 
and causes insulin deficiency. STZ methylates DNA, causing DNA fragmentation and 
killing pancreatic β-cells [95,97]. In addition to the pancreas, STZ may also have 
toxic effects on other organs. To reduce nonspecific toxicity, diabetes is often induced 
through multiple injections of low doses of STZ that cause repetitive low-grade β-cell 
damage. The Animal Models of Diabetic Complications Consortium protocol recom-
mends daily intraperitoneal injections of 40–50 mg/kg of STZ for 5 consecutive days 
[95]. STZ-induced diabetic mice may exhibit significant weight loss, due to insulin 
deficiency and severe hyperglycemia, but do not develop hypertension. Excisional or 
incisional wounds can be created in STZ-induced diabetic mice as described above. 
However, there is no significant delay in wound closure for STZ-treated mice as there 
is in db/db mice, which also demonstrate decreased granulation tissue formation, 
decreased wound bed vascularity, and diminished proliferation during the wound- 
healing process [98,99]. Therefore, compared with db/db mice, STZ-induced diabetic 
mouse model may not be the most appropriate model to study impaired wound heal-
ing. Other diabetic animal models include STZ-induced diabetic rats, in which STZ 
is injected intraperitoneally for a few consecutive days (2–5 days) at 45–70 mg/kg per 
injection [100]. A variation of the STZ-induced diabetic rat model is by adding an 
8-week high-fat diet prior to the multiple STZ injections. The addition of a high-fat 
diet establishes an ischemic diabetic rat model. Ischemia—restricted blood supply to 
the body’s organs—is one of the main characteristics of chronic wounds. Excisional 
wounds in this modified model resemble the interrupted healing process including de-
layed wound closure, increased inflammatory response, and excessive and prolonged 
production of reactive oxygen species (ROS) and matrix metalloproteinases (MMPs) 
[101]. However, in spite significant efforts to modify db/db or STZ wound models to 
more closely resemble chronic wound phenotype, wounds generated in these animals 
eventually heal resembling all phases of acute healing process.
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In summary, murine models are the most frequently used animal models for 
wound-healing studies. The ease to acquire and maintain, relatively low costs, genetic 
homogeneity reproducibility, and the many manipulations already developed have 
facilitated the investigation of in  vivo wound-healing processes that mimic a wide 
array of physiological/pathological conditions. In addition, the many mutant strains 
(both spontaneous and induced) enable the dissection of specific signaling pathways. 
However, there are significant anatomical and physiological differences between the 
mouse, rat, and human skin. Mice and rats have loose skin with much higher hair 
follicle density compared with the human skin, and the mouse skin has very thin epi-
dermis. Caution must be taken when one tries to extrapolate results obtained in these 
models to clinical applications [2].
Besides those discussed above, skin grafting and human skin xenograft in mice 
have also made it possible to study the wound-healing processes under special 
circumstances (e.g., early lethality of mutant mouse strains and patient skin biop-
sies). In vivo wound models have also been developed that include partial-thickness 
wounds, blisters, burn and caustic agents (such as alkalies), and infections. However, 
the murine skin, especially the mouse skin, has very thin epidermis and abundant hair 
follicles, making it technically difficult to induce such wounds with consistency and 
reproducibility. The porcine model is more suitable for some of these applications.
4.3  Porcine models of wound healing
The porcine wound-healing model was developed by Mertz and Eaglstein in 1978 
[9] and used since then to obtain a better understanding of wound-healing processes 
including scar formation, regeneration, and wound infection. Among all the in vivo 
wound-healing models commonly used, the porcine skin is structurally most similar 
to the human skin, including parameters such as epidermal thickness and dermal- 
epidermal thickness ratios and similar patterns of hair follicles and blood vessels 
[9,102]. The histological location of epidermal keratins 10 and 16 and dermal colla-
gen IV, vimentin, and fibronectin is also similar to humans [103]. Biochemically, the 
porcine skin contains dermal collagen and a dermal elastic content more similar to the 
human skin than other commonly used mammals and has similar biomechanical prop-
erties [104]. Moreover, the resident immune cells in the porcine skin, including den-
dritic cells, are similar to those in the human skin [105]. In addition to these significant 
similarities between the porcine and human skin, there are also important differences. 
For example, the porcine skin has only apocrine sweat glands, while the human skin 
has eccrine sweat glands distributed over the entire body that also serve as essential 
sources of keratinocytes during epithelialization [106]. Importantly, pig wounds, simi-
larly to human, heal primarily by epithelialization, whereas murine, rabbit, and canine 
wounds heal primarily by contraction, making the porcine model the most appropriate 
for certain aspects of wound-healing studies (Fig. 4) [9,107]. Sullivan and colleagues 
compared studies of wound therapy assessment in different animal models and found 
that porcine wound models were 78% concordant with human studies [9]. This far 
exceeded other animal wound models, which were only 53% concordant with human 
studies and more similar to in vitro studies [9]. Yorkshire specific pathogen-free (SPF) 
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crossbred pigs are usually chosen for wound-healing studies due to their analogous 
repair mechanisms to humans as elaborated, and other strains such as the red Duroc 
pigs are used as models of hypertrophic scarring [108,109]. The anatomical location 
of wounding is important when performing scar studies since the wounds near tension 
areas scar differently.
Fig. 4 Porcine full-thickness wound healing. (A) Schematic illustration showing the layout 
of experimental wounds in the pig model. Each quadrant can include multiple wounds and 
represents independent treatment conditions (color coded). Representative H&E-stained 
transverse sections of porcine full-thickness wounds at 4, 6, 8, and 10 days post wounding. 
White arrows indicate the edges of the initial wound area. Progression of reepithelialization 
is indicated by black arrows. By day 4, granulation tissue is formed in the wound bed. 
Meanwhile, keratinocytes migrate across granulation tissue to close the open wound. 
Reepithelialization is complete by day 8, and scab is cleared by day 10. Morphological 
features are indicated as E, epidermis; D, dermis; G, granulation tissue; SC, scab; and HF, hair 
follicle.
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The ample skin area of pigs allows for multiple wounds in the same animal that 
can be divided into several treatment groups and assessed over time (Fig. 4). Multiple 
biopsies can be taken from a single wound to assess wound closure by histology or for 
RNA/protein and microbiology analyses, allowing simultaneous assessment of multi-
ple cellular processes including epithelialization, erythema, transepidermal water loss, 
scar formation, inflammatory cell infiltrate, bacterial infection, collagen deposition, 
and stem cell recruitment. The ability to compare various treatments on the same ani-
mal and to perform assessments during the course of healing makes the porcine model 
advantageous over rodent wound-healing models [107]. Disadvantages of the porcine 
model are their high costs for purchase and maintenance, their large size that makes 
them difficult to manage, and that in pigs it is challenging to induce and maintain 
diabetes [110] or to mimic a nonhealing wound model. In addition, administering 
anesthesia to a pig requires a skilled veterinarian. Some reagents, such as antibodies, 
are less readily available than for other animal species. Lastly, transgenic pigs are 
more difficult to produce than other animals used in wound-healing studies such as 
mice and rats.
Various models to study wound healing in pigs include incisional, excisional (deep 
partial or full thickness), wound infection, second-degree burn, keloid, laser injury, 
UV radiation injury, and skin hypoxia [111-116]. These models have been published 
and validated in studies testing different formulations including a variety of commonly 
used wound care products.
Overall, pigs provide a versatile vertebrate model that can reproduce the numer-
ous etiologies of normal and impaired wound-healing process. Porcine wound models 
have increased our understanding of normal and pathological wound-healing process 
and have provided ample preclinical data, justifying continued development. Taken 
together, wound-healing studies conducted on large animals are extremely valuable 
and allow for initial preclinical evaluation for testing potential treatment modalities.
4.4  Rabbit ear wound model
The rabbit ear model has been extensively used for studying wound healing in the 
context of ischemia and infection. Since ischemia and infection play a significant role 
in the development of chronic wounds, the rabbit ear model has contributed to a better 
understanding of how these processes are deregulated in chronic wounds. The isch-
emic wound is created by suturing off the arterial blood supply to the ear, and then, 
the wound is created using a punch biopsy, creating a full-thickness wound down 
to the cartilage of the ear [117,118]. A benefit of this model has been its use to test 
effects of bacteria on wound healing and potential therapeutic treatments. It has been 
shown using the rabbit ear model that wounds infected with P. aeruginosa resulted in 
impairment of healing through biofilm [16,119]. In addition, it was found that topical 
application of growth factors that include platelet-derived growth factor B (PDGF-B), 
keratinocyte growth factor 2 (KGF-2), and vascular endothelial growth factor (VEGF) 
resulted in improved healing, demonstrating that this model can be used for effec-
tive testing of potential therapeutic treatments that could be translated to the clinic 
[17,120,121]. Advantages of this model include that rabbits are relatively inexpensive 
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to maintain, their wounds heal primarily by epithelialization due to the underlying car-
tilage, and multiple replicates within a single animal can be made. As such, the rabbit 
ear model fails to fully recapitulate the human setting due to the dermis being firmly 
attached to the underlying cartilage and an avascular wound base—features that are 
not present in human wounds.
4.5  Ischemic wound models
Ischemic models of wound healing have been developed to study the effects of inad-
equate blood supply to tissue, which is characteristic of chronic nonhealing wounds. 
Several animal models have been developed to study ischemia with varying degrees 
of efficiency. The primary porcine model for ischemia is by means of a full-thickness 
bipedicle flap, whereby the dermis is prevented from readhering to the subcutaneous 
tissue, thus preventing revascularization [18]. The impaired reepithelialization, delayed 
recruitment of the adaptive immune response, and diminished organization and abun-
dance of endothelial cells, characteristic of ischemic tissue, are produced in this model 
with accuracy and reliability [18,122]. A rabbit ear ischemic wound model has also 
been developed in which the main arteries to the rabbit ear are ligated, leaving the ear 
devoid of blood flow [123,124]. Wound-healing times are lengthened in the ischemic 
ear and show other signs characteristic of ischemia [118]. Another primary model, the 
murine limb-ligation model, was developed to mimic ischemia that occurs in the el-
derly population who often develop ischemia in their extremities. The murine limb- 
ligation model produces severe, acute ischemia [125]. Ischemia occurred to a similar 
extent in older mice as compared with younger ones, but the older mice experienced 
substantially impaired arteriogenesis and functional recovery upon wounding [125]. 
While other models to study ischemia do exist, these three primary models can depict 
with relatively significant accuracy the different aspects of chronic wound ischemia.
4.6  Denervation wound models
Neuropathy is a characteristic typical of many chronic wounds that can result from di-
abetes or sustained pressure load [1]. As a result, patients lose the protective sensation 
of pain and become unaware of the development of a wound. Denervation models are 
used to study wound healing in the context of neuropathy. These models can be created 
in vivo using mice and porcine models by surgically exposing the T9 to L1 vertebrae 
and transecting the nerve endings [102,126]. The animals are then allowed to recover, 
and wounds can then be created by excision. The response to sensation is determined by 
stimulating with a needle at the wound site to verify successful nerve resection. An ad-
vantage of this model is that they resemble DFU and pressure ulcer neuropathy and can 
be used to test potential therapeutics to improve sensation and wound healing [102,126].
4.7  In vivo models of wound infection
Recent advances in high-throughput sequencing technologies have facilitated studies 
of the complex microbial communities residing on the human skin [127]. These novel 
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methods have characterized the diversity of cutaneous microbiome at specific body 
locations, including animal models and more importantly human chronic wounds 
[127-130]. Microbiomes of chronic wounds play significant roles in impaired wound 
healing, even in the presence or absence of clinical signs of infection [129,131]. The 
fact that chronic wound bioburden exists predominantly in the form of a biofilm 
[132] has imposed development of polymicrobial biofilm infection models. Biofilms 
facilitate genetic exchange of virulence factors, whereby bacterial resistant genes can 
be transferred to susceptible bacteria [133,134], while bacteria within biofilms are 
more resistant to antimicrobial agents than those in the free-floating planktonic state 
[135], thus more closely mimicking chronic wound environment. In one of the first 
polymicrobial wound infection models, the authors used four aerobic and anaerobic 
bacterial species commonly detected in chronic wounds (S. aureus, P. aeruginosa, 
Enterococcus faecalis, and Finegoldia magna) to develop biofilms in vitro and then 
transferred them into full-thickness wounds in mice [136]. Although not statistically 
significant at all time points, polymicrobial biofilms in this infected wound model 
had a clear trend of delayed wound closure, indicating that multibacterial species bio-
films promote a more pathogenic wound phenotype. Remarkably, the polymicrobial 
biofilms were more resistant to antimicrobial agents (bleach and gentamicin) than 
monospecies biofilms, suggesting that synergistic interactions between bacterial spe-
cies impart protection from therapeutic agents [136]. Another valuable in vivo bio-
film model in New Zealand rabbit ear was developed to assess wound chronicity. The 
monospecies wound biofilms of Klebsiella pneumoniae, S. aureus, and P. aerugi-
nosa in rabbit ear wounds lead to impaired wound closure compared with uninfected 
wounds [137]. S. aureus and P. aeruginosa were also used to form polymicrobial bio-
films in the rabbit model, which showed enhanced delay in wound closure compared 
with their monospecies counterparts, confirming a synergistic interaction between 
both bacterial species. Lastly, pig models for studies focusing on wound biofilms 
provide major advantages [115,138] such as their similarity to the human skin and 
its large surface area that allows the creation of multiple wounds that can be assessed 
for both microbial load and host response simultaneously (Fig. 4A). Partial-thickness 
or full-thickness infection models in pigs have been extensively used to understand 
host-pathogen interaction in a polymicrobial wound environment. Importantly, por-
cine infected wound models have been extensively utilized for preclinical testing of 
topical antimicrobials [114,139-141]. Further development of polymicrobial wound 
models in conjunction with characterization of the chronic wound microbiome will 
aid the development of more specific and efficient biofilm-targeted therapies for 
chronic wounds.
5.  Conclusion
Preclinical testing using in vitro and in vivo wound-healing models remains in-
dispensable for addressing safety, toxicology, and efficacy in a dose-response 
fashion in development new therapies. However, rising incidence of nonhealing 
wounds and limitations of currently available therapeutics underscore the need for 
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improved effectiveness of preclinical predictions of human treatment responses. 
Previous progress was hampered by the lack of understanding regarding the lim-
itations of current preclinical wound models, along with gaps in understanding 
of the complex molecular and cellular network of processes that guide wound 
healing and their dysregulation in patients. Recent data suggest that studies fo-
cusing on mechanism of healing impairment in patients can provide the rationale 
and hypothesis driving future preclinical and basic research [142]. In addition, 
advances of iPSC technologies that provide opportunity to generate multiple cell 
types and tissues from patients’ somatic cells coupled with progress in tissue en-
gineering that allow building complex 3-D tissue structures that closely resem-
bles human skin may prove advantageous in future preclinical testing. The most 
recent advances in cell biology and microfabrication have already enabled the 
development of microengineered models of the functional human skin—known as 
organ-on-chips. Future developments in microengineered wound-on-chip models 
incorporating primary cells from patients and adding multiple organs-on-chip may 
provide the basis for preclinical models that more accurately may represent human 
condition with greater predictive power.
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PDGF platelet-derived growth factor
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IL-8 interleukin-8
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IL-1 interleukin-1
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CCL14 CC motif chemokine ligand 14
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CCL27 CC motif chemokine ligand 27
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1. Introduction
Wound healing is a multistep process that often concludes with scar formation. Healing 
occurs through the four overlapping phases of hemostasis, inflammation, proliferation, 
and tissue remodeling. These phases are interactive and orchestrated primarily through the 
release of soluble mediators that stimulate cells at the wound edges to migrate, proliferate, 
and synthesize the components necessary to restore the protective function of the skin. 
While all stages of wound healing are vital for a desired outcome of adequate wound clo-
sure, inflammation is particularly critical to skin repair and can regulate scarring outcomes. 
In addition to reducing microbial content in the wound, immune cells are now known to 
influence and direct many of the proliferative events that are needed for wound closure and 
tissue remodeling [1-3]. Thus, a regulated and appropriate inflammatory response sup-
ports proper repair [4,5]. Together, the accumulated evidence suggests that any attempts 
to regenerate skin must consider the complexity and role of the immune system in skin 
repair. This chapter focuses on the role of inflammation in wound healing and the potential 
to target the inflammatory response to improve healing outcomes and skin regeneration.
2.  Stages of wound healing
As mentioned above, effective skin wound healing generally proceeds through the 
four intersecting phases of hemostasis, inflammation, proliferation, and remodeling 
(or resolution) (Fig. 1). Hemostasis and inflammation are the first two stages of the 
wound-healing process, and they occur in quick and overlapping succession. Tissue 
injury damages capillaries, and hemostasis is necessary to prevent excessive hemor-
rhage. The control of blood loss begins immediately after injury when platelets ag-
gregate and adhere to the exposed extracellular matrix. The clotting cascade, which 
involves the successive conversion of clotting enzymes into their active forms, is also 
initiated, ultimately resulting in a fibrin clot. As platelets are activated, they degranu-
late, releasing growth factors and chemotactic factors [6,7]. Resident mast cells also 
degranulate quickly in response to trauma, releasing an additional set of inflammatory 
mediators [8]. Dermal keratinocytes at the site of injury further promote the inflamma-
tory response, responding quickly to tissue damage by producing pro-inflammatory 
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cytokines [9]. Overall, the release of inflammatory mediators and chemoattractants by 
multiple cell types results in the vascular changes that are typical of an acute inflam-
matory response along with recruitment of leukocytes from the circulation. Leukocyte 
infiltration, particularly neutrophils, is important to effective wound decontamination. 
As discussed below, wound leukocytes can also provide signals that initiate the down-
stream proliferative events of wound healing and influence scar formation.
As microbial content is controlled and inflammation subsides, leukocytes slowly 
exit the wound or undergo apoptosis [5]. The resolution of inflammation overlaps with 
the beginning of the proliferative phase of repair. Growth factors released from leuko-
cytes, keratinocytes, fibroblasts, and other cell types stimulate growth and movement 
of the resident cells to repair the wound [5,10,11]. One to 2 days post injury, kerati-
nocytes at the wound margins begin to migrate and proliferate. Once a single layer of 
cells covers the wound, keratinocytes stop migrating and begin to anchor to the base-
ment membrane, forming a newly stratified epidermis. Blood vessel formation (an-
giogenesis) also occurs, supplying nutrients and oxygen [12]. Fibroblasts within the 
dermis produce collagen and repair the extracellular matrix [13,14]. Myofibroblasts, 
specialized contractile fibroblasts, initiate contraction of the wound, pulling the mar-
gins closer together, while collagen is synthesized [13]. During the final remodeling 
phase of repair, the assembled collagen undergoes degradation and resynthesis into 
more organized fibers. Collagen also undergoes cross-linking to stabilize the fibrils 
and add strength to the wound [10]. This constant cycle of collagen remodeling can 
last up to 20 years after wounding, although the skin will never achieve a completely 
normal structure. Because dermal repair in adults is always imperfect, the final strength 
of the remodeled wound is generally only 70%–80% of the original tissue [15].
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Fig. 1 Pattern of infiltration of immune cells in healing wounds. In response to wounding, 
inflammatory cells infiltrate the wound bed to control infection and stimulate downstream 
events vital to healing. The relative density of neutrophils, macrophages, and lymphocytes is 
depicted over time. Neutrophils infiltrate first, followed by macrophages and lymphocytes. 
Proper repair involves the coordinated response and interplay of these cells.
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3.  Inflammation and skin regeneration
The prominent inflammatory response that occurs in wounds has demonstrable down-
stream effects on tissue repair, and well-regulated inflammation has been suggested 
to be critical to optimal skin healing [1,5]. Almost immediately following injury, im-
mune cells initiate an inflammatory response at the site of the wound [16]. While this 
response is essential to the prevention of infection, studies in multiple models suggest 
that inflammation also supports skin regeneration and more perfect repair outcomes 
[5,17,18,116]. A balanced level of inflammation is critical to healing, as disequilib-
rium of the response can lead to untoward outcomes. Of relevance to tissue regenera-
tion, aberrancies of wound inflammation have been linked to both impaired healing, 
such as chronic skin ulcers, and to excessive scar formation and skin fibrosis.
Evidence that inflammation can influence scar formation is abundant. This evidence 
derives both from the study of scar-forming wounds and from studies of nonscarring 
wounds. In particular, inappropriate inflammation has been linked to the formation 
of hypertrophic scars, scars that are raised and characterized by excessive formation 
of disorganized collagen. Keloids are another type of scar that has been suggested to 
have immunologic pathogenesis [5,18]. Keloids are large skin scars that grow beyond 
the bounds of the original injury site and contain disorganized collagen in whorl-like 
architecture [19]. Once excised, keloids frequently recur, creating a difficult clinical 
problem. Individual susceptibility to keloid formation appears to have a genetic com-
ponent, although the specific genetics that underlies this pathology remains poorly 
understood [20].
Insight into the role of inflammation in wound healing and skin regeneration also 
comes from wounds that heal better than normal and without a scar. Early gestation 
fetal wounds (within the first and second trimester) heal rapidly in the absence of an 
inflammatory response and without a scar. By the third trimester, wounding invokes 
an increased inflammatory response, and fetal wounds at this stage are marked by 
inflammation and scar formation. Studies of privileged healing inside and outside of 
the uterus suggests that healing properties of the fetus are intrinsic and independent on 
the environment, thus providing additional support for the concept that inflammatory 
reduction results in less scarring. When inflammatory cells are introduced in the fetal 
wound, the result is delayed healing and scar formation [21]. Another tissue that ex-
hibits a privileged healing phenotype is oral mucosa. Like fetal wounds, oral wounds 
heal rapidly and have minimal scar formation. Studies in at least three different models 
of oral mucosal healing demonstrate that this special healing pattern is associated with 
reduced inflammation [8]. Taken together, studies from the rapidly healing, scar-free 
fetal and oral mucosal tissues give a clear indication that reduced inflammation leads 
to faster, reduced scar healing. Such studies might be interpreted to suggest that adult 
skin repair might be improved by eliminating the inflammatory response. However, 
most studies of adult skin do suggest that a certain level of inflammation (in particular 
wound macrophages) is required for adequate wound repair [22].
Below, we review the immune cells, mediators, and receptors that are prominent in 
wounds, with an emphasis on what is known about their role in scar formation and in 
supporting skin regeneration (summarized in Table 1).
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3.1  Mast cells
Mast cells are widely distributed in the body and are prominent near surfaces exposed 
to the environment, including the skin. Mast cells are often the first immune cell to re-
spond to trauma and initiate an immune response [23]. These cells respond to a variety 
of stimuli: physical trauma, chemical exposure, allergens, and microbes. All of these 
challenges activate mast cells to degranulate and quickly release preformed biological 
mediators. Often thought of as primarily part of a hypersensitivity reaction, mast cells 
unmistakably influence the tissue repair process [8,23]. Factors released from mast 
cells can influence the activation, migration, and proliferation of endothelial cells, ke-
ratinocytes, and fibroblasts within skin [24,25]. Mast cells also secrete proangiogenic 
factors that can promote blood vessel formation. Evidence for an essential role of mast 
cells in normal wound closure is mixed, with some studies suggesting that wounds 
heal normally without mast cells and others demonstrating a slight deficit in healing in 
mast cell-deficient animals [8]. In contrast, though, excessive levels of mast cells have 
linked to the development of hypertrophic scars and keloids [8]. Experimental studies 
in both pigs and mice suggest that pharmacological inhibition of mast cell activation 
yields normal wound closure with reduced scar formation [26,27]. The finding that 
Cell type Beneficial Detrimental
Neutrophils Phagocytosis of microbes Release of harmful enzymes 
and oxygen radicals, 
damaging normal tissue
Mast cells Stimulation of angiogenesis and 
proliferation of keratinocytes/fibroblasts
Promote scar formation
Macrophages
M1  Enhanced inflammation—
impaired healing
M2 Stimulation of angiogenesis and collagen 
synthesis
 
T cells
CD4 Controversial  
CD8  Controversial
DETC Stimulation of reepithelialization 
Stimulation of macrophage migration
 
NKT Controversial Controversial
Treg Downregulation of inflammation. 
Stimulation of reepithelialization
  
Table 1 Effects of immune cells on healing outcomes
Functions of immune cells involved in wound healing. A summary of the role of each immune cell involved in the 
wound-healing response is shown. The benefits of inflammatory cell infiltration such as controlling infection and stimu-
lating growth and other downstream factors necessary for healing are further discussed in the text. Excessive numbers of 
inflammatory cells can lead to damage and detrimental effects on healing including chronic inflammation and increased 
scarring.
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mast cell content is also reduced in the privileged healing of the oral mucosa further 
supports the association of mast cells with scar formation (Schrementi and DiPietro, 
unpublished data). Finally, increased mast cell content and maturity have been linked 
to the switch from nonscarring to scarring phenotype in fetal wounds [8]. Together, 
the accumulated data suggest that mast cell activity can spur a fibrotic response in skin 
wounds.
Many mechanisms by which mast cells might influence scar formation have been 
suggested. Firstly, activated mast cells release known profibrotic mediators such as 
transforming growth factor-β (TGF-β) and platelet-derived growth factor (PDGF) [28]. 
Other factors from mast cells that can influence fibroblast function and might promote 
scar formation include histamine, tryptase, and chymase. Direct mast cell to fibroblast 
contact via gap junctions has also been shown to stimulate fibroblast proliferation 
and myofibroblast differentiation [29]. As multiple experimental studies demonstrate 
a role for mast cells in scar formation, mast cell function seems likely to be an import-
ant variable that requires consideration for any skin regeneration strategies.
3.2  Neutrophils
Due to their abundance in circulation and the ability to mobilize quickly, neutrophils 
are the first infiltrating cell to arrive at the injury site from circulation, and they con-
tinue to increase in number for several days after injury. Neutrophils respond to prod-
ucts from platelet degranulation and clot formation, as well as bacterial components 
[10]. Because of their longevity at the wound site, neutrophils have several functions 
in early and late phases of inflammation [30]. During the early response, the main role 
of the neutrophil is to kill microbes and prevent infection. They are able to bind to 
microorganisms, ingest them through phagocytosis, and use enzymes and oxygen rad-
icals to destroy them [31]. The activity of many enzymes and chemicals used by neu-
trophils to control microbes is not pathogen-specific and can cause bystander tissue 
damage. During phagocytosis, leakage of toxic lysosomal contents into the surround-
ing normal tissue can occur. Moreover, the release of oxygen free radicals and pro-
teolytic enzymes can damage nearby normal tissue [32]. Notably, proteases released 
by neutrophils can be problematic for healing wounds when neutrophil counts are 
high. The additional tissue destruction then causes persistent inflammation and more 
tissue damage, which prevents the wound from progressing through the proper stages 
of repair. Thus, the consequences of damage to the surrounding tissue can represent a 
negative outcome of their antimicrobial function.
Research into the exact role of the neutrophil in wound repair is a continuing field. 
Some studies demonstrate that neutrophils are important for efficient wound repair, es-
pecially when the host is under microbial pressure. Clinical observations support this 
idea, as patients with neutrophil impairments such as defects in trafficking or gran-
zyme function are more likely to develop a wound infection, often leading to a slow 
healing or chronic wound [33]. In normal patients, an idiopathic persistent neutrophil 
response increases the overall inflammatory response and can lead to poor wound 
healing, fibrosis, and excess scarring [34]. High levels of neutrophil proteases, such 
as serine proteases and matrix metalloproteinases (MMPs), have also been reported 
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in chronic, nonhealing wounds [35,36]. However, in animal models, administration 
of neutrophil antisera does not alter wound repair as long as the wound is kept sterile 
[37]. Additionally, in a diabetic strain of mice noted for delayed repair, neutropenia 
accelerated wound closure by 50% [30]. Finally, in wounds that heal faster with less 
scarring, such as fetal wounds, neutrophils are physiologically different compared 
with adult neutrophils and produce fewer cytokines, thus lowering the inflammatory 
response [38]. Oral mucosal wounds, which also exhibit rapid scarless healing, ex-
hibit a diminished neutrophil infiltration after wounding that leads to a diminished 
cytokine response [18]. Taken together, these studies are consistent with the notion 
that too much inflammation negatively affects healing. While a number of studies 
have demonstrated an important role for neutrophils in promoting wound healing and 
contributing to the resolution of inflammation after injury, a complete picture of the 
role of the neutrophil in the healing process has yet to be elucidated.
3.3  Macrophages
Macrophage content in skin wounds peaks several days after injury and is composed 
of both resident and newly arriving cells. Following wounding, monocytes extravasate 
into the wound bed from the blood stream and mature into macrophages, greatly in-
creasing the number of macrophages in the tissue. In the wound, macrophages phago-
cytose microorganisms and apoptotic cells while attaching themselves to extracellular 
matrix within the tissue. The phagocytosis of apoptotic cells is a key signal that is 
believed to alter the macrophage phenotype from primarily pro-inflammatory to pri-
marily reparative, a phenotype that supports tissue regrowth [12,39]. A continuum of 
macrophage phenotypes exists in wounds, and among these, the mature reparative 
phenotype has received a great deal of experimental attention [40]. Reparative macro-
phages, sometimes called M2, produce growth factors that stimulate angiogenesis and 
fibrogenesis, and in adult wounds, this phenotype is essential for proper repair [34,41]. 
More specifically, recent studies using genetically modified mice that are specifically 
void of macrophages or mice that are depleted of macrophages show that the loss of 
macrophages yields a significant delay in wound healing [22,42,43].
Because macrophages can stimulate fibroblast proliferation and collagen synthesis, 
pathological overactivity of macrophages might be expected to cause a fibrotic scar 
response. In support of this idea, macrophages do secrete many profibrotic factors in-
cluding TGF-β and connective tissue growth factor (CTGF) [44]. Recent studies also 
strongly suggest that the overexpression of stromal-derived factor 1 (SDF1/CXCR4), a 
factor that recruits and stimulates macrophages, might contribute to hypertrophic scar 
formation, and the use of CXCR4 antagonist has been shown to inhibit scar formation 
in a mouse model of hypertrophic scars [45]. Similarly, the macrophage chemoat-
tractant monocyte chemoattractant protein-1 (MCP-1/CCL2) has been linked to skin 
fibrosis [46]. This idea that macrophage dysfunction might underlie scar formation in 
skin is complemented by many studies in other tissues such as liver, lung, and kidney 
that suggest that macrophages can stimulate fibrosis [47]. Additional direct evidence 
for a role of macrophages in scar formation in skin wounds is needed, leaving the door 
open for future investigations.
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3.4  T cells
T cells are an important part of innate and adaptive immune system. T-cell subsets 
including CD4+, CD8+, NKT, γδT cells (dendritic epidermal T cells, DETC), and 
regulatory T cells (Tregs, CD4+CD25+Fox-p3+) have been reported to play signifi-
cant roles in wound healing. Following migration of macrophages and neutrophils into 
the wound, T cells including CD4+ helper cells and CD8+ cytotoxic T cells infiltrate 
the wound at around day 7 in an acute mouse wound model [48]. CD4+ cells from 
day 7 wounds express immunoregulatory or inflammatory cytokines including IFN-γ, 
TGF-β1, IL-10, and IL-17, while CD8+ cells express IFN-γ and TGF-β1 [48]. The 
functions of CD4+ and CD8+ T cells in skin wound healing and tissue regeneration, 
however, are not well understood, as there are several conflicting reports. The absence 
of CD4+ or CD8+ T cells has been reported to have no effect on wound closure [49]. 
However, wound breaking strength and collagen synthesis were shown to be signifi-
cantly increased in the absence of CD8+ cells in one study [49] but not in another [48]. 
In contrast, CD4+ cell deficiency has been consistently shown to have no effect on 
collagen content and wound breaking strength [48,49].
An additional subset of T cells, natural killer T (NKT) cells, infiltrate into early skin 
wounds at a time similar to neutrophils. NKT cells seem to inhibit skin repair, as NKT 
cell-deficient mice exhibit accelerated wound closure, an augmented production of 
neutrophil and macrophage chemokines (CXCL-1, CXCL-2, CCL-3, and CCL-4) and 
TGF-β, and increased collagen deposition [50,51]. Some questions about NKT cells 
and skin repair remain, though, as another study, using a different NKT cell-deficient 
mouse strain demonstrated different results including decreased TGF-β production, 
myofibroblast differentiation, collagen deposition, and wound breaking strength [52].
DETC, which are resident cells, are very early and rapid responders to tissue dam-
age. After T-cell receptor (TCR) stimulation, DETC can be activated by damaged 
keratinocytes to produce to critical growth factors responsible for keratinocyte prolif-
eration and migration [53-55]. DETC-deficient mice display a significantly impaired 
skin wound closure [53]. Additionally, DETC−/− mice have delayed macrophage in-
filtration into burn wounds suggesting that DETC affect macrophage migration [56]. 
Therefore, DETC not only play a role in reepithelization but also have an impact on 
the inflammatory response during the healing process.
Tregs have an indispensable role in maintaining immune homeostasis by generally 
inhibiting the over reactive immune response. Activated Tregs are known to accu-
mulate in early skin wounds. They impede IFN-γ production and pro-inflammatory 
macrophage infiltration. The depletion of Tregs results in delayed wound reepitheli-
alization [57].
While multiple studies demonstrate a role for many types of T cells in skin wound 
repair, the role of T cells in scar formation has received less attention. In hypertrophic 
scar tissue of burn patients, there are increased numbers of TGF-β-producing CD4+ 
cells. Fibroblasts treated with conditioned medium of burn patient CD4+ cells demon-
strate an increased rate of proliferation and collagen synthesis, suggesting CD4+ cells 
have an indirect immunoregulatory role in hypertrophic scar or fibrosis by interfer-
ing with the functions of fibroblasts [58]. Another T-cell type that seems likely to 
262 Skin Tissue Models
 influence scar formation is the regulatory T cell. The immunoregulatory roles of Tregs 
and the connection between inflammation and scar formation suggests that Tregs may 
influence scar formation, a function that needs to be explored in future studies. More 
investigations are also needed to understand whether other T cell types that are known 
to modulate healing, including DETC and NKT cells, influence scar formation and 
skin regeneration capacity.
3.5  Keratinocytes
Although they are not myeloid-derived, skin keratinocytes are an important part of the 
immune system [59]. The skin epithelium provides a protective barrier and as such 
is an important part of innate immunity. Keratinocytes also produce numerous anti-
microbial molecules, further contributing to a strong defensive blockade. Following 
skin injury, though, keratinocytes take on immune roles well beyond barrier func-
tion. Keratinocytes express Toll-like receptors (TLRs) and so are able to respond to 
a variety of external stimuli. TLRs, which are described further below, allow kerati-
nocytes to respond to endogenous molecular patterns that are associated with tissue 
damage. In response to tissue damage, keratinocytes produce numerous chemokines 
and cytokines that assist in the recruitment of inflammatory cells to the wound [60]. 
Keratinocytes can also produce growth factors that stimulate tissue repair, such as 
TGF-β and vascular endothelial growth factor (VEGF) [61]. Some mediators pro-
duced by activated keratinocytes, such as IL-1, influence healing outcomes via cross 
talk with dermal fibroblasts [62].
4.  Inflammatory mediators and receptors
A very large number of inflammatory mediators and receptors have been implicated as 
critical to wound healing. Below, we review some of the factors that have been shown 
to be most important to scar formation in wounds and thus important to the modulation 
of skin regeneration.
4.1  IL-1
IL-1 is produced by numerous cells including neutrophils, macrophages, keratino-
cytes, and fibroblasts. In response to injury, preformed IL-1 is quickly released and 
activated and in turn upregulates adhesion molecules in capillaries, facilitating macro-
phage and neutrophil infiltration. IL-1 also induces proliferation of keratinocytes and 
endothelial cells [11,63]. Thus, IL-1 plays a pivotal role in promoting host defense 
at the wound site by amplifying the immune response and can also directly affect 
tissue repair [64]. The activity of IL-1 in wounds is modulated by the presence of a 
receptor antagonist (IL-1ra), which inhibits IL-1 cellular signaling, reducing its pro- 
inflammatory effects [65].
An overabundance of IL-1 has been suggested to impair healing, as IL-1 levels are 
high in chronic wounds [66]. IL-1 receptor antagonist-deficient mice exhibit delayed 
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wound healing, accompanied by an altered cytokine secretion profile and collagen 
deposition [67]. Interestingly, though, IL-1 production by epithelia has been linked 
to scar formation in skin wounds. In the skin, the epidermis produces IL-1, and the 
administration of an IL-1 receptor antagonist has been shown to block scar formation 
in a rabbit model of hypertrophic scars [62]. Overall, then, a balanced production of 
IL-1 seems essential to appropriate repair and skin regeneration.
4.2  IL-6
In the skin, IL-6 not only is mainly produced by keratinocytes but also can be secreted 
by neutrophils, fibroblasts, and macrophages [68,69]. IL-6 is a pro-inflammatory cy-
tokine that has also been shown to cause keratinocyte proliferation [70]. IL-6-deficient 
mice display a significant postponement in healing including delayed reepithelializa-
tion and angiogenesis [71]. These deficiencies can be rescued via reconstitution with 
recombinant IL-6. IL-6 production has also been associated with scar formation. In 
particular, the overproduction IL-6 by macrophages and fibroblasts is associated with 
keloid scar formation [72,73]. Inhibition of both IL-6 and IL-6r by antibody neutral-
ization reduces collagen and fibronectin gene expression, indicating that IL-6 can reg-
ulate collagen and ECM synthesis [74]. These studies indicate that like IL-1, a careful 
balance of IL-6 is necessary for proper wound repair.
4.3  Transforming growth factor-β
TGF-β has a pivotal role in regulating the immune response to wounding [75,76]. 
There are three isoforms of TGF-β in mammals: TGF-β1, TGF-β2, and TGF-β3. 
These isoforms can influence cell proliferation, differentiation, migration, and sur-
vival within the wound bed. Although the three isoforms appear to have similar ac-
tion through cellular signal transduction, they are differently regulated and expressed 
during wound healing [77]. Immediately after injury, platelets release TGF-β1 that is 
chemotactic for inflammatory cells and mitogenic for collagen-producing fibroblasts. 
During healing, TGF-β1 continues to be produced and causes an increase in matrix 
protein synthesis while decreasing matrix protein degradation, thereby serving as an 
important regulator of scar formation [78]. TGF-β1 has also been implicated in the 
development of hypertrophic scarring and keloid formation [79]. TGF-β1 is produced 
at higher levels within keloid scars. The addition of TGF-β1 neutralizing antibodies to 
adult wounds has been shown to reduce scarring. Conversely, the addition of TGF-β1 
to nonscarring fetal wounds results in scar formation [78,80]. TGF-β2, mainly se-
creted by wound fibroblasts, is also involved in the stages of wound healing, mainly in 
the recruitment of inflammatory cells and fibroblasts to the wound area. Application 
of TGF-β2 to a wound increases angiogenesis and the rate of reepithelialization [81]. 
Although it has a similar structure, the role of TGF-β3 in healing is very different from 
the other isoforms. TGF-β3, which is synthesized by keratinocytes and fibroblasts, has 
potential antiscarring effects [82]. In mice, TGF-β3 is present at high levels in scarless 
fetal wounds while at lower levels in adult wounds. TGF-β3 knockout mice exhibit 
scarring of normally scarless fetal wounds [83]. In the adult wound, the application of 
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exogenous TGF-β3 reduces scarring [78,84]. The ratio of TGF-β3/TGF-β1 has been 
suggested to dictate healing outcomes. In a mouse model of dermal healing, higher 
ratios lead to scar reduction, and lower ratios lead to scar formation [79]. The scarless 
healing of the oral mucosa also is marked by a higher level of TGF-β3 expression 
compared with TGF-β1 [85]. The utility of altering the levels of and proportions of 
TGF-β1 and TGF-β3 to reduce scars has been examined in human studies. In hu-
man studies, Ferguson et al. reported the results of three double-blind, randomized 
controlled trials that evaluated the effects of adding active, human TGF-β3 to human 
wounds. The results of phase I and II trials showed that the application of TGF-β3 
improved the appearance of the scars as compared with controls. However, in phase III 
studies, the application of TGF-β3 failed to significantly alter scarring [86].
4.4  Tumor necrosis factor-α
TNF-α is another early mediator of the inflammatory response that plays an important 
role in healing. TNF-α amplifies inflammation through cellular signaling pathways, 
promotes leukocyte infiltration, and contributes to microbial defense [87]. The effect 
of TNF-α on wound healing seems to be dependent on several factors and is dose- 
dependent. Small doses of TNF-α aid in protection from host infection, stimulate in-
flammation, and cause macrophages to release growth factors that promote healing 
[11,88]. However, at higher levels, TNF-α has been shown to suppress the synthesis of 
extracellular matrix, vital to proper wound repair, and to cause prolonged inflamma-
tion and slower healing [11]. Consistent with this observation, high levels of TNF-α 
are found in chronic wounds [89]. In human patients, the drug infliximab (a monoclo-
nal antibody) has been used to inhibit TNF-α in chronic wounds. In a clinical study on 
a group of nine patients total, application of this inhibitor resulted in complete (100%) 
resolution in five patients and 75% resolution in the remaining four patients [90].
4.5  Secretory leukocyte protease inhibitor
SLPI is an inhibitor of serine proteases and is expressed near the end of the inflam-
matory phase of wound healing. SLPI-deficient mice show impaired cutaneous (heal-
ing?) marked by constitutive production of inflammatory cytokines and abundant 
leukocyte activation. Consistent with the known effects of excess inflammation, these 
mice exhibit delayed wound closure and increased scar formation [91]. Thus, SLPI 
has been suggested as a potential candidate for enhancing wound healing and reducing 
scar formation.
4.6  IL-10
The cytokine IL-10 is produced by a variety of immune cells such as T cells, mono-
cytes, and macrophages [92]. IL-10 can also be produced by skin cells such as ke-
ratinocytes and fibroblasts [93,94]. IL-10 downregulates the expression of collagen 
I, collagen III, and α-SMA and upregulates the expression of MMP1 and MMP8 in 
TGF-β-treated dermal fibroblasts [95]. Significant information suggests that IL-10 
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production influences scar formation in skin wounds. IL-10 is abundantly produced 
in nonscarring fetal wounds, and fetal wounds produced in IL-10 knockout mice ex-
hibit adultlike scar formation [96]. Studies in adult mice show that the treatment of 
skin wounds with IL-10 leads to improved collagen deposition along with decreased 
pro-inflammatory mediators such as IL-6, MCP-1/CCL2, MIP-2, and MIP-1α /CCL3 
[94,97]. In another study, adult murine skin wounds injected with IL-10 show smaller 
scars, reduced deposition of collagens including collagen I and collagen III, and de-
creased α-SMA-positive fibroblasts [95]. These studies suggest that IL-10 not only 
downregulates the inflammatory response, creating an environment favorable for tis-
sue regeneration, but also has a direct effect on collagen synthesis and degradation. 
A role for IL-10 in improving healing outcomes by reducing scar formation has been 
shown in sheep models as well [98]. Observations in human normal skin wounds fur-
ther support the idea that IL-10 can reduce scar formation. In humans, midgestational 
fetal skin secretes high levels of IL-10 in keratinocytes and fibroblasts, while IL-10 is 
absent in neonatal skin [94]. Human hypertrophic scar formation has been shown to 
coincide with a prolonged decrease in the expression of IL-10 [99]. Finally, a clinical 
trial has now shown that treatment of incisional skin wounds with low concentrations 
of IL-10 yields a significantly improved macroscopic scar appearance [100]. Together, 
these studies strongly suggest that IL-10 is a critical factor that negatively regulates 
inflammation and scar formation during wound healing. Therefore, IL-10 has poten-
tial as a therapeutic agent to prevent or reduce scar formation and to promote skin 
regeneration.
5.  Toll-like receptors
Toll-like receptors are a group of pattern recognizing molecules that are present on the 
surface or endosomal vesicles of many cells including leukocytes and skin-resident 
cells such as keratinocytes. TLRs recognize small segments of pathogens known as 
pathogen-associated molecular patterns (PAMPs). There are 13 known TLRs at this 
time. The cell surface receptors (TLR1, TLR2, TLR4, and TLR6) recognize bacterial 
and fungal components. Intracellular TLRs such as TLR3, TLR7, TLR8, and TLR9 
recognize internal PAMPs such as microbial DNAs or RNAs [101]. Although TLRs do 
not normally recognize most host molecules, they can interact with ligands produced 
by injured or damaged cells; these ligands are termed damage-associated molecular 
patterns (DAMPs). Thus, TLRs present on the surface of sentinel skin cells provide 
a recognition system for tissue damage and possible infection [101,102]. In the skin, 
TLR2 and TLR4 are the most abundant and are found on the surface of keratinocytes, 
fibroblasts, dendritic cells, mast cells, and macrophages [103]. When a TLR binds 
with a cognate PAMP or DAMP, a conformational change occurs that results in a 
complex signaling cascade, leading to induction of important mediators such as tran-
scription factors, cytokines, chemokines, and growth factors [101-103]. Until recently, 
little was known about the function of TLRs in skin wound healing.
Recent studies in mouse wound models have shown that TLR production is mod-
ulated during healing and the expression of TLR1–9 and 13 mRNAs are all greatly 
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increased in early skin wounds [104]. The functional significance of the TLR ex-
pression in wounds has been examined for a few specific TLRs. TLR3 activation 
probably occurs through binding of RNAs released from necrotic or damaged cells 
during injury. TLR3 production is significantly elevated in mouse skin wounds, 
and TLR3 colocalizes with keratinocytes, fibroblasts, neutrophils, macrophages, 
and endothelial cells [105,106]. TLR3 knockout mice exhibit delayed skin wound 
closure, reduced angiogenesis, and impaired recruitment inflammatory cells [105]. 
Treatment of murine wounds with the TLR3 agonist poly I/C significantly promotes 
healing [106]. Experiments in genetically deficient mice have also demonstrated a 
role for TLR4 and TLR9 in wound healing that is similar to that described for TLR3 
[107,108]. In the context of poorly healing diabetic wounds, however, TLRs seem 
to play a different role. More specifically, activation of TLRs, especially TLR2 and 
TLR4, seems to contribute to the prolonged inflammation and healing impairment 
seen in diabetic skin wounds [109,110]. The role of TLRs in wound healing is a new 
but promising field of study, and most of the published studies focus on the role of 
TLRs in inflammatory regulation in acute wound healing. However, a recent study 
discovered that fibroblasts isolated from human hypertrophic scar express signifi-
cantly higher levels of TLR1, TLR2, TLR3, TLR5, TLR6, TLR7, TLR8, TLR9, 
and TLR signaling pathway adapter molecule, MyD88. These cells also exhibited 
increased expression of inflammatory mediators including IL-6, IL-8/CXCL8, 
MCP-1/CCL-2, and PGE-2 when compared with fibroblasts from normal skin [111]. 
The authors speculate that increased expression of the pro-inflammatory mediators 
recruits leukocytes, which produce TGF-β, stimulating fibroblasts to produce ECM. 
Therefore, TLRs especially TLR4 activation may be partially responsible for ex-
cessive ECM production during HTS formation. Further exploration is needed to 
find the direct evidence of the functions and involvement of TLR signaling in tissue 
regeneration, especially collagen synthesis and scar formation. Taken together, the 
accumulated studies suggest that TLRs may play important roles in the regulation of 
inflammatory response and ECM production by binding to PAMPS and/or DAMPS 
during the wound-healing process.
6.  Summary and conclusions
As described above, many studies now implicate immune cells and mediators as caus-
ative agents in enhancing scar formation and preventing complete skin regeneration 
(Fig. 2). These studies suggest that the modulation of inflammation might be a promis-
ing therapeutic to encourage skin regeneration and minimize scar formation following 
injury. At the current time, several common treatments that are used to reduce scar for-
mation are in fact known to cause a reduction in wound inflammation. These include 
the injection of steroids to prevent or treat hypertrophic scars and the use of moist or 
occlusive dressings. In particular, the creation of a moist environment mimics the cre-
ation of a mature epidermis, promotes reepithelialization, and reduces scar formation 
as compared with a dry wound environment [112]. In animal models too, the use of 
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global anti-inflammatory treatments, such as celecoxib, has been shown to decrease 
inflammation and reduce scar formation [113].
Despite the considerable amount of information now available on how specific 
immune mediators might influence scarring and skin regeneration, the therapeutic 
development and use of targeted immunomodulators at sites of injury has been quite 
limited. There are several likely reasons for this situation. First, the appropriate ther-
apeutic immunomodulation of skin regeneration will most certainly be challenging, 
as any dampening of the immune response must consider the likelihood of increased 
wound infection. Second, although several specific approaches (such as alterations 
of TGF-β1/3 ratios or introduction of exogenous IL-10) have shown great success in 
animal models, results in human subjects have often been less compelling. These ca-
veats to development suggest that novel approaches will be needed to predict which 
types of immunomodulation will be most successful in the human skin. One possible 
approach might be the use of computational modeling of the inflammatory response 
in skin wounds [114,115]. The ability to model outcomes might permit a more ratio-
nal selection of the key mediators that can be safely targeted to improve skin regen-
eration. Such an approach will require the development of increasingly sophisticated 
and complex models to allow successful and accurate clinical predictions.
Acute wound
IL-10, SLPI, TGF-β3
IL-1, IL-6, TNF-α, TLR2, TLR4
IL-1, IL-6, TGF-β1
ScarPoorly healing woundRegenerative healing
Fig. 2 Dominant effects of immune mediators and receptors on healing outcomes. Mediators 
and receptors with well-described influence on healing outcomes are shown. The function of 
specific mediators in wounds is often dependent upon the level of production. IL-10 not only 
downregulates the inflammatory response but also has a direct effect on collagen synthesis 
and degradation, with an overall effect of supporting regenerative repair. SLPI inhibits 
inflammation, thus supporting improved repair. High levels of TGF-β3, such as found in 
fetal wounds, foster scarless healing. In contrast, overexpression of IL-1, IL-6, and TNF-α or 
overstimulation of TLR2 and TLR4 has been shown to result in excessive inflammation, thus 
leading to poorly healing or chronic wounds. Overexpression of IL-1, IL-6, and TGF-β1 is 
associated with abnormal scar formation such as hypertrophic scars and keloids.
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1. Introduction
In its simplest form, the mammalian skin comprises two layers, the ectoderm-derived 
epidermis and a layer of mesenchyme, the dermis. A closer look however reveals a 
striking complexity of the skin including an intricate network of vasculature and in-
nervation and elaborate structures arising from the epidermis during embryonic de-
velopment such as hair follicles (HFs) and sebaceous and sweat glands [1]. The HF 
is a complex miniorgan that is unique in its remarkable ability to undergo cycles of 
regeneration for a lifetime [2,3]. Despite this high regenerative capacity, under normal 
circumstances, HFs develop during embryogenesis but never in adult tissues [4], leav-
ing patients suffering from alopecia or severe injuries and burns in despair.
HFs are composed of cells originating from three distinct stem cell pools: epithelial 
and mesenchymal stem cells and neural crest cells giving rise to melanocytes [5,6]. 
HF development and hair growth involves not only reciprocal interactions between 
epidermal stem cells and specialized niche cells in the dermis [7], which makes HFs 
an exceptional model system to study stem cell (SC) self-renewal and their function 
in tissue homeostasis [8,9] and regeneration [10,11], but also the interaction of SCs 
with their niche [12–14]. Apart from SC biology, HF research involves various fields 
including immunology [15,16], chronobiology [17], metabolism [18], neurobiology 
[19], pigmentation research [20], and endocrinology [21]. Furthermore, as the HF 
cycles between a state of relative quiescence (telogen) and a state of rapid growth 
(anagen) [1], the HF and its entire microenvironment undergo transformations. In 
telogen, the HF has its minimal length, which elongates and generates a pigmented 
hair shaft (HS) in anagen. This proliferative phase is followed by a short period of 
 apoptosis-driven organ involution (catagen) leading back to telogen. Not only the mor-
phology of the HF and its associated sebaceous glands changes but also its immune 
system, the expression and secretory profile, and the surrounding dermis including the 
adipose tissue, innervation, and perifollicular vasculature [3,22–25], making the HF 
an ideal model for systems biology analyses.
With the development of a method to isolate and culture epidermal cells in the pres-
ence of fibroblasts or fibroblast-derived growth factors by Rheinwald and Green in the 
1970s [26–29] and to grow hair ex vivo by Philpott and colleagues in 1990 [30–35], 
skin and HF research has thrived enormously. Detailed protocols for the establishment 
of in vitro skin equivalents (SEs) have enabled an expanding network of scientists to 
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construct artificial skin in their laboratories. However, these bioengineered SEs still 
lack the complexity of mammalian skin including HFs, vasculature, or hypodermis. 
Recently, different approaches of introducing additional skin-derived cell types into 
classical SEs harboring epidermal cells and fibroblasts only have been developed, in 
order to resemble the complexity of the human skin more closely.
Based on the current knowledge on epidermal and dermal cells and their interac-
tions during HF morphogenesis and hair cycling in adult tissue, many researchers have 
attempted to generate mature HFs with different experimental strategies. These mostly 
involve embryonic or neonatal rodent cells. Besides, patent applications aiming at de 
novo HF generation both by companies and academic researchers have been increasing 
lately [36], but until recently, all approaches to generate human HFs in vitro have failed.
In this chapter, we will discuss how HFs develop during embryogenesis and why new 
follicles do not grow in adult tissue under normal circumstances. We will describe the 
approaches developed in the last quarter of a century to study HFs in vitro from mono-
layer cell culture systems to ex vivo human HF organ cultures and three-dimensional ar-
tificial skin models and exemplify recent innovative attempts to generate HFs in the dish.
2.  Hair follicle morphogenesis
HF organogenesis occurs early during embryonic development with the appearance of 
dermal cells toward the end of the first trimester [3,37]. In mice, HFs develop in waves 
from embryonic day 12.5 to 18.5 and result in a number of different hair types: primary 
or tylotrich (guard) HFs, characterized by huge hair bulbs, long straight hair, and two se-
baceous glands; secondary or nontylotrich (awl, auchene, and zigzag) HFs with thinner 
and shorter HSs and one sebaceous gland; and vibrissae HFs with specialized sensory 
functions [37]. HF morphogenesis depends on reciprocal signaling between epidermal 
stem cells and specialized cells of the underlying mesenchyme, which aggregate form-
ing the dermal condensate (DC) and will later become the dermal papilla (DP, Fig. 1) of 
the HF [7]. Dermal signals induce a focal thickening in the basal layer of the epidermis 
(hair germ or hair placode) and stimulate epidermal stem cells to grow downward and 
invaginate into the dermis, thereby engulfing the cells of the DC, which leads to the for-
mation of the DP (Figs. 1 and 2A) and further drives HF formation [37]. As the follicle 
grows downward, it is encapsuled by the highly proliferative, transit- amplifying matrix 
cells at the leading edge. The formation of the HF lumen is mediated by early outward 
movement of keratin 79 (K79) epidermal cells from within the cores of developing hair 
buds and into the epidermis [38]. The inner layers of the HF differentiate into concentric 
cylinders and generate the inner root sheath (IRS) and the central HS, while the outer 
root sheath (ORS) is continuous with the basal layer of the interfollicular epidermis 
(IFE). The IRS cells migrate outward from the base of the hair buds. Subsequently, K79+ 
cells are lost from the epidermis, thereby leaving behind a gap above the future site of 
the hair canal [38]. Once the HF reaches the bottom of the dermis, the HF becomes 
fully mature. However, matrix cells continue dividing, and their successors terminally 
differentiate to form the growing hair that exits the skin surface. In the mouse back skin, 
HF morphogenesis is completed between postnatal days 6 and 8 [37,39,40]. The ability 
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of the HF to regenerate is due to the presence of a pool of stem cells located in the bulge 
region of the HF, which forms a special niche that is critical for controlling SC self- 
renewal and thus the process of regeneration [41]. Bulge stem cell identity specification 
occurs early during HF morphogenesis in the embryo [41].
3.  Hair follicle cycle
Matrix cells are transit-amplifying cells that undergo only a limited number of divi-
sions before they terminally differentiate. Once the supply of matrix cells declines, 
HFs enter the so-called hair growth cycle, which starts with a degenerative phase 
called catagen. In murine skin, catagen occurs between postnatal days 14 and 18 in 
waves starting from the head caudally toward the tail and from the spinal cord down 
to the sides of the mouse [42].
During catagen, apoptosis of epithelial cells in the bulb and ORS leads to a com-
plete regression of the lower “cycling” portion of the HF. This translocates the DP 
upward to rest below the permanent, noncycling part of the follicle [42,43] (Fig. 2B).
Fig. 1 Hair follicle morphogenesis depends on epithelial-mesenchymal interactions. 
(A) Reciprocal signaling between cells of the developing epidermis and the underlying 
mesenchyme induces hair follicle (HF) formation during embryogenesis. (B) Mesenchymal 
cells subsequently form a dermal condensate (DC), which will later become the dermal papilla 
(DP) of the hair follicle. (C) The dermal papilla instructs the surrounding epithelial cells that 
ensheathe the DC during the initial down growth, to proliferate and differentiate into complex 
HF structures and produce the hair shaft, and controls hair follicle cycling.
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Upon degeneration, HFs enter a quiescent, resting stage called telogen, which lasts 
only 2 days in the first and more than 2 weeks in the second hair cycle in mice. Once 
quiescent epidermal SCs located in the lowest permanent portion of the HF, the bulge 
region, are activated, their progeny become transit-amplifying cells and divide rapidly 
to regenerate the lower portion of the HF in a phase called anagen, which resembles 
HF morphogenesis [4,42]. While in the mouse, anagen lasts for 2 weeks, human HFs 
may remain in anagen up to 6 years [44].
While transit-amplifying cells ultimately commit to terminal differentiation and 
produce the HS, the early progeny of stem cells on the way to becoming transit- 
amplifying cells maintains their slow-cycling properties and stemness. These cells 
home back to the bulge SC niche when hair growth terminates and serve as the pri-
mary SCs in the next hair growth cycle [12]. In contrast, initial bulge SCs reside as a 
resource to replenish the tissue upon injury [12]. HF and melanocyte SCs are miscella-
neous in the bulge and hair germ. During hair cycle initiation, melanocyte SCs divide 
to produce proliferative and committed melanocyte progenitors. These melanocytes 
(B)(A)
Adult, telogenNeonatal
K14 PDGFRaH2BeGFP DAPI
(C)
Adult, anagen + ectopic HF
Fig. 2 Hair follicle neogenesis does not occur in adult skin. (A) Murine neonatal skin contains 
follicles in different stages of morphogenesis including hair germ stages (yellow arrow heads), 
hair pegs, and hair follicles with enveloped DPs (white arrow head). (B) During catagen, 
epithelial cells at the base of fully developed HFs undergo apoptosis and regress, while the DP 
(white arrow heads) moves upward until it comes to rest beneath the stem cells of the hair follicle 
bulge. (C) De novo HFs never develop in the adult skin unless Wnt/β-catenin signaling is activated 
in epidermal stem cells, which drives existing follicles into anagen and induces the formation of 
ectopic follicles (EF) in the interfollicular epidermis and from existing hair follicles. Like anagen 
HFs (white arrow heads), these EFs have associated DPs (orange arrow heads).
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reside within the HF matrix of anagen follicles and generate melanin pigment, which 
is transferred to differentiating hair cells, and degenerate during catagen [1]. SCs of 
the sebaceous gland lineage terminally differentiate into sebocytes filled with lipids, 
which lubricate the skin’s surface once they degenerate to release their contents [45].
In order to maintain skin homeostasis and to control HF growth and regression, 
proliferation and differentiation of epithelial cells must be tightly regulated and co-
ordinated. Several signaling pathways have been implicated in HF development and 
cycling, including the PDGF, Wnt, FGF, Notch, Bmp, Shh, and TGFβ pathways, with 
essential instructive signals coming from fibroblasts forming the DP [7,37]. HF growth 
can be affected not only by deregulated paracrine and endocrine factors but also by the 
surrounding dermal niche, thereby leading to hair loss.
4.  Dermal papilla cells instruct hair follicle 
morphogenesis and control hair cycling
Classical tissue recombination and transplantation experiments have revealed a pivotal 
role for dermal fibroblasts in regulating various aspects of HF biology, such as HF for-
mation and regenerative hair cycling. While the contribution of epidermal cells to HF 
morphogenesis has been extensively investigated, our knowledge about the development 
of the DP and its functions in HF morphogenesis, growth, and HF cycling is limited. 
Novel DP-specific genetic tools now permit studying epidermal-dermal interactions and 
the signaling pathways involved during development and adulthood [46–49].
Several signaling pathways have been implicated in mesenchyme instruction 
during embryogenesis and subsequent DP formation as well as DP-derived instructive 
signaling that is essential to activate epithelial progenitors and initiate HF regenera-
tion and growth [7,50]. While interdependent interactions between Wnt/β-catenin and 
ectodysplasin signaling pathways have been shown to determine DC formation before 
epithelial placodes appear [51], a recent study suggests that the commitment to the DP 
lineage likely occurs once the embryonic mesenchyme is exposed to Fgf20 derived 
from the epithelial placode, and cells of the early DC may already have committed 
to the DP fate [52]. Once committed, these dermal cells undergo lineage maturation 
and progressively acquire terminally differentiated characteristics. While paracrine 
PDGF signaling stimulates dermal mesenchyme proliferation essential for the assem-
bly of (normal and ectopic) DPs [53,54], recent studies have shown that mesenchy-
mal PDGF signaling is dispensable for HF induction and formation [48]. In contrast, 
 epidermis-derived sonic hedgehog (Shh) is a crucial hair-inductive signal controlling 
the expression of DC- and DP-specific genes and thus DP maturation and maintenance 
of its function, thereby driving HF morphogenesis [40,55,56], whereas dermal dele-
tion of the hedgehog effector smoothened inhibits follicle formation [57].
DP cells are specialized mesenchymal cells derived from the papillary dermal fibro-
blast lineage [58], which differ from interfollicular dermal fibroblasts by unique proper-
ties such as the formation of aggregates in culture and the ability to induce HFs [58,59]. 
As mentioned previously, HF morphogenesis depends on reciprocal cross talk between 
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epidermal cells and fibroblasts and occurs during late embryonic and early postnatal de-
velopment but never in adult tissues [7], and thus, in adult skin, wound healing results in 
a lack of HFs at the wound site in contrast to scar-free healing in fetal or neonatal tissue 
[60]. Only in rabbits and mice wounding-induced HF neogenesis has been described 
in adult tissues [61–63]. This is either due to a decline in papillary fibroblasts in the 
adult skin or because fibroblasts change their gene signature and lose their hair- inductive 
properties with age [57,64]. However, activation of Wnt/β-catenin signaling in the epi-
dermis drives stem cells of the IFE and sebaceous glands into the HF lineage and repro-
grams adult dermal fibroblasts via paracrine signals to a neonatal state, thereby inducing 
formation of de novo follicles with associated DPs in the adult skin [53,57,65] (Fig. 2C). 
Interestingly, the newly induced follicles are not guard hairs but zigzag follicles corre-
sponding to the third wave of HF development, likely because the dermal fibroblasts are 
reprogrammed to a neonatal but not embryonic state. These findings suggest that remod-
eling dermal signaling in adult fibroblasts may restore their hair- inductive capabilities. 
Indeed, reestablishing a neonatal gene signature in adult fibroblasts and the subsequent 
increase in the number of papillary fibroblasts facilitate HF neogenesis during skin re-
generation upon injury of the adult skin [57,58]. Furthermore, β-catenin ablation in der-
mal fibroblasts promoted HF regeneration in neonatal and adult wounds, while dermal 
β-catenin stabilization inhibited HF neogenesis in neonatal wounds [64], suggesting that 
modulating dermal Wnt signaling may support in vitro HF regeneration as well.
In contrast to other fibroblasts of the papillary lineage, DP cells retain their capacity 
to induce HF neogenesis. This was shown in elegant studies where dissected rat vibris-
sae DPs were implanted into afollicular skin or beneath amputated vibrissae follicles, 
thereby inducing de novo HF formation in an ectopic site or hair fiber formation, 
respectively [66–69]. Interestingly, if the DP is removed surgically, lower follicle DS 
cells pitch in for the DP cells and restore functional hair growth [70–72], and the ger-
minative epithelium transforms DS into DP cells, as shown in an in vitro assay [73]. 
Similarly, dissected human DPs induced HF formation when implanted into transected 
athymic mouse vibrissae follicles [74] and human microdissected DS cells from the 
base of male scalp skin follicles resulted in new HFs when grafted into small wounds 
of an immunologically incompatible female recipient forearm [75]. This indicates that 
HF-derived dermal cells have hair-inductive abilities and that DS and DP cells belong 
to a restricted group of immune-privileged tissues that can be transplanted to foreign 
sites without being rejected [76].
Recent studies have demonstrated that cells of the DP rarely divide [47] and that HF 
dermal stem cells repopulate the DP and DS and modulate HF type [77]. Furthermore, 
while it was shown that DP cell number specifies hair size, morphology, and HF cy-
cling [78], an increase in DP cell numbers subsequent to activation of Wnt/β-catenin 
signaling did not result in hair type switching [47,79,80], despite the fact that only few 
DP genes seem to define HF type [81,82].
In conclusion, DP cells are specialized cells that are essential to induce HFs in vivo, 
and maintaining their gene signature and thus their hair-inductive properties is key to 
generating de novo follicles in vitro. Importantly, DP cells may have a much broader 
therapeutic potential than inducing new HFs for regenerative medicine. As DP cells 
can be reprogrammed into induced pluripotent (iPS) SCs more readily than many other 
cell types [83,84] and the noninvasive isolation method of HF plucking  represents a 
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huge advantage, DP cells may be used as a source to study or correct various diseases. 
Besides, recent studies have revealed that scalp HFs from patients suffering from an-
drogenic alopecia have normal bulge stem cell populations [85], but their DPs display 
altered expression patterns compared with healthy donor HF as recently shown in im-
mortalized DP cell lines derived from balding and nonbalding scalp [86], suggesting 
that modulating gene expression in diseased DPs might serve as a therapeutic inter-
vention to restore hair growth.
5.  Experimental models for hair follicle research
Current models to study HF growth range from normal and genetically modified 
mice, which are reviewed elsewhere [87,88] or are published on the Sanger Mouse 
Resources Portal (http://www.sanger.ac.uk/mouseportal) [89], in vivo reconstitution 
and human skin transplantation assays in immunocompromised mice, to monolayer 
cultures of specific cell types isolated from human HFs, hair follicle organ cultures 
(HFOCs), and three-dimensional coculture systems. Each of these model systems has 
advantages to address specific HF functions and may provide novel therapies for HF 
disorders. Although studies in animals have provided important insights in HF devel-
opment and cycling and the signaling cascades involved, in vitro studies with human 
HFs are essential, not only because of recent legal restrictions for the use of animal 
models for the cosmetic industry. Human HF growth differs from that of rodents and 
other mammals as (i) it does not occur in synchronized waves, (ii) anagen of human 
scalp HF may last up to 6 years [44], (iii) human hair has a reduced function in thermo-
regulation [90], but most importantly (iv) due to the more dramatic effect of androgens 
in humans, which stimulate HF growth in some body parts but inhibit hair growth on 
the scalp and other body sites [91].
6.  Human follicle organ cultures
An important milestone in the history of hair research was achieved by Philpott and 
colleagues, who developed ex vivo human HFOCs under serum-free conditions in 
1990, which not only maintained HFs alive but also allowed HF elongation at similar 
rates to that seen in vivo [30]. As reviewed in great detail by Langan et al. [92], a 
series of ex vivo studies of intact human HFs grown in submerged culture systems 
or at the air-liquid interface have led to major advances in hair research. Although 
hair cycling in vivo cannot be recapitulated entirely in HFOCs, this simple, easily 
 accessible, and translationally relevant model system is very versatile and allows 
a wide range of assays to address the impact of physical or chemical cues on HF 
elongation, proliferation, apoptosis, cytotoxicity, pigmentation, and regenerative HF 
cycling (e.g., HF staging). Novel methods allow gene knockdown by siRNA technol-
ogy or in situ fluorescence labeling of specific HF SC populations in HFOCs, thereby 
permitting the study of new aspects and biological functions with different scientific 
approaches.
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7.  Monolayer cell culture systems of distinct hair follicle 
cell types
The establishment of a method to isolate and culture epidermal cells in the 1970s 
[26–29] was key to studying the effect of various growth factors and chemicals on 
epidermal cell proliferation, apoptosis and expression, and secretory profiles in 
two-dimensional (2-D) culture systems. Meanwhile, various companies sell defined, 
serum-free media for maintaining epidermal cells in undifferentiated and proliferative 
states and for inducing terminal differentiation. The identification of markers for spe-
cific HF epidermal (stem) cell populations especially in the mouse allowed the isola-
tion and functional analysis of specific subsets of HF epidermal cells in vitro [93,94].
The most commonly used technique to isolate DP (and also adjacent DS) cells is 
surgical microdissection of human HFs or rodent vibrissae follicles or dispase and sub-
sequent collagenase treatment of the lower portion of anagen follicles [59,67]. Larger 
numbers of DP cells can be isolated from the mouse skin by fluorescence-activated 
cell sorting (FACS) of dissociated dermal tissue [58] with DP-specific markers such as 
prominin-1 (CD133) [47]. However, as discussed below, DP cells are difficult to propa-
gate and analyze in 2-D cultures as they almost immediately lose their innate properties 
in the dish [95]. Other HF-derived cells investigated in monolayer cultures or cocul-
tures with epidermal and dermal cells include melanocytes [96] and sebocytes [97].
Although both epidermal and DP cells change their properties in vitro, important 
information about their interactions can be gained when coculturing these two cell 
types in  vitro or by adding conditioned medium from either cell type to the other 
[98]. For example, epidermal stem cells cocultured with DP cells display increased 
proliferative and migratory potential [99] and induced hair-specific differentiation in 
transwell coculture systems [100] or by using DP cell-conditioned medium [101].
8.  Bioengineered skin equivalents
Since Rheinwald and Green managed to isolate and grow skin epithelial cells in the 
presence of fibroblasts or fibroblast-derived growth factors [26–29], the development 
of three-dimensional (3-D) bioengineered SEs has thrived enormously. These days, 
human SEs are used not only for research and drug screening like EpiDerm (MatTek) 
or EpiSkin (L’Oreal) but also in regenerative medicine (e.g., the FDA approved bilayer 
skin substitutes Integra and Apligraf) to provide an artificial skin barrier and epithe-
lial covering for large or chronic wounds to promote the healing process [102–104]. 
Such SEs created from autologous epidermal cells in  vitro have been successfully 
used to treat chronic wounds [105]. Scientists have been searching for new scaffolds 
especially replacing animal-derived dermal matrix [106] or alternative tissue and cell 
sources as well as specific subsets of HF epidermal and dermal cells [107–111] in 
an effort to improve human skin substitutes and their production, especially for the 
generation of autologous skin grafts. For example, Higgins et al. reported increased 
support of SEs if human interfollicular fibroblasts are replaced by human HF dermal 
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cells (DP and DS) [112]. However, bioengineered human SEs available at present are 
simplistic and devoid of HFs, blood vessels, and nerves, which together make the skin 
a highly complex tissue (Fig. 3).
Recently, different innovative approaches of introducing additional skin-derived 
cell types into classical SEs harboring epidermal cells and fibroblasts only have 
been developed, in order to resemble the complexity of the human skin more closely 
(Fig. 4). These include addition of endothelial cells and adipose-derived mesenchymal 
SCs as well as bioengineered vascular networks and adipose tissue [113–119], which 
would support epidermal cell growth and differentiation and improve the survival of 
grafted tissue. Naturally, incorporating HFs in such bioengineered skin substitutes is 
a major goal, both because of the appearance of the transplanted artificial skin and 
because several studies indicate that HFs promote wound healing: wounds heal faster 
if HFs of rodent skin are in an active anagen growth phase rather than in the resting 
telogen, and transplantation of terminal anagen HFs into chronic leg ulcers promoted 
wound healing [120,121].
9.  Hair follicle generation in in vivo reconstitution and SE 
transplantation assays
In  vivo hair reconstitution assays were developed to study the early events of HF 
development. In these assays, a mixture of individually prepared epidermal cells or 
specific HFSC populations and mesenchymal cells from rodent embryonic or neonatal 
skin is grafted onto dorsal skin of immunocompromised recipient mice within a silicon 
chamber or by intradermal injection [122–125], which subsequently  regenerate intact 
(A) (B)
Fig. 3 Classical skin equivalents lack hair follicles. (A) Hematoxylin and eosin staining of 
a human skin equivalent (SE) section. Classical SEs lack hair follicles and other complex 
structures found in vivo. (B) Immunofluorescent staining of SE section with antibodies targeting 
keratin 14 (basal epidermal cells, red) and involucrin (differentiation marker, green) (and 
DAPI counterstaining to visualize nuclei, blue) reveals stratification of the artificial epidermis. 
Epidermal cells were seeded onto devitalized human dermis substrates submerged in a medium 
containing a feeder layer of irradiated fibroblasts, which provide essential growth factors.
Fig. 4 Innovative approaches of in vitro hair follicle neogenesis. (A) Classical skin 
equivalents comprise fibroblasts in a collagen matrix and are overlayed with epidermal cells 
that stratify once they are raised to the air-liquid phase. (A) Higgins et al. (2013) managed 
to maintain the hair-inductive properties of DP cells by culturing human DP cells in hanging 
drop culture systems. The size of the DP-like spheres is similar to DPs in situ. (C) Recently, 
a group of scientists generated microfollicles from human cultured DP and epidermal cells 
and melanocytes entirely in vitro and introduced them into skin equivalents grown under 
dynamic perfusion on multiorgan chips (MOCs). To further improve the complexity of these 
SEs, subcutaneous tissue or other cell types could be included. These next-generation skin 
equivalents comprising in vitro-generated microfollicles can be used to study HF biology and 
for drug testing. (D) Hair follicles can be generated in vivo in skin reconstitution assays by 
injecting cultured human DP spheres in combination with murine or human epidermal cells into 
grafting chambers on top of immunocompromised mice or by transplanting in vitro-generated 
dermal-epidermal composites (DECs) onto the back skin of nude mice.
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skin epithelium comprising normal-appearing HFs (Fig. 4). This ability of DP cells to 
induce de novo HF development, when combined with epithelial cells, has long fasci-
nated HF researchers. Furthermore, generating new HFs from patient- derived DPs and 
competent epithelial cells has long been considered a viable therapeutic intervention 
for restoring hair growth. However, while murine DP cells often display impressive 
inductive capabilities in reconstitution assays [126], human DP cells independent of 
the patient age are less prone to induce HF neogenesis. Unlike cultured rat DPs, cul-
tured human DPs do not form papilla-like aggregates within the dermis, highlighting 
 species-specific differences [67]. While reconstitution assays with homo-specific hu-
man epidermal and dermal cells had not been successful, in 2007, Ehama et al. re-
ported the generation of “chimeric” HF-like structures consisting of human epithelial 
and murine DP cells in a chamber assay [127]. However, these HF-like structures had 
no bulge region, nor all epithelial layers found in intact HFs, and the DP-like tissue 
failed to express DP markers. Human epidermal ORS and DPs grown in 3-D collagen 
matrices have been shown to form tubular structures in vitro [128] and organize them-
selves into epidermoid cyst-like spheroids [128,129], but do not result in intact HFs. 
Sriwiriyanont et al. reported HF neogenesis in SEs harboring mouse DPs and human 
epidermal cells grafted onto nude mice [130]. Others managed to induce HF neogene-
sis by combining human scalp DP cells and mouse epidermal cells in flap grafts [131] 
or by injecting human DP cells grown as spheroids, mixed with mouse keratinocytes 
in “patch” reconstitution assays [132].
Finally, in 2013, Higgins et al. managed to grow human hair in vivo in a hybrid re-
constitution/recombination assay by placing DP-like aggregates formed of human scalp 
DP cells grown as spheroids in hanging drop culture systems between separated epider-
mis and dermis, which was recombined and transplanted onto immunocompromised 
mice [95]. In another study, skin substitutes were generated by seeding human neonatal 
foreskin keratinocytes onto a dermal substrate composed of collagen gel and human 
scalp DP cells cultured at the air-liquid interface [133]. Two months post transplanta-
tion onto immunocompromised mice, HFs of human origin with hair bulbs, DS, con-
centric layers of IRS and ORS, HR, and sebaceous glands were detected. Leiros et al. 
developed SEs from cultured human scalp HF epidermal SCs and DP cells seeded onto 
a devitalized dermal matrix, which were then transplanted onto nude mice. Although 
no fully mature HF was observed, HF-like structures with concentric layers of human 
origin were detected [134], indicating that cultured epidermal and dermal cells isolated 
from the adult human scalp are capable of producing new HFs in vivo.
10.  Dermal papilla cell properties are lost in two 
dimensional cell culture systems
One key step in generating HF-like structures from cultured human DP cells was a 
change from culturing the DP cells in monolayers to 3-D culture systems, which al-
lowed the formation of spheroids [132]. Similar to Kang et  al., Yen et  al. reported 
the formation of keratinocyte-DP hybrid spheroidal microtissues comprising DPs sur-
rounded by epidermal cells by coculturing DP and epidermal cells on a surface that is 
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nonadherent for keratinocytes (EVAL), thereby forcing the epidermal cells to attach 
to DP cells. These aggregates eventually merged to larger microtissues that detached 
and formed spheroids capable of inducing hair in vivo [135]. As reported recently, 
human DP cells lose their innate characteristics in response to an altered gene expres-
sion almost immediately upon seeding the cells in a conventional tissue culture dish 
[95]. In this study, Higgins et  al. compared the expression profile of native human 
DPs and DP cells cultured in monolayers for several passages. Dramatic changes in 
the transcriptome were seen as soon as DP cells were put in culture, while passaging 
the cells did not induce prominent changes any more. The changes involved almost 
4000 transcripts, many of them involved in HF development. Importantly, by growing 
human DP cells in hanging drop cultures and thereby creating a microenvironment 
allowing self-aggregation, spheroids of roughly 3000 cells mimicking physiological 
DPs formed, which partially rescued the transcriptional changes caused by monolayer 
cultures and thus the hair-inductive properties (Fig. 4). These human DP spheroids 
induced human HFs in in vivo reconstitution assays, as mentioned above.
Miao et al. [136] created DP spheroids from cultured DPs on a Matrigel scaffold. 
As reported by Higgins et al. [95], the DP aggregates restored the transcriptome of 
normal DPs, which is lost in 2-D culture systems.
Similarly, Ohyama et al. performed a microarray from freshly isolated, microdis-
sected human anagen DP cells and human DP cells cultured in conventional fibroblast 
medium [137], which also revealed significant differences in the expression pattern 
and loss of DP signature gene expression upon 2-D culture. This study reported 118 
human DP signature genes, which partially overlapped with the DP genes reported 
from studies performed on pure flow-sorted mouse DP cells [50,138,139]. Analysis of 
the expression data confirmed upregulation of the WNT, BMP, and FGF signaling path-
ways in intact DPs. What is more, the authors developed a culture medium containing 
6-bromoindirubin-39-oxime, recombinant BMP2, and basic FGF to stimulate these sig-
naling pathways, which not only maintained expression of in situ DP signature genes 
in primarily cultured human DP cells but also restored DP signature gene expression in 
conventionally cultured DP cells. Importantly, DP-like cell aggregates cultured in this 
medium resulted in de novo HFs of human origin when placed between enzymatically 
separated afollicular murine sole epidermis and dermis and transplanted onto immu-
nocompromised mice [137]. Although the authors did not report generation of new 
human HFs in vitro and DP cell growth in the so-called “DP activation culture (DPAC)” 
medium was only moderate [137], the newly developed culture medium provides an 
enormous advantage as DP cells can be cultured and rapidly expanded under conven-
tional conditions before restoring DP gene signature and function with DPAC medium.
11.  A hairy revolution for next-generation skin 
equivalents
Despite the advances in culturing DP cells in 3-D culture systems that allowed to mul-
tiply DP cells while maintaining the hair-inductive properties of DP cells, the studies 
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described above reported de novo generation of human HF-like structures from cul-
tured human epithelial and DC cells only upon transplantation onto immunocompro-
mised mice but not in vitro.
A group of scientists from the Technical University in Berlin has finally managed 
to grow human hair entirely in the dish [140]. They isolated DP and epidermal cells 
and melanocytes from dissected human HFs and expanded them into multiple pas-
sages. DP cells were kept under low adherent culture conditions resulting in DP-like 
spheroids, which were subsequently coated with extracellular matrix protein compo-
nents mimicking the basal membrane, and thus retained the hair-inductive properties. 
Thereafter, in cocultures, epidermal cells and melanocytes were forced to attach to 
the DP spheroids, thereby permitting further HF development. The resulting bioengi-
neered microfollicles, which produced hair fibers [140], were inserted into SEs cul-
tured under dynamic perfusion in a chip-based bioreactor (multiorgan chip, MOC) 
developed by the same group as reported at the European Society for Animal Cell 
Technology (ESACT) Meeting [141]. This microfluidic chip-based system extended 
the culture period of microfollicles inserted into SEs in the MOC.
These SEs with integrated, in vitro-generated human microfollicles cultured under 
dynamic perfusion take us one step closer to mimicking the complexity of the skin 
and provide a next-generation model system to study epithelial-mesenchymal interac-
tions and many other aspects of HF biology and for the in vitro testing of hair growth 
modulating agents.
Considering that HF development involves a plethora of molecular and cellular events 
that are tightly controlled in a spatial and temporal manner, it is not surprising that bioen-
gineered HFs are imperfect or incomplete structures. Nonetheless, these incomplete HF-
like structures are valuable for researchers to analyze events in HF morphogenesis and to 
test various compounds, but what is more, they provide the basis for improved structures 
yet to be developed. These next-generation SEs that promote de novo HF generation are 
expected to promote normal skin function, wound healing, and skin appearance and can 
be used to study human HF morphogenesis and regeneration with cultured adult skin cells.
12.  Conclusion
Grafting of hair-inductive dermal tissue is limited since only as many new HFs can be 
generated as DPs have been obtained from donor tissue. Similarly, characterization of 
human DPs has been unsatisfactory on the one hand because of the lack of efficient 
isolation and propagation methods of DP cells and on the other hand due to the loss 
of innate, hair-inductive characteristics when taken out of the context of their HF mi-
croenvironment. Recent advances in culturing DP cells in three-dimensional culture 
systems allowing the maintenance of the gene signature of DP cells in vitro and thus 
the hair-inductive properties of these specialized cells offer new opportunities to mul-
tiply hair-inductive DP cells isolated from the adult human skin and to grow HF-like 
structures in vitro. These minifollicles are still far from being optimal but are a prom-
ising evidence that by modulating culture conditions, hairy SEs and in vitro-generated 
human HFs for transplantation will be possible in near future.
292 Skin Tissue Models
For people suffering from alopecia or patients with insufficient HFs to provide DP 
cells, induced pluripotent stem cell (iPSC) technology in combination with defined 
protocols to differentiate these cells into DP-like cells may provide an additional cell 
source for in vitro generation of HFs. Notwithstanding, integration of HFs into bioengi-
neered SEs by incorporating cultured dermal cells with hair-inductive properties will be 
a key step to recreating a functional skin resembling the in vivo situation. However, to 
mimic the full complexity of human skin, many other skin-derived cell types including 
endothelial or nerve cells or adipocytes need to be introduced as well.
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1. Introduction
Skin innervation includes a wide variety of sensory end organs, among which intraepi-
dermal free nerve endings, dermal free nerve endings and dermal nerve endings asso-
ciated with (sensory) corpuscules [1]. These nerve endings allow skin sensoriality and 
included multiple receptor types (e.g., thermoreceptors, mechanoreceptors, nocicep-
tors, and pruriceptors) that act through sensory proteins such as those in the transient 
receptor potential (TRP) family [2]. Furthermore, neurotransmitter, growth factors, 
and cytokine secretion also occur, which mediate the control of skin functions and 
skin pathologies via the nervous system [3–5]. Conversely, the skin produces growth 
factors and neuromediators that guide neuronal growth within the skin [5–8]. The den-
sity of innervation, the nerve regrowth, the maintenance of innervation, the survival of 
neurons, and the formation of dendritic trees are all influenced by a complex balance 
among growth factors, neurotrophins, and semaphorins [6,9,10]. To grow in the extra-
cellular matrix, neurons must produce matrix proteases. The cellular mechanisms that 
govern neurocutaneous interactions in this communication are dynamic and multilat-
eral [7,11]. Furthermore, nerve endings and skin cells share the same receptors, me-
diators, and anatomical connections, as well as many of the same interactions. Hence, 
they constitute the neuro-immuno- cutaneous system (NICS) [12].
The interactions between the neurons and skin are increasingly apparent [12,13]. 
Because these interactions play very important roles in physiological and patho-
logical conditions, there is a need to understand the mechanisms that govern the 
NICS at molecular, cellular, and tissue levels. For these reasons, in vitro models 
are required [14]. Over the last decade, new, interesting, and sophisticated in vitro 
models have been developed. However, there is a need to adapt these models to bet-
ter understand the mechanisms underlying innervation and the interactions between 
the neurons and skin. These interactions are particularly difficult to study because 
the structure of skin innervation must be reconstructed in vitro. Indeed, nerve end-
ings rapidly lose their connection with skin cells when the neurons are cut, which 
is induced by collecting skin samples. The study of neurons in vitro without skin 
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cells is feasible but is not  sufficient to understand all the mechanisms underlying 
cutaneous innervation. Thus, coculture and 3-D culture methods were developed. 
However, such studies are extremely limited for human neurons. Current models 
use primary cells and cell lines, but future studies will likely utilize stem cells that 
have been differentiated into sensory neurons to replace animal and human neurons 
and neuronal cell lines [15–18].
The aim of this review is to present and explain the importance of these different 
models for studying mechanisms of innervation and neurocutaneous interactions.
2.  Models
In vitro models used to study cutaneous innervation and interactions in the NICS may 
be a monoculture or multicellular or three-dimensional (3-D). Monoculture models 
consist of one skin cell type (including neurons) cultured alone. Multicellular models 
comprise two or more skin cell types cultured together. 3-D models are cultured in 
three dimensions and involve one or more skin cell types. 3-D models that have char-
acteristics similar to normal skin, as permitted by the reconstructed skin and skin ex-
plant (organotypic). For these models, primary cells, cell lines, and cells differentiated 
from stem cells or tissue may be used (Fig. 1).
2.1  Origin and preparation of cells
All types of skin cells can currently be extracted and cultured as primary cells from the 
human or animal skin, including keratinocytes, melanocytes, Langerhans cells, Merkel 
cells (MCs), fibroblasts, mast cells, endothelial cells, and adipocytes. Additionally, the 
skin element can be an explant, reconstructed skin, a dermal or epidermal equiva-
lent, or extracellular matrix or an equivalent. Primary sensory neurons (PSNs) and 
Schwann cells are easily obtained from the dorsal root ganglia (DRGs) of animals. 
For neuronal or skin part, cell line may be used, but only a few cell lines have been 
evaluated for each cell type to study innervation mechanisms. For stem cells, differ-
entiation, validation of the characteristics of the desired cellular type, and integration 
of the cells into a model are currently being assessed; although not described here, 
sensory neuron-like cells can be obtained.
2.1.1  Neurons
Classically, PSNs from DRGs (rats or mice), pigs, or rodent cell lines are used. For 
primary neuronal cells, the animals are euthanized and prepared. DRGs are extracted 
using a clamp along the spine and are then used as a complete explant [19], or they 
are mechanically and/or enzymatically dissociated to obtain single cells [20–22]. 
Dissociation results principally in a mixture of PSNs and Schwann cells. After ex-
traction, sensory neurons are in a postmitotic state. For cell lines, different neurons or 
sensory neurons are used. ND7-23 and F-11 cells are sensory neuron-like cell lines 
[23,24]. They were obtained via cell fusion between the mouse neuroblastoma cell 
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line N18Tg2 and rat neonatal, for ND7/23, or embryonic, for F-11, sensory DRG 
neurons; therefore, these cells contain the genetic material of both species. PC12 cells 
were derived from a rat pheochromocytoma that differentiated into cells with the char-
acteristics of neurons following the addition of NGF [25]. The cell lines are cultured 
under growth conditions for multiplication using a classic commercial medium con-
taining serum and other additives. Classically, F-11 cells are maintained in Ham's F12 
(F12) containing 10% fetal bovine serum (FBS) and hypoxanthine, aminopterin, and 
thymidine (HAT). ND7/23 cells are cultured in DMEM with 10% FBS. PC12 cells are 
cultured in RPMI-1640 with 10% horse serum and 5% FBS or in DMEM/F12 with 
10% FBS. After extraction or maintenance in growth conditions, the cells are seeded, 
and the medium is changed.
2.1.2  Skin cells
Primary skin cells of human or animal origin are extracted via the enzymatic and me-
chanical dissociation of dermal or epidermal tissue. The dermis and epidermis must 
first be separated via enzymatic digestion. Keratinocytes, melanocytes, MCs, and 
Langerhans cells are then obtained from the epidermis, and fibroblasts are obtained 
Fig. 1 Main types of models. The main types of models used for studying innervation 
mechanisms. (A) Monoculture model: one cell type, neurons or skin cells, is cultured 
alone. (B) Coculture model: two or more cell types are cultured together. (C) Coculture 
compartmentalized with microchannel: one or more cell types are cultured in distinct 
compartments. Neuronal extensions may move between compartments but not the cell bodies 
and slightly trophic factors. Contact between cells occurs via nerve endings. (D) Coculture 
compartmentalized with a Boyden channel: one or more cell types are cultured in distinct 
compartments. Neuronal extensions may move between compartments but not cell bodies 
and slightly trophic factors. Contact between cells is avoided. (E) 3-D coculture model: a skin 
explant or reconstructed skin are cultured with neurons. (F) Skin-nerve preparation: segments 
of skin and the attached neurons are extracted from an animal as a complete unit.
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from the dermis. After the dissociation of these cells, it is equally possible to generate 
reconstructed skin or its equivalent made up of a unique epidermal sheet or dermal 
matrix and including all the other desired skin cells. The different techniques used 
to obtain cells and reconstructed skin samples will not be explained in this chapter. 
From the skin sample, it is equally possible to generate skin explants using punch bi-
opsies or epidermal sheets after the dissociation of the dermis and epidermis [14,26]. 
For keratinocytes, HaCaT or A431 are the most commonly used cell line. For Merkel 
or Langerhans cells, there are no satisfactory cell lines to use in studying innervation 
mechanisms. For mast cells, the mouse raw264.7 or human U937 cell lines are used. 
For Langerhans cells, the mouse XS52 and XS106 cell lines are used.
2.2  Monoculture models
Monoculture models consist of one of the multiple cell types that make up the skin, 
including neurons. These cells are cultured alone (without other cell types) and are 
subjected to an controlled environment that permits the study of cutaneous innervation 
mechanisms, such as those related to the many factors produced by skin cells.
2.2.1  Neurons
To use neurons in this type of model, the medium may contain calcium, one or more 
types of neurotrophins and a specific complement, such as B27 or N2. Serum is usu-
ally avoided because its composition cannot be controlled. In the majority of cases, 
the support (culture plate) must be prepared with a coating that can be used alone 
or mixed, including polylysine, Matrigel, laminin, collagen, and fibronectin. For the 
extraction of primary neurons, the neurons are crushed. Consequently, in culture con-
ditions, the neurites (cytoplasmic extensions from the body of a neuron, such as axons 
or dendrites) regenerate and may be studied. For sensory cell lines, serum deprivation 
and the addition of neurotrophins or cell-producing neurotrophins promote the exten-
sion of neurites for analysis.
The entire peripheral nerve explant may be used to understand innervation mech-
anisms. Tonge et  al. presented different methods to extract, culture, and study am-
phibian and mammalian peripheral nerve explants, including those from mice [19]. 
For example, explanted mouse DRGs present robust axonal growth and can thus be 
studied. The nerves could be compartmentalized or cultured on Matrigel or collagen 
coating, and axonal outgrowth may be clearly observed from the cut ends of periph-
eral nerves upon the addition of trophic factors or drugs. Matrigel, collagen, or lami-
nin were able to support neurite growth. However, collagen produced a lower growth 
of the axons than the Matrigel due to the composition. Results obtained with these 
models showed than NGF, NT-3, GDNF but not BDNF, or NT-4 increase the axonal 
growth in Matrigel. This growth is blocked by K252a (a kinase inhibitor) in NGF and 
NT3 conditions. The authors report also the presence of subpopulations of neurons 
expressing CGRP or phosphorylated heavy neurofilaments.
Generally, determining the effects of trophic or toxic factors on the regeneration 
of sensory neuron neurites is achieved via comparative measurements, with a  control, 
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of the length of neurites. These measurements are based on the total length of the 
 neurons, including the branches. To preferentially identify complete phenotypes, 
types, or subtypes of neurons and/or the nerve fiber morphology of cells, immunocy-
tochemistry (ICC) and patch-clamp analyses are performed.
Dissociated cells from DRG are a simple model to study cutaneous innervation 
mechanisms. Taneda et al. cultured DRG neurons in serum-free conditions with 10 ng/
mL of NGF in DMEM/F12 and an N2 supplement [27]. The cells were seeded at 5000 
cells per well in a 96-well plate coated with poly-d-lysine and laminin. After 24 or 
48 h, the cells were fixed in 4% paraformaldehyde and analyzed using phase- contrast 
microscopy. The authors examined the effects of neurotrophin on NGF-induced neu-
rite growth. In this model, they showed that the neurotrophin inhibited the NGF-
induced neurite growth. In the absence of NGF, neurotrophin had no effect.
The cell lines represent an alternative interesting way to study cutaneous innerva-
tion. Lebonvallet et al. used a monoculture of PC12 cells differentiated into neurons 
using NGF to study neurite growth. After dissociation, PC12 cells were seeded at 
5.104 cells per well in 12-well plates coated with poly-l-lysine (alternatively, plates 
may be coated with collagen I). The cells were incubated in growth medium (DMEM/
F12 10% FCS) for 24 h. The medium was removed and replaced with DMEM/12 con-
taining 10 ng/mL of hydrocortisone, 5 μg/mL of insulin, B27, and 10 ng/mL of NGF. 
Cells were maintained for 5 days alone or with a skin explant, but any other conditions 
with the addition of neurotrophins or active ingredients may be realized. After these 
5 days, random live-cell imaging was performed for each condition, and images were 
analyzed to measure lengths. Results suggest that skin explant (representing a skin 
lesion) produce a mix of attractive growth factors.
2.2.2  Skin cells
Keratinocytes, fibroblasts, MCs, endothelial cells, immune cells, and other skin 
cell types may be used to study the molecular process involved in neuron guidance. 
However, neurons control skin functions, homeostasis, and wound-healing processes 
through the use of soluble neuronal growth factors and neuropeptides [3,13,28,29]. 
The addition of neuronal factors (neuropeptides, neurotransmitters, or neurotrophins) 
in skin cell cultures is obviously a potentially simple way to study the putative effects 
of neurons on these cells. Methods to culture keratinocytes are abundant but are gen-
erally based on low-calcium medium supplemented with epidermal growth factor and 
other additives, such as bovine pituitary gland extract. Commercial medium has been 
recommended for keratinocytes. Differentiated keratinocytes require high levels of 
calcium (between 1.5 and 2 mM).
After extraction, fibroblasts may be amplified and cultured through the use of, for 
example, DMEM/F12 with 10% FBS. Cheret et al. presented an interesting model for 
culturing fibroblasts [29]. Human fibroblasts were plated in individual wells coated 
with fibronectin and containing cloning rings in their middle (to mimic scratching), 
and after 2 days of culture, the cloning rings were removed, and fresh culture medium 
containing different neuropeptides (CGRP, VIP, substance P, and NGF) was added to 
the fibroblasts for either 24 or 48 h. A positive control for myofibroblast  differentiation 
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was performed in parallel by adding TGF-β1 to the culture medium. After 24 and 
48 h, the culture medium was removed, and RNA was extracted to perform a real-time 
PCR analysis for α-SMA. The results revealed a significant increase of the expression 
of α-SMA in fibroblasts treated with the different neuropeptides in comparison with 
expression in the untreated sample, indicating that the different neuropeptides tested 
stimulated the differentiation of fibroblasts into myofibroblasts and, consequently, 
may participate at the wound-healing process.
Leon et al. used mast cells to determine their effects on innervation [30]. They used 
conditioned medium and identified multiple factors that are produced by mast cells. 
Peritoneal mast cells were obtained from rats at a purity of 90%. Conditioned medium 
was obtained from mast cells cultured in DMEM with 10% FCS for 24 h and was then ap-
plied to chicken embryonic DRGs for 24 h or 48 h. Leon et al. showed that neurite exten-
sion was promoted by the conditioned medium. This effect was altered when the medium 
was incubated with anti-NGF antibodies suggesting a role for NGF. Using ICC, ELISA, 
and PCR analyses, the authors confirmed that the NGF was produced by mast cells.
The roles of MCs in the NICS have been studied [31]. Factors associated with neu-
ron survival are expressed by MCs. Because MCs represent a summary of the NICS by 
themselves, the addition of neurotransmitters or nerve growth factors to MC monocul-
tures allows the effects of the peripheral nervous system (PNS) on these skin cells to be 
studied. Epidermal cells from piglet snout skin samples were dissociated via enzymatic 
digestion with trypsin. The cells were incubated with a magnetic microbead-conjugated 
antibody against CD56, MCs purified using magnetic cell sorting and seeded. Different 
media were used to promote cell survival, proliferation, and cytoplasmic extension. 
Neurotrophins such as NT3, BDNF, and NGF were unable to modify the MCs mor-
phology. However, bFGF induced cytoplasmic extension outgrowth. Finally, to per-
form more long-term cultures, DMEM/F12 with 7% FCS and 7% horse serum was 
used, with the goal of identifying a factor that promotes MC survival.
2.3  Multicellular models
Cocultures of neurons and skin cells have recently been proposed. The cells of the skin and 
neurons can be cultured in a compartmentalized manner or mixed together in a monolayer 
or 3-D culture. It is possible to coculture neurons and all skin cell types or with a skin 
equivalent such as reconstructed skin, reconstructed epidermis, or a skin explant. Different 
methodologies, including with compartmentalization, of coculturing between DRG neu-
rons and keratinocytes [32–34], fibroblasts [35], eosinophils/mast cells [36], Langerhans 
cells [37,38], and sweat glands [39] have been proposed. However, the medium must be 
adapted to permit the survival and functionality of all cell types in the culture [7,33,40]. 
Most models are flexible and may be adapted for all cell types and applications.
2.3.1  2-D compartmentalized models
Compartmentalized models are an interesting way because cellular body of neuron is 
separated of direct contact of skin cells to mimic physiology of the skin. Depending of 
experiment, contact between cells or only trophic factors are analyzed.
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A simple model in two step permits to avoid direct contact between keratinocytes 
and cellular bodies of neurons using a temporary divider while at the beginning of cul-
ture [41]. Human primary keratinocytes and DRG neurons were seeded and cultured 
at the maximum levels in a petri dish with distinct compartments formed by a two-
well silicon rubber chamber. The keratinocytes were maintained in Epilife 7S (with 
low calcium). DRGs were maintained in Epilife 7S with 1.8 mM calcium and 10% 
FBS. After 1 day, separation between the chambers was removed, and the medium was 
replaced with Epilife 7S with 1.8 mM calcium (thus, keratinocyte differentiation was 
initiated) for a maximum of 8 days. After removal of the compartmentalization, the 
neurites grew toward the keratinocytes and formed an organized structure in a cluster 
of cells, as observed via ICC using PGP9.5 and β-tubulin antibodies. The neurites, 
using ICC, showed a penetration into the keratinocyte cluster. These data suggested 
that keratinocytes produce neurotrophic factors and neurons possess the machinery to 
progress in a cluster of cells such as an epidermis. Blockage of NGF or its receptor 
showed no modification of the results suggesting an absence or low implication of 
NGF in this model. Furthermore, the authors described than Schwann cells (using 
vimentin stain) were present in the model. Schwann cells were described present near 
to neurons, up to the cluster of keratinocytes but do not penetrate into.
More complex, the model of Chateau et al. described cocultures between neurons 
and epithelial cells using specific tricompartmentalized chambers. The authors showed 
that MCs form neuroepithelial connections in vitro, and they used a homemade tricom-
partmentalized model separated by microchannels. Cells from the spinal cord were 
used in the first well, DRGs were seeded in the second well and a mixture of epidermal 
cells was seeded in the last well. The culture using a glial conditioned medium for 
2 days was maintained for 15 days before analysis. After 15 days, many neurites could 
be observed. Contact between MCs and neurons was observed using ICC with cyto-
keratin 20 antibodies to stain MCs and PGP9.5 to stain neurons. The advantages of tri-
compartmentalization are that a third cell type may be studied. Results showed that it is 
possible to reconstruct neuroepithelial connexion in vitro, and this could be a synapsis.
It is also possible to realize a completely separate culture but with a communication 
between cells using the classical Boyden chamber or transwell. Ulmann et al. used the 
primary or sensory neuronal cell line ND7/23 and primary keratinocytes or the cell line 
A431 [7,33]. To coculture neurons and keratinocytes, they were seeded at 5000 cells/
mL and 12,500 cells/mL, respectively, in MCDB medium in a 24-well plate. If compart-
mentalization was needed, the keratinocytes were seeded at 5 × 104 cells on Transwell 
cell culture inserts (0.4 μm pore size) to avoid contact but permit the diffusion of soluble 
factors. The calcium concentration was adjusted in a manner that was dependent of the 
experimental treatment. This model permits observation of the effects of keratinocytes 
on neurons, the effects of components of the medium, such calcium, on the cells and the 
identification of diffusible factors, such as NT3, BDNF, and NGF. Keratinocytes were 
analyzed via ICC using cytokeratin antibodies, and for neurons, PGP9.5 antibodies were 
used. The authors showed that the high level of Ca2+ was required for neurite extension, 
but not for survival of all neurons. Neurite expansion was also induced by NGF, BDNF, 
keratinocytes, or dehydroepiandrosterone (DHEA) but not by NT3, GDNF, pregnen-
olone, or progesterone. The keratinocytes induced neurite growth, which impacted 
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 essentially a subpopulation of neurons (cellular bodies at 17–25 μm) expressing SP and 
responding to capsaicin. This effect was diminished but not abolished by K252a sug-
gesting the presence of a dependent and independent trk pathway.
As an alternative with previously described model, it exits possibility to provide 
a model using a Teflon chambers. Roggenkamp et al. proposed a model adapted to a 
Campenot chamber for studying compartmentalized neuron and keratinocyte cocul-
tures [35,42,43]. A coculture between porcine DRG neurons and healthy or atopic skin 
cells was established. The cells were separated by a Teflon divider to prevent the blend-
ing of the media. In this model, cells can communicate via neurite extension through 
artificial microchannels or slowly via trophic factors. The DRG neurons were seeded in 
the middle compartment. After 1 day, keratinocytes or fibroblasts or neurotrophins and/
or the associated neutralizing antibodies (GDNF and NGF) were seeded in the other 
well. In each compartment, the medium was changed every 2 days. The cells and over-
all effectiveness of the model were analyzed using ICC, PCR, and ELISA. The authors 
showed that NGF and GDNF induced neurite growth. The cumulative neurite length 
CGRP positive induced by NGF or GDNF was more important with NGF than GDNF 
suggesting that the neurotrophins impact different subpopulation of neurons. Healthy 
and atopic keratinocytes and fibroblasts expressed NGF and BDNF in distinct propor-
tion and were able to induce neurite growth. The atopic keratinocyte produced more 
quantity of NGF. Kumamoto et al. developed an alternative to the Campenot chamber 
by adapting a commercial product, Axis(r), to study neurite growth [44,45]. The Axis 
chamber consisted of two distinct compartments separated by microgrooves. Human 
keratinocytes and/or mouse primary DRG neurons were seeded in the chamber, and the 
medium, which consisted of Epilife S7 and low level of calcium, was changed daily. 
For the analysis, the previously described method was used. The authors noted that 
there is neurite extension when keratinocyte are present. This growth was decreased 
when anti-BDNF antibody was used but not anti-NGF and anti-GDNF. Application of 
semaphorin 3A (a repulsive factor) in the medium reduced the neurite extension. The 
authors showed equally that microflow induced by a difference of quantity of medium 
in the two chambers induced neurite extension independently of NGF.
2.3.2  3-D models
Using a modified Boyden chamber, Tominaga developed a 3-D culture model using 
a type I collagen matrix [46,47]. Ice-cold collagen I or Matrigel was prepared and 
deposited in a 24-well Boyden chamber (0.4 μm pore). After gel formation, DRG neu-
rons were seeded with 0.1 ng/mL of NGF. In the well under the Boyden chamber, 
medium containing 10 ng/mL of NGF was placed. After 48 h, the cells were fixed, and 
the number of tau fibers (revealed via ICC) crossing the membrane was determined. 
The expression of matrix metalloproteinase was evaluated via PCR and Western blot 
analyses, and their activities were determined using the zymogram method. In this 
model, only neurons were cultured in the upper matrix, and an attractive factor was 
added to the well, but we can imagine that any skin cell type could be placed under the 
Boyden chamber. The authors showed that neurites passed through the membrane de-
pendently of NGF concentration in the well under the chamber. The neurite extension 
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was limited by GM6001, an MMP inhibitor. More precisely, MMP-2, MMP8, and 
MT5-MMP were implicated. Furthermore, the expression levels of these MMPs were 
reduced with semaphorin 3A.
Currently, three models of reinnervated reconstructed skin and their derivatives 
have been published. In 2003, Gingras proposed a method for producing a reinner-
vated reconstruction of the skin [40]. A chitosan/collagen sponge was colonized by 
human fibroblasts and, when necessary, by human umbilical vein endothelial cells 
(HUVECs). Keratinocytes were added to the model opposite to the DRG neurons from 
mice. After preparing the sponge, fibroblasts and HUVECs were seeded on the sponge 
and maintained for 17 days in DMEM containing 10% FBS and 100 μg/mL of ascorbic 
acid. Next, mouse DRG neurons were deposited on top of the sponge. The medium 
was replaced with DMEM/F12 containing 10% SVF, 10 ng/mL of NGF, 0.4 μg/mL 
of hydrocortisone, 5 μg/mL of bovine insulin, and 100 μg/mL of ascorbic acid. After 
7 days, the sponge was flipped over and reseeded with fibroblasts. After 3 days, the 
same quantity of keratinocytes was added. The culture was maintained for 4 days with 
immersion and then stopped or for 7 days with the immersion initiated on day 14 at the 
air-liquid interface. In this model, the neurite extensions were observed in the dermis 
reaching more than 770 μm at 14 days but not in the epidermis. The authors showed that 
NGF was necessary for neurite extension. The endothelial cells induced an increase of 
neurite growth, and the keratinocytes maintained the neurite formation. Roggenkamp 
developed a similar model using a polyester/polypropylene matrix and collagen gel 
inserts. Pig DRG neurons were placed in collagen I gel, and a portion was placed in 
the matrix. Subsequently, they were recovered by fibroblasts. After 24 h, keratinocytes 
were seeded. After 48 h, the model was cultured at the air-liquid interface for 12 days. 
The medium was refreshed daily with medium containing 10% FBS, 0.4 μg/mL of 
hydrocortisone, and 50 μg/mL of ascorbic acid. Using this model, the authors assessed 
epidermal homeostasis, pathological skin, and neurite growth. They showed that atopic 
keratinocytes induced an increase of epidermal thickness, neurite length, and concen-
tration of CGRP. An alternative model was recently described by Martorina et al. that 
involves using human dermal microtissue, including fibroblasts, and epithelialization 
by HaCaT cells [48]. Neurons are very close to the epidermis. The authors showed the 
functionality of the models via calcium imaging using capsaicin as a cell activator.
At the interface between reconstructed skin and a skin explant, Nagase used epider-
mal sheets on collagen gels seeded with PC12 cells [26]. PC12 cells were seeded in 
collagen I gel in transwells in six-well plates. Hence, five epidermal sheets from foot-
pad skin of adult Wistar rats were prepared via enzymatic dissociation with dispase, 
embedded in 0.5 mL of collagen, and placed in the upper well containing gel with 
PC12 cells. In this model, the authors principally observed that PC12 cells participated 
in the proliferation of MCs in the epidermis and maintained histological homeostasis 
of epidermal sheets, but other phenomena may also be assessed using this model.
The most complete model is the skin explant, but the environment is lesser con-
trolled. Lebonvallet et al. developed a model of skin explants that were reinnervated 
with sensory neurons from rat DRGs [49–51]. An equivalent of one-fourth of the total 
DRGs from one rat was seeded in one well of an uncoated 12-well plate. After 1 or 2 h, 
the cells were exposed to DMEM/F12 containing 10 ng/mL of hydrocortisone, 5 μg/mL 
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Table 1 Main features of monoculture and multicellular models to 
study cutaneous innervation
 Monolayer 3-D models
 Monoculture Multicellular
Cells Neuronal/cutaneous
Fibroblast, 
keratinocytes, 
Merkel cells, 
neurons
Neuronal and 
cutaneous, typically 
consisting of 
keratinocytes and 
neurons
Skin equivalent, 
pseudodermis or 
epidermis, skin explant or 
reconstructed epidermis, 
epidermal sheets, ex vivo
Source Primary cells or cell lines Primary cells, cell lines, or 
tissues
Level/scale Mechanistic, 
cellular, 
physiological/
pathological
Mechanistic, 
cellular interaction, 
compartmented or 
not, communication 
or not, physiological/
pathological
Mechanistic, cellular 
interaction, tissue, 
physiological/pathological, 
integrative
Methods/
techniques 
 
 
 
 
 
Cytotoxicity, 
migration and 
neurite growth, 
electrophysiology, 
biochemistry, 
molecular biology, 
labeling, imagery, 
video microscopy
Cytotoxicity, 
migration and 
neurite growth, 
electrophysiology, 
biochemistry, 
molecular biology, 
labeling, imagery, 
video microscopy
Histology, topic, 
cytotoxicity, migration 
and neurite growth, 
electrophysiology, 
biochemistry, molecular 
biology, labeling, imagery, 
video microscopy 
of insulin, and 25 ng/mL of NGF. Subsequently, a human skin explant 6 mm in di-
ameter was placed at the center of the well and maintained for 10 days. The  medium 
was changed after 2–3 days. After 10 days, many changes were observed. The authors 
showed that epidermal thickness, epidermal density, and innervation were higher 
when the skin explants were reinnervated. With this model, it is possible to perform 
electrophysiological analyses of neurons using topical applications to the epidermis, a 
histological analysis of reinnervation in the explant or of epidermal and dermal char-
acteristics, and an analysis of neuronal growth around the explants. It is equally pos-
sible to perform omics analyses on the supernatant and the explants. In place of the 
normal skin, it is also possible to study pathological or wounded skin. Chéret et al. 
adapted the model to assess reinnervation during wound healing by making slight 
modifications and adding a wound in the center of skin samples [29].
Another interesting model uses a complete skin-nerve preparation that is collected 
from a mouse or rat and is maintained for survival [52,53]. The nerve and skin are 
microdissected, maintaining their unique organic structure, and placed in a bath spe-
cifically adapted to the chamber for the analysis of electric stimuli. This model is ideal 
for studying neuronal activity, for phenotyping the sensory nerves in the skin, and for 
making comparisons with the human skin using pharmacological treatments.
A comparison of the possible monoculture and multicellular models is shown in 
Table 1.
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3.  Choice of model design and limitations
Using skin cells and neurons, different models have been developed to study innerva-
tion mechanisms and skin interactions. Monocultures are available but are not suffi-
cient to understand and integrate all of the required parameters; thus, complementary 
cocultures and 3-D models provide very interesting approaches. The latter are more 
difficult to develop than a simple culture because the medium must be adapted for 
two cell types, but they offer different and more possibilities. All cells and elements 
may or may not be compartmentalized and in contact, and the model must be adapted 
depending on several parameters, such as the type of study performed and the level of 
interaction or cellular integration chosen. The goal of the project is important for the 
design of the model. The choice of the model will depend on [1] the method and scale 
of work (e.g., physiological, pathophysiological, or preclinical studies; cytological, 
histological, or functional studies; morphological, biochemical, or electrophysiolog-
ical studies; and whether the culture is in a solution or uses a topical application or 
both) and [2] the focus of the work (e.g., cutaneous neurogenic inflammation, neurite 
growth, cellular tropism, reinnervation, epidermal homeostasis, signal integration and 
modality, wound healing, or pruritic pathologies, such as atopic dermatitis and psoria-
sis). Indeed, the constraints and results may be completely different depending on the 
model chosen, which is why early study choices are important.
3.1  Living materials (human, animal or cell line)
The choice of the living material and origin of the samples will depend on the study 
performed and the associated technical constraints. Cells or tissues are derived from 
humans or animals (commonly pigs, rats, and mice), primary cells (including stem cell) 
or cell lines. Skin element can be an explant, reconstructed skin, a dermal or epidermal 
equivalent, extracellular matrix or an equivalent, keratinocytes, and skin cells, such as 
MCs, fibroblasts, mast cells, Schwann cells, bone marrow cells, endothelial cells, or 
adipocytes. For neuronal equivalents, sensory neurons or sensory-like neurons are used.
A major difficulty associated with these models is the routine culturing of normal 
human sensory neurons, which is limited due to the limitations related to obtaining neu-
rons from humans for ethical reasons. Consequently, sensory neurons from an animal 
origin, cell line or other source recently differentiated from human stem cells are used. 
Because it is very difficult to obtain human neurons, the principal bias in the coculture 
models could be the heterologous origin of the cells; skin cells usually have a human 
origin, whereas neurons are usually obtained from rodents. Unlike with immunologic 
research, there are no scientific data showing that the coculturing of neurons and skin 
cells of different origins modifies their properties in these models. The problems asso-
ciated with heterologous models may be resolved by eliminating human cell types, but 
this would not elucidate the potentially different reactions between human and animal 
cells. However, a major advantage of heterologous models is that, for example, the 
mRNA may be differentially analyzed by using a specific animal probe, which would 
not be possible in a homologous model. A major advance in neurocutaneous interaction 
research is and will continue to be the use of neurons, especially sensory neurons, dif-
ferentiated from human stem cells to replace nonhuman neurons [16,17,54–57].
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The culture of primary neurons of an animal origin (especially rats or mice) is fre-
quently performed but must be restrained, especially in the context of cosmetologi-
cal research because it is forbidden by the European Union. Consequently, sensory 
 neuron-like cell lines may be used in the models. PC12 cells are widely used to study 
the NGF receptor. However, major problems related to their similarity to primary cells 
may be present. For each cell type, not all potentialities of sensory neurons are repro-
duced. Rat PSNs present very good neurite growth after 1–3 days, whereas PC12 cells 
clearly show reduced performance; however, this difference may be due to the absence 
of Schwann cells with the PC12 cells [49]. Another difference is related to function. In 
fact, TRPV1 is less sensitive to the capsaicin on PC12 cells than on the PSN. On PC12 
cells, TRPV1 is activated by a minimum of 80 μM of capsaicin, whereas less than 1 μM 
is sufficient to affect PSNs. In 2016, Yin et al. performed a transcriptome analysis com-
paring ND7/23 and F-11 cells and mouse DRG sensory neurons. ND7/23 and F-11 cells 
presented major differences in expression from one another and from the DRG neurons 
[58]. The principal explanation given by the authors is that the cell lines do not represent 
all of the sensory neuron subtypes present in and extracted from DRGs. Other studies 
investigating functionality in response to different agonists using calcium imagery of 
cell lines showed important differences in responses between cells depending on the 
agonist [59]. F-11 cells do not respond to a PAR-2 agonist, and ND7/23 cells do not 
respond to trypsin. Regarding neurite growth, Ulmann et al. showed that neurogenesis 
was completely suppressed in ND7/23 cells by the trk inhibitor K252a when compared 
with the response of primary neurons [60]. Concerning skin cells, few cell lines are 
available for each cell type. The results from these lines are not always identical to 
those from primary cells, but only limited data are available to support the observed ef-
fects on innervation mechanisms. For keratinocytes, human HaCaT or A431 is the most 
commonly used cell line. Ulmann et al. showed that A431 cells provoked a tendency 
for reduced neurite growth (approximately 25%) in rat PSNs when compared with the 
response in rat primary keratinocytes [7]. This difference may be due a reduced potential 
of A431 cells or to interspecies incompatibilities. In place of normal primary cells or cell 
lines, it is equally possible to use skin cells from a pathological individual. Roggenkamp 
et al. used a compartment model of primary sensory pig neurons and healthy or atopic 
keratinocytes or fibroblasts [35]. The team showed that atopic keratinocytes induced an 
increase in neurite length relative to results in healthy controls. However, this effect was 
not sufficient to demonstrate that pathological characteristics were conserved in all case 
in in vitro cultures. Such studies are needed. Similarly, cells that have been modified 
via transfection or KO/I may be introduced in cultures. These approaches are a more 
recently developing trend, and they are providing new and promising data.
In conclusion, for an optimal model, the use of PSNs from animals is currently rec-
ommended because they are simple to obtain and represent the full range of subtype 
diversity of neurons. However, for ethical reasons, this choice is not optimal; thus, it is 
necessary to develop lines from stem cells and validate the efficiency of sensory neu-
rons. PC12 and ND7/23 cells may be an interesting alternative to study neurite growth. 
If the use of sacrificed animals is forbidden for cosmetic research, PC12, ND7/23, or 
F-11 cells may be used, with extreme caution taken in the interpretation of the results 
due to biases of the cell lines in terms of the function of the studied domain. Human, 
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animal, or skin cell lines may be used to study innervation mechanisms. The limits of 
skin cell lines have not been studied.
3.2  Design and medium
The choice will depend on the scale of the analysis and whether it is necessary to 
integrate all parameters or if a specific feature is needed. In the case of the global 
approach, with all interactions and a histological analysis, a model based on a skin 
explant in coculture with neurons is optimal. It is basically possible to analyze [1] 
the protein, RNA, and tissue of the skin explant and [2] the protein, RNA, and elec-
trophysiological profile/activity of the neurons. Furthermore, analysis of nerve fiber 
growth is possible both within and outside the skin explant. The supernatant may be 
collected and analyzed, with the disadvantage that the molecules produced by skin ex-
plants (keratinocytes and fibroblasts) and neurons are mixed. Reconstructed skin has 
similar characteristics except that all cells are not present in the model; consequently, 
all interactions are not present. However, a culture may be better maintained with re-
constructed skin without the model degrading. Skin explants are more representative 
of lesional/inflamed skin, and the survival and maintenance of a skin explant for more 
than 10–14 days is affected by apoptosis and necrosis of the cells and tissue. Another 
difficulty related to reinnervated skin is the low reproducibility of the density of skin 
innervation between experiments, but low reproducibility is probably similar to that of 
reconstructed skins. A reference protocol is available to study and compare epidermal 
innervation density and may be adapted for these models [61]. However, performing 
a comparison between reinnervated skin and normal human skin currently lacks inter-
est because densities are highly variable among experiments and among individuals 
and locations under in vivo conditions. However, with some additional development, 
reinnervated skin is very close to being used as a preclinical model. Skin-nerve prepa-
rations (dissection of the skin with attached nerves from the spinal cord) are also 
possible from rats and mice, which provide the advantage that the models are fully 
integrative; however, they are strictly limited to characterizations of neurons.
For a specific and more controlled approach, cocultures and monocultures are more 
adaptable techniques. Innervation mechanisms and interactions can be observed at the 
cellular level. Under monoculture conditions, transcriptomic, proteomic, and electro-
physiological analyses are possible, as are measurements of cell morphology and neur-
ite extension. Supernatants contain unique elements produced by cells and those added 
based on the protocol, and analyzing it is simple. In noncompartmented cocultures, two 
or more cell types (generally keratinocytes and neurons) are mixed, but the same meth-
odology used for monocultures may be utilized. Tsutsumi et al. revealed the importance 
of the manner and order of seeding cells between neurons and keratinocytes [62]. They 
showed that different seed models resulted in different organizational structures and 
concluded that the method for seeding the cells is important for the interpretation of the 
results. Whether the cells communicate is of interest; consequently, responses between 
them may be studied, for example, trophic effect of keratinocytes on the growth of 
neurites of neurons or the proliferative effect of neurons on keratinocytes. Furthermore, 
the presence of additional cells, in comparison with monoculture models, may modify 
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the responses of one or more cells to the studied parameters. As with reinnervated skin 
explants or reconstructed skin, the disadvantage associated with multicellular cultures 
is the presence in the supernatant of molecules produced/released by the mixture of all 
cells. This problem may be mitigated by compartmentalization with microgrooves be-
tween neurons and skin cells. Many models can be established using modified Boyden, 
Campenot, and Axis(r) chambers [35,43,44]. In these cases, diffusible factors (added 
or produced) may diffuse slowly between compartments, consequently, permitting the 
tropism of neurites, without the cellular body, into the target compartment. The uncon-
trolled diffusion of factors between compartments remains an unresolved problem and 
has been discussed [62]. Another difficulty with multicellular models is the compatibil-
ity of the medium for two cellular types and the seeding procedure. The medium must 
be adapted to permit the survival and functionality of all cells in the culture [7,33]. Even 
if the medium enables survival, it may also interfere with the culture, or an ingredient 
may be unnecessary. A simple example is calcium: neurons need calcium to correctly 
develop; however, high calcium concentrations provoke the differentiation of keratino-
cytes, which may or may not be desirable as the characteristics of keratinocytes are very 
different in basal or differentiated states. Ulmann et al., using a coculture model of neu-
rons and keratinocytes or trophic factors, showed that under low-calcium conditions, 
axonal growth in sensory neurons was induced by NGF and BDNF but not by NT3 
and GDNF, which is in contrast to the findings of another study that used high-calcium 
conditions [7,63]. Tsutsumi showed that there is no morphological interaction between 
keratinocytes and neurons in the presence of low calcium concentrations, unlike the re-
sults obtained using 1.8 mM calcium [62]. The team suggested that differentiated kera-
tinocytes produce a trophic substance that affects neurons and that basal keratinocytes 
do not. B27, another component of medium used to culture or coculture neurons, does 
not appear to be necessary in cocultures of neurons and keratinocytes or of neurons and 
a skin equivalent. Using a coculture model including DRGs and human reconstructed 
skin, Gingras et al. showed that B27 supplementation was not necessary for the model; 
in contrast, it was necessary for culturing neurons alone [40]. A more recent model of 
rat DRG and human skin explant coculturing did not use B27 in the medium [49].
The choice of the model depends on the type of analyses needed to resolve the 
question. Different models are available for 2-D and 3-D cultures. In my opinion, a 
simple monoculture or 2-D model should first be implemented to avoid interfering 
parameters. In further experiments, more complex models may be used to permit a 
global and mostly histological approach.
4.  Applications
These different models are very versatile, and most techniques are applicable to 
them. Furthermore, the 3-D models may be studied using histological techniques, 
which provide an interesting new dimension to studies of the skin. A compilation of 
the applications and associated models is presented in Table 2, but it is not exhaustive 
because many mixed combination and applications of the models presented here are 
possible.
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4.1  Neurite/axonal growth, cellular tropism and cellular 
communication
Cultures of sensory neurons are helpful to understand the effects of factors that are 
produced by epidermal or dermal cells and that participate in the innervation mecha-
nisms of these cells. Neurons are dependent on particular neurotrophins for survival 
and guidance, such as NGF, BDNF, NT-3, and GDNF. Axon cone growth of neurons 
may be guided by specific factors. The growth of the axon cone results from attractive 
factors or neurotrophins, such as NGF and repulsive factors, such as semaphorins. 
Cultures and cocultures of sensory neurons are used to identify/study/screen sub-
stances (like active ingredients, growth factors, or other biological molecules) that 
are implicated in neuron growth, tropism, cone growth, and associated molecular 
mechanisms. Similarly, stressors or pro-wound-healing factors may be analyzed us-
ing a particular model that utilizes neurons cultured in the presence of slices of in-
jured skin [70].
A model based on the coculture of F-11 cells and primary keratinocytes has been 
described [33]. The F-11 cell line has been conventionally used to mimic peptidergic 
nociceptive neurons. The morphological and functional characteristics of F-11 were 
evaluated first, followed by the influence of keratinocytes on axonal development or 
Application/theme of the studies Models/cellular type
Neurite/axonal growth and cellular 
tropism, interaction/contact
3-D [26,40,64,65]
Multicellular, compartmented, monolayer 
[7,35,43,44,66]
Multicellular, monolayer [7,41,62,67,68]
Monoculture [46,69]
Monoculture, monolayer [21,29,70–72]
Cutaneous neurogenic 
inflammation
Multicellular, monolayer [32,73,74]
Monoculture, monolayer [75]
Reinnervation 3-D [40,49,50]
Monoculture [46]
Epidermal homeostasis 3-D [26,29,49,76]
Signal integration and modality 3-D/ex vivo [48,51–53]
Monoculture, monolayer [77,78]
Multicellular, monolayer [68]
Atopic dermatitis 3-D [76]
Monoculture [46]
Multicellular, compartmented, monolayer [35,43]
Wound healing 3-D [29]
Monoculture [69]
Monoculture, monolayer [29,70]
Pruritus 3-D [51]
Monoculture [46]
UV irradiation Multicellular, multilayer [79]
Table 2 Applications and associated models
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neuropeptides release. These neurons express markers of sensory neurons and are able 
to release neuropeptides after activation by capsaicin. Neuropeptide release was de-
tected even at a low concentration of calcium, and axonal growth was not influenced 
by variations in calcium concentration. These properties were demonstrated when 
F-11 cells were cocultured with keratinocytes, but they had no significant influence 
on the development of axons or the release of neuropeptides. This coculture model, in 
which keratinocytes and neurons are maintained under low-calcium conditions, may 
be useful for studying the close contact between keratinocytes and sensory neurons.
Another model may be employed to study the role of skin in neuronal growth. In 
this model, keratinocytes are replaced with a whole-skin explant, and sensory neurons, 
with PC12 cells that have been differentiated into neurons. PC12 cells were plated, 
and a skin punch biopsy (skin explant) was placed in the center of the culture well. The 
cocultures were maintained in medium for 10 days. Every 2 days, neurite lengths of the 
PC12 cells were evaluated. Two conditions were compared: PC12 cells cultured alone 
and PC12 cells culture with the skin explant. The results indicate that the skin explants 
had a trophic effect on the neurites of PC12 cells. In this model, the skin explants may 
also be considered as lesional skin [71].
Contact between cells can be specifically evaluated, and the trophic effect of kera-
tinocytes or fibroblasts on neurons has been demonstrated using compartmentalized 
models. Neurons and other cellular types are placed in separate compartments of a cul-
ture using microchannels and a separate chamber that permits contact between differ-
ent cells via neurites [35,43,44] or in a classical Boyden chamber/transwell that does 
not permit cell contact but solely the circulation of soluble factors [7]. Microchannels 
allow neurons to pass into the other compartment only by projecting neurites because 
the channels are narrower than the bodies of the cells [43,66],. Based on electron mi-
croscopy and photomicroscopy results and using the compartment model or another 
model, contacts between sensory axons and cells of the epidermis have been described 
for keratinocytes, Langerhans cells, and MCs [38,41,66–68].
4.2  Reinnervation and epidermal homeostasis models
The first approaches to the study of the skin utilized fresh animal and human skin ex-
plants. Skin innervation and its effect on the epidermis were evaluated [3–5], including 
the potent participation of newly studied molecules on wound healing, such as neuros-
erpin [80], or the mechanism underlying skin sensitivity [81]. However, this approach 
is static, and not all conditions can be applied for ethical and technical reasons [14].
3-D coculture models are the most complete models and allow for a more compre-
hensive view of, for example, reinnervation or epidermal homeostasis. In 3-D in vitro 
skin models, these interactions are lost because of the lack of nerve endings [14]. 
In vitro 3-D skin models have been developed using skin explants [49], reconstructed 
skin [40], or epidermal sheets [26].
The model using reconstructed skin developed by Gingras is ideal to study rein-
nervation and axonal growth due to the lack of interference caused by previous an-
cient reinnervation in the case of explant. In this model, a collagen sponge populated 
with human endothelial cells and/or human fibroblasts was used. The authors used 
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 histological methods to demonstrate that the elongation was maximal within 14 days 
of culture. Thus, different modalities may be evaluated using this model, such as the 
influence of Schwann cells [64] or hair follicles [65].
A skin explant model is ideal for studying epidermal homeostasis because the epi-
dermis is reinnervated, and all cells are present [49,82]. Previous human skin explant 
models have included a coculture of PSNs from rats. After 10 days of culture, the skin 
explant was analyzed. Using histological techniques, the epidermal thickness, cell 
density, and cell integrity of the innervated skin explant were found to be higher when 
the explants were reinnervated in comparison with changes in the noninnervated con-
trols. The proliferation of epidermal cells was not modified, but apoptosis decreased 
significantly. Therefore, this innovative model using skin explants and neuronal cocul-
tures allows improved skin integrity and could be useful to study interactions between 
the skin and the PNS. Furthermore, electrophysiological activity was assessed, and the 
role of the trophic effects of skin explants was confirmed [51,71]. Based on a model 
using reinnervated atopic reconstructed skin, Roggenkamp suggested that neurons 
strongly influence keratinocyte proliferation [76].
4.3  Wound-healing models
Based on the close interactions between the skin and the PNS, there is increasing 
evidence that cutaneous innervation is an important modulator of the normal wound- 
healing process. It is well established that neurotransmitters and nerve growth factors 
that are released into the skin have immunoregulatory roles and can exert mitogenic 
actions; they can also influence the functions of the different types of skin cells during 
the wound-healing process [28].
The study of wound healing using a 3-D model [29] was conducted using an 
adapted model of a reinnervated skin explant, as previously described [49]. A hu-
man skin wound-healing assay was designed with internal injuries on 6 mmØ human 
skin explants inflicted with a smaller 3 mmØ punch. Skin explants were incubated 
with a panel of molecules secreted by neurons or PSNs from rats. In a simple culture 
(without neurons), injured human skin explants were maintained in the same medium 
and supplemented with SP, CGRP, or VIP at different concentrations. Every 2 days, 
half of the culture was discarded and replaced with fresh culture medium containing 
neuropeptides. The results were compared with results from a coculture of neurons 
and wounded skin. Different culture times were evaluated, corresponding to different 
phases of wound healing. This study showed that the peripheral sensory nervous sys-
tem plays a crucial role in this process by affecting the proliferation and remodeling 
phases of skin wound healing. Communication between skin cells and sensory neu-
rons is mediated by neuropeptides, such as SP, CGRP, and VIP.
Another coculture type has been established between fibroblasts and neurons in a 
collagen sponge [69]. In this case, the role of neurons in the contractile potential of 
fibroblasts on a sponge was evaluated. PC12 cells were differentiated by the addition 
of NGF to the culture medium. The fibroblasts were obtained from rats (as were the 
PC12 cells). PC12 cells and fibroblasts were seeded on a 3-D collagen matrix. The 
differentiation of fibroblasts into myofibroblasts, as a marker of the progression of the 
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wound-healing process, was evaluated in the presence or absence of PC12 cells, and 
the resulting contraction of the collagen matrix was considered. The results show that 
PC12 cells had a strong influence on fibroblast differentiation and the contractibility 
of the collagen matrix.
4.4  Models of cutaneous neurogenic inflammation
A coculture model of pig keratinocytes and pig sensory neurons can be used to un-
derstand/mimic more complex mechanisms, such as neurogenic inflammation skin 
tests, or for screening active ingredients and to understand their cellular functions 
[32,73,74]. In this model, epidermal keratinocytes and sensory neurons of piglets 
were extracted via enzymatic and mechanical dissociation. The cells were seeded in 
a 96-well plate and dissociated. The keratinocytes and neurons adhered to the sup-
port. After several days, the neurons had long extensions and formed contacts with 
neighboring cells. Immunolabeling showed that keratinocytes and neurons expressed 
SP and TRPV1. To evaluate cutaneous neurogenic inflammation, the cells were incu-
bated with capsaicin, a TRPV1 agonist. The release of SP in the coculture was mea-
sured via ELISA. The assay revealed that the neuropeptide SP is released in response 
to capsaicin. This model allows for the evaluation of neurogenic inflammation based 
on the level of SP release into the supernatant via TRPV1 activation [32]. Using this 
model, the effect of tacrolimus as a regulator of neurogenic inflammation was vali-
dated, as was its mechanism of action [73]. It is also possible to assess the “soothing” 
effect of a factor or a sample by pretreating the cells. Thus, it has been shown that 
sangre de drago has a “soothing” effect on cutaneous neurogenic inflammation by 
reducing the release of SP after the addition of capsaicin if the product is incubated 
with the cells prior to exposure to capsaicin [74]. Similarly, Le Garrec et al. adapted 
a model using rat DRG neurons and human keratinocytes instead of pig cells to study 
ciguatoxins [34]. Using this model, the authors show that ciguatoxin (P-CTX-2) in-
duced a release of SP and CGRP dependant of voltage-gated sodium channels. The 
ciguatoxin-induced sensory disturbances in ciguatera fish poisoning may involve the 
release of these neuropeptides. Moreover, the authors showed the influence of extra-
cellular calcium on the release of neuropeptides elicited by P-CTX-2.
4.5  Pathological skin
Coculture models may be used to understand skin pathologies, such as atopic dermati-
tis, pruritus, or lesional skin resulting from UV irradiation. The model may be adapted 
to study pathological skin samples, for example, by replacing normal human kerati-
nocytes, fibroblasts, or skin explants with the corresponding atopic cells/tissues. UV 
irradiation may also be used on cells to mimic naturally UV-damaged cutaneous cells 
(dermal, epidermal, and neuronal cells) [79]. Furthermore, using pathological skin or 
components of pathological skin, secondary treatments may be applied.
To study atopic dermatitis, Roggenkamp et al. [35] adapted a model using the com-
partmentalized chambers of Campenot et  al. [43]. In this model, the authors used 
PSNs from pigs and human keratinocytes or fibroblasts from atopic patients. The cells 
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were separated using a Teflon module that permitted the passage of neuron fibers via 
microchannels. In this model, the authors highlighted the roles of pathological kera-
tinocytes and fibroblasts in neurite outgrowth from neurons. More recently, in a 3-D 
atopic reconstructed skin model, Roggenkamp confirmed the role of keratinocytes 
in neurite growth and showed that neurons increase the growth of keratinocytes in 
response to CGRP [76].
5.  Conclusions
New models are available to study different features of neuron-skin interactions. These 
models may be characterized by monolayers or by 3-D, multicellular, or monoculture 
designs to study different parameters of physiological and pathological neurocutane-
ous interactions, such as axon growth and tropism, epidermal homeostasis, wound 
healing, atopic dermatitis, pruritus, and neurogenic inflammation. These models could 
also be helpful for preliminary investigations and the screening of active substances 
that could be used by cosmetic or pharmaceutical industries. Further advances could 
be made through the use of sensory neurons from stem cells to replace animal neurons. 
Also, the realization and validation of a reinnervated skin explant model for preclini-
cal use would be a great advance.
Abbreviations
2-D/3-D two-dimensional/three-dimensional
A431 keratinocyte cell line
B27 neuronal medium supplement
BDNF brain-derived neurotrophic factor
bFGF basic fibroblast growth factor
Capsaicin TRPV1 agonist
CD56 cluster of differentiation 56
DMEM Dulbecco's modified Eagle's medium
DRG dorsal root ganglia
ELISA enzyme-linked immunosorbent assay
F11 sensory neuronal cell line. Rat-mouse hybridoma
F12 Ham's F12
FBS fetal bovine serum
GAP43 growth associated protein 43
GDNF glial-derived neurotrophic factor
HaCaT keratinocyte cell line
HAT hypoxanthine-aminopterin-thymidine
HUVEC human umbilical vein endothelial cell
ICC/IHC immunocytochemistry/immunohistochemistry
K252a Trk inhibitor
KO/I knock-out/knock-in
MC Merkel cells
N18TG2 mouse neuroblastoma
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1. Introduction
The notion of adipose tissue as an inert energy storage depot has long been foregone. 
The discovery of adipokines and their systemic effects has fueled the emergence of the 
concept of adipose tissue as an endocrine organ. Adipose tissue has been found to have 
key roles in regulating immunity and inflammation in both physiological and patholog-
ical settings. In humans, recent studies suggest that there are two distinct adipose layers 
associated with the skin. One is a subcutaneous adipose depot, and the other is the 
so-called dermal white adipose tissue that underlies the reticular dermis and encloses 
mature hair follicles. There is increasing evidence indicating a major role of adipose 
tissue in a variety of skin diseases. Concurrently, dermal white adipose tissue has been 
found to be essential in several cell-related mechanisms in dermal and epidermal tis-
sues. Despite these facts, research aiming at characterizing the full role of this adipose 
tissue depot in skin tissue homeostasis and wound healing is scarce. This is partially 
due to the lack of adequate in vitro tools that allow an accurate recapitulation of what 
happens in the actual skin tissue. The development of novel in vitro models of the skin 
to study dermal white adipose tissue and its role on wound healing is therefore a need.
Advances in the biomaterials and cell biology fields are paving the way to the fab-
rication of in vitro constructs that mimic the structure and function of the native adi-
pose tissue considering its individual components and its mechanical and biochemical 
properties. Such constructs will allow unveiling the inner workings of each component 
of adipose tissue, contributing to achieve functional adipose tissue models and to bet-
ter understand its role in the skin.
This chapter overviews the main components of adipose tissue, what is currently 
known about their role in wound-healing events and hair formation and the state of the art 
in terms of available in vitro models. Furthermore, future trends are explored toward the 
fabrication of adequate in vitro models to study the role of dermal white adipose tissue.
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2.  Adipose tissue
Adipose tissue has been commonly distinguished in two main types, white and brown 
adipose tissue [1,2]. More recently, beige adipose tissue was added to this distinction 
[3,4]. At different stages of development, different adipose types dominate the body. 
Newborn tissue consists mostly of brown adipose tissue to prevent hypothermia, while 
in adult humans, white adipose tissue dominates [2,3,5,6]. It is also known that mes-
enchymal precursor cells of neural crest or mesodermal origin give rise to different 
adipose depots. However, while it is known that brown adipocytes are derived from 
a myogenic factor 5+ (Myf5+) lineage, white adipose tissue adipocyte precursors 
origin has not been fully described [3,7,8]. Nonetheless, it is consensual that the depot 
location, along with morphological and functional cues, allows distinguishing each 
type of adipose tissue.
Adipose depots can be found mainly in subcutaneous and visceral locations; the 
major subcutaneous distribution of white adipose tissue includes superficial and deep 
abdominal and gluteal-femoral depots, while the visceral depots surround vital organs 
within the peritoneum and rib cage [9–12]. On the other hand, subcutaneous brown ad-
ipose tissue is mainly located around the shoulders, ribs, and axilla and visceral brown 
adipose tissue around perivascular, periviscus, and solid organs [9–11,13]. The dis-
tinction between white and brown adipose tissue also relates to their function. White 
adipose tissue has a major endocrine role controlling whole-body homeostasis, while 
brown adipose tissue is mainly thermoregulatory, being their components and respec-
tive interactions crucial for regulation of nonshivering events [1,3,14].
Adipose tissue is maintained from a pool of precursor cells, precommitted to differ-
entiate into adipocytes. Self-replication and adipogenic differentiation of these pread-
ipocytes are driven upon activation of the transcriptional factors nuclear hormone 
receptor peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer 
binding protein-α (C/EBPα) [15–17]. PPARγ is required during terminal embryonic 
adipogenesis, while C/EBPα is crucial for the dynamics of adipose tissue in adults 
[16,17]. Throughout life, the size and remodeling of the adipose tissue is dependent 
on the energy balance of the whole body. Expansion of the tissue occurs through the 
lipid enrichment of preexisting adipocytes, which increase in size (hypertrophy), or 
by the recruitment of preadipocytes from resident pools to increase of the number of 
adipocytes (hyperplasia) [16,18–22].
In a homeostatic state, diet-derived fatty acids synthesized in the liver and incor-
porated into water-soluble lipoproteins are uptaken by adipocytes through very-low-
density lipoprotein (VLDL) receptors present in the cell membrane, and free fatty 
acids (FFAs) enter in the cell mediated by facilitated diffusion [23,24]. FFAs and cy-
tokines/adipokines are the key regulatory elements for different processes mediated 
by adipose tissue. In the absence of glucose, adipocytes release fatty acids in the cir-
culation to balance the carbohydrates required for cell metabolism [25]. Adipokines 
produced by adipocytes such as leptin and adiponectin also have important roles in 
different organs. Leptin receptor is highly expressed in the mediobasal hypothalamus 
[26–28], and its activation leads to repression of the orexigenic pathways and induc-
tion of anorexigenic pathways leading to food intake and energy expenditure [25]. 
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This adipokine also regulates insulin sensitivity in the muscles and in the liver. In 
the first case, leptin acts directly on AMP-activated protein kinase (AMPK) reducing 
intramyocellular lipid levels and indirectly through central neural pathways [29]. In 
the liver, leptin inhibits proinsulin synthesis and secretion [25,30–32]. Similarly, ad-
iponectin has an effect on insulin sensitivity by mediating the activation of AMPK in 
the skeletal muscle and liver. The expression of adiponectin receptor 1 and 2 regulated 
by the activation of AMPK leads to increased fatty acid oxidation and glucose uptake 
in the liver and inhibition of glycogenesis in the liver [33,34].
2.1  Adipose tissue cellular content
Depending on the location and physiological/pathological condition, adipose tissue 
has a different cellular composition [35]. Adipocytes are the main cellular component 
of adipose tissue, but the morphology of the adipocytes determines each type of adi-
pose tissue varying from white to brown adipose tissue. Adipocytes in white adipose 
tissue are characterized by having a single lipid droplet for efficient energy storage, 
while adipocytes from brown adipose tissue present multiple lipid droplets and nu-
merous mitochondria expressing UCP-1 [1–3,7,9]. Regarding beige adipocytes, the 
characteristics are shared with brown and white adipose tissue [9,36].
Besides adipocytes, there are other cell types interacting and coordinating adipose 
tissue functions (Fig. 1). Subcutaneous and visceral adipose depots are innervated, 
vascularized endocrine organs comprising precursor cells, fibroblasts, vascular cells, 
immune cells, and neurons, which altogether constitutes a stromal vascular fraction of 
adipose tissue [7,33].
The interaction between adipocytes and vascular cells such as endothelial cells and 
pericytes modulates adipose tissue angiogenesis and vascular remodeling, which are 
critical to accommodate increasing fat stores [7,33,37–39]. This is mainly mediated 
by a range of angiogenic factors (VEGF-A, bFGF, HGF, and leptin) and  cytokines 
and adipokines (TNF-α, resistin, and A-FABP) produced by the adipocytes [40–42]. 
Other adipokines have also been implicated in the interaction between adipocytes and 
endothelial cells due to vasoactive properties. Leptin [43] and adiponectin [44,45] 
enhance the NO-dependent vasorelaxation through the activation of AMPK/pro-
tein kinase B (Akt) signaling cascade in the endothelial cells. Leptin also unleashes 
an NO-independent vasorelaxation mechanism promoted by the production of 
 endothelium-derived hyperpolarizing factor (EDHF) [40,43].
Fibroblasts, the main element of adipose tissue associated to the production of 
extra components [33], interact with adipocytes through endocrine signaling [46]. 
Adipokines such as adiponectin and leptin are released by adipocytes and recognized 
by human dermal fibroblasts through their receptors adiponectin receptor 1 (AdipoR1) 
and receptor 2 (AdipoR2) and leptin receptor (Ob-Rb) [47]. It is known that fibro-
blasts respond to these signals by increasing hyaluronic acid and collagen production 
as a regulatory pathway to maintain the dermal homeostasis [46,47].
Resident adipose tissue macrophages (ATM) are critical cellular constituents of 
adipose tissue due to their role in systemic homeostasis such as in the control of the re-
lease of lipids into the bloodstream, through a balanced storage of the excess released 
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by adipocytes [35,48]. Critically, they are also implicated in adipose tissue-related 
disorders, such as obesity and insulin resistance [48–50].
Adipose tissue T cells (ATT) commonly referred to T cells residing in adipose tis-
sue are key mediators of metabolic and inflammatory states. Subpopulations of T cells 
differ according to regional fat depot and are associated with both systemic inflamma-
tion and insulin resistance [51]. However, the mechanisms of adaptive immune sys-
tem surveillance in adipose tissue are still quite elusive. There are evidences that the 
immune response in adipose tissue is controlled by ATT via an antigen-driven process 
involving a fat-specific antigen that may be critical in maintaining a low inflammatory 
state in lean individuals [52]. But what protein or carbohydrate antigens are being 
recognized is yet to be discovered [53].
2.2  Adipose tissue extracellular matrix
Adipose tissue microenvironment is regulated not only through mono- and heterotypic 
cell-cell interactions [7] but also through the interaction of cells with the extracellular 
Adipose stem cells 
Fibroblasts
Collagen
Laminin
Fibronectin
Adipocytes
Pericytes
Adipocyte precursors
Neurons
Microvascular
endothelial cells
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Adipose tissue
Neuronal cells
Stromal cells
Extracellular
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Fig. 1 Adipose tissue components. Adipose tissue is an endocrine, innervated, and 
vascularized organ with a collagen-, laminin-, and fibronectin-rich extracellular matrix. 
Mature adipocytes are the main component cellular of the adipose tissue. However, other cell 
types such as precursor cells, fibroblast, vascular cells, immune cells, and neurons, which 
altogether constitute a stromal vascular fraction, are also present.
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matrix (ECM), which also defines the mechanical features of each type of adipose tis-
sue. In general, adipose tissue ECM is mainly composed of collagen, elastin, laminin, 
and sulfated glycosaminoglycans [7,54,55]. Some authors suggest that the composi-
tion varies with the species, type of fat depots, and differentiation process [56], but 
complete evidence that these variations are not dependent on protein characteristics, 
experimental conditions, and methodologies is yet to be clarified.
Adipose tissue ECM is as dynamic as the tissue itself in the sense that ECM remod-
eling is regulated by insulin, by the energy metabolism, and by mechanical forces that 
vary with the adipogenesis and the state of mature adipocytes. In fact, up to 6 days of 
differentiation, the expression of collagen IV, nidogen I (entactin), and various laminin 
complexes was upregulated in mouse 3T3-L1 preadipocyte cultures [57,58], while a 
decrease of collagens type I and type III was observed [56], marking a transition from a 
fibrillar to a laminar state. Moreover, after 12 days of differentiation, the values of col-
lagens I and III returned to the levels of day 0, and the levels of collagens IV, V, and VI, 
although decreasing, remained above the initial ones [56,59]. The high and low expres-
sion of, respectively, collagens I, III, IV, VII, VIII, and X and collagens II and IX has 
been also confirmed in human adipose tissue in addition to adipocytes in culture [60].
2.3  Pathophysiology of adipose tissue
Adipose tissue malfunctioning has been associated to obesity, type 2 diabetes, and 
atherosclerosis. In obesity cases, an unbalanced diet and lifestyle leads to an increased 
size of adipose tissue depots, either by hypertrophy or hyperplasia of adipocytes, and 
fat deposition in other vital organs [16,25,33]. This in turn results in unbalanced ad-
ipokine secretome and to increased secretion of inflammatory cytokines [16,25,33]. 
According to several studies, abnormal levels of adipokines such as adiponectin [61], 
nesfatin [62,63], omentin [64], and resistin [65] result in disturbances in glucose 
tolerance and insulin action. Similar effects on insulin action have been noticed in 
lipidic metabolites or lipokines [66,67]. Concomitantly, hypertrophic adipocytes can 
present necrotic-like abnormalities and are responsible for a decrease in adipose tis-
sue function [11,68]. This functional atrophy is accompanied by an enhanced re-
leased of pro-inflammatory factors, such as TNF, interleukin-1β (IL-1β), IL-6, IL-8, 
leptin, resistin, and monocyte chemoattractant protein-1 (MCP1), and a reduction 
in anti-inflammatory factors, such as IL-10 and adiponectin [11,16,33,69]. All of 
this has detrimental effects on insulin-related mechanisms and on glucose output, 
which ultimately may lead to type 2 diabetes. Furthermore, the increased release of 
pro-inflammatory adipokines promotes the recruitment of macrophages and T cells, 
while local hypoxia, due to a reduction of vasculature, activates hypoxia-inducible 
factor (HIF) 1α inducing adipose tissue fibrosis [11,19]. The ensuing lipolysis results 
in the release of FFAs that are taken by other organs, resulting in its accumulation 
and lipotoxicity [11,16,70], which in turn is bound to disturbed insulin action and 
glucose metabolism. Interestingly, contrary to hypertrophy, adipocyte hyperplasia 
may counterbalance the deleterious effects of hypertrophy since it results in meta-
bolic correct adipose tissue with normal insulin-related parameters [11]. However, 
the mechanisms by which hyperplasic events may have beneficial effects over hyper-
trophic ones are not completely elucidated.
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Therefore, a combination of factors triggered by obesity, namely, inflammation, is 
probably what leads to diabetes and atherosclerosis. Moreover, while the exact mech-
anisms leading to atherosclerosis in obese patients are elusive, its pronounced associ-
ation with type 2 diabetes suggests that the underlying causes might be common [71].
3.  Dermal white adipose tissue
Traditionally, abdominal subcutaneous white adipose tissue was considered for 
many years as a unique and the largest depot of skin-associated white adipose tis-
sue. However, latest studies in mice revealed that, during development, a common 
 precursor in dermal mesenchyme gives rise to both dermal fibroblasts anddermal 
white adipocytes [72]. Moreover, it was also demonstrated that the development of 
adipocytes in the skin is independent from subcutaneous white adipose tissue devel-
opment [73]. Dermal white adipocyte precursors were also shown to be capable of re-
generating skin adipocytes during hair cycle and after wounding [74,75], as discussed 
in the next sections. Based on this, a new nomenclature to refer to the skin-associated 
adipose tissue as dermal white adipose tissue was defined, which is expected to retro-
spectively change the view on many previous studies [76]. This new depot refers to the 
thick layer of dermal white adipocytes that encloses mature hair follicles.
3.1  Role in skin function
In humans, unlike mice, the absence of a continuous muscle layer separating der-
mal from subcutaneous adipose tissue impedes a clear anatomical distinction between 
them. However, several studies in mice have highlighted that these differences go 
beyond the depot location and that dermal white adipose tissue responds to several 
independent cues [73,74,77,78]. Among them, the dermal white adipose tissue depot 
appears to react to temperature [77] by increasing its thickness in cold or thinning out 
when in warm environments. Moreover, the increase in dermal white adipose tissue 
size has been also connected to defensive responses due to an abundant production of 
antimicrobial peptides by differentiating preadipocytes after bacteria exposure [78]. In 
accordance to that, the hypertrophy of dermal white adipose tissue was associated to 
increased susceptibility to and severity of skin infection [78].
3.2  Role in hair follicle cycle
In addition to a role in the overall skin function, dermal white adipose tissue depots 
display a high kinetic activity surrounding the hair follicles, varying with the hair 
cycle and then impacting their function and metabolism [74,79]. Hair formation relies 
on cyclic events that are organized in an anagen phase, where proliferative epithelial 
stem cells closely communicate with dermal papillae cells and hair shaft is produced, a 
catagen phase that comprises the regression of the hair follicle, and by a telogen phase, 
where cells are relatively quiescent [80,81]. During this last phase, signaling from adi-
pocyte precursor cells activates hair follicle growth. This has been particularly evident 
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in a bidirectional regulation through BMP [74] and WnT/β-catenin [79] signaling. In 
the anagen phase, keratinocytes produce proadipogenic factors downstream of Wnt/β-
catenin signaling cascade, directly stimulating the expansion of dermal white adipose 
tissue depot size [79]. Dermal white adipose tissue adipocytes have shown to produce 
BMP2 during catagen/early telogen phase, causing follicles to be noncompliant to 
activation cues [82]. As this BMP signaling blocks anagen induction [83], it has been 
suggested that it is required for hair follicle stem cells quiescence [83]. The hair fol-
licles are activated again, entering in anagen phase only when that signaling is finally 
reduced. While the involvement of BMP signaling in hair follicle cycling seems to be 
consensual, how it occurs still needs to be further investigated, as it appears that both 
hair follicle epithelial and dermal papillae cells are BMP-producing cells [84,85].
4.  Dermal white adipose tissue action during wound 
healing
Another set of highly dynamic events where dermal white adipose tissue role has been 
more and more recognized is cutaneous wound healing (Fig. 2) [75]. This process is quite 
complex as it involves a coordinated action of multiple cell types and factors toward skin 
repair, as extensively reviewed elsewhere [86]. The main phases of skin wound healing 
include three different stages after injury: inflammation, proliferation, and remodeling 
[87]. In a very simplistic way, after the formation of a clot by platelet cells, periph-
eral blood mononuclear cells infiltrate the wounded area to clear debris. Subsequently, 
 proliferation phase is characterized by keratinocyte migration from wound edges and 
by the migration of fibroblasts that generate a transitory ECM, which is then remodeled 
in the final stage of wound healing lasting several weeks [87]. Upon disruption of skin 
homeostasis by an insult/injury, the first alterations detected in the dermal white adipose 
tissue depot are a change in size, as a consequence of preadipocyte proliferation and re-
population by mature adipocytes [75], and in the secretome [75]. Consequently, dermal 
white adipose tissue affects the cutaneous healing cascade. A more evident effect over 
the proliferation phase of healing, particularly in keratinocyte and fibroblast migration, 
has been associated to a potential role of dermal white adipose tissue, respectively, in 
wound reepithelialization [88–93] and cutaneous fibrosis [94,95].
4.1  Action in reepithelialization
Factors such as leptin, adiponectin, and possibly TNFα play a pivotal role in kerati-
nocyte proliferation/migration [88–90] during skin wound healing. It is known that 
leptin, predominantly produced and released by adipose tissue [96], is also actively 
produced by skin resident cells. Its secretion is triggered shortly after injury and pro-
longed throughout the various healing stages at the wound site [97]. Nonetheless, its 
specific role and its origin have just started to be unveiled. So far, studies on leptin- 
deficient obese mice (ob/ob) characterized by a severely delayed wound healing that is 
related with their mild diabetic phenotype revealed that systemic or topical application 
of leptin stimulates keratinocyte proliferation at the wound edges and consequently 
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reepithelialization of skin wounds [88]. Moreover, leptin topically administered to 
wild-type mice led to accelerated healing. The effect of dermal white adipose tis-
sue on reepithelialization seems to be corroborated by studies focused on the role 
of adiponectin, exclusively secreted from adipose tissue. Low levels of this adipo-
kine, either in adiponectin-deficient mice [89] or in diabetic ulcers [91], lead to a se-
verely delayed reepithelialization and peripheral hyperkeratinosis in diabetic wounds. 
Accordingly, after administration of adiponectin, both systemically and topically, im-
paired healing was partially reversed and linked to an activation of ERK signaling in 
keratinocytes [89]. Considering that ERK pathways are required for keratinocyte pro-
liferation and migration, these findings suggest that adiponectin positively regulates 
Dermal white adipose tissue role
Re-epithelializationHair-follicle cycling
Fibroblasts migration
Wound healingHomeostasis
WnT/β-catenin/
BMP signaling
BMP2
Epidermis
Papillary dermis
Reticular dermis
Dermal WAT
Subcutaneous AT/
hypodermis
Fig. 2 Overview of the dermal white adipose tissue role in different skin-related events. It 
is known that dermal white adipose tissue is involved in the regulation of hair cycle function 
and metabolism contributing to skin homeostasis and in the reepithelialization and cutaneous 
fibrosis during wound healing.
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the  reepithelialization process during cutaneous wound healing [89]. Adiponectin was 
also shown to promote upregulation of keratin gene transcripts within hours after in-
jection in mice ear and dorsal excisional wounds [92]. In this study, the faster reep-
ithelialization and the generally improved wound healing appeared to result from a 
downstream effect of adiponectin promoting cellular proliferation at the basal epithe-
lial cell layer and pilosebaceous units.
Although there are no particular works demonstrating the involvement of dermal 
white adipose tissue, other factors besides the referred adipokines produced by white 
adipose tissue in general might also play a role in reepithelialization. This is the case 
of TNFα that was reported as a factor actively secreted by the subcutaneous depot of 
white adipose tissue [98]. This cytokine has been pointed out to be a common initi-
ator of keratinocyte activation with downstream paracrine effects [99]. It is known 
that TNFα acts in an autocrine way directly in keratinocyte migration, with further 
paracrine effects on fibroblasts to produce FGF7 (KGF) [93]. This action in particular 
is related with fibroblasts migration and deposition of ECM, thus indirectly affecting 
keratinocyte motility and consequently reepithelialization. However, little is known 
about the expression/secretion of this molecule by dermal white adipocytes and its 
direct involvement in skin wound-healing mechanisms.
4.2  Dermal fibroblasts recruitment and wound matrix 
production
As mentioned above, dermal white adipose tissue appears to have also an active role 
in fibroblasts recruitment and proliferation, leading to a subsequent downstream ef-
fect on ECM production at the later remodeling phase. In fact, as soon as 5 days after 
wounding, resident adipocyte precursors were found to rapidly proliferate and dif-
ferentiate, recruiting fibroblasts which then repopulate the wound bed along with the 
mature adipocytes [75]. Moreover, the importance of a mature adipogenic phenotype 
for an efficient cross talk with fibroblasts that promote migration is demonstrated. 
In lipoatrophic mice, when mature adipocytes are absent, an aberrant recruitment of 
fibroblasts to the wound site occurs. Activated fibroblasts with ER-TR7+ phenotype 
were detected in wound borders but not in wound bed, suggesting that they are just re-
cruited there in the presence of mature adipocytes [75]. These observations are also re-
lated with another work that blocked adipogenesis using pharmacological antagonists 
of the master adipogenic factor PPARγ [75]. In vitro fibroblasts treated with increased 
concentrations of the antagonist remained unaltered. After injection of this antagonist 
in mice, a striking reduction of mature adipocytes was observed, but not of adipocyte 
precursors. Following that, despite normal reepithelialization, revascularization, and 
recruitment of macrophages and neutrophils during the wound healing, low migra-
tion of fibroblasts to wound site led to diminished ECM deposition and consequent 
reduced dermal reconstruction [75]. This showed that the effect in this migration is 
not due to the antagonist administration itself, but due to the absence of mature adipo-
cytes. Despite this knowledge, the exact particularities of the communication between 
fibroblasts and dermal white adipocytes and their mechanistic action are still elusive. 
Additionally, the fact that the adipocytes maturation degree strongly influences the 
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wound healing cascade might be related with the cytokine profile produced differently 
by these cell types in distinct differentiation degrees. This suggests a possible para-
crine effect of mature components of dermal white adipose tissue over other skin cells.
Furthermore, it has been more and more recognized the involvement of adipocytes 
and their precursors in skin fibrosis. This appears as a consequence of fibrotic dermis 
deposition during wound healing by the activated myofibroblasts, which is normally 
associated with an atrophy of subcutaneous adipose tissue [94]. The origin of these my-
ofibroblasts has been highly debatable due to the variety of models of fibrosis that have 
been used. However, recent findings using a lineage-tracing strategy to label mature 
adipocytes in a bleomycin-induced fibrosis model revealed that, in the dermal white 
adipose tissue, the adipocyte lipid vesicle marker perilipin colocalized with αSMA 
myofibroblast marker [94]. This was also accompanied by a morphological change 
from a round shape characteristic of adipocytic cells to a spindle-like shape. This data 
revealed that in dermal fibrosis some of the myofibroblasts in dermal fibrosis derive 
in fact from adipocytes. Additional studies also validated these observations, showing 
that the  fibrosis-associated protein FIZZ1 was capable of inducing the transformation 
of cultured adipocytes into myofibroblasts expressing αSMA [95]. Moreover, the dele-
tion of this profibrotic protein in transgenic mice significantly reduced the severity of 
skin fibrosis, highlighting the contribution of adipocyte-origin myofibroblasts in this 
phenomenon. Nonetheless, the origin of these myofibroblasts is not only restricted to 
mature adipocytes but also linked to adipocyte precursor cells. When stimulated  in vitro 
by TGF-beta 1 and bleomycin, these cells are able to acquire a myofibroblast pheno-
type. Also, the induction or the inhibition of adipogenesis in mice had reversing effects 
in skin fibrosis, underlining the close correlation between adipogenesis and fibrosis. 
Taken together, these findings demonstrate that these adipocytic cells play a key role in 
fibrosis. However, further insights on the interactions of these cells as part of the dermal 
white adipose tissue depot with surrounding skin cells during fibrosis are still needed.
5.  Models to study the role of dermal white adipose 
tissue
5.1  Animal models
Several animal models have been used to study particular functional and mechanistic 
traits of skin homeostasis and healing. Rats, mice, and pigs have been traditionally 
the most used animals in such experimentations. In the case of the small rodents, 
their skin presents several important differences in comparison with the human skin. 
The rat and mice skin is loosely attached to the subcutis [100], and healing happens 
mainly through contraction [100]. In opposition, the skin of pig is the one that presents 
more similarities with the human skin in terms of structure and because it is firmly at-
tached to the subcutis [100,101]. Critically, porcine skin wound healing is achieved by 
reepithelialization, such as in the human skin [101]. Notwithstanding the differences 
between these animal models, there are many more studies in rodents, and only some 
of these focuses on dermal white adipose tissue.
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A-ZIP mice that completely lack white adipose tissue and early B-cell factor-null 
(EBF−/−, a protein present in dermal white adipocytes) mice were compared to assess 
the role of adipocyte progenitors in skin homeostasis [74]. While A-ZIP mice did not 
show any skin changes, in EBF-null mice, hair follicle cycle was disrupted, and hair 
follicles remained in late catagen or telogen phases. These effects were correlated with 
the absence of adipogenic lineage cells, establishing a regulatory role of these cells, 
and consequently of dermal white adipose tissue, in epidermal stem cell activity and 
hair follicle cycling. Knockout mice for Mpzl3, a protein related with the rough coat 
phenotype, were used to determine the role of that protein in the skin. These mice 
presented a significant reduction of overall adipose tissue, but in particular dermal 
white adipose tissue [102]. These changes were accompanied by increased dermal 
thickness, sebaceous gland hypertrophy, and a tendency to develop inflammatory skin 
diseases, which reinforces the regulatory role of dermal white adipose tissue both at 
the physiological and pathological levels. This is also confirmed with other transgenic 
models that present defects in dermal white adipose tissue, Fatp4-null mice [103] and 
Dgat2-null mice [104] showed disturbances in adipose tissue content that were ac-
companied by abnormalities in dermal and/or epidermal function. In the first case, dis-
ruption of Fatp4 gene, involved in fatty acid transport, generated an altered fatty acid 
composition of epidermal ceramides that originated hyperproliferative hyperkeratosis 
with decreased epidermal barrier function. Defects in epidermal barrier function were 
also found in Dgat2-null mice that lack DGAT2 enzyme. This enzyme is involved 
in triglyceride synthesis, and mouse lacking the enzyme was found to be lipopenic, 
which had a clear effect on skin barrier function due to thinner epidermis, orthohyper-
keratosis of the stratum corneum, and flattened dermal-epidermal junction. Similarly, 
APOC1 mice produced to study the role of APOC1 protein in lipoprotein metabolism 
and the lack of dermal white fat presented a set of cutaneous abnormalities, such as 
epidermal hyperplasia and hyperkeratosis and sebaceous gland atrophy [105]. Mouse 
models where cutaneous fibrosis was induced show consistent atrophy of the adipose 
component of the skin [94,106–109], which is in line to what is reported in human 
subjects with the same disease. A study using bleomycin-challenged mice to induce 
skin fibrosis demonstrated that the loss of dermal white adipose tissue precedes skin 
fibrotic lesions [94]. Critically, the authors showed that adiponectin-positive dermal 
white progenitors or adipogenic cells gave rise to dermal myofibroblasts, clearly sug-
gesting a huge role of dermal white adipose tissue in the disease.
While transgenic mouse models are versatile and very useful to uncover particu-
lar molecular pathways, their contribution to reveal the role of dermal white adipose 
tissue in humans is somewhat limited by the significant morphological differences 
between human and rat/mouse skin and by the differing skin wound-healing mech-
anisms. On the other hand, although having the greatest similarities to humans, in-
cluding the hypodermis adipose chambers and its lipid content [110], pig models are 
expensive to maintain and require specialized facilities that are not accessible for most 
groups. Furthermore, there are variations in the biological response of skin tissue ac-
cording to the breed of pigs [111]. In alternative, humanized rodent models have long 
been proposed to overcome the functional differences between small rodent skin and 
human skin [112,113]. Nonetheless, although the human xenografts maintain some 
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functionality, the wound-healing process is obviously severely affected by the fact 
that the recipient animals must be immunocompromised [114]. All these facts only 
illustrate the need to develop adequate in vitro models to study dermal white adipose 
tissue function that are cheap and easy to set up in any lab with cell culture capabilities 
and that can effectively bridge fundamental research with clinical research.
5.2  In vitro models: A tissue engineering perspective
Tissue engineering is a relatively new field that appeared in the context of severe short-
age of donor material to replace injured tissues and organs. It is based on a multidis-
ciplinary approach involving engineering, biology, and medical sciences to create or 
engineer tissue analogues [115]. Classically, Tissue Engineering involves the use of 
cells, an ECM surrogate, or scaffold, and growth factors that under the right conditions 
form tissue or organ analogues. Additionally, given the potential of tissue-engineered 
constructs to mimic native tissues, they have also been used as 3-D in vitro models with 
superior reliability and reproducibility as compared with typical 2-D cultures [116].
Based on the concept of tissue engineering, the pursuit for reliable 3-D adipose 
tissue models has been following different routes. Regarding the type of cells used, 
3T3-L1, a murine preadipocyte cell line, is one of the most common cell source used 
to study various aspects of adipocyte biology including adipogenesis. In fact, a third of 
works in the last 5 years reporting its use are related to adipogenesis and obesity- related 
characteristics [117]. The main advantages of cell lines are that they are easier to cul-
ture, have fewer associated costs, and deliver homogenous response to experimental 
conditions. However, they are a not good option to extrapolate the in vitro results to 
in vivo conditions [117] and therefore depending on the questions to be answered might 
not be the best ones to generate in vitro models. Others such as primary cells (ma-
ture adipocytes) and adult stem cells have been explored as well. Primary adipocytes 
have the advantage of being obtained from multiple sources thus allowing the study of 
age- and gender-dependent adipogenic. However, limited proliferation is a significant 
hindrance in the use of primary adipocytes for the generation of reproducible models. 
The higher proliferation capacity of adult stem cells and the potential to differentiate 
into the adipogenic lineage have been the basis for the greater number of approaches 
that have been exploring these cells to obtain 3-D in vitro adipose tissue models [117].
In what concerns the 3-D structure in which cells are organized in the mimicking 
of the native tissue, scaffold-free approaches [118] have been recently introduced in 
the field taking advantage of the high degree of similarity between cell-produced ECM 
and tissues' native ECM. Nonetheless, the classical perspective of growing/differen-
tiating cells within synthetic- or natural-origin scaffolds has been highly explored to 
recreate some features of the native adipose tissue (Fig. 3). Independently of the type 
of cells used, an overview of in vitro strategies to obtain 3-D models of adipose tissue 
and the main outcomes achieved so far is provided next.
5.2.1  Cell-sheet based models
Scaffold-free 3-D models, such as spheroids, have been proposed as 3-D tissue mod-
els with enhanced value to address and study cellular mechanisms in vitro [119,120]. 
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Despite this, one of the disadvantages of these models is the residual or absent ECM 
that is known to play a key role in tissue physiology and pathophysiology. Cell sheet 
engineering, which relies on the recovery of cells as sheets retaining cell-cell and 
cell-ECM junctions, has been posed as an impressive alternative to overcome that 
issue [118]. In fact, by stacking different cell sheets, it is possible to create 3-D 
constructs composed of cells and their self-produced ECM components that there-
fore mimic in a highly accurate manner native tissue microenvironment. Adipose tis-
sue microenvironments based on this technology were recreated by inducing human 
adipose- derived stem cells to produce ECM and then to differentiate toward the ad-
ipogenic lineage [121–124]. One of the works provided a deep understanding of the 
adipogenic  differentiation process by analyzing the effect of the culture conditions 
over the  differentiation of the generated cell sheets [124]. Cell sheets with different 
degrees of differentiation were obtained, and 3-D constructs with diverse secretomes 
were created by assembling the cell sheets in varied combinations. This strategy 
will be of benefit to mimic different adipose tissue microenvironments according to 
(patho)physiological features, thus allowing the study of mechanisms of interest in 
a more accurate mode. In other works, adipose cell sheets were stacked to engineer 
adipose substitutes that engage in adipokine secretion and lipolysis after β-adrenergic 
receptor stimulation, two major native adipose tissue functions [122]. The same 
strategy was used to produce adipose tissue substitutes with a surface area superior 
to 33 cm2 where adipocytes were embedded in an ECM composed of fibronectin, 
collagens I and IV, as in native adipose tissue, and adipokine production was compa-
rable with native adipose tissue [123]. Importantly, similar constructs were combined 
Cell sheet-based
models
Biomaterial-based
models
Cells embedded in their own
ECM, demonstrating a high
degree of  similarity with
tissues native ECM
Growing/differentiating
cells within synthetic- or
natural-origin scaffolds
Toxicology screening/ drug development
Understanding of adipose tissue associated-
disease mechanisms
Generation of improved skin substitutes
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Fig. 3 In vitro models of adipose tissue. Both the classical tissue engineering approach of 
growing/differentiating cells within synthetic- or natural-origin scaffolds and the scaffold-free 
strategy have been explored to recreate some features of the native adipose tissue aiming to 
achieve in vitro 3-D models of adipose tissue useful not only for toxicology screening and 
drug development but also to better understand associated disease mechanisms and ultimately 
to lead the generation of improved skin substitutes.
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with  endothelial cells to create  prevascularized adipose tissue-like analogues [123]. 
These were stable for at least 11 weeks and were able to produce significant amounts 
of leptin, PAI-1, and  angiopoietin-1 proteins, which was reflected in a superior abil-
ity to support capillary-like structure formation. The strategy described in these last 
three works [122–124] aims at producing fully functional adipose tissue analogues 
for tissue replacement but which can be of great value for toxicology screening and 
drug development.
5.2.2  Biomaterial-based models
As mentioned before, the classical biomaterial-based tissue engineering concept has 
been explored beyond the tissue replacement and repair/regeneration context in the 
development of tissue models. So far, few in vitro works were able to develop reli-
able models that allow distinguishing or representing features of the adipose tissue. 
Additionally, these are mainly focusing on white adipose tissue potentially because 
there are still many uncertainties about what distinguishes the different adipose tissue 
depots.
A wide range of materials (both synthetic and of natural origin including decellu-
larized matrices) and culture conditions (differentiation or differentiation plus main-
tenance culture media, number of cells, and dynamic environment) have been tested 
to recreate in vitro adipose tissue. The achieved degree of similarity with the native 
adipose tissue has been mainly focusing on the level of adipogenic differentiation 
achieved within the different 3-D structures, the stability of the obtained construct, and 
on their vascularization (Table 1).
Like for many other tissue engineering strategies, the use of ECM-derived proteins/
peptides or decellularized tissue has been a highly explored approach in the construc-
tion of adipose tissue-like analogues. While this rationale has demonstrated successful 
achievements in different areas [125,126], it is somehow questionable concerning ad-
ipose tissue engineering since, as mentioned above, adipose tissue ECM composition 
greatly reflects a balance between collagens I and IV, depending on its maturation/
differentiation stage. Nonetheless, collagen I [127] and collagen I-hyaluronic acid 
[128] sponges, collagen and alginate microspheres [129], and gelatin-hyaluronic acid 
gels [130,131] are among the different materials used as platforms to differentiate 
 adipose-derived stem cells into the adipogenic lineage. Although cells were able to 
differentiate, in a direct comparison with human platelet-poor plasma (PPP), alginate 
and fibrin gel, a collagen sponge did not perform and the PPP and alginate systems 
[127]. Interestingly, other works have also shown enhanced differentiation of 3T3-
L1 preadipocytes in alginate modified with either early embryonic laminin and hyal-
uronic acid [132] or laminin [133]. Peptides present in ECM proteins and known to 
directly interact with integrins such as αVβ5 and α1β1 have been also incorporated 
in poly(ethylene glycol) (PEG) hydrogels [134] and poly(amidoamine) foams [135] 
to promote adipogenic differentiation. However, either the condition with RGDs was 
not compared with the nonfunctionalized one, or the lack of striking differences pre-
vents concluding about the relevance of this approach in the generation of adipose 
tissue-like environments. Alternatively, the decellularization of human adipose tissue 
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Similarity with 
the native adipose 
tissue Biomaterial Cell types and number Main achievements References
ECM-derived 
proteins
Platelet-poor plasma (PPP), 
alginate, fibrin gel, and 
collagen I sponge
Human adipose-derived 
stem cells
(5 × 106 cells/mL of polymer 
solution)
Differentiation was lower in collagen 
sponges than in PPP and alginate 
systems
[127]
Gelatin-hyaluronic acid Porcine adipose-derived 
stem cells
(5 × 104 cells/scaffold)
Cryogels with higher percentage of 
gelatin were further considered for 
adipogenic differentiation due to higher 
similarities with the matrix
[131]
Alginate, laminin, and 
hyaluronic acid (HA-l-Alg)
Murine preadipocyte cell 
line 3T3-L1
(~3 × 105 cells)
Enhanced adipogenic differentiation 
when alginate is modified with either 
early embryonic laminin and hyaluronic 
acid or laminin
[132,133]
Laminin-alginate Murine preadipocyte cell 
line 3T3-L1
(5 × 104 cells/mL of beads)
Functionalization 
with peptides 
derived from ECM 
proteins
Poly(ethylene glycol) 
functionalized with RGD
Human adipose-derived 
stem cells
(2 × 106−2 × 107 cells/mL of 
hydrogel)
The degree of differentiation varied 
with the peptide conformation and 
consequently associated to initial cell 
adhesion number
[134]
Poly(amidoamine) oligomer 
microporous foam (OPAAF) 
functionalized with RGD
Murine preadipocyte cell 
line 3T3-L1
(2 × 106 cells/scaffold)
OPAAF scaffolds support adipogenic 
differentiation, but comparison with 
RGD-free structures is not performed
[135]
Table 1 Overview of the strategies followed to attain biomaterial-based adipose tissue-like 
microenvironments
Continued
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Decellularized 
adipose tissue
Polyacrylamide 
functionalized with 
decellularized human 
lipoaspirate
Human adipose-derived 
stem cells
(0.5 × 104 cells/cm2)
The presence of the biochemical cues 
from the native adipose tissue favors 
adipogenic differentiation
[136,137,139]
Methacrylated chondroitin 
sulfate in combination 
with milled decellularized 
adipose tissue
Human adipose-derived 
stem cells
(2.5 × 105 and 5.0 × 105 cells/
scaffold)
Decellularized tissue Human adipose-derived 
stem cells
(1 × 106 cells/scaffold)
Mechanical 
properties
Collagen and hyaluronic 
acid
Murine preadipocyte cell 
line 3T3-L1
(1 × 106 cell/mL)
Scaffolds with increasing percentages 
of hyaluronic acid reaching a Young's 
modulus of approximately 6.7 kPa 
showed higher expression of the 
adipogenic differentiation marker adipsin
[128]
Hyaluronic acid and gelatin Human adipose-derived 
stem cells
(2.5 × 104 cells/cm2 of 
hydrogel)
Hydrogels with a Young's modulus close 
to the one of native tissue (3.5 kPa) 
supported adipogenic differentiation on 
their surface
[130]
Human decellularized 
adipose tissue
Human adipose-derived 
stem cells
(1 × 106 cells/scaffold)
Higher adipogenic differentiation was 
attained in the scaffolds with a Young's 
modulus of 3.67 kPa, which seemed 
to add to the biochemical cues of the 
decellularized adipose tissue forming the 
3-D structures
[138]
Table 1 Continued
Similarity with 
the native adipose 
tissue Biomaterial Cell types and number Main achievements References
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Stability and 
vascularization
Laminin-coated silk 
scaffolds
Endothelial cells 
(8 × 105 cells/scaffold) 
cocultured with human 
adipose-derived stem cells 
(4 × 105 cells/scaffold) 
triggered into the adipogenic 
differentiation
At late time points in a dynamic culture, 
endothelial cells were organized into 
continuous capillary-like structures 
within a stable adipogenic construct
[143]
Silk scaffolds Liquefied adipose tissue 
containing unilocular 
adipocytes and endothelial 
cells
Under dynamic conditions of a 
dynamic culture, a vascularized tissue-
like microenvironment containing 
physiologically relevant mature 
unilocular adipocytes responsive to 
an acute inflammatory stimulus was 
attained
[144]
Dermal white 
adipose tissue 
mimicking 
 
 
Collagen type I 
 
 
 
 
Human mature adipocytes 
(~1.07 × 105 cells per 
hydrogel) 
 
 
Full-skin equivalent containing the 
underlying subcutaneous adipose tissue 
able to release adipocyte-specific factors 
such as adipsin, visfatin, leptin, and 
PAI-1 in levels comparable with those of 
control cultures of mature adipocytes
[145] 
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has been explored as a way to preserve in a higher degree the composition and the 
structure of the native ECM. In fact, the biochemical cues of the decellularized ECM 
have been shown to contribute to an inductive microenvironment for the adipogenic 
differentiation not only if used to functionalize the surface of polyacrylamide gels 
[136] and within photo-cross-linkable methacrylated chondroitin sulfate as a bioactive 
matrix [137] but also as a part of the whole decellularized 3-D structure [136,138,139].
Despite being known that the biomechanics of the 3-D support structure adds into 
the role of the biochemical factors in stimulating the adipogenic differentiation, it is 
not clear if the decellularized adipose tissue actually preserves this function. In fact, 
decellularized adipose tissue ECM was solubilized and used to prepare microporous 
and bead foams under conditions that, together with the concentration of soluble 
ECM, affected the mechanical properties of the generated 3-D structure. Moreover, 
higher adipogenic differentiation was observed in the microporous foam with a 
Young's  modulus of 3.67 ± 0.38 kPa [138], which is the 3–4 kPa range measured for 
human adipose tissue [140,141]. Similar Young's modulus (3.5 kPa) was achieved 
for glutaraldehyde cross-linked hyaluronic acid/gelatin and human platelet-poor 
plasma gels, but adipogenic differentiation was not carried out in the materials but 
on their surface [130]. Interestingly, higher expression of adipogenic differentiation 
markers was observed with scaffolds composed of collagen and with increasing 
percentages of hyaluronic acid that reached the Young's modulus of approximately 
6.7 kPa [128].
To be reliable and functional, in vitro adipose model tissue-like structures have to 
possess appropriate stability. From the works that have addressed the stability of adi-
pose tissue-like constructs generated in vitro up to 12 weeks after implantation in dif-
ferent animal models [129,131,138,142], some suggested that this stability is in great 
part provided by their vascularization. This has been also demonstrated in vitro in two 
works that aimed developing physiologically relevant and long-term models of human 
adipose tissue. Human adipose-derived stem cells cultured in adipogenic differentia-
tion medium for 7 days were seeded onto a 3-D silk porous scaffold precultured with 
microvascular endothelial cells, and the cocultured structure was further kept in static 
conditions and then transferred into spinner flasks for up to 6 months [143]. The dy-
namic culture allowed not only achieving the required stability but also the organiza-
tion of the endothelial cells into continuous capillary-like structures. In a subsequent 
work [144], liquefied adipose tissue was used to repopulate the silk scaffolds in order 
to better represent the complexity of native adipose tissue and in particular the physi-
ologically relevant mature unilocular adipocytes. The adipocyte functionality in vitro 
and the applicability of the generated model to respond to an acute inflammatory stim-
ulus (TNFα) was demonstrated.
Despite this exciting work that provides the most advanced proof of concept of 
a biomaterial-based white adipose tissue model to study associated disease mecha-
nisms and drug responses, the specificities of the dermal white adipose tissue are not 
addressed. Recently, a full-skin equivalent containing the underlying subcutaneous 
adipose tissue was reported [145]. The culture conditions were optimized to allow 
a release of adipocyte-specific factors such as adipsin, visfatin, leptin, and PAI-1 in 
levels comparable with those of control cultures of mature adipocytes.
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6.  Future trends
Adipose tissue moved from being understood as a simple storage of lipids and energy 
to being a complex endocrine organ that regulates many different processes dependent 
on their depot location. In particular, dermal white adipose tissue complexity is finally 
being unveiled, and its role has been described to be of major importance in both skin 
homeostasis, namely, in hair follicle cycle signaling, and in skin wound healing. So 
far, taken together the data herein described, one can extrapolate which adipokines, 
generally detected in white adipose tissue, have shown promising skin wound- healing 
effects, but its secretion by dermal white adipose tissue is yet to be  investigated. 
Developmental cues that are currently under investigation will have a striking effect 
on the design of new approaches to act as models to explore the therapeutic role of 
this depot under the wound-healing context. Moreover, these findings will also impact 
wound management and treatment strategies by supporting the development of im-
proved skin substitutes aimed to regenerate and restore full tissue functionality.
The majority of adipose tissue models described up to date take advantage of tis-
sue engineering approaches; nonetheless, they are still in their infancy regarding the 
complexity of the niche. In this sense, there is the need for generating models with 
higher complexity taking advantage of cutting-edge tools including advanced material 
processing, incorporation of factors, and different cell players with unprecedented pre-
cision. Moreover, in order to understand its action, there is the urgent requirement of 
addressing specific questions regarding how this depot is regulated. It is critical to un-
derstand that the ECM of this depot, in addition to unveiled factors and cellular roles, 
also reflects its (patho)physiological state being therefore key in the construction of 
accurate and reliable models of great interest to understand adipose tissue-associated 
diseases and to study new therapeutics.
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1.  Introduction
The skin is the largest organ of the body and provides the main barrier between the 
internal and external environment. As well as providing protection to the body against 
chemical and physical insults and microbiological invasion, it also contributes to both 
temperature and water regulation by acting as a barrier [1]. The barrier function of 
the skin is critical and, if disrupted, results in nonspecific innate and specific adaptive 
immune responses as part of the body's defense mechanism. In addition to eliciting 
immune responses to external insults, the skin participates in local “sterile” immunity 
including allergic and autoimmune responses and tumor immunity [2].
The skin is a structurally complex organ that consists of three separate and anatom-
ically unique layers with each stratum having a distinct composition, characteristic, 
and function. The epidermis, which consists of the stratum corneum and viable epider-
mis, forms the outermost layer of innate skin. The stratum corneum, which presents 
the greatest barrier to permeation, is a 10–25 μm-thick layer that possesses a unique 
arrangement commonly referred to as a “brick and mortar” construct: the bricks being 
relatively nonpermeable protein-rich corneocytes and the mortar consisting of an or-
derly configured lipid-rich medium, that is, cholesterol, triglycerides, and ceramides 
[3,4]. Essentially, the function of this layer is to control the absorption of substances 
into the skin and also for maintenance of fluid homeostasis. The other layers of the 
epidermis include the stratum granulosum, stratum spinosum, and stratum basale 
within which a dynamic activity takes place whereby cells from the stratum basale un-
dergo differentiation and move upward to form the stratum corneum, a process known 
as cornification [5]. The viable epidermis is additionally populated with a number of 
immune cells and melanocytes. Located beneath the epidermis is the dermis layer 
that is a 3–5 mm-thick stratum composed of collagen, reticulin, and elastin woven 
within mucopolysaccharide network [3]. The dermis layer also houses a variety of 
skin appendages that include apocrine glands, blood vessels, hair follicles, and aspects 
of the lymphatic system. The innermost and often the thickest layer of the skin struc-
ture is known as the hypodermis. This layer is essentially populated with adipocytes 
that specialize in accumulating fats and hence provide thermoregulation. The authors 
recommend the comprehensive and detailed review of the skin and its structure by 
Monteiro-Riviere [6].
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2.  Immunological overview of the skin
The immunologic response of the skin can be attributed to a variety of distinct aspects 
within its gross structure and often described in context of a conceptual framework 
known as skin-associated lymphoid tissues (SALT), which mediates and coordinates 
the response between the different layers [7]. At a rudimentary level, the epidermis 
houses a number of immunocompetent cells and biological response modifiers in-
cluding keratinocytes, Langerhans cells (LCs), melanocytes, and epidermotrophic 
lymphocytes. In contrast, the dermis is mostly populated with fibroblasts and den-
dritic cells (DCs) but work together with the epidermal immunocompetent cells to 
bring about the appropriate immune response post stimuli [8,9]. Importantly, all 
pathological diseases and/or responses have, to some extent, an underlying immune 
component [10].
3.  Cells in epidermal immunity
The stratified, squamous epidermis is not only made up of more than 90% keratino-
cytes that provide the barrier integrity required for protection but also responsible 
for the production of cytokines that regulate the skin immune response cascade. One 
of the most important families of cytokines in the skin is the interleukin-1 (IL-1) 
family that is composed of a group of 11 cytokines that are synthesized not only by 
keratinocytes but also fibroblasts and macrophages. These work by modulating key 
responsive effects such as the activation of T and B lymphocytes, increase the ex-
pression of adhesion factors on endothelial cells (i.e., the intercellular adhesion mol-
ecule, ICAM-1), and affect the activity of the hypothalamus during an inflammatory 
insult [11,12]. Keratinocytes in the skin are able to produce a number of interleukins, 
 colony-stimulating factors, growth factors, chemotactic factors, and immunosuppres-
sive factors, which have a myriad of effects on keratinocytes and immunologic cells 
in the skin [13]. Keratinocyte production of IL-1 and TNF-α is well established and 
is known to activate immunologic cells in the skin including lymphocytes, macro-
phages, and DCs [14].
LCs are a specific subset of DCs that are associated with the epidermis. They are 
antigen-presenting cells that originate from the bone marrow and populate the epider-
mis—being most prominent in the stratum spinosum but absent in the stratum cor-
neum. Identified by their unique racket-shaped Birbeck granules and expression of 
CD1a and CD207 surface marker proteins, LCs are members of the major histocom-
patibility complex class II (MHC II) molecules and adopt a “sentinel” role by being 
directly responsible for the initiation of both innate and adaptive immune responses 
to skin-relevant antigens [15]. LCs are antigen-presenting cells with one of their main 
roles being to bind and process antigens and migrate to the lymph nodes to present the 
antigens to naive T cells.
Melanocytes are DCs located in the stratum basale layer of the epidermis and epi-
dermal appendages and have a close anatomical relationship with keratinocytes [16]. 
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Although intensively documented for their modulation of skin pigmentation, mela-
nocytes have also been suggested to contribute to immunologic responses within the 
skin via the secretion of cytokines including IL-3, IL-6, and TNFα complexes [17]. 
Melanocytes have also been shown to express MHC II molecules, which are import-
ant for initiating immune responses. However, recent studies have highlighted that 
the evidence is not, as yet, fully conclusive of the exact role melanocytes play in skin 
immunology [18–20].
4.  Cells in dermal immunity
Two distinct populations of DCs are located within the dermis, namely, dermal den-
dritic cells (DDCs) and plasmacytoid dendritic cells (pDCs). The populations are 
characterized by the production of different cytokines and may initiate different in-
flammatory pathways after activation although it is unlikely that these roles are exclu-
sive. The DCs in the dermal layer possess more motility than the LCs in the epidermis 
and are able to migrate within the collagen fibril structure of the dermis [2]. In contrast 
with LCs, the DDCs lack Birbeck granules and have higher expression of CD1a but 
show near absent expression of CD207 and CD36 [21].
Macrophages can be found localized within the dermis and have a high degree of 
motility and phagocytic capacity. While they are present in much fewer numbers in 
the dermis in comparison with DCs, they are capable of presenting antigens to T cells 
and activating immune responses through cell surface signaling and cytokine secretion 
[2]. Circulating monocytes are immature macrophages, which can be recruited to the 
skin in response to infection or injury. They are often regarded as guardians within 
the immunologic cascade and are attracted to a compromised wound site through the 
localization of growth factors/cytokines/chemokines that are released by platelets and 
other cells following a barrier insult [22]. These monocytes then differentiate accord-
ingly into macrophages that are thereafter focused on the phagocytosis of the foreign 
bodies and associated damaged tissues at the site of injury. Furthermore, it has been 
documented that LCs may also bring about an immune response by phagocytosis as a 
result of stimulation by immunoglobulins IgE and IgG and thereby contribute to the 
overall regulatory mechanism [23].
Other innate immune cells including neutrophils, eosinophils, basophils, and mast 
cells may also be recruited to the skin following activation. The first cells recruited 
by DC or macrophage activation are typically neutrophils that primarily phagocytose 
pathogens. Eosinophils, basophils, and mast cells are associated with allergic and anti-
parasitic responses in the skin [2]. Mast cells in the skin are located in close proximity 
to T lymphocytes (TCs) and are well-known for their participation in a number of 
immune and inflammatory processes [24,25].
The majority of adaptive immunologic responses in the skin are determined by 
TCs. There is almost double the number of TCs present in the skin (approximately 
20 million) in comparison with those found in the blood [26]. Within the skin, TCs 
are predominantly located in the blood vessels and the lymphatic system within the 
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dermis. A smaller number of TCs are located in the epidermis for T-cell immune 
surveillance and mainly express the α/β T antigen receptors: CD2+, CD3+, CD4+ 
inducer, and CD8+ suppressor lymphocytes. These specialist cells may migrate from 
the vessels into the dermis by adhering to the expressed ICAM-1 in response to the 
presence of antigens or a compromised skin barrier. Cytotoxic TCs express CD8+ 
and kill cells that express specific antigens presented on a cell by human leukocyte 
antigen I. Helper TCs produce cytokines and promaturation signals that enable ef-
fector cells to mediate an attack and steer the response. Regulatory TCs suppress 
autoimmune responses and help to resolve inflammation [2]. An overview of the 
immune functions present within the stratified layers of the native skin in response to 
inflammation can be seen in Fig. 1.
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Fig. 1 A schematic representation of the mechanisms of immune functions in response to 
inflammation from a stimulus.
Modified from Stamatas GN, Morello AP, Mays DA. Early inflammatory processes in the 
skin. Curr Mol Med 2013;13(8):1250–69.
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5.  Justification for skin models
With the ever-increasing exposure to a variety of new chemicals found in personal, 
health-care, and environmental products, there is a critical need for the detailed 
characterization of these compounds in line with current legislative regulations and 
protocols. Similar requirements for safety testing apply for novel excipients and per-
meation enhancers. Although toxicity is often considered as the primary objective of 
an assessment, the ability of the compound to elicit an adverse dermal allergenic or 
immunogenic response also needs to be considered due to the ease of exposure/route 
of entry [27]. In addition, as the immune system plays an important role in the de-
velopment and pathogenesis of most skin diseases, there is a requirement for more 
robust in vivo-like in vitro models when developing novel therapies [28]. Historically, 
test methods such as the guinea pig maximization test [29], the Buehler test [30], and 
the local lymph node assays [31,32] were exploited. However, the majority of these 
models suffer from questionable human biological relevance and severe ethical con-
straints. With an underlying abetment of the 3Rs for animal use in experiments (i.e., 
reduction, replacement, and refinement), the implementation of the seventh amend-
ment to the EU Cosmetics Directive, and the updated Helskinki ECHA/NI/17/01 leg-
islative guideline within the Registration, Evaluation, Authorization and Restriction 
of Chemicals (REACH) 1907/2006 regulation, more physiological accurate and bio-
logically responsive models of these tissues/organs are required [27]. Moreover, these 
pseudotissues and pseudoorgans can additionally or, alternatively, be used as models 
to elucidate disease pathways/mechanisms/progression to further medical applications 
and therapeutic understanding.
6.  In vitro cell culture modeling
Tissue or cell culture is a generalized term used to describe the process of removing 
cells, tissue, or organs from an animal (or plant) and subsequently grow them in a 
sustained artificial environment that mimics the native in vivo setting. In simplistic 
terminology, this environment consists of a suitable vessel containing a liquid feed—
termed culture medium—and being incubated at the appropriate temperature and at-
mosphere. Originally devised by Ross Harrison in 1907 as a technique to establish 
long-term nerve cell culture, the field has now rapidly progressed over the years with 
significant technological advancements and development of a number of high-impact 
commercialized products and protocols [33].
Cells directly dissociated from parental organ/tissue and cultured thereafter are of-
ten referred to as “primary cell cultures” and regarded as the “gold standard” as they 
essentially maintain the same characteristics as the native tissue. However, sourcing of 
these cells often possesses difficulties due to ethical constraints, and the cells, them-
selves, only offer a limited working life span due to their innate characteristic of senes-
cence, that is, biological aging and/or the Hayflick limit [34]. An alternative option is 
to use established or immortalized cell “lines” that are derived from a native cancerous 
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state or generated using viral vectors, hybridoma technology, or overexpression of 
regulatory proteins such as telomerase and the P450 family of enzymes. However, a 
key disadvantage of using cell lines is that they tend to deviate genetically and, more 
importantly, phenotypically compared with their tissue of origin [35]. In contrast, their 
availability, pseudocharacteristic likeness, and ease of use offer researchers a valuable 
complement to existing in vivo experiments by allowing for a more controlled manip-
ulation of cellular functions and processes.
Tissue engineering is a term coined to describe an interdisciplinary field that ap-
plies engineering and life science principles toward the development of biological 
substitutes that restore, maintain, or improve tissue function [36]. Ideologically, the 
field aimed to develop and create transplantable tissues/organs to replace those under-
going natural aging, having diseases, or subjected to traumatic injury [37]. However, 
current demand and advances in novel technologies have caused a bias during model 
development toward toxicity assessment and biomedical applications as these, in vi-
tro, cell culture models can ultimately provide a simple, fast, and cost-effective tool 
alternative and also help minimize the exploitation of animals during the drug devel-
opment pathway. Although a number of human skin model equivalents exist and have 
been exploited for skin irritation studies, they have not been able to accurately mimic 
the underlying immune component present in most disease states leading to failure of 
many investigational drugs at the preclinical phase or during clinical trials [28]. As 
such, only a handful of these can be considered to be truly “immunocompetent” and 
hence suitable for performing skin sensitization studies [38,39].
7.  Epidermal cell culture models: Keratinocyte 
monocultures
Single-cell keratinocyte cultures are the most simple in vitro cell culture models avail-
able that mimic the epidermal layer of the skin. These may be constructed from human 
cell lines or from human primary keratinocyte sources (Table 1). The immortalized 
human keratinocyte cell line, HaCaT, is one of the best characterized and widely used 
cell line models that maintains full epidermal differentiation and proliferation capacity 
up to 140 passages [46,47]. Additionally, there has been extensive research regarding 
the culture of human primary keratinocytes over the past 20 years, and there are now 
many standardized isolation and propagation protocols established for keratinocyte 
skin models and many which are available commercially [27,48,49]. Reconstituted 
human epidermal equivalent (RHE) models are designed to represent the epidermis 
and are constructed from primary normal human keratinocytes cultured on a collagen 
matrix at an air-liquid interface. The primary normal human epidermal keratinocyte 
(NHEK) source varies between models but typically originates from neonatal foreskin 
or adult mammary tissue samples. Cells are differentiated at an air-liquid interface 
producing 8–12 layers of human keratinocytes that mimic a pseudo stratum corneum 
and functional epidermal keratinocyte layers. While the viable keratinocyte functional 
layers are representative of human skin, the barrier properties of RHE models possess 
significantly enhanced permeability properties in comparison with the human skin 
Skin model Specifications Readout parameter Limitations References
EDI-Co Skin The epidermis only, primary 
keratinocytes
Histology, cytotoxicity assessment 
assay (MTT/MTS), IL-1α and IL-8 
release
Pseudo 2-D/3-D 
microenvironment, no 
immune cells
www.edigmbh.de
EpiDerm Reconstituted human epidermal 
equivalent (RHE) based 
on normal human-derived 
epidermal keratinocytes (NHEK) 
on collagen-coated TCP
Histology; cytotoxicity assessment 
assay (MTT/MTS); IL-1α, 
PGE2, and LDH release; sodium 
fluorescein permeability
Pseudo 2-D/3-D 
microenvironment, no 
immune cells
www.mattek.com
Epidermal Skin Test 
1000 (EST1000)
Reconstructed epidermal 
model from primary human 
keratinocytes
Histology, cytotoxicity assessment 
assay (MTT/MTS), expression 
markers: KI-67, CK 1/10/5/14, 
transglutaminase, collagen IV, 
involucrin, β1 integrin
Pseudo 2-D/3-D 
microenvironment, no 
immune cells
[40]
EpiSkin (L'Oreal: 
Invitroskin)
RHE based on adult human 
keratinocytes on a collagen 
substrate
Histology, cytotoxicity assessment 
assay (MTT/MTS), IL-1α release
No immune cells [41-43]
LabCyte EPI-MODEL Keratinocytes embedded within 
agarose gel
Cytotoxicity assessment assay 
(MTT/MTS)
No immune cells [44,45]
Prediskin (Transkin) Donor sample and/or RHE Histology, cytotoxicity assessment 
assay (MTT/MTS)
No immune cells www.biopredic.com
Reconstituted 
human epidermis 
(RHE-EPI/001)
Human primary keratinocytes 
seeded on a polycarbonate filter 
Histology, cytotoxicity assessment 
assay (MTT/MTS) 
No immune cells 
 
www.straticell.com 
 
Table 1 Keratinocyte-only skin-based models
Modified from Grindon C, Combes R, Cronin MT, Roberts DW, Garrod JF. Integrated decision-tree testing strategies for skin corrosion and irritation with respect to the requirements of the EU REACH 
legislation. Altern Lab Anim 2008;36(Suppl. 1):65–74.
360 Skin Tissue Models
in vivo [50]. Nevertheless, RHE models are widely used for research purposes includ-
ing assessment of skin irritation, corrosion, hydration, and toxicological screening 
(phototoxicity and genotoxicity) and the assessment of drug candidates. Typical read-
outs of these models include cell histology, cell viability (cell mitochondrial activity 
MTT assay and LDH release profile), barrier integrity (TEER/TEWL measurements 
and sodium fluorescein permeability), and cytokine release, for example, IL-1α, IL-6, 
IL-8, and TNF α.
8.  Epidermal and dermal cell culture models: 
Keratinocyte and fibroblast co-cultures
More recently, full-thickness in vitro human skin models or living skin equivalents 
(LSE) have been developed that are designed to mimic both the dermis and epider-
mis layers (Table 2). The lower dermal compartment is composed of a collagen ma-
trix containing primary normal human dermal fibroblasts (NHDF) that supports the 
growth of an upper epidermal compartment of layers of primary NHEK cells cultured 
at an air-liquid interface. These models benefit from a more in  vivo-like morphol-
ogy and growth characteristics including a pseudo basement membrane structure that 
demonstrates keratin production and appropriate cell junctions [51,52]. Importantly, 
the coculture setup also allows for interplay of cellular signals between the fibroblasts 
and keratinocytes in the model. These models are used for similar purposes as the ke-
ratinocyte and RHE models described above including skin responses, dermal toxicity, 
and drug screening with similar readouts based on observational histology, basic cell 
health assays, barrier integrity, and cytokine release [53,54].
9.  Epidermal and dermal cell culture models: Co-cultures 
systems incorporating melanocytes
Primary melanocytes have also been incorporated into coculture models alongside ke-
ratinocytes and/or fibroblasts (Table 3). These models are utilized particularly by the 
cosmetics industry to assess the impact of skin-lightening agents and formulations on 
skin pigmentation [56]. While melanocytes are DCs within the epidermis, these cells 
are not considered to be the key immunologic cells within the skin and have limited 
relevance outside of the cosmetics industry [57].
10.  Epidermal and dermal cell culture models: Diseased 
state models
Several in  vitro cell culture models of skin diseases including psoriasis, keloid 
scars, dystrophic epidermolysis, and squamous cell carcinoma have been developed 
(Table 4). However, the majority of these are based on primary keratinocytes sourced 
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Skin model Specifications Readout parameter Limitations References
EpiDermFT NKEK and NHF Histology; cytotoxicity assessment 
assay (MTT/MTS); IL-1α, PGE2, 
and LDH release; sodium fluorescein 
permeability
Pseudo 2-D/3-D 
microenvironment, 
no immune cells
www.mattek.com
EpiSkin RealSkin  Histology, cytotoxicity assessment 
assay (MTT/MTS), IL-1α release
No immune cells www.episkin.com
IGB human skin 
model (Fraunhofer EU 
00F36047)
Keratinocytes and 
fibroblasts in collagen 
matrix
Histology, cytotoxicity assessment 
assay (MTT/MTS), IL-1α release
No immune cells www.tissue-factory.com
Phenion FTSM Primary keratinocytes 
and fibroblasts seeded 
onto novel 3-D collagen 
scaffold
Histology, TUNEL cell viability, IL-6 
and IL-8 release
No immune cells [85]
StrataTesT human 3-D 
skin
Proprietary NIKS human 
keratinocytes. NIKS 
cells and normal human 
fibroblasts. Twenty-four 
well-plate format
Histology, cytotoxicity assessment 
assay (MTT/MTS), IL-1α release, 
membrane integrity based on changes 
in transepithelial electrical resistance 
(TEER) measurement
No immune cells www.stratatechcorp.com
Vitrolife-Skin RHE 
 
 
Keratinocytes and 
fibroblast coculture on 
collagen sponges. A-L 
interface
Histology, cytotoxicity assessment 
assay (MTT/MTS), LDH release, IL-2 
release 
No immune cells 
 
 
www.gunze.co.jp; [86] 
 
 
Table 2 Keratinocyte and fibroblast skin-based models
Modified from Grindon C, Combes R, Cronin MT, Roberts DW, Garrod JF. Integrated decision-tree testing strategies for skin corrosion and irritation with respect to the requirements of the 
EU REACH legislation. Altern Lab Anim 2008;36(Suppl. 1):65–74.
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Skin model Specifications Readout parameter Limitations References
iPSC-based models Induced pluripotent 
stem cells as fibroblasts, 
keratinocytes, 
melanocytes
Histology, cytotoxicity 
assessment assay (MTT/
MTS), cytokine release 
and biomarker profiling, 
melanin content
Pseudo 2-D/3-D microenvironment 
due to culture technique, early 
development, ethical constraints, 
limited immunologic aspects, 
limited barrier properties
[55]
MelanoDerm Primary normal human 
melanocytes (NHM) 
and NHEK cells seeded 
on a collagen matrix
Histology, melanin 
content assay
Pseudo 2-D/3-D microenvironment 
due to culture technique, ethical 
constraints, limited immunologic 
aspects
www.mattek.com
Reconstituted human 
pigmented epidermis 
(RHE-MEL/001)
Primary human 
melanocytes and 
keratinocytes seeded on 
a polycarbonate filter
Histology, cytotoxicity 
assessment assay (MTT/
MTS), cytokine release 
and biomarker profiling, 
melanin content
Pseudo 2-D/3-D microenvironment 
due to culture technique, limited 
immunologic aspects, limited 
barrier properties
www.straticell.com
SkinEthic RHPE 
 
 
 
Primary human 
melanocytes and 
keratinocytes seeded on 
a polycarbonate filter 
Histology, cytotoxicity 
assessment assay (MTT/
MTS), cytokine release 
and biomarker profiling, 
melanin content
Pseudo 2-D/3-D microenvironment 
due to culture technique, early 
development, ethical constraints, 
limited immunologic aspects, 
limited barrier properties
www.skinEthic.com 
 
 
 
Table 3 Keratinocyte and fibroblast skin-based models incorporating melanocytes
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Keloid epidermis 
(fibroblasts)
Indirect coculture of keloid 
epidermis with keloid 
fibroblasts
Histology, cytotoxicity assessment 
assay (MTT/MTS), cytokine release 
and biomarker profiling
Pseudo 2-D/3-D 
microenvironment, 
no immune cells
[58,59]
3-D hypertrophic 
scar SE
Reconstituted epidermis of 
keratinocytes on a matrix 
containing fibroblasts
Histology, cytotoxicity assessment 
assay (MTT/MTS), cytokine release 
and biomarker profiling
No immune cells [59,60]
Recessive 
dystrophic 
epidermolysis 
bullosa 3-D SE
Immortalized patient-derived 
keratinocytes and fibroblasts 
in deepidermalized porcine 
dermis
Histology, cytotoxicity assessment 
assay (MTT/MTS), cytokine release 
and biomarker profiling
No immune cells [61,62]
Melanoma Human malignant melanoma 
cells (A375), NHEK and 
NHDF cells
Histology, cytotoxicity assessment 
assay (MTT/MTS), cytokine release 
and biomarker profiling
No immune cells www.mattek.com/
products/melanoma/
3-D psoriasis SE Normal human primary 
epidermal keratinocytes and 
human primary psoriatic 
fibroblasts harvested from 
psoriatic lesions
Histology, cytotoxicity assessment 
assay (MTT/MTS), cytokine release 
and biomarker profiling, validated 
drug panel screening
No immune cells www.mattek.com; [63,64]
Squamous cell 
carcinoma SE 
 
 
 
Commercially available 
and/or patient-derived 
cell lines (A375, WM35, 
SK-mel-28, SSC-12B2), 
human keratinocytes and 
fibroblasts, dermal matrix
Histology, cytotoxicity assessment 
assay (MTT/MTS), cytokine release 
and biomarker profiling, validated 
drug panel screening 
 
No immune cells 
 
 
 
 
[65,66] 
 
 
 
 
Table 4 Disease state models
Modified from Bergers LI, Reijnders CM, van den Broek LJ, Spiekstra SW, de Gruijl TD, Weijers EM, et  al. Immune-competent human skin disease models. Drug Discov Today 
2016;21(9):1479–88.
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from patients with the disease, cultured alone, or in association with fibroblasts [28]. 
While this provides a good model with respect to understanding the differences in 
keratinocyte function between normal and healthy cells, keratinocytes only play a 
minor role in many immunologic skin disorders. For example, psoriasis is a chronic 
inflammatory skin disease that alongside epidermal hyperplasia and abnormal kerati-
nocyte differentiation is also associated with abnormal circulation of polymorphonu-
clear leukocytes, infiltration of activated TCs and DCs, and altered levels of cytokines 
[67]. Gaining a better understanding of immune skin responses (e.g., sensitization, 
irritation, and inflammation) and immune skin diseases (e.g., eczema, dermatitis, and 
psoriasis) in vitro will require the use of more complex models that incorporate key 
innate or adaptive immune responses represented in the skin in vivo.
11.  Advanced epidermal and dermal cell culture models
Although the dermal models mentioned above have contributed significantly to the 
field of skin research, a number of limitations exist that prevent their continual and/or 
translational application. These defining factors include a range of interrelated prop-
erties and center on (i) the expressed phenotypic differences when cultured in a 2-D 
environment compared with a 3-D; (ii) the implementation of an air-liquid interface 
during culture; (iii) the native source and pedigree of cells, that is, species and cell 
type; (iv) the limited presence and/or localization of skin-specific appendages, for 
example, hair follicles, sweat pores, and sebaceous glands; (v) the lack of comple-
mentary immunocompetent cell subpopulations; and (vi) the identification/detection/
quantification of the (required) readout signal from the model following a test stimuli.
With the ongoing desire to establish a unified skin cell model that could be ex-
ploited by the multiarray of dermal researcher, technological advances have led to the 
step-by-step standardization of a human dermal equivalent. The initial characteriza-
tion of a suitable cell model requires confirmation that a “valid” skin equivalent exists 
despite the origin of the cells and their in vitro culture microenvironment. As such, an 
extensive inventory of a variety of products and techniques has been developed over 
the past two decades that includes novel (3-D) biomaterials, surface modification tech-
niques (e.g., charge, topography, and chemical moieties), incorporated perfusion/mi-
crofluidic loops, external stimuli, and growth factor supplementation—resulting in the 
generation of a human stratified skin equivalent [68]. This “trueness” factor is often 
determined through morphological characterization, correct profiling/expression of 
cell surface markers, and the presence of a functional barrier integrity through TEER/
TEWL measurements. Following this justification, assessment of the detrimental ef-
fects of novel compounds tends to be based on a combination of visual observations 
of barrier integrity through simple histology and feedback from induced cytotoxic 
effects using (LD50) viability assays and/or end point assays such as the MTT/MTS 
mitochondria activity assay, redox reaction, and/or LDH release profile.
However, the most crucial aspect of these models is the limitation in the incorpora-
tion of a population of immune cells to truly represent the in vivo (adaptive and innate 
Immunocompetent human in vitro skin models  365
immunologic) environment of the skin. The ability of a substance to cause damage—
either through corrosion, irritation, or sensitization—when applied to the skin is deter-
mined as part of the assessment criteria for the topical testing of new chemicals and/or 
novel therapeutics. Corrosion can be regarded as a severe irreversible process leading 
to cell death (i.e., necrosis), whereas irritation initiates a complex cascade within the 
inflammatory pathway that causes changes to epithelial and endothelial cells within 
the tissues. Therefore, it is now considered fundamental that the next-generation im-
munocompetent skin models should encompass these immunologically responsive 
cells within a complex construct of stratified skin layers. This representation of native 
skin based on keratinocytes- and fibroblasts-populated layers would therefore allow 
immune cells to localize into and/or migrate out from the 3-D microenvironment as 
would be in an in vivo setting following the appropriate stimuli or insult.
12.  In silico epidermal and dermal cell culture models
Given the complex nature and specialist skills required to ascertain permeation and 
sensitization data in skin models, it is unsurprising that the scientific community has 
also investigated the possibilities of predicting these parameters via the use of compu-
tational models. Accurate and robust in silico predictions of skin permeation have the 
potential to significantly reduce the time and costs of research projects and as such are 
of general interest to researchers. The emergence of ever-increasingly sophisticated 
predictive models was arguably catalyzed by the publication of a database of 97 per-
meation coefficients for 94 compounds by GL Flynn in 1990 [69]. It was the first time 
that data of this type had been compiled in a single repository, and it allowed Flynn to 
propose a simple model for skin permeation related to the molecular water and lipo-
philicity of the compound.
Flynn's dataset was rapidly adopted and exploited by the scientific community, which 
quickly led to the development of a number of quantitative structure-property relation-
ship models, which attempted to predict, not just explain, the permeability coefficients 
of small molecules. The first of these, established by Potts and Guy [70], showed a 
quantitative linear relationship between permeation, lipophilicity, and molecular weight 
(Eq. 1) that was able to accurately explain 67% of the variance seen in the Flynn dataset:
(1)
where log Kp is the permeation coefficient, log Kow is the octan-1-ol-water partition 
coefficient, and MW is the molecular weight of a compound.
By quantifying Flynn's initial algorithmic ideas, Potts and Guy demonstrated that 
the physicochemical properties of a compound could be linked to its permeability 
through the skin using multiple linear regression analysis techniques. However, the 
correlation between predicted and experimental values for this model was relatively 
low. This led to investigations into other properties that could possibly be influencing 
permeation through the skin. Using a subset of 60 compounds from the Flynn dataset 
log . log . .K K MWowp = - -0 71 0 0061 6 3
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(deliberately excluding outliers such as the hydrocortisones), Barratt [71] showed that 
a robust and predictive QSPR model could be achieved by building a QSPR incorpo-
rating molecular volume, the octanol-water partition coefficient, and the melting point 
of a compound (Eq. 2):
(2)
where log Kp is the permeation coefficient, log Kow is the octan-1-ol-water partition co-
efficient, MV is the molecular volume, and MPt is the melting point of the compound.
In the same year, Potts and Guy refined their initial model [72] and from a subset of 
the Flynn dataset that contained only 37 nonelectrolyte compounds generated a QSPR 
model that also included a term for molecular volume and replaced their original par-
tition coefficient term, with descriptors related to the number of hydrogen bond donor 
and receptor activity of the molecule (Eq. 3):
(3)
where log Kp is the permeation coefficient, MV is the molecular volume, åa2H rep-
resents the total hydrogen bond donor activity, and åb2H accounts for the total hydro-
gen bond acceptor activity.
A number of incremental QSPR models of percutaneous absorption followed, but 
it was not long before attention turned toward the limitations of the Flynn dataset for 
constructing predictive models and the limitations of linear modeling techniques in 
general given the multiplicity of routes that molecules can access to permeate through 
the skin (i.e., transcellular, inter/paracellular, and transappendageal transport). As 
Flynn had collated the information for the initial database from 15 different sources, 
the values lacked internal consistency because they had been collected in a variety of 
experimental manners. By critically evaluating the experimental methodologies used 
to obtain permeation coefficients and combining datasets from Kirchner [73], Degim 
[74], and Johnson [75], among others, Mass and Cronin [76] were able to produce a 
new dataset of 116 molecules that showed an improvement in predictive ability of a 
QSPR (r2 = .87) for skin permeation using only the original descriptors of molecular 
weight and log P initially identified by Potts and Guy (Eq. 4):
(4)
where log Kp is the permeation coefficient and MW is the molecular weight of a 
compound.
High-quality datasets such as this have since been employed by scientists to build and 
validate nonlinear computational models, such as artificial neural networks (see, e.g., 
[77,78]), designed to enhance predictions by accounting for the complex and competing 
mechanisms of permeation across the skin. Success in being able to accurately predict 
permeation has also led to the development of models that are able to provide infor-
mation on potential skin sensitization, such as Pred-Skin [79,80], which is able to give 
accurate predictions of sensitization for compounds based on their molecular structure.
log . log . . .K K MW MPtp ow= - - -0 82 0 0093 0 039 2 36
log . . . .K MVp
H H= - -å å0 0256 1 72 3 93 4 852 2a b –
log . log . .K P MWp = - -0 74 0 091 2 39
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13.  In vitro immunocompetent skin models
Only a relatively few validated, in vitro, cell culture models exist that explicitly incor-
porate immune-responsive cells as a functional component of the entirety (Table 5). 
Although diseased state skin models exist and considered as immunologic competent, 
this “immunology” is stand-alone and physiologically biased toward the projected 
prognosis. As such, these models tend to be exploited solely in therapeutic develop-
mental studies for focused diseased state—the reader is directed to an excellent review 
article by Bergers and colleagues [28].
Skin model Specifications
Readout 
parameter Limitations References
Nott-
Sheff 3-D 
K-F-DC
Coculture 
of dendritic 
cells, within 
an agarose gel, 
alongside primary 
fibroblasts and 
keratinocytes
Histology, 
cytotoxicity 
assessment 
assay (MTT/
MTS), 
cytokine 
release and 
biomarker 
profiling, DC 
migration
Pseudo 2-D/3-D 
microenvironment, 
early development, 
ethics and cell 
procurement 
limitations, no T 
cells
[27]
Skin 
equivalent 
with T cells
Decellularized 
deepidermized 
dermis seeded 
with human 
primary 
keratinocytes 
cocultured with 
activated T cells 
obtained from 
human donors 
allogeneic to the 
skin
Histology, 
cell viability, 
TUNEL 
staining, 
cytokine 
release, PCR, 
flow cytometry
Pseudo 2-D/3-D 
microenvironment, 
early development, 
limited fibroblast 
interaction
[59]
Skin 
equivalent 
with 
Langerhans 
cells 
 
 
 
 
 
Air-liquid 
interface-
differentiated 
epidermis 
integrated with 
MUTZ-3 cells 
on fibroblast-
populated 
collagen I 
hydrogel 
Histology, 
cytotoxicity 
assessment 
assay (MTT/
MTS), 
cytokine 
release and 
biomarker 
profiling, DC 
plasticity and 
migration
Pseudo 2-D/3-D 
microenvironment, 
early development, 
no T cells 
 
 
 
 
 
 
[81] 
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Although the culture of a single dermal-derived immune cell population (e.g., TCs, 
macrophages, DCs, and monocytes) may provide an immunologic response readout 
signal following stimulation, recent evidence suggests that for a complex organ, such 
as the skin, it is the interaction between different cell populations in a suitable culture 
environment that exerts the resultant outcome [82–84]. Accordingly, it is known that 
keratinocytes account for 90% of the epidermis and secrete cytokines and interleukins 
capable of modulating and directing the immune cells accordingly. Similarly, sedate 
and activated fibroblasts also participate in this immunologic pathway and coordinate 
the required response to the stimuli. As such, it can be considered that, in the case 
of the skin, it is the interplay between keratinocytes, fibroblasts, and a population of 
DCs to be the simplest representation of an immunocompetent skin equivalent. This 
hypothesis was taken to practice by Chau and colleagues who developed a human 3-D 
immunocompetent skin model based on primary keratinocytes, fibroblasts, and DCs 
differentiated from donor blood-derived monocytes [27]. In response to sensitization, 
the model allowed dendritic cell migration and demonstrated an upregulation of CD86 
and HLA-DR. However, IL-1α, IL-6, and IL-8 were not upregulated in response to 
DNCB or SDS stimulation and put into question the reliability and/or indicative solu-
ble marker for validation. Similarly, Kosten and colleagues developed a “skin equiva-
lent” model that incorporated LCs alongside human keratinocytes and fibroblasts [81], 
whereas van de Bogaard and colleagues' skin equivalent model exploited T cells on 
a keratinocyte-loaded decellularized dermis [59]. Although both teams demonstrated 
positive cross talk between the cells and a degree of cytokine/chemokine interaction, 
they report that the mechanisms controlling general inflammation are different to the 
native environment and so are at an early stage of development. Taken together, the 
innate immunologic response in the skin is a highly complex and controlled environ-
ment that is orchestrated by a variety of cell types and requires further investigation to 
fully understand and/or mimic using an in vitro system.
14.  Conclusion
It can be seen that the number of human skin equivalent skin models has significantly 
expanded over the past few years. Originally developed as layer-specific monoculture 
of skin cells on a flat culture substrate, these next-generation advanced dermal mod-
els incorporate a number of factors that drive the formation of the required in vivo 
tissue architecture. It has been found that not only do the physical and mechanical 
architecture (i.e., 3-D, biomaterial, topography, and perfusion) of the culture substrate 
contribute to the correct phenotypic expression of the cells but also there is a need to 
ensure that correct cell-to-cell signaling and interaction occur through the incorpora-
tion of the many different cell types naturally present in native skin. Although compu-
tational modeling and in silico programs can provide additional insight to the field of 
skin research, a fully functional in vitro model of immuno-responsive skin is still at 
developmental infancy. Fortunately, with the advances in tissue engineering, material 
science, and cell biology, the future adaptation of these models in both their construc-
tion and biological readout parameters will continue to further the understanding of 
skin disease, drug delivery, and in vitro toxicology assessment.
Immunocompetent human in vitro skin models  369
Conflict of interests
The authors have no conflict of interests.
References
 [1] Aulton ME. Aulton's pharmaceutics: the design and manufacture of medicines. Edinburgh: 
Churchill Livingstone; 2007.
 [2] Richmond JM, Harris JE. Immunology and skin in health and disease. Cold Spring Harb 
Perspect Med 2014;4(12):a015339.
 [3] Benson HAE, Watkins AC. Topical and transdermal principles and practice. New Jersey: 
John Wiley and Sons, Inc.; 2012.
 [4] Elias PM, Menon GK. Structural and lipid biochemical correlates of the epidermal per-
meability barrier. Adv Lipid Res 1991;24:1–26.
 [5] Hadgraft J. Skin, the final frontier. Int J Pharm 2001;224(1–2):1–18.
 [6] Monterio-Riviere NA. Structure and function of skin. In: Monterio-Riviere NA, editor. 
Toxicology of the skin. New York: Informa Healthcare; 2010.
 [7] Streilein JW. Skin-associated lymphoid tissues (SALT): origins and functions. J Invest 
Dermatol 1983;80(Suppl):12s–6s.
 [8] Haniffa M, Gunawan M, Jardine L. 2015. Human skin dendritic cells in health and dis-
ease. J Dermatol Sci 2015 Feb;77(2):85–92.
 [9] Salmon  JK, Armstrong  CA, Ansel  JC. The skin as an immune organ. West J Med 
1994;160(2):146–52.
 [10] Pasparakis M, Haase I, Nestle FO. Mechanisms regulating skin immunity and inflamma-
tion. Nat Rev Immunol 2014;14(5):289–301.
 [11] Dinarello CA. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J 
Immunol 2011;41(5):1203–17.
 [12] Flacher V, Sparber F, Tripp CH, Romani N, Stoitzner P. Targeting of epidermal Langerhans 
cells with antigenic proteins: attempts to harness their properties for immunotherapy. 
Cancer Immunol Immunother 2009;58(7):1137–47.
 [13] Schmitt  D. Immune functions of the human skin. Models of in  vitro studies using 
Langerhans cells. Cell Biol Toxicol 1999;15(1):41–5.
 [14] Kupper  TS. The activated keratinocyte: a model for inducible cytokine production by 
non-bone marrow-derived cells in cutaneous inflammatory and immune responses. J 
Invest Dermatol 1990;94(6 Suppl):146S–50S.
 [15] Mizumoto  N, Takashima  A. CD1a and langerin: acting as more than Langerhans cell 
markers. J Clin Invest 2004;113(5):658–60.
 [16] Ramata-Stunda A, Boroduskis M, Vorobjeva V, Ancans J. Cell and tissue culture-based 
in vitro test systems for evaluation of natural skin care product ingredients. Environ Exp 
Biol 2013;11:159–77.
 [17] Ericsson  AD, Dora  J, Cao  S. Melanocytes: morphological basis for an exteroceptive 
sensory system for monitoring ultraviolet radiation. Physiol Chem Phys Med NMR 
2003;35(1):27–42.
 [18] Dell'anna ML, Picardo M. A review and a new hypothesis for non-immunological patho-
genetic mechanisms in vitiligo. Pigment Cell Res 2006;19(5):406–11.
 [19] Tokura Y, Fujiyama T, Ikeya S, Tatsuno K, Aoshima M, Kasuya A, et al. Biochemical, 
cytological, and immunological mechanisms of rhododendrol-induced leukoderma. J 
Dermatol Sci 2015;77(3):146–9.
370 Skin Tissue Models
 [20] Xie H, Zhou F, Liu L, Zhu G, Li Q, Li C, et al. Vitiligo: how do oxidative stress-induced 
autoantigens trigger autoimmunity? J Dermatol Sci 2016;81(1):3–9.
 [21] Bueno  V, Sant'Anna  OA, Lord  JM. Ageing and myeloid-derived suppressor cells: 
possible involvement in immunosenescence and age-related disease. Age (Dordr) 
2014;36(6):9729.
 [22] Beanes SR, Dang C, Soo C, Ting K. Skin repair and scar formation: the central role of 
TGF-beta. Expert Rev Mol Med 2003;5(8):1–22.
 [23] Bruynzeel-Koomen  C, van der Donk  EM, Bruynzeel  PL, Capron  M, de Gast  GC, 
Mudde  GC. Associated expression of CD1 antigen and fc receptor for IgE on epi-
dermal Langerhans cells from patients with atopic dermatitis. Clin Exp Immunol 
1988;74(1):137–42.
 [24] Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997;77(4):1033–79.
 [25] Theoharides  TC, Alysandratos  K-D, Angelidou  A, Delivanis  D-A, Sismanopoulos  N, 
Zhang B, et al. Mast cells and inflammation. Biochim Biophys Acta 2012;1822(1):21–33.
 [26] Clark RA. Skin resident T cells: the ups and downs of on site immunity. J Invest Dermatol 
2010;130(2):362–70.
 [27] Chau DYS, Johnson C, MacNeil S, Haycock JW, Ghaemmaghami AM. The development 
of a 3D immunocompetent model of human skin. Biofabrication 2013;5(3):035011.
 [28] Bergers LI, Reijnders CM, van den Broek LJ, Spiekstra SW, de Gruijl TD, Weijers EM, et al. 
Immune-competent human skin disease models. Drug Discov Today 2016;21(9):1479–88.
 [29] Magnusson B, Kligman AM. The identification of contact allergens by animal assay. The 
guinea pig maximization test. J Invest Dermatol 1969;52(3):268–76.
 [30] Robinson MK, Nusair TL, Fletcher ER, Ritz HL. A review of the Buehler guinea pig skin 
sensitization test and its use in a risk assessment process for human skin sensitization. 
Toxicology 1990;61(2):91–107.
 [31] Kimber  I, Pichowski  JS, Betts  CJ, Cumberbatch  M, Basketter  DA, Dearman  RJ. 
Alternative approaches to the identification and characterization of chemical allergens. 
Toxicol In Vitro 2001;15(4–5):307–12.
 [32] Kimber I, Hilton J, Dearman RJ, Gerberick GF, Ryan CA, Basketter DA, et al. An inter-
national evaluation of the murine local lymph node assay and comparison of modified 
procedures. Toxicology 1995;103(1):63–73.
 [33] Ambrose CT. An amended history of tissue culture: concerning Harrison, burrows, mall, 
and carrel. J Med Biogr 2016;https://doi.org/10.1177/0967772016685033.
 [34] Khokhlov AN. Does aging need its own program, or is the program of development quite 
sufficient for it? Stationary cell cultures as a tool to search for anti-aging factors. Curr 
Aging Sci 2013;6(1):14–20.
 [35] Geraghty RJ, Capes-Davis A, Davis  JM, Downward  J, Freshney RI, Knezevic  I, et  al. 
Guidelines for the use of cell lines in biomedical research. Br J Cancer 2014;111(6):1021–46.
 [36] Langer R, Vacanti JP. Tissue engineering. Science 1993;260(5110):920–6.
 [37] Berthiaume F, Maguire TJ, Yarmush ML. Tissue engineering and regenerative medicine: 
history, progress, and challenges. Annu Rev Chem Biomol Eng 2011;2:403–30.
 [38] Johansson H, Albrekt AS, Borrebaeck CA, Lindstedt M. The GARD assay for assessment 
of chemical skin sensitizers. Toxicol In Vitro 2013;27(3):1163–9.
 [39] Reuter H, Spieker J, Gerlach S, Engels U, Pape W, Kolbe L, et al. In vitro detection of 
contact allergens: development of an optimized protocol using human peripheral blood 
monocyte-derived dendritic cells. Toxicol In Vitro 2011;25(1):315–23.
 [40] Hoffmann J, Heisler E, Karpinski S, Losse J, Thomas D, Siefken W, et al. Epidermal-
skin-test 1,000 (EST-1,000)—a new reconstructed epidermis for in vitro skin corrosivity 
testing. Toxicol In Vitro 2005;19(7):925–9.
Immunocompetent human in vitro skin models  371
 [41] Botham  PA. The validation of in  vitro methods for skin irritation. Toxicol Lett 
2004;149:387–90.
 [42] Spielmann  H, Liebsch  M, Botham  PA, Fentem  JH, Roguet  R, Cotovio  J, et  al. The 
ECVAM international validation study on in vitro tests for acute skin irritation: report on 
the validity of the EPISKIN and EpiDerm assays and on the skin integrity function test. 
Altern Lab Anim 2007;35(6):559–601.
 [43] Zuang V, Balls M, Botham PA, Coquette A, Corsini E, Curren RD, et al. Follow-up to 
the ECVAM prevalidation study on in vitro tests for acute skin irritation. The European 
Centre for the Validation of alternative methods skin irritation task force report 2. Altern 
Lab Anim 2002;30(1):109–29.
 [44] Katoh M, Hamajima F, Ogasawara T, Hata K. Assessment of human epidermal model 
LabCyte EPI-MODEL for in vitro skin irritation testing according to European Centre 
for the Validation of alternative methods (ECVAM)-validated protocol. J Toxicol Sci 
2009;34(3):327–34.
 [45] Katoh M, Hamajima F, Ogasawara T, Hata K. Assessment of the human epidermal model 
LabCyte EPI-MODEL for in  vitro skin corrosion testing according to the OECD test 
guideline 431. J Toxicol Sci 2010;35(3):411–7.
 [46] Boukamp  P, Petrussevska  RT, Breitkreutz  D, Hornung  J, Markham  A, Fusenig  NE. 
Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte 
cell line. J Cell Biol 1988;106(3):761–71.
 [47] Boukamp  P, Popp  S, Altmeyer  S, Hülsen  A, Fasching  C, Cremer  T, et  al. Sustained 
nontumorigenic phenotype correlates with a largely stable chromosome content during 
long-term culture of the human keratinocyte line HaCaT. Genes Chromosomes Cancer 
1997;19(4):201–14.
 [48] Li L, Fukunaga-Kalabis M, Herlyn M. Establishing human skin grafts in mice as model 
for melanoma progression. Methods Mol Biol 2015;13:1–10.
 [49] van de Sandt J, Roguet R, Cohen C, Esdaile D, Ponec M, Corsini E, et al. The use of hu-
man keratinocytes and human skin models for predicting skin irritation. Altern Lab Anim 
1999;27(5):723–43.
 [50] Kandárová H, Hayden P, Klausner M, Kubilus J, Kearney P, Sheasgreen J. In vitro skin 
irritation testing: improving the sensitivity of the EpiDerm skin irritation test protocol. 
Altern Lab Anim 2009;37(6):671–89.
 [51] Chioni  AM, Grose  R. Organotypic modelling as a means of investigating epithelial- 
stromal interactions during tumourigenesis. Fibrogenesis Tissue Repair 2008;1(1):8.
 [52] Pruniéras M, Delescluse C, Regnier M. The culture of skin. A review of theories and 
experimental methods. J Invest Dermatol 1976;67(1):58–65.
 [53] Hakelius M, Saiepour D, Göransson H, Rubin K, Gerdin B, Nowinski D. Differential 
gene regulation in fibroblasts in co-culture with keratinocytes and head and neck SCC 
cells. Anticancer Res 2015;35(6):3253–65.
 [54] Nolte SV, Xu W, Rennekampff HO, Rodemann HP. Diversity of fibroblasts—a review on 
implications for skin tissue engineering. Cells Tissues Organs 2007;187(3):165–76.
 [55] Gledhill  K, Guo  Z, Umegaki-Arao  N, Higgins  CA, Itoh  M, Christiano  AM. Melanin 
transfer in human 3D skin equivalents generated exclusively from induced pluripotent 
stem cells. PLoS One 2015;10(8):e0136713.
 [56] Ryu  JH, Seok  JK, An  SM, Baek  JH, Koh  JS, Boo  YC. A study of the human skin- 
whitening effects of resveratryl triacetate. Arch Dermatol Res 2015;307(3):239–47.
 [57] Duval C, Cohen C, Chagnoleau C, Flouret V, Bourreau E, Bernerd F. Key regulatory role 
of dermal fibroblasts in pigmentation as demonstrated using a reconstructed skin model: 
impact of photo-aging. PLoS One 2014;9(12):e114182.
372 Skin Tissue Models
 [58] Moulin VJ. Reconstitution of skin fibrosis development using a tissue engineering ap-
proach. Methods Mol Biol 2013;961:287–303.
 [59] van den Bogaard EH, Tjabringa GS, Joosten I, Vonk-Bergers M, van Rijssen E, Tijssen HJ, 
et al. Crosstalk between keratinocytes and T cells in a 3D microenvironment: a model to 
study inflammatory skin diseases. J Invest Dermatol 2014;134(3):719–27.
 [60] van den Broek LJ, Niessen FB, Scheper RJ, Gibbs S. Development, validation and testing 
of a human tissue engineered hypertrophic scar model. ALTEX 2012;29(4):389–402.
 [61] Cogan J, Weinstein J, Wang X, Hou Y, Martin S, South AP, et al. Aminoglycosides restore 
full-length type VII collagen by overcoming premature termination codons: therapeutic 
implications for dystrophic epidermolysis bullosa. Mol Ther 2014;22(10):1741–52.
 [62] El Ghalbzouri A, Jonkman M, Kempenaar J, Ponec M. Recessive epidermolysis bullosa 
simplex phenotype reproduced in vitro: ablation of keratin 14 is partially compensated by 
keratin 17. Am J Pathol 2003;163(5):1771–9.
 [63] Jean J, Lapointe M, Soucy J, Pouliot R. Development of an in vitro psoriatic skin model 
by tissue engineering. J Dermatol Sci 2009;53(1):19–25.
 [64] Tjabringa G, Bergers M, van Rens D, de Boer R, Lamme E, Schalkwijk J. Development 
and validation of human psoriatic skin equivalents. Am J Pathol 2008;173(3):815–23.
 [65] Commandeur  S, de Gruijl  FR, Willemze  R, Tensen  CP, El Ghalbzouri  A. An in  vitro 
three-dimensional model of primary human cutaneous squamous cell carcinoma. Exp 
Dermatol 2009;18(10):849–56.
 [66] Linde N, Gutschalk CM, Hoffmann C, Yilmaz D, Mueller MM. Integrating macrophages 
into organotypic co-cultures: a 3D in vitro model to study tumor-associated macrophages. 
PLoS One 2012;7(7):e40058.
 [67] Korthuis RJ, Unthank JL. Experimental models to investigate inflammatory processes in 
chronic venous insufficiency. Microcirculation 2000;7(6 Pt 2):S13–22.
 [68] Elliott NT, Yuan F. A microfluidic system for investigation of extravascular transport and 
cellular uptake of drugs in tumors. Biotechnol Bioeng 2012;109(5):1326–35.
 [69] Gerrity  TR, Henry  CJ. Principles of route-to-route extrapolation for risk assessment. 
New York: Elsevier Science Ltd.; 1991.
 [70] Potts RO, Guy RH. Predicting skin permeability. Pharm Res 1992;9(5):663–9.
 [71] Barratt MD. Quantitative structure-activity relationships for skin permeability. Toxicol 
In Vitro 1995;9(1):27–37.
 [72] Potts RO, Guy RH. A predictive algorithm for skin permeability: the effects of molecular 
size and hydrogen bond activity. Pharm Res 1995;12(11):1628–33.
 [73] Kirchner LA, Moody R, Doyle E, Bose R, Jeffery J, Chu I. The prediction of skin perme-
ability data by using physicochemical data. Altern Lab Anim 1997;25:359–70.
 [74] Degim IT, Pugh WJ, Hadgraft J. Skin permeability data: anomalous results. Int J Pharm 
1998;170(1):129–33.
 [75] Johnson ME, Blankschtein D, Langer R. Permeation of steroids through human skin. J 
Pharm Sci 1995;84(9):1144–6.
 [76] Moss GP, Cronin MTD. Quantitative structure-permeability relationships for percutane-
ous absorption: re-analysis of steroid data. Int J Pharm 2002;238(1):105–9.
 [77] Deği̇m T, Hadgraft J, İlbasmiş S, Özkan Y. Prediction of skin penetration using artificial 
neural network (ANN) modeling. J Pharm Sci 2003;92(3):656–64.
 [78] Lim CW, Fujiwara S, Yamashita F, Hashida M. Prediction of human skin permeability 
using a combination of molecular orbital calculations and artificial neural network. Biol 
Pharm Bull 2002;25(3):361–6.
 [79] Alves VM, Capuzzi SJ, Muratov EN, Braga RC, Thornton TE, Fourches D, et al. QSAR 
models of human data can enrich or replace LLNA testing for human skin sensitization. 
Green Chem 2016;18(24):6501–15.
Immunocompetent human in vitro skin models  373
 [80] Braga RC, Alves VM, Muratov EN, Strickland J, Kleinstreuer N, Trospsha A, et al. Pred-
skin: a fast and reliable web application to assess skin sensitization effect of chemicals. J 
Chem Inf Model 2017;57(5):1013–7.
 [81] Kosten IJ, Buskermolen JK, Spiekstra SW, de Gruijl TD, Gibbs S. Gingiva equivalents 
secrete negligible amounts of key chemokines involved in langerhans cell migration com-
pared to skin equivalents. J Immunol Res 2015;627125.
 [82] Chung E, Choi H, Lim JE. Development of skin inflammation test model by co-culture of 
reconstituted 3D skin and RAW264.7 cells. Tissue Eng Regen Med 2014;11:87–92.
 [83] De Wever B, Sandrine K, Pascal D. Human skin models for research applications in phar-
macology and toxicology: introducing NativeSkin®, the “missing link” bridging cell cul-
ture and/or reconstructed skin models and human clinical testing. Appl In Vitro Toxicol 
2015;1(1):26–32.
 [84] Hewitt NJ, Edwards RJ, Fritsche E, Goebel C, Aeby P, Scheel  J, et  al. Use of human 
in vitro skin models for accurate and ethical risk assessment: metabolic considerations. 
Toxicol Sci 2013;133(2):209–17.
 [85] Zöller NN, Kippenberger S, Thaçi D, Mewes K, Spiegel M, Sättler A, et al. Evaluation of 
beneficial and adverse effects of glucocorticoids on a newly developed full-thickness skin 
model. Toxicol In Vitro 2008;22(3):747–59.
 [86] Uchino T, Tokunaga H, Onodera H, Ando M. Effect of squalene monohydroperoxide on 
cytotoxicity and cytokine release in a three-dimensional human skin model and human 
epidermal keratinocytes. Biol Pharm Bull 2002;25(5):605–10.
Further reading
 [1] Grindon C, Combes R, Cronin MT, Roberts DW, Garrod JF. Integrated decision-tree test-
ing strategies for skin corrosion and irritation with respect to the requirements of the EU 
REACH legislation. Altern Lab Anim 2008;36(Suppl. 1):65–74.
 [2] Stamatas GN, Morello AP, Mays DA. Early inflammatory processes in the skin. Curr Mol 
Med 2013;13(8):1250–69.
 [3] Young B, Heath JW. Wheater's functional histology. 4th ed. London: Churchill Livingstone; 
2000. p. 162. ISBN 0-443-05612-9.
 [4] Carlson MW, Alt-Holland A, Egles C, Garlick  JA. Three-dimensional tissue models of 
normal and diseased skin. Curr Protoc Cell Biol 2008. Chapter 19:Unit 19.9.
This page intentionally left blank
Section E
Emerging technologies for the 
development of 3D skin models
This page intentionally left blank
Skin Tissue Models. https://doi.org/10.1016/B978-0-12-810545-0.00016-4
© 2018 Elsevier Inc. All rights reserved.
16Additive manufacturing in the development of 3D skin tissues
Kelsey N. Retting, Deborah G. Nguyen
Organovo Inc., San Diego, CA, United States
1 Introduction
Additive manufacturing is the process of building three-dimensional (3D) structures 
layer by layer using a computer-controlled system or computer-aided design (CAD). 
Three-dimensional printing is a form of additive manufacturing that offers both geo-
metric and material flexibility to allow a high degree of customization in many ap-
plications. A 3D printing device uses materials ranging from plastics, resins, alloys, 
metals, polymers, and ceramics to create objects through precise deposition in the x, 
y, and z dimensions [1]. In recent years, 3D printing has gone from a specialized niche 
technology to a widely applicable approach, allowing both engineers and the public 
the ability to produce customized objects from cars to medical devices to machine 
parts. In medicine, 3D bioprinting has allowed physicians to produce skull implants, 
orthodontic devices, hearing aids, and external orthopedic devices that are tailored to a 
patient’s unique dimensions [2]. Progress in this arena has been so rapid that the FDA 
has had to issue “leapfrog” draft guidance, even as it continues to try and understand 
the impact of the technology on developing new devices [3].
On the heels of the accelerated use of 3D printing in general, 3D bioprinting has 
also begun to emerge as a transformational technology. Human organs are not random 
collections of cells, but instead contain cells arranged in specific locations in three 
dimensions. This spatial context enables cells to form specific contacts with each other 
and deliver local chemical cues, leading to activation of certain pathways and inhibi-
tion of others. Bioprinting incorporates the deposition of cells and/or cell-containing 
materials (referred to as “bioink”) into an automated approach with the potential to 
mimic native biologically accurate structure and function of tissues and organs. Much 
like traditional additive manufacturing, the bioink is deposited in specific locations 
in three-dimensional space layer by layer, with the resulting structure demonstrating 
the sort of spatial arrangement more typical of human tissues. The flexibility of this 
tissue-engineering platform allows bioprinted tissues to be produced in various forms 
including tubes, patches, sheets, and organoids and can generate compartmentalized 
architecture within the x, y, and z axes to create laminar and planar patterning. The 
utilization of bioprinting is a disruptive technology in the field of biomedical research 
with implications for advancing drug development and personalized medicine by cre-
ating tissue models for preclinical in vitro use and restoring and replacing damaged 
and diseased tissue. In this chapter, we will briefly review the different bioprinting 
approaches, outline the unique structural requirements of an engineered skin tissue, 
and then describe efforts to employ bioprinting for the fabrication of the human skin.
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2  Bioprinting: Deposition approaches and biomaterials
2.1  Deposition approaches
The desire to create complex 3D tissues that accurately model the biological responses 
of native human tissue has driven the development of several fundamentally different 
deposition technologies, each with different biomaterial compatibility (Table 1 and 
Fig. 1; modified review article table below). Because the process needs to enable fab-
rication of a wide variety of complex structures, the 3D bioprinting system must be ca-
pable of spatially directing a wide variety of cell types, biomaterials, and bioreagents 
to the print surface with a high level of control, all while preserving cell viability. The 
fabrication time and overall cytocompatibility of the engineered tissue will depend 
on the size and complexity of the structure geometry, choice of cellular input, and 
biomaterials.
2.1.1  Extrusion-based bioprinting
Perhaps the most widely utilized approach in 3D printing is extrusion-based print-
ing, which produces a continuous deposition of material from a cassette or syringe 
cartridge through an orifice under pressure that is dispensed through pneumatic, 
 piston-driven, or screw-driven force [4]. The volume of material dispensed is di-
rectly proportional to the area displaced. A major advantage of bioprinting with an 
extrusion-based approach is the ability to utilize high-viscosity hydrogels including 
highly cellular bioinks and cellular aggregates. Material can be deposited as aggre-
gates including cylindrical filaments or spheres [5,6]. Incorporation of multiple print 
heads can further enhance versatility by allowing for combinations of materials to be 
bioprinted simultaneously. The minimum feature size of this methodology can vary 
depending upon the cell-containing biomaterials and on the cell type(s) included. An 
advantage of this methodology is that it can generate larger feature sizes often around 
100–500 μm, which can allow for scalability and rapid printing of both large volumes 
and replicate structures [6]. The resolution, however, may be lower than other printing 
approaches and may limit finer cell patterning.
2.1.2  Droplet-based bioprinting
To achieve finer feature sizes like thin lines, small compartments, or single cell layers, 
a variety of methods that involve the creation and deposition of droplets at defined po-
sitions in three-dimensional space have been developed. Inkjet bioprinting involves the 
ejection of droplets containing either cells or biomaterials from a  reservoir in  response 
to a pressure pulse generated by thermal or piezoelectric forces. Thermal approaches 
electrically heat the print head to quickly create a small bubble that forces droplets from 
the nozzle. In contrast, piezoelectric approaches generate vibrations or acoustic waves 
inside the printer head to break the bioink into droplets that are then ejected [7,8]. 
Both inkjet methods generate droplets in the picoliter to microliter range, enabling the 
creation of very fine patterns. Microsolenoid valve bioprinting utilizes an electrome-
chanical valve to generate droplets. The voltage pulse directs current through a coil 
Category Technology Description
Basic 
dispense 
types Resolution
Volume 
dispensed Cell density Viscosity References
Extrusion-
based
Positive 
displacement/
extrusion
Deposition of cellular 
material with or 
without hydrogel by 
extrusion through an 
orifice
Cylinders, 
sheets, lines, 
spheres, dots
>50 μm Microliter-
milliliter
Low-high, 
up to 100% 
cellular
High [4-6,37,58,59,63]
Droplet-
based 
 
 
 
 
 
 
 
 
 
 
 
 
Inkjet Ejection of small 
volumes of material in 
a pressurized reservoir 
following a thermal or 
piezoelectric pulse
Droplets, 
liquid 
overlays
> 25 μm Picoliter-
microliter
Low Low [7,9,32]
Microvalve/
microsolenoid 
valve
Controlled deposition 
of material in 
pressurized reservoir 
through electronically 
controlled valve
Droplets, 
thin films, 
liquid 
overlays
>2 mm Microliter Low Low [7,10,23,25,31]
Laser-driven 
transfer 
 
 
Generation of small 
droplets by a focused 
laser on a surface 
containing the print 
material
Droplets 
 
 
 
1–125 μm 
 
 
 
Femtoliter-
nanoliter 
 
 
High, up to 
108 cells/mL 
 
 
Low-
medium 
 
 
[12,13,15,33,34] 
 
 
 
Table 1 Summary of bioprinting approaches
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and in turn creates a coincident magnetic field that opens the solenoid valve to release 
bioink from a pressurized chamber [7]. This approach can employ a lower range of 
pneumatic pressure compared with inkjet bioprinting, therefore reducing the amount 
of shear stress applied to cellular material and potentially reducing cell damage. When 
compared with inkjet, microsolenoid valves generate larger cell-containing droplets 
of 10 μL or more and can also be utilized in a spraying mode to provide relatively thin 
layers of cellular or other biomaterials. In general, the droplet-based methods can gen-
erate relatively high-resolution structures from 20 to 100 μm, although the resolution 
of microvalve dispensing may be slightly lower. Both approaches are limited by the 
low range of viscosity and low cell density required to avoid shear stress or cell clog-
ging. In addition, cell suspensions may encounter cell sedimentation and aggregation, 
which can alter the cell density in the dispensed droplets and reduce tissue to tissue 
reproducibility [9,10]. In some cases, droplet-based printing approaches rely on fast 
gelation rates to polymerize or stabilize material following deposition, which may 
limit the types of materials that can be used [11].
Laser-based bioprinting, laser-assisted bioprinting (LABP), or laser-induced for-
ward transfer (LIFT) utilizes laser pulses to dispense droplets. The laser is focused on 
a “donor slide” or ribbon, comprising a surface with an energy absorbing substrate, 
such as gold, and a bioink layer. Energy from the focused laser is transferred from the 
absorbing layer to the bioink, inducing high gas pressure and evaporation that propels 
a droplet toward a print surface or “collector slide.” The collector slide can contain 
hydrogel, which cells can be printed onto or embedded into. The donor and collector 
slides can be moved relative to each other to create patterning in the xy axis and then 
repeated to produce layers and 3D patterns. The size of the droplet can be adjusted by 
altering the pulse energy, the gap distance, the size of the focused laser spot, and the 
thickness of the absorbing substrate [12,13]. Laser bioprinting creates smaller droplets 
than inkjet approaches (picoliter to femtoliter range), which enables very high- resolu-
tion patterning both in 2D and in 3D [14,15]. In addition, because it is nozzle-free, this 
technique can accommodate higher cell densities (up to 108 cells/mL) and hydrogel 
viscosities [16]. Despite these advantages, the heat generated from laser energy and 
the prolonged fabrication time compared with other methods can damage cells and 
reduce viability, thus limiting its utility for some applications.
Droplet-basedExtrusion-based
Inkjet Microsolenoid
valve 
Laser-driven
transfer
Thermal Piezoelectric
Positive-displacement /
extrusion
Pressure
•  Mechanical
•  Pneumatic
Thermal
actuator
Piezoelectric
actuator
Absorbing layer
Biomaterial
Valve
Laser
Fig. 1 Diagram of bioprinting approaches.
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2.2  Biomaterials
2.2.1  Cellular materials
Current in  vitro skin models incorporate a variety of cell types including primary 
cells and cell lines to recapitulate both epidermal and dermal layers. Common skin 
cell lines utilized in fabrication approaches include the immortalized human keratino-
cyte cell line HaCaT, the human foreskin fibroblast cell line HFF-1, and the murine 
NIH3T3 fibroblast cell line [17,18]. Although cell lines minimize variability, differ-
ences in proliferation and differentiation rates, metabolism, and species-specific phys-
iology can be seen in comparison with the intact human skin [19,20]. Primary human 
keratinocytes and dermal fibroblasts may offer the most accurate representation of 
native cell function. However, it is important to consider the impact of variability in 
proliferative capacity and matrix production from donor to donor, as well as the differ-
ences between neonatal and adult cells. For disease modeling, primary cells derived 
from tissue biopsies or from iPS cells of diseased patients can be substituted for nor-
mal cells [21,22]. Additional aspects such as immunogenicity must be considered if 
the tissue is to be used for therapeutic applications such as tissue grafts. Because they 
can be expanded after removal from the body, autologous sources (i.e., the patient’s 
own cells) of both keratinocytes and dermal fibroblasts are a viable option for clinical 
use. The high proliferative capacity and multipotency of stem cells make them an 
attractive alternative for skin engraftment approaches due to their lack of significant 
immunogenicity [23].
2.2.2  Biomaterials
To build architecturally defined tissues, bioprinting platforms use bioinks with a vari-
ety of cellular densities and matrix components. Reconstructing native tissue requires 
an interplay of cell-cell and cell-matrix interactions in appropriate cellular density, 
spatial patterning, and matrix composition to maintain tissue integrity, viability, and 
function. The relative cellularity of a bioink formulation can range from 0% to 100% 
[24]. Acellular materials or hydrogels can be applied for structural support or consti-
tute space-saving regions in which there are no cells; hydrogels have also been used as 
sacrificial materials to create void spaces in vascular structures prior to tissue matura-
tion [25-27]. High density cellular bioinks can harness the natural cell-cell interactions 
stimulated by close proximity to promote organized architecture based on physiolog-
ical and biological properties [5,28-30]. Modifications to the bioink can be used to 
create architectural features (both large and small) and microenvironments and may 
incorporate specialized ECM to augment or inhibit intracellular interactions and dif-
ferentiation. By combining cells and matrix and modifying the relative ratio of these 
components, both hypercellular and hypocellular tissues can be readily fabricated with 
high reproducibility. Engineered in vitro skin models incorporate a variety of biomate-
rials to recapitulate the architecture of the native skin, including both natural polymers 
(i.e., collagen [10,23,31-34], hyaluronic acid [35,36], fibrin [23,32,36], gelatin [37], 
and alginate [12,37]) and synthetic polymers (i.e., polyethylene glycol (PEG) [9,38], 
polyethylene glycol diacrylate (PEGDA) [36], polylactic acid (PLA) [39], polyglycolic 
acid (PGA) [40], poly(ε-caprolactone) (PCL) [41], and poly (lactic-co-glycolic acid) 
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(PLGA) [42]). The stiffness or viscosity of the hydrogel matrix can be tuned via 
chemical manipulation, temperature, cross-linking density, and polymer density [11]. 
Regardless of whether it is natural or synthetic, the matrix material must be noncy-
totoxic and compatible with the bioprinting approach; the selection of appropriate 
materials must take into account viscosity, gelation time, rheological properties, and 
sheer stress in order to balance the capability of the fabrication platform with the need 
for a viable tissue with the desired architecture [43,44].
3  Architectural considerations for skin tissue engineering
The native human skin exhibits a complex layered architecture consisting of epider-
mal, dermal, and hypodermal layers. The epidermis, or outermost layer, is composed 
mainly of keratinocytes that are organized into a highly stratified architecture distin-
guished by both morphology and differentiation state. The basal keratinocytes that 
form the proliferative base layer align atop a basement membrane and can be distin-
guished by their columnar morphology and expression of cytokeratins 5 and 14 (CK5 
and CK14). As the basal cells differentiate, they migrate upward, become more flat-
tened, and express cytokeratins 1 and 10 (CK1 and CK10), forming the spinous layer. 
These spinous keratinocytes continue to differentiate into a distinct granular layer, 
in which granules are present in the cells with expression of key markers involucrin 
and filaggrin. Cells in the granular layer then terminally differentiate, creating a waxy 
and lipid-rich layer known as the stratum corneum that serves as a protective bar-
rier. Between the epidermal and dermal layer is the dermal-epidermal junction (DEJ), 
composed of basement membrane components including type IV collagen, laminin, 
and heparan sulfate proteoglycans. This basement membrane serves to anchor the epi-
dermis to the dermis and provides cues to the basal keratinocytes that perpetuate their 
function; autoimmune targeting of basement membrane components leads to debilitat-
ing blistering conditions [45,46].
Supporting the epidermal layer is the dermis, composed mainly of dermal fibro-
blasts and connective tissue or extracellular matrix (ECM). The dermal layer is hy-
pocellular compared with the epidermis with a complex mixture of ECM including 
collagens, elastin, proteoglycans, and glycosaminoglycans. The dermal layer can 
be subdivided into an upper papillary layer containing thinner collagen fibers and 
a lower reticular dermal layer composed of thicker collagen fibers and fewer fibro-
blasts. Below the dermal layer is the hypodermal layer, comprising adipose and con-
nective tissue and containing blood and lymphatic vessels. Specialized cell types can 
be found in all layers of skin tissue including innate and adaptive immune cells and 
melanocytes. The native skin is also populated with vasculature and nerve networks as 
well as appendages including hair follicles, sebaceous glands, and sweat glands [46]. 
When engineering skin tissue, researchers must consider what architectural features 
are critical to include for their target application and then determine the appropriate 
fabrication methodology necessary to achieve those features (Fig. 2).
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Fig. 2 Histology of native skin. (A) Hematoxylin and eosin staining (H&E) of bilayered architecture showing disinct epidermis (upper layer) 
and dermis (lower layer). Inset shows immunofluorescent staining of epidermis with differentiated and stratified keratinocyte layers: basal 
layer stained red for cytokeratin 14 (CK14), spinous layer stained green for cytokeratin 10 (CK10), spinous/granular layer stained blue for 
involucrin (IVL), and white cell nuclei (DRAQ5). (B) Schematic of skin tissue reproduced with permission from [50].
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3.1  Manually fabricated 3D skin tissues
Manually fabricated in vitro skin models are commonly used for routine predictive as-
sessment in the cosmetic and chemical industries, with end points including skin irrita-
tion, corrosion, absorption, and sensitization. Epidermal skin tissues can be  produced 
in the laboratory by manually seeding a monolayer of keratinocytes from a cell sus-
pension and subsequently differentiating the cells at an air-liquid interface to create 
an epidermal tissue layer. Epidermal tissue models containing keratinocytes alone can 
recapitulate many functional aspects of skin tissue; however, a full- thickness skin pro-
vides an advantage by allowing signaling cross talk between dermal fibroblasts and 
epidermal keratinocytes, which has been shown to improve epidermal thickness and 
organization [47,48]. A full-thickness skin tissue can be achieved in a similar fashion 
by manually seeding the epidermal keratinocytes onto a previously seeded and cul-
tured mixture of dermal fibroblasts and collagen matrix [49,50].
Despite their widespread use, manually fabricated layered skin tissue models lack 
some complexity in relation to native architecture, which may reduce correlation 
with in vivo data [17,50,51]. In addition, reproducibility of manually fabricated skin 
tissues may be lower than desired. Alternative methods can be employed to achieve 
three-dimensional tissue structures including seeding of cells onto porous microcar-
rier scaffolds, spheroids/cell aggregates, and bioprinting [5,52,53]. Tissue-engineering 
approaches utilizing cell-seeded porous biomaterial scaffolds, such as static surface 
seeding and cell injection, can enable the creation of larger structures [54]. However, 
seeded scaffolds suffer from a lack of precision of cell placement and nonuniform 
cell distribution that can result in insufficient intracellular interactions and mechanical 
properties, impeding subsequent development of the native-like cellular density re-
quired for normal skin function. Spheroids and aggregates can provide higher cellular 
density and can be used as building blocks to create spatially arranged clusters by 
utilizing inherent properties of cell-cell and cell-matrix adhesion [5,30]. Spheroids can 
be formed by seeding cells on to nonadhesive surfaces or by incubating a suspension 
as a hanging drop [55]. When allowed to fuse in micromolds containing recesses, 
spheroids can also be used to fabricate simple shapes [56]. By virtue of their simple 
fabrication approaches and low cellular input requirements, spheroids can be adapted 
to high-throughput applications. It may be difficult, however, to control the uniformity 
of spheroid size and to achieve the desired microarchitecture and reproducible cell pat-
terning associated with native tissue. Furthermore, the air-liquid interface required for 
native skin development and function may not be compatible with in vitro fabrication 
methodologies that require continuous cell submersion in culture media.
3.2  Bioprinted 3D skin tissues
When compared with both manual seeding and other 3D fabrication approaches, bio-
printing confers many advantages. Automated processes like bioprinting often lead to 
improved reproducibility when compared with manual approaches. Manual full- thick-
ness 3D skin models often require a minimum of 3–4 weeks to obtain a layered skin-
like structure. Bioprinting can be employed to overlay sheets of cells  simultaneously 
to create complex architecture from the beginning, thus enabling a shorter time period 
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for maturation [49]. A key limitation of both cell-seeded scaffolds and  spheroids is 
the ability to control deposition with microscale x, y, and z dimensional precision. 
Using a flexible bioprinting approach, engineers can incorporate specialized cell pop-
ulations in precise controlled architecture into either full-thickness skin or individual 
layers such as epidermal tissue or dermal tissue alone to better model complex ef-
fects. Deposition of specialized cell types like follicular dermal papillae, sebocytes, 
or cancer cells within specific layers or 3D compartments within the tissue could al-
low for the formation of hair follicles and sebaceous glands and even melanomas for 
compound efficacy and disease modeling, as well as implantation where appropriate. 
Finally, another advantage of an automated bioprinting approach is scalability; larger 
bioprinted skin structures can be fabricated as implants or engraftments to reconstruct 
the 3D morphology of a wound, while miniaturized tissues can be produced to enable 
high-throughput applications for in vitro compound screening purposes in multiwell 
formats [24,57]. Bioprinted skin models therefore have the potential to fill unmet 
needs in many applications of skin research including cosmetic, chemical, pharma-
ceutical, wound healing, and disease modeling. Researchers have begun to utilize a 
variety of bioprinting approaches to achieve these goals (Table 2).
3.2.1  Extrusion-based bioprinted skin
Extrusion-based bioprinting has been successfully utilized to develop reproduc-
ible, spatially controlled architecture in  vitro for multiple tissue types including 
liver and kidney, thus enabling biochemical, genetic, and histological interrogation 
following exposure to modulators of interest for toxicology and disease modeling 
[58-62]. Researchers at Organovo, Inc. recently demonstrated a novel scaffold-free 
 extrusion-based bioprinted skin model using the NovoGen Bioprinter Platform. In 
this study, tissues were fabricated with normal primary human dermal fibroblasts and 
primary keratinocytes to produce tissue that exhibited distinct layered epidermal and 
dermal compartments with stratified epidermal architecture and collagen production 
in the dermal layer. The model was developed in a multiwell format for screening ap-
plications and exhibited an injury response to known toxicants SDS or Triton X upon 
treatment, with reduced viability and demonstrated spikes in IL1a production within 
the time frame of exposure [63].
Extrusion-based printing approaches have also recently been used to explore fab-
rication of skin appendages. Research by Liu et al. utilized a pneumatic 3D bioprint-
ing system with two cell-laden bioinks composed of murine embryonic epithelial 
progenitor cells, gelatin, and cross-linked alginate in a layered crisscross pattern to 
generate square-pore structures. These structures, which also contained a milieu of 
ECM components including bone morphogenetic protein-4 (BMP-4) and planter der-
mis to mimic an inductive niche, were subsequently cultured in vitro to induce sweat 
gland morphogenesis [37]. Normal architecture of a sweat gland is a bilayered tissue 
consisting of a hollow center lined by an inner layer of secretory (luminal) cells and 
an outer layer of myoepithelial cells surrounded by a basement membrane. Glands 
are formed by invaginations of CK5/CK14 positive cells. As the tubular structure ex-
tends, cells of the inner layer differentiate into CK8/CK18 luminal cells, while cells 
of the outer layer remain CK5/CK14 positive [64]. In this study, cell aggregation and 
Technology Biomaterials Cell types
Bioink cell 
density Resolution
Aspect 
of skin 
bioprinted Dermal approach
Epidermal 
approach
Key results 
achieved
Tissue 
structure, 
dimensions References
Extrusion-
based
nd Primary human dermal 
fibroblasts, primary 
human epidermal 
keratinocytes
>50 million 
cells/mL
100 μm Dermis +  
epidermis
Fibroblast layers Keratinocyte 
layers
Proliferation 
observed by PCNA 
staining 14 days 
post print
4 × 4 mm2 [63]
Alginate, 
gelatin
Murine embryonic 
epithelial progenitor 
cells
nd 300–400 μm Gland 
structure
n/a n/a Viability observed 
by fluorescence 
5 days post print
20 × 20 × 5 mm 
crisscross 
blocks and 
square pores
[37]
Droplet-
based, 
microvalve
Collagen Primary adult human 
dermal fibroblasts, 
primary adult 
human epidermal 
keratinocytes
1 million  
cells/mL
200–900 μm (interdispensing 
distance), nanoliter range 
droplets, 1–3 psi, valve open time 
450–600 μs
Dermis +  
epidermis
Alternating printed 
layers of fibroblast 
suspension and 
collagen
Alternating 
printed layers 
of keratinocyte 
suspension and 
collagen
85%–95% viable 
by calcein AM 
staining 3 h after 
dispensing
10 × 10 mm2, 
10 layers
[10]
Collagen HFF-1, HaCaT 0.5–5 million 
cells/mL
500 μm (interdispensing 
distance), nanoliter range 
droplets, 1.4–2.7 psi; valve open 
time 750 μs
Dermis +  
epidermis
Alternating printed 
layers of HFF-1 
suspension and 
collagen
Alternating 
printed layers 
of HaCaT 
suspension and 
collagen
84%–98% viable 
by propidium 
iodide staining 
7 days post print
6 × 6 × 1.2 mm, 
16 layers
[31]
Collagen, 
fibrinogen, 
thrombin
Amniotic fluid-derived 
stem cells (AFS) and 
mesenchymal stem 
cells (MSC)
16.6 million 
cells/mL
nd Dermis Alternating layers 
of AFS or MSC in 
fibrinogen/collagen 
and thrombin
n/a Wound healing 
enabled, GFP-
tagged cells not 
observed after day 7
2.0 × 2.0 cm,  
5 layers
[23]
Droplet-
based, inkjet
PEG-based 
bioink
Primary human 
dermal fibroblasts 
(HDFa), primary 
human epidermal 
keratinocytes
9 million  
cells/mL
Dosing distance 0.05–0.90 mm, 
valve open time 200–250 μs, air 
pressure 0.25–1.25 bar, feed rate 
10 mm/s, thickness 0.01–0.05 mm
Dermis Alternating layers 
of fibroblast 
suspension and 
bioink topped with 
seven circular 
bioink layers
Manually 
deposited 
keratinocyte 
suspension
Dermal 
compartment viable 
up to 7 weeks by 
MTT
6 × 5.5 mm 
base, 15 
layers; 2.7 mm 
radius cylinder, 
seven layers
[9]
Collagen, 
fibrinogen, 
thrombin
Human microvascular 
endothelial cells 
(HMVEC), 
neonatal human 
dermal fibroblasts 
(NHDF), neonatal 
human epidermal 
keratinocytes (NHEK)
2 million  
cells/mL
nd HMVEC 
microvessel 
network
Manually 
deposited 
fibroblasts in 
collagen with 
fibrinogen overlay
Manually 
deposited 
keratinocytes in 
collagen
PKH26 staining 
visible 6 days 
post print, wound 
healing enabled
2.5 × 5 cm ×  
1.2 mm 
thickness 
with HMVEC 
grid pattern 
embedded
[32]
Droplet-
based; 
laser driven 
transfer 
 
 
 
 
 
 
 
 
Alginate, 
blood plasma, 
Matrigel
NIH3T3, HaCaT 33–66 million 
cells/mL
80–140 μm droplet, 70 μm line 
width and 200 μm line spacing, 
laser fluences 3–6 J/cm2, 50 μm of 
cell-containing bioink transferred
Dermis +  
epidermis
n/a n/a 90% ± 10% 
cell viability 
immediately post 
transfer
9.6 × 9.6 mm 
2D chessboard 
pattern
[12]
Collagen, 
Matriderm
NIH3T3, HaCaT 33 million 
cells/mL
0.1–1 nL transferred volume, 
laser fluences 1–2 J/cm2, 60 μm 
of cell-containing collagen 
transferred
Dermis +  
epidermis
20 layers of 
NIH3T3 cells 
embedded within 
collagen
10–20 layers 
of HaCaT cells 
embedded 
within collagen
Proliferation 
observed by Ki-67 
staining 10 days 
post print
10 × 10 × 2 mm [33]
Collagen, 
Matriderm 
 
 
NIH3T3, HaCaT 
 
 
 
41 million 
cells/mL 
 
 
60 μm of cell-containing collagen 
transferred 
 
 
Dermis +  
epidermis 
 
 
20 layers of 
NIH3T3 cells 
embedded within 
collagen 
20 layers of 
HaCaT cells 
embedded 
within collagen 
Ki-67 staining 
observed in 
suprabasal layers 
11 days post 
engraftment
2.3 × 2.3 cm 
 
 
 
[34] 
 
 
 
Table 2 Examples of bioprinted skin
nd, not discussed; n/a, not applicable.
Technology Biomaterials Cell types
Bioink cell 
density Resolution
Aspect 
of skin 
bioprinted Dermal approach
Epidermal 
approach
Key results 
achieved
Tissue 
structure, 
dimensions References
Extrusion-
based
nd Primary human dermal 
fibroblasts, primary 
human epidermal 
keratinocytes
>50 million 
cells/mL
100 μm Dermis +  
epidermis
Fibroblast layers Keratinocyte 
layers
Proliferation 
observed by PCNA 
staining 14 days 
post print
4 × 4 mm2 [63]
Alginate, 
gelatin
Murine embryonic 
epithelial progenitor 
cells
nd 300–400 μm Gland 
structure
n/a n/a Viability observed 
by fluorescence 
5 days post print
20 × 20 × 5 mm 
crisscross 
blocks and 
square pores
[37]
Droplet-
based, 
microvalve
Collagen Primary adult human 
dermal fibroblasts, 
primary adult 
human epidermal 
keratinocytes
1 million  
cells/mL
200–900 μm (interdispensing 
distance), nanoliter range 
droplets, 1–3 psi, valve open time 
450–600 μs
Dermis +  
epidermis
Alternating printed 
layers of fibroblast 
suspension and 
collagen
Alternating 
printed layers 
of keratinocyte 
suspension and 
collagen
85%–95% viable 
by calcein AM 
staining 3 h after 
dispensing
10 × 10 mm2, 
10 layers
[10]
Collagen HFF-1, HaCaT 0.5–5 million 
cells/mL
500 μm (interdispensing 
distance), nanoliter range 
droplets, 1.4–2.7 psi; valve open 
time 750 μs
Dermis +  
epidermis
Alternating printed 
layers of HFF-1 
suspension and 
collagen
Alternating 
printed layers 
of HaCaT 
suspension and 
collagen
84%–98% viable 
by propidium 
iodide staining 
7 days post print
6 × 6 × 1.2 mm, 
16 layers
[31]
Collagen, 
fibrinogen, 
thrombin
Amniotic fluid-derived 
stem cells (AFS) and 
mesenchymal stem 
cells (MSC)
16.6 million 
cells/mL
nd Dermis Alternating layers 
of AFS or MSC in 
fibrinogen/collagen 
and thrombin
n/a Wound healing 
enabled, GFP-
tagged cells not 
observed after day 7
2.0 × 2.0 cm,  
5 layers
[23]
Droplet-
based, inkjet
PEG-based 
bioink
Primary human 
dermal fibroblasts 
(HDFa), primary 
human epidermal 
keratinocytes
9 million  
cells/mL
Dosing distance 0.05–0.90 mm, 
valve open time 200–250 μs, air 
pressure 0.25–1.25 bar, feed rate 
10 mm/s, thickness 0.01–0.05 mm
Dermis Alternating layers 
of fibroblast 
suspension and 
bioink topped with 
seven circular 
bioink layers
Manually 
deposited 
keratinocyte 
suspension
Dermal 
compartment viable 
up to 7 weeks by 
MTT
6 × 5.5 mm 
base, 15 
layers; 2.7 mm 
radius cylinder, 
seven layers
[9]
Collagen, 
fibrinogen, 
thrombin
Human microvascular 
endothelial cells 
(HMVEC), 
neonatal human 
dermal fibroblasts 
(NHDF), neonatal 
human epidermal 
keratinocytes (NHEK)
2 million  
cells/mL
nd HMVEC 
microvessel 
network
Manually 
deposited 
fibroblasts in 
collagen with 
fibrinogen overlay
Manually 
deposited 
keratinocytes in 
collagen
PKH26 staining 
visible 6 days 
post print, wound 
healing enabled
2.5 × 5 cm ×  
1.2 mm 
thickness 
with HMVEC 
grid pattern 
embedded
[32]
Droplet-
based; 
laser driven 
transfer 
 
 
 
 
 
 
 
 
Alginate, 
blood plasma, 
Matrigel
NIH3T3, HaCaT 33–66 million 
cells/mL
80–140 μm droplet, 70 μm line 
width and 200 μm line spacing, 
laser fluences 3–6 J/cm2, 50 μm of 
cell-containing bioink transferred
Dermis +  
epidermis
n/a n/a 90% ± 10% 
cell viability 
immediately post 
transfer
9.6 × 9.6 mm 
2D chessboard 
pattern
[12]
Collagen, 
Matriderm
NIH3T3, HaCaT 33 million 
cells/mL
0.1–1 nL transferred volume, 
laser fluences 1–2 J/cm2, 60 μm 
of cell-containing collagen 
transferred
Dermis +  
epidermis
20 layers of 
NIH3T3 cells 
embedded within 
collagen
10–20 layers 
of HaCaT cells 
embedded 
within collagen
Proliferation 
observed by Ki-67 
staining 10 days 
post print
10 × 10 × 2 mm [33]
Collagen, 
Matriderm 
 
 
NIH3T3, HaCaT 
 
 
 
41 million 
cells/mL 
 
 
60 μm of cell-containing collagen 
transferred 
 
 
Dermis +  
epidermis 
 
 
20 layers of 
NIH3T3 cells 
embedded within 
collagen 
20 layers of 
HaCaT cells 
embedded 
within collagen 
Ki-67 staining 
observed in 
suprabasal layers 
11 days post 
engraftment
2.3 × 2.3 cm 
 
 
 
[34] 
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 differentiation were observed within the pore-like structure with epidermal marker 
expression (CK5 and CK14) transitioning to luminal epithelial marker expression 
(CK18 and CK19), suggesting successful movement toward a sweat gland phenotype. 
These data demonstrate that a 3D bioprinted microenvironment can direct formation 
of skin appendages including glandular morphogenesis and may also pave the way 
toward formation of sebaceous glands and hair follicles (Fig. 3).
3.2.2  Droplet-based bioprinted skin
Several methods utilizing droplet-based approaches to bioprint multilayered 3D 
skin tissues composed of dermal fibroblasts and keratinocytes have been reported 
[9,10,23,31,32]. In two recent microvalve studies, skin tissue was fabricated by first 
dispensing a nebulized mist of cross-linking agent followed by collagen droplets to 
form a basal gel layer [10,31]. The process was repeated layer by layer to increase 
structure thickness. During the process, fibroblasts or keratinocytes were dispensed 
dropwise onto partially cross-linked hydrogel to embed within selected layers, pro-
ducing spatially distinctive cell layers separated by collagen to represent the dermis 
and epidermis, respectively. The authors demonstrated that these engineered skin tis-
sues composed of collagen-encapsulated primary adult epidermal keratinocytes or 
dermal fibroblasts maintained distinct layers visible by confocal microscopy after 
4 days of culture [10]. One advantage described for the microvalve approach is that it 
permits noncontact droplet dispensing onto nonplanar surfaces such as polydimeth-
ylsiloxane (PDMS) molds, which may be critical for future fabrication of tailored 
skin grafts. Expanding on this method, V. Lee et al. performed a follow-up study in-
creasing the number of cell layers printed (13 layers in total) in the tissue with HFF-1 
and HaCaT cell lines and extending culture conditions to include a 14-day air-liquid 
interface. Distinct epidermal and dermal layers were again maintained. It was also 
observed that the epidermal layer thickened over time suggesting that the tissue was 
differentiating, although keratinocyte stratification was incomplete [31]. Both studies 
Fig. 3 Examples of skin tissue fabricated by extrusion-based bioprinting approaches. 
(A) Organovo NovoGen Bioprinter Platform. (B) Histological analysis showed bilayered 
architecture with distinct epidermal and dermal compartments and stratified epidermal 
keratinocytes (H&E). Trichrome staining (TCM) demonstrated collagen production (blue) in 
the dermal compartment. Immunofluorescent staining showed a distinct layer of cytokeratin 
10 (CK10) positive keratinocytes (red) and blue nuclei (DAPI), indicating development of 
a spinous layer within the epidermis. Further immunofluorsencent analysis confirmed the 
presence of cytokeratin 5 (CK5)-positive basal keratinocytes (green) with distinct columnar 
morphology beneath a layer of flattened, differentiated spinous/granular involucrin  
(IVL)- positive keratinocytes (red) with blue nuclei (DAPI).
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reported high viability (>85%) associated with the microvalve approach. This may 
have been due to their use of a relatively large-diameter nozzle (150 μm) and low 
pneumatic pressure (1–3 psi) to minimize the cell damage associated with inkjet and 
laser-based approaches. Despite these benefits, the authors cited some limitations of 
the approach including cell clogging at higher cell suspension concentrations (fibro-
blasts >3.0 × 106 cells/mL) and reduced viability at low concentrations.
A combination of automated and manual approaches was utilized by Rimann et al. 
to produce a full-thickness model [9]. First, a microvalve droplet approach was em-
ployed to produce dermal equivalents in a predefined pattern with seven alternating lay-
ers each of chemically defined UV cross-linked PEG-based bioink and primary human 
dermal fibroblasts in suspension. The printing design also included deposition of seven 
circular acellular bioink layers on top of the dermal structure to form a cylinder shape 
used for collection of the manually added primary human keratinocyte suspension. The 
dermal equivalents alone cultured in the absence of keratinocytes maintained viability 
for up to 7 weeks, highlighting that bioprinted tissues can serve as long-term culture 
models. Upon addition of the keratinocytes, constructs were subsequently cultured for 
14 days at an air-liquid interface. Histological evaluation did not show mature epider-
mal stratification and interestingly showed migration of the epidermal keratinocytes 
into the dermis, especially into dermal equivalents with short maturation times. This 
suggests that proper maturation and composition of the dermal layer may be import-
ant to achieve correct epidermal architecture. Although proper epidermal stratification 
and fibroblast spacing were not fully achieved, collectively, these microvalve studies 
demonstrate promising advances in achieving layered architecture in vitro.
Droplet-based bioprinted skin tissues have also been designed for therapeutic ap-
plications like wound healing and burn injuries. Recent work by Yanez et al. utilized 
a modified inkjet printer to deposit human microvascular endothelial cells (HMVEC) 
together with a manually mixed combination of collagen, neonatal human dermal fi-
broblast cells, and neonatal human epidermal keratinocytes to create a full- thickness 
skin graft. In this study, a dermal layer of fibroblast and collagen mixture was man-
ually deposited followed by a layer of fibrinogen. A grid-like pattern of HMVEC in 
thrombin was then inkjet printed to create a microvasculature network on top of the 
dermal layer. Finally, an epidermal layer containing a mixture of keratinocytes in col-
lagen was manually added to create a tissue with integrated printed vasculature em-
bedded within a bilayered skin graft. When implanted into the back of athymic nude 
mice, tissue retained viability, epidermal and dermal layers, and promoted neovascu-
logenesis [32]. Droplet-based methodologies have also been incorporated into an in 
situ bioprinting approach for wound repair in vivo. Researchers dispensed alternating 
layers of cell-laden fibrin-collagen hydrogels (containing green fluorescent protein 
(GFP)-labeled amniotic fluid-derived stem (AFS) cells) and thrombin directly into a 
murine full-thickness wound [23]. When followed histologically over time, the GFP-
labeled cells did not permanently integrate into surrounding tissue, but were believed 
to guide tissue repair through secretion of growth factors. The tissue covered 100% of 
the wound and enabled accelerated wound closure and increased neovasuclarization 
compared with hydrogel alone, suggesting that noncontact droplet-based bioprinting 
may be a viable therapeutic approach for wound healing (Fig. 4).
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Fig. 4 Examples of skin tissue fabricated by droplet-based bioprinting approaches. (A) Schematic of deposition approach with 
multilayered skin cells and collagen. (B) Confocal microscopy images of printed skin after 4 days in submerged culture conditions with 
keratin-containing keratinocyte layer (green) and b-tubulin-containing fibroblasts (red). (C) Confocal microscopy images of printed skin 
after 7 days in submerged culture conditions showed layered architecture with distinct epidermal and dermal compartments. Live cell 
nuclei are stained green with distinct rounded keratinocyte and elongated fibroblast morphologies.
Reproduced with permission from Lee W, Debasitis JC, Lee VK, Lee JH, Fischer K, Edminster K, et al. Multi-layered culture of human 
skin fibroblasts and keratinocytes through three-dimensional freeform fabrication. Biomaterials 2009;30(8):1587–95. Lee V, Singh G, 
Trasatti JP, Bjornsson C, Xu X, Tran TN, et al. Design and fabrication of human skin by three-dimensional bioprinting. Tissue Eng Part C 
Methods 2014;20(6):473–84.
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Laser-based bioprinting of skin tissues has been demonstrated by a group from the 
Hannover Medical School and Laser Zentrum Hannover [12,33,34]. Their initial work 
utilized a donor slide with labeled murine NIH3T3 fibroblasts or human HaCaT ke-
ratinocytes encapsulated within a hydrogel of alginate and blood plasma printed onto 
a collector slide containing Matrigel. They produced 2D patterning in the form of a 
chessboard with alternating green- and blue-labeled cells, highlighting the ability of 
the bioprinter to produce specific predefined patterns with high resolution and without 
major changes in cell viability and proliferation [12]. Follow-up work demonstrated 
the production of 3D patterned structures by overlaying seven alternating layers of 
red- and green-labeled keratinocytes. Having verified both xy and z patterning ca-
pability, this method was then used to produce more complex bilayered skin tissue 
architecture by dispensing 20 layers of NIH3T3 cells embedded within neutralized 
collagen gel onto a Matriderm collector slide followed by 10–20 layers of HaCaT 
cells embedded within the same gel matrix on top, with droplet volumes ranging from 
0.1 to 1 nL. [33,34]. The authors show histologically that the individual layers of the 
tissue do not intermix over the 10-day culture period. Furthermore, the cells are viable 
and form intercellular adhesions between epidermal cells and a basal lamina between 
epidermal and dermal layers. Although the tissues exhibit features of the normal skin, 
histological analysis showed that collagen remnants from the printing process still 
detected within the epidermis and keratinocytes that were not stratified into distinct 
differentiated layers, suggesting that the embedding of keratinocytes into a matrix 
may impair epidermal tissue formation. Interestingly, the bioprinted skin tissue mor-
phology was improved when engrafted into a dorsal skinfold chamber in nude mice; 
bioprinted skin cultured in vivo had improved organization within the epidermis and 
vascular invasion into the Matriderm from the wound bed [34]. Side-by-side compar-
ison of constructs cultured in vitro and in vivo demonstrates the importance of the 
surrounding microenvironment to modulate tissue differentiation and further supports 
the potential for bioprinted skin tissues in therapeutic applications (Fig. 5).
4  Summary and future directions
Three-dimensional bioprinting allows for the reproducible fabrication of spatially or-
dered and complex multicellular structures with controlled microenvironments, thus 
providing more native biophysical and biochemical cues to enhance cellular cross 
talk and tissue differentiation. Recent progress in bioprinting 3D skin tissues provides 
proof of concept that this approach can produce viable tissues composed of distinct 
dermal and epidermal layers. The variety of methodologies employed successfully 
to date highlights the versatility of these automated computer-controlled design plat-
forms and the broad compatibility of the skin with the use of automated manufac-
turing approaches. However, most approaches to date have yielded tissues that lack 
both the cell density of native tissue and a fully mature stratified epidermis. To go 
beyond these basic features, complex tissue designs will require incorporation of ad-
ditional specialized cell types such as immune cells, melanocytes, and dermal papilla 
cells and microcompartment appendages like sebaceous glands, eccrine glands, and 
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hair  follicles. Incorporation of perfusable vasculature may also be necessary for larger 
tissues including skin grafts and for providing oxygen and nutrients to support the 
long-term viability of smaller full-thickness tissues. In most research to date, each 
investigator has applied their singular bioprinting technique of interest to generate 3D 
skin tissues. Continuing advancements in each specific deposition method and in the 
biomaterials available may improve printing resolution and tissue architecture to more 
closely mimic native skin. However, integration of these fabrication platforms will 
likely be key to increasing capability; the method that works best to create the layered 
dermal and epidermal compartments may not be effective for creating planar com-
partments containing additional features such as sweat glands, and the biomaterials 
currently compatible with keratinocytes and dermal fibroblasts may not support more 
specialized cell types. Despite the progress made on fabrication, many studies still fail 
to verify the functional attributes of their engineered skin equivalents. Postfabrication 
maintenance of complex engineered tissue requires tight regulation of environmen-
tal elements such as media and physical stress and strain to support viability, induce 
differentiation, and preserve the skin-like attributes for utilization in vitro. Bioprinted 
In vitro
Laser absorbing layer
Laser pulse
Gel with cells
In vivo
(A)
(C)
(B)
Fig. 5 Examples of skin tissue fabricated by laser-based bioprinting approaches.  
(A) Schematic of laser deposition approach. (B) Fluorescent microscopy demonstrated 2D 
micropatterning of fluorescently labeled fibroblasts (green) and keratinocytes (red,left panel), 
alternating red- and green-labeled keratinocyte layers (center panel), and distinct epidermal 
and dermal layering of full-thickness skin tissue with fibroblasts stained in red (pan-reticular 
fibroblast), and keratinocytes are stained in green (cytokeratin 14, right panel). (C) Masson’s 
trichrome staining of cells (red) and collagen (green) showed differences in morphology 
between bioprinted skin tissues cultured in vitro or in vivo.
Reproduced with permission from Koch L, Deiwick A, Schlie S, Michael S, Gruene M, Coger 
V, et al. Skin tissue generation by laser cell printing. Biotechnol Bioeng 2012;109(7):1855–63. 
Michael S, Sorg H, Peck CT, Koch L, Deiwick A, Chichkov B, et al. Tissue engineered skin 
substitutes created by laser-assisted bioprinting form skin-like structures in the dorsal skin fold 
chamber in mice. PLoS One 2013;8(3):e57741.
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skin tissues remain to be validated for use in assessment of irritation, corrosion, ab-
sorption, and sensitization of topical chemicals. In addition, these engineered tissues 
have not yet been used as in vitro disease models, an area where novel culture systems 
are sorely needed [65,66]. Future studies will be required to define a framework of 
appropriate standards to validate the use of bioprinted models in these areas, thus con-
tributing to the principle of the 3Rs (replacement, reduction, and refinement) in order 
to decrease reliance on animal research and to ultimately provide enhanced predict-
ability of human response. While the field is young, advances in bioprinting in vitro 
skin tissues have the potential to transform disease modeling, drug development, and 
personalized medicine.
Abbreviations
3D three-dimensional
CAD computer-aided design
iPSC induced pluripotent stem cell
ECM extracellular matrix
CK cytokeratin
Glossary
Bioink Cells and/or cell-containing biomaterials used in the fabrication of tissue.
Biomaterials Substances compatible with living cells that can provide structural support 
during the fabrication or long-term culture of bioprinted 3D tissues.
Bioprinting An automated, spatially controlled 3D printing approach used to create ex vivo 
tissues and organs through the deposition of cell-containing “bioink.”
Dermis Layer of tissue supporting the epidermal layer composed mainly of dermal fibroblasts 
and connective tissue.
Droplet-based bioprinting Bioprinting methods that involve the creation and deposition of 
droplets at defined positions in three- dimensional space.
Epidermis Outermost layer of the skin composed mainly of keratinocytes organized into a 
highly stratified architecture distinguished by morphology and differentiation state.
Extracellular matrix (ECM) Complex mixture of extracellular molecules  surrounding cells 
that provides structural support and biochemical cues.
Extrusion bioprinting Bioprinting approach where material is deposited from a cassette or 
syringe cartridge through an orifice under pressure by pneumatic, piston-driven, or screw-
driven force.
Inkjet bioprinting Droplet-based bioprinting approach involving the ejection of droplets 
containing either cells or biomaterials from a reservoir in response to a pressure pulse gen-
erated by thermal or piezoelectric forces.
Laser bioprinting Droplet-based bioprinting approach utilizing laser pulses to create and 
dispense droplets onto a receiving surface.
Microsolenoid valve bioprinting Droplet-based bioprinting approach that uses the opening 
and closing of an electromechanical valve to generate droplets.
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1.  Introduction
The fabrication and application of 3-D skin tissues using iPSC-derived cells lie at the 
interface of the fields of tissue engineering and stem cell biology [1,2]. Tissue engi-
neering approaches to generate skin tissues use three-dimensional (3-D) extracellular 
matrices (ECM) as scaffolds that provide cells with a physical framework to create the 
spatial organization required to support cellular functions that occur in tissues [1,3,4]. 
For many years, 3-D skin tissues have been constructed with adult stem cells that 
differentiate to display in  vivo-like tissue architecture and function [5]. These 3-D 
skin-like tissues have been derived from cells differentiated from multipotent stem 
cells, capable of giving rise to multiple cell types, or from unipotent stem cells that 
can differentiate into a single cell type [6,7]. Induced pluripotent stem cells (iPSCs) 
now offer a novel source of stem cells that can be guided to specific cell lineages to 
yield progenitor cells that can be differentiated to a broad spectrum of cell types with 
functions well suited to skin tissue fabrication [1,8,9].
Skin-like tissues are composed of a stratified epithelium that is formed by differen-
tiated keratinocytes and dermis that contains fibroblasts that generate ECM and growth 
factors that guide epithelial growth and differentiation [1,10–12]. Three-dimensional 
skin tissues have been used to perform assays for tissue penetration, metabolism, pho-
totoxicity, and irritation to predict the absorption, metabolism, and toxicity (ADME/
Tox) features of test compounds. In addition, these tissues have been customized to 
study mechanisms of skin disease and acute and chronic skin processes such as wound 
healing, UV irradiation response, fibrosis, and inflammation. Fabricating skin tissues 
using iPSC-derived cells offers new opportunities to advance all of these experimental 
and drug screening outcomes by potentially eliminating barriers that currently limit 
skin tissue standardization and reproducibility needed for these applications.
Currently, potential new drugs are primarily screened using conventional, 2-D 
monolayer culture assays that do not display architectural and functional features of 
the human skin and are not highly predictive of drug responses in vivo [10]. The use 
of iPSC-derived cells has the potential to generate more reproducible, patient-specific 
skin tissues than are currently available to improve such preclinical safety and tox-
icity testing and drug development using a more “personalized” or patient-specific 
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approach [1,13–16]. This will require the development of approaches to screen and 
identify iPSC-derived cells that are best suited for the fabrication of 3-D skin tissues. 
In addition, these tissues can be used to determine the developmental capacity and 
cellular functions of iPSC-differentiated cells when incorporated into the in vivo-like 
tissue microenvironment of skin-like tissues and to enable ways to better assess their 
cellular behavior, safety, and efficacy before the future therapeutic use of iPSC- derived 
cells in humans.
This review will present an overview of the relevance of iPSC reprogramming and 
specific functional cell types for the generation of skin-like tissue models. We will 
first describe the features of cell reprogramming and the subsequent differentiation 
of iPSCs into cells able to fabricate these tissues. We will then discuss approaches 
through which iPSC-based technologies may be broadly applied for the fabrication 
of skin tissues and how they may help overcome barriers currently limiting the trans-
lational use of skin tissues. A schematic overview of reprogramming of primary cells 
to iPSCs and their sequential differentiation and incorporation into 3-D tissues is 
shown in Fig. 1.
2.  Reprogramming to iPSCs and differentiation into cell 
types needed for 3-D skin tissue fabrication
The breakthrough discovery of somatic cell reprogramming to create induced 
pluripotent stem cells (iPSCs) and decade of progress that has followed has 
Fig. 1 Derivation of induced pluripotent stem cells for skin tissues. Fibroblasts isolated from 
patients (A) are reprogrammed to a pluripotent state in monolayer culture (B). Following 
reprogramming, iPSCs can be maintained indefinitely in culture and differentiated when 
needed into mature cell types that can be patient- or disease-specific (C). These differentiated 
cells can be incorporated into 3-D skin models (D) and used for a variety of assays and 
applications for drug discovery or studying skin disease pathways (E).
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opened dramatic new opportunities to transform human health [1,7,17]. This 
transformative technology was first demonstrated by Yamanaka et  al., who 
showed that mouse iPSCs could be generated by delivering four transcription 
factors (Oct4/Klf4/Sox2/cMyc, OKSM) into skin-derived fibroblasts that repro-
grammed them to a pluripotent state [18]. This was followed by the reprogram-
ming of human iPSCs using the same transcription factors [19]. These cells 
demonstrated many features similar to human embryonic stem cells (hESCs) 
including cellular morphology, growth kinetics, unlimited expansion potential 
[20], telomerase activity, global patterns of gene expression, and capacity to dif-
ferentiate into cells from all germ layers [7,21]. Since their discovery a decade 
ago, tremendous progress has been made applying iPSC technology. Patient-
specific, iPSC-derived cells are now being used for modeling both monogenic 
and sporadic disease types. In combination with 3-D organoid technology, 
 iPSC-derived cells have recently been used in large-scale, drug screening appli-
cations for diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis, 
and fragile X syndrome and in regenerative medicine in an ongoing clinical trial 
using iPSC-derived retinal pigmented epithelial cells [17]. Importantly, iPSCs 
offer an alternative source of cells for 3-D tissue fabrication in addition to the 
primary, patient-derived cells typically used. Following their reprogramming 
from patient-derived somatic cells, iPSCs can be maintained indefinitely un-
der defined culture conditions and subsequently differentiated into lineage- and 
patient-specific cells with a wide spectrum of cellular phenotypes. As a result, 
the controlled differentiation of functional cell types from iPSCs can establish a 
replenishing cell source for skin tissue fabrication.
To harness the potential of pluripotent stem cells for skin tissue fabrication, it 
is necessary to predictably and reproducibly control the differentiation of iPSCs to 
specific cell lineages and cell types. The directed differentiation of iPSCs recapitu-
lates lineage fate decisions that occur during human embryonic development in vivo 
[8,22–24]. One important variable in establishing iPSC differentiation is the substrate 
or cell feeder layers that provides essential cell-cell or cell-matrix contact needed to 
direct iPSC-derived cells to specified lineages [25,26]. Another factor directing plu-
ripotent stem cell differentiation is the presence of soluble growth factors [27], such 
as WNT, Nodal, and BMP, which are dynamically coordinated during specification to 
endodermal, ectodermal, or mesenchymal cell lineage fates. Outcomes of exposure 
of pluripotent stem cells to these signaling mediators are temporally controlled. For 
example, BMP signaling during the early stage of differentiation induces ectodermal 
specification but inhibits neuronal differentiation during later stages of differentiation 
where it promotes selection of definitive ectoderm or epidermal lineages needed for 
skin tissue fabrication [28]. By providing specific growth substrates and a well- defined 
soluble growth milieu, it is possible to provide a controlled environment that can be 
tuned to modulate gene expression profiles specifically needed for the differentiation 
of iPSCs to a skin cell type of interest.
Methods that rely on temporally controlled growth substrates and well-defined 
growth factor combinations have been developed to differentiate iPSCs into multiple 
cell types that can be incorporated into 3-D skin tissues. Deriving these cell types, 
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including keratinocytes, fibroblasts, melanocytes, endothelial cells, macrophages, and 
folliculogenic epithelial stem cells, is as follows:
 (A) Keratinocytes—iPSC-derived keratinocytes have been shown to support the differentia-
tion of surface epithelial cells that possess long-term self-renewing properties in 3-D skin 
tissue models. These studies have shown that both the ECM substrate and the growth me-
dia used are critical for this process. Early reports showed that BMP4 effectively directs 
the differentiation of mouse ESCs into epidermal cells when undifferentiated ESCs were 
grown on ECM deposited by human neonatal fibroblasts [29,30]. Human ESCs have been 
differentiated into keratinocytes using BMP4 and ascorbic acid [31] or in growth media 
containing all-trans retinoic acid, BMP4, and FAD medium containing insulin, adenine, 
hydrocortisone, cholera toxin, and EGF and were supported by a fibroblast feeder layer 
[32]. In a report comparing different growth surfaces, keratinocytes were derived from 
iPSCs using supplementation of retinoic acid, BMP4, and cultured sequentially on vi-
tronectin, fibronectin, and type I collagen, which increased differentiation efficiency. 
iPSCs have been differentiated to keratinocyte lineages by culturing them in the pres-
ence of BMP4, vitamin A, and all-trans retinoic acid on a decellularized human dermal 
 fibroblast-derived ECM and through the preferential adherence to type IV collagen, which 
allowed selection based on the expression of keratinocyte markers, keratin 14 and p63 
[33]. Treatment of  iPSC-derived keratinocytes with Y-27632 and EGF stimulated prolifer-
ation and enabled derivation of sufficient number of cells to produce 3-D skin tissues [34]. 
Long-term renewal of human iPSC-derived keratinocytes was achieved by differentiating 
keratinocytes from teratomas generated from iPSCs. These human iPSC teratoma-derived 
keratinocytes were used to fabricate 3-D skin tissues that were engrafted into mice and 
successfully persisted for 12 weeks [35].
 (B) Fibroblasts—As fibroblasts are known to regulate cell-cell cross talk and ECM produc-
tion needed for skin tissue growth and differentiation [36,37], they are a critical cell type 
for the fabrication of 3-D skin tissues. Fibroblasts have been successfully generated from 
hESCs, which has been informative for their generation from iPSCs. hESCs have been 
differentiated into fibroblasts from embryoid bodies (EBs) embedded in type I collagen 
that expressed fibroblast markers such as vimentin and αSMA and displayed typical fi-
broblast phenotypes, migratory properties, and gel contraction [38, 39]. Similarly, fibro-
blasts have also been generated using EBs derived from iPSCs by using ascorbic acid and 
TGFβ2  supplementation [40]. iPSCs have been differentiated into fibroblast and epithelial 
lineages from the same source, suggesting an ectomesenchymal origin for these cell types 
[11]. The step-by-step differentiation of fibroblasts from iPSCs has been shown to occur 
over the course of 28 days as fibroblastic cells emerge from iPSCs that show a similar 
phenotype to fibroblasts differentiated from pluripotent hESCs (Fig. 2).
 (C) Melanocytes—Melanocytes are melanin-producing cells that protect the skin from UV ir-
radiation and are responsible for skin pigmentation. They were first generated from hESCs 
and were successfully grafted when incorporated into human 3-D skin tissue equivalents 
[41]. Melanocytes have been generated from both hESCs and hiPSCs using BMP4 to re-
capitulate developmental stages of differentiation from neural crest-like cells and have 
been differentiated from mouse and human iPSCs using Wnt3a, SCF, and ET-3 [42,43]. 
iPSC-derived melanocytes have been shown to transfer melanin to iPSC-derived keratino-
cytes which confirmed their functionality and provided evidence of an all iPSC-derived 
epidermal-melanin unit in the skin [44]. Several disease models have attempted to recapit-
ulate pigmentation defects using human iPSC-derived melanocytes, including Hermansky-
Pudlak and Chédiak-Higashi syndromes [45].
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 (D) Macrophages and endothelial cells—Evaluating how inflammatory responses and an-
giogenesis may contribute to altered wound healing and a range of skin disorders could 
be achieved by incorporating macrophages and endothelial cells into 3-D skin tissues. 
Currently, human iPSCs have been differentiated into cells in monocyte/macrophage lin-
eages [46,47] that were proved to be MYB-independent, tissue resident macrophages re-
lated to cell types such as microglia, Kupffer cells, and Langerhans cells and were not 
related to hematopoietic stem cell origin, which are known to be MYB-dependent (i.e., 
skin macrophages) [48]. Endothelial cells have also been derived from iPSCs [49–52]. 
Using these cells to create blood-vessel-like structures in 3-D skin tissues would model 
skin disorders and could enable more efficient in vivo grafting of 3-D tissues.
 (E) Skin appendages—Folliculogenic epithelial stem cells (EpSCs) are cells that can generate 
keratinocytes and all hair follicle cell lineages and are defined by the presence of surface 
markers CD200 and ITGA6. Recently, EpSCs have been differentiated from iPSCs [53]. 
It has also been shown that a functional “integumentary organ system” can be generated 
after in vivo transplantation of iPSC-derived EBs that were embedded in collagen gels. 
This approach demonstrated the feasibility of efficiently generating epithelium and skin 
appendage cells, including hair follicles and sebaceous glands, from iPSCs that will be 
beneficial for the construction of 3-D skin-like tissues [54].
Since stromal and epithelial compartments of the skin are interdependent through 
their paracrine growth factor signaling [37], iPSCs offer an advantage by allowing 
3-D skin tissues to be constructed from multiple, isotypic cell types that can be 
derived from patient-specific iPSC clones. Further refinement of reprogramming 
to iPSCs and differentiation to multiple skin-specific cell types will improve our 
understanding of key regulatory signals needed to generate iPSC-derived cells with 
optimal functional properties that can further improve the morphology and function 
of 3-D skin tissues.
Fig. 2 iPSCs show emergence of fibroblasts during sequential stages of differentiation. 
Human embryonic stem cells (hESCs) and iPSCs were differentiated in parallel, using 
identical differentiation procedures, and monitored for cell morphology at various stages 
of differentiation. Representative images show the morphology of hESCs and two human 
foreskin-derived iPSC lines at days 1, 4, 7, 10, 14, 21, and 28 after initiation of differentiation. 
Fibroblast differentiation was first seen at the periphery of iPSC colonies (days 1 and 4). Cells 
soon acquired features of elongated stellate cells (day 10) that followed a similar time course 
to hESC differentiation. Cell lines showed characteristic fibroblast morphology at days 21 and 
28 after iPSC differentiation [11].
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Reprogramming somatic cells to a pluripotent state opens new opportunities 
for improvements in the fabrication of skin-like tissues. This will occur by devel-
oping approaches through which iPSC-derived cells can be tested to determine if 
they offer functional improvements when compared with the parental skin cells 
from which these iPSCs were originally reprogrammed [12, 20]. In order to be 
utilized for 3-D tissue fabrication, fibroblasts derived from iPSCs need to pro-
duce the ECM proteins and growth factors that are required to support epithelial 
growth and differentiation and maintain their functional stability throughout the 
tissue fabrication process. The potential uses of iPSC-derived fibroblasts for en-
gineering the 3-D skin can be advanced by leveraging the improved cellular func-
tions seen when fibroblasts have been differentiated from iPSCs and compared 
with the primary fibroblasts from which they were initially reprogrammed. For 
example, it has been shown that iPSC-derived fibroblasts that were initially re-
programmed from senescent fibroblasts from elderly patients showed augmented 
cellular function that included evasion of cell senescence, elongation of telomeres, 
and enhanced mitochondrial function [55]. This suggests that iPSC reprogramming 
may partially reverse the “biological clock” of the somatic cells from which they 
were reprogrammed.
Next, fibroblasts derived from iPSCs have been shown to produce greater amounts 
of ECM proteins than the parental cells from which they were derived, which may 
improve tissue fabrication when incorporated into skin tissues. These studies were 
performed in a skin tissue model that simulates the features of dermis when grown 
in the absence of keratinocytes [12]. In this tissue model, dermal fibroblasts pro-
duce and assemble an endogenous, human stroma-like tissue composed of collagen 
and fibronectin. Such dermis-like connective tissue structures have been defined as 
“self-assembled” ECM tissues [56]. When these tissues are grown in the presence 
of ascorbic acid, iPSC-derived fibroblasts have been shown to have elevated ECM 
production and deposition, when compared with the parental fibroblasts from which 
they were reprogrammed [12]. The analysis of the composition of these stromal 
tissues has revealed that those containing iPSC-derived fibroblasts produced greater 
amounts of type III collagen when compared with tissues derived from their pa-
rental fibroblasts, indicating their similarities to provisional matrix seen during the 
early stages of wound repair. This demonstrates that iPSC-derived fibroblasts may 
represent a replenishing source of potent fibroblasts that may be useful to study a 
range of connective tissue disorders of the skin, such as chronic wounds and fibrosis. 
Importantly, functional differences between iPSC-derived fibroblasts and fibroblasts 
from which they were reprogrammed were only fully revealed when these cells 
were incorporated into the complex, in vivo-like 3-D tissue environments that more 
closely mimic human dermis.
Another existing challenge currently facing skin tissue fabrication using adult- 
derived primary cells is the incomplete repertoire of structural proteins that are pres-
ent in the dermal compartment of these tissues. For example, the absence of mature 
elastin and specific basement membrane proteins in current skin tissue models using 
adult-derived cells limits their ability to mimic chronic skin changes resulting from ag-
ing or UV exposure [36]. It may be possible to generate iPSC-derived tissue  scaffolds 
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that generate more complex dermal tissue constructs that more faithfully represent 
the stromal compartment of the human skin. This may be possible, as it has been 
shown that iPSC-derived fibroblasts produce and self-organize stromal tissue struc-
tures, known as “self-assembled” connective tissues that mimic the morphology and 
functional features of their in vivo counterparts [12]. Producing such broad repertoire 
of stable ECM components that have been shown to be assembled into a  dermis-like 
tissue by iPSC-derived fibroblasts would be a helpful advance in developing sustain-
able skin tissues that would also be critical to developing tissue models that will mimic 
chronic conditions of the skin.
Together, this demonstrates that fibroblasts differentiated from iPSCs can acquire 
an augmented biological potency when compared with their parental fibroblasts as 
characterized by their increased production and assembly of ECM, which are func-
tional features important for application of these cells in 3-D skin tissues [56]. This 
suggests that iPSC-derived cells will require rigorous phenotypic analysis in a variety 
of skin tissue models to determine if they have acquired functional properties that shift 
fibroblasts to an enhanced functional state, which can be leveraged to optimize skin 
tissue fabrication. A schematic of iPSC reprogramming and differentiation processes 
and their application in 3-D skin tissues is shown in Fig. 3.
Fig. 3 Generation of skin tissue models from iPSC-derived skin cells and potential 
applications. (A) iPSCs are generated by the transfer of transcription factors to adult somatic 
cells to become pluripotent resulting in reprogramming to an embryonic-like state. (B) iPSCs 
are differentiated to cells with functional and phenotypic properties of skin cells such as 
fibroblasts and keratinocytes, which (C) can then be characterized and introduced into 3-D 
skin tissues. These tissues can be used for applications and assays listed above.
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3.  Achieving tissue complexity by incorporating multiple 
iPSC-derived cell types into 3-D skin tissues
The implementation of iPSC-based approaches for tissue engineering is an exciting 
and rapidly evolving field that can be applied to 3-D skin tissue fabrication. Levenberg 
et al. first demonstrated that ectodermal and mesenchymal cells differentiated from 
hESCs could self-organize into tissues displaying 3-D epithelial structures that could 
integrate into the host upon transplantation [57]. Subsequent studies have demon-
strated that both epithelial cells [29] and stromal fibroblasts [11,12,24] generated 
from iPSCs could be incorporated into 3-D skin tissues that support the generation 
of a fully differentiated epithelium [29,40]. iPSCs derived from skin fibroblasts have 
been differentiated into stable and functional fibroblast lineages and incorporated into 
3-D skin models that support morphological development of foreskin-derived kerati-
nocytes [11] by producing soluble factors that stimulate epithelial growth and repair 
in 3-D skin tissues [12,58] (Fig. 4). Thus, tissues constructed with fibroblasts derived 
from iPSCs demonstrate 3-D tissue organization and functional features typical of the 
human skin. Three-dimensional human skin equivalents (HSEs) have been generated 
with iPSC-derived fibroblasts and iPSC-derived keratinocytes [40] or with primary 
human dermal fibroblasts that were combined with iPSC-derived keratinocytes [32]. 
More recently, human epidermal equivalents (HEEs) were generated from hESC- and 
iPSC-derived keratinocytes and subjected to sequential high-to-low humidity environ-
ments to generate a functional epidermal permeability barrier that will be essential for 
more precise skin disease modeling or drug development and testing [33].
Greater cellular complexity has been achieved by constructing 3-D skin tissues 
with fibroblasts, keratinocytes, and melanocytes that demonstrated melanosomes and 
the presence of pigmentation [44]. Human skin equivalents were also constructed 
with human primary fibroblasts and keratinocytes and micropatterned vascular net-
works. Alginate microchannels were created in the dermis of these tissues using 3-D 
printing that structured iPSC-derived endothelial cells, which allowed formation of 
vascular structures with robust endothelial barrier function. These 3-D human vascu-
larized skin constructs supported neovascularization when they were engrafted into 
SCID mice [49].
4.  Applications of 3-D skin tissues using iPSC-derived cells
An important opportunity in the development of 3-D skin tissues will be to gener-
ate personalized, tissue “surrogates” of their in  vivo counterparts [3,14]. This will 
require the development of patient-derived cell lines that will be reprogrammed to 
iPSCs and that stably express their functional phenotypes after incorporation into 
3-D tissues. The reprogramming of iPSCs from the dermis and epithelium of patients 
with skin diseases may enable the differentiation of iPSC-derived cells that could be 
used to fabricate disease-specific, skin tissue models that can recapitulate key stages 
of skin disease pathogenesis. Recent studies have shown that disease phenotypes of 
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Fig. 4 iPSC-derived fibroblasts support the development of a fully differentiated epithelium 
when incorporated into the stroma of 3-D skin tissues. Fibroblasts from two independent 
differentiations of hESCs and iPSCs were incorporated into a collagen gel, seeded with 
foreskin keratinocytes, and grown at an air-liquid interface. H&E staining of tissues reveals 
that BJ (A), hESC-derived EDK6 (D), hESC-derived EDK7 (G), iPSC-derived iPDK2 (J), and 
iPSC-derived iPDK4 (M) cells had an elongated morphology in the collagen gel and supported 
the growth and differentiation of keratinocytes. Immunostaining of these tissues shows the 
expression of fibroblast marker Thy-1 (green) in the stromal compartment of all tissues and 
K18 (red) within ESC- and iPSC-derived cells (B, E, H, K, and N). Type IV collagen (red), a 
basement membrane component, is localized at the region between the stromal and epidermal 
compartment, illustrating the initiation of basement membrane assembly in these skin tissues 
(C, F, I, L, and O) [11].
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iPSC-derived cells show improved functional phenotypes in 3-D tissue structures in 
skin tissues rather when compared with conventional monolayer cultures [59–62]. To 
date, iPSC-derived keratinocytes have been generated from patients with recessive 
dystrophic epidermolysis bullosa (RDEB) harboring COL7A1 mutation that causes 
chronic blistering. These RDEB patient-specific iPSC-derived keratinocytes were 
used to generate 3-D skin equivalents and formed all epidermal layers successfully 
[32]. Revertant iPSC-derived keratinocytes from patients with epidermolysis bullosa 
containing a mutation in the COL17A1 gene have been used in a 3-D skin tissue and 
demonstrate their promise as a screening platform to develop new therapies to treat 
patients with this disorder [63]. Attempts to model melanocyte disorders such as neu-
rofibromatosis type 1 have used pluripotent stem-cell-derived cells, but these have 
not yet been adapted for 3-D skin tissue models [64]. Similarly, melanocyte disorders 
including albinism, Griscelli syndrome, and vitiligo would benefit from developing 
iPSC-derived cells incorporated into 3-D skin tissue models [65]. In addition, a fetal 
rat model of myelomeningocele (MMC), a neural tube defect characterized by multi-
ple central and peripheral nervous system defects and skin defects, has been used to 
test 3-D human skin equivalents as a mean of fetal tissue modeling. In this study, kera-
tinocytes were differentiated from iPSCs that were reprogrammed from amniotic fluid 
of fetuses with twin-twin transfusion syndrome and trisomy 21. These iPSC-derived 
keratinocytes were then used to construct skin-like tissues leading to full or partial 
skin defect when implanted into a fetal rat MMC model [34].
Such application of iPSC-based technologies can facilitate the use of these skin 
disease models for precision medicine in ways that will lay the groundwork for per-
sonalized drug screening targeted to treating skin disease progression [1,2]. Through 
continued refinement of such disease-specific skin models using cells differentiated 
from patient-specific iPSCs, these skin tissues will lead to more personalized drug 
screening strategies that will enable a shift in the use of iPSC-derived cells from the 
current standard “disease in a dish” to more advanced “disease in a tissue” [2,7,16].
5.  Future development and applications of iPSC-derived 
cells in 3-D skin tissues and associated challenges
Despite their potential, the application of cells derived from disease- and 
 patient-specific iPSCs faces barriers that currently limit their implementation in 3-D 
skin tissues [14].
The application of iPSC-derived cells and tissues for regenerative therapies to 
treat human diseases will require the development of reliable methods to evaluate 
and ensure their safety and efficacy before application to humans [15,18,66,67]. For 
example, cells differentiated from iPSCs go through discrete developmental stages 
as early mesenchymal progenitors and emerge committed to specific mesenchymal 
lineage fates [68]. It has been previously shown that mesenchymal stem cells (MSCs) 
differentiated from iPSCs demonstrate differentiation to fat, cartilage, and the bone 
but do not support epithelial development of the skin in 3-D tissues [11]. Since the 
morphology of MSCs and fibroblasts appears identical in 2-D culture and since flow 
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cytometry cannot definitely identify them as fibroblasts, it is only possible to confirm 
their fibroblast identity by confirming that they can support epithelial growth and dif-
ferentiation in 3-D tissue context. Thus, 3-D skin tissues can be used to better under-
stand the biological potency and functional phenotype of iPSC-derived cell lineages 
in a 3-D skin-like tissue context. By monitoring the capacity of iPSC-derived skin 
cells to contribute to normal skin morphogenesis, these tissues provide a platform to 
fully characterize the functional properties of iPSC-derived cells in ways that cannot 
be accomplished using conventional 2-D monolayer cultures. Importantly, incorpora-
tion of iPSC-derived cells in their in vivo-like tissue context will advance the study of 
developmental processes in the skin and can elucidate gene regulatory networks and 
signaling pathways that can modulate tissue organization and maturation. Skin tissues 
therefore offer a significant improvement when compared with 2-D cultures as a func-
tional readout of the differentiation state of iPSC-derived cells in ways that will further 
determine optimal cues needed to guide their morphogenesis.
It has been demonstrated that reprogramming iPSCs from primary cells may result 
in the accumulation of genetic mutations and aberrant karyotypes due to viral integra-
tions or following prolonged culture that could alter their phenotype or differentiation 
potential in 3-D tissues [67,69]. To overcome the problem of viral integration, several 
nonviral reprogramming methods have been applied to iPSC reprogramming. These 
include delivering a plasmid vector [70], using episomal plasmids as “minicircle vec-
tors” [71,72], expressing OKSM mRNA [73], directly delivering OKSM proteins [7], 
or inducing expression of OKSM factors with microRNA [74] or with small molecules 
[21,69,75]. Additionally, nonintegrating viral methods such as Sendai virus have been 
developed. When reprogramming methods were compared, Sendai virus was shown 
to be the most efficient nonintegration method to reprogram somatic cells to iPSCs 
[76]. Whole-genome profiles of DNA methylation of iPSC clones have shown signifi-
cant variability following reprogramming to iPSC, including retention of somatic cell 
memory and aberrant DNA methylation in these clones [77]. This suggests that future 
evaluations of iPSC-derived cells will require the development of reliable methods to 
assess their phenotypic maturation and functional outcomes before they can be incor-
porated into skin tissue models.
Changes in the epigenetic profile occur upon iPSC reprogramming and subsequent 
differentiation [77–79]. The stepwise differentiation of specific cell types from iPSC is 
characterized by a progressive restriction of their differentiation potential and an increase 
in lineage-specific gene expression. Such differentiation is associated with changes in 
nuclear arrangement, including remodeling of chromatin structure, histone modifica-
tions, and DNA methylation that guide expression of genes that determine cell lineage 
fate and function [78]. For example, iPSC differentiation is accompanied by increased 
DNA methylation of silenced chromatin and decreased methylation at sites of active 
gene transcription [77–79]. Profiling these changes can provide valuable information as 
to changes in the differentiation status and lineage stability of iPS cell populations differ-
entiated to skin cell lineages. In order to generate stable cell phenotypes that will be most 
optimal for use of iPSC-derived skin tissues, it will be essential to develop sophisticated 
profiling tools that can rapidly identify epigenetic marks that can more accurately define 
lineage fate and functional properties of cells derived from iPSCs.
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Epigenetic changes and establishment of a methylation signature early in the pro-
cess of differentiation from a pluripotent cell are critical in defining the lineage iden-
tity and cell phenotype that will determine the properties of 3-D skin-like tissues. It is 
known that the tissue microenvironment plays a critical role in the epigenetic regula-
tion of gene expression in skin tissues [80]. This indicates that the 3-D tissue microen-
vironment can modify DNA methylation in ways that make iPSC-derived cells more 
in vivo-like when incorporated into complex skin tissue context. As it is known that 
methylation changes that occur during reprogramming of iPSCs can be transmitted to 
cells differentiated from them at a relatively high frequency [81], it will be important 
to elucidate the underlying epigenetic mechanisms that occur upon reprogramming or 
subsequent differentiation from the pluripotent state. Further defining the differentia-
tion state of iPSC-derived cells that display distinctive epigenetic features will serve 
as a fingerprint to identify optimal cells for skin tissue fabrication. For example, eval-
uating methylation status of iPSC-derived cells will be useful in determining whether 
a reprogrammed cell can differentiate into specific functional lineages. Methylation 
status may also help to identify iPSC clones that are incompletely reprogrammed and 
thus cannot be used to generate skin cells useful for 3-D tissue fabrication.
In addition, iPSC-derived cells are known to harbor a residual DNA methylation 
signature related to their cell of origin [77]. This “epigenetic memory” is thought to 
predispose iPSC clones to differentiate along lineages related to the cell type from 
which the iPSCs were initially derived, thus restricting differentiation to alternative 
cell fates [77,82]. This suggests that an epigenetic memory of the tissue of origin may 
impact the phenotypic stability of iPSC-derived cells used in tissue fabrication. There 
is still considerable debate over the extent of epigenetic changes associated with repro-
gramming [78,81,82] as whole-genome profiles of DNA methylation at  single-base 
resolution show significant reprogramming variability [83]. Differentiation to gener-
ate stable cell lineages remains challenging due to these epigenetic changes [14,84]. 
Through continued refinement of such mechanisms that are currently limiting the sta-
ble and reproducible differentiation of skin cell lineages from iPSCs, we can further 
understand molecular and epigenetic changes critical to derivation of specified func-
tional cell types best suited for skin tissue fabrication. Importantly, using 3-D tissues 
to assess cell functionality will markedly improve upon existing methods to determine 
the utility of iPSC-derived cells in 3-D tissues. The maturation status of cells differ-
entiated in vitro from iPSCs is difficult to determine and will require even greater 
stringency to define biologically meaningful functions of these cells in skin disease 
models. Future findings that will further define the specific cell and tissue types that 
display distinctive phenotypic functional and epigenetic features will help to identify 
optimal cells for skin tissue fabrication.
Gene editing technologies, such as CRISPR/Cas9 [85–89], hold future promise 
to modify specific gene signatures in iPSC-derived skin cells either by correcting 
disease-causing mutations or through modification of expression of genes that may 
lead to an improved phenotype for tissue fabrication or for applications important 
for skin disease modeling. Optimizing skin disease-specific or customized 3-D tissue 
models will benefit from incorporating iPSC-derived cells that have undergone gene 
editing, which can provide novel ADME/Tox readouts. Combining CRISPR gene 
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editing of iPSCs with skin tissue fabrication can improve disease-specific, skin-like 
tissues, when multiple isogenic cell types can be derived that all contains the same 
gene modification that will be valuable for developing customized skin disease phe-
notypes in 3-D skin tissues. The future utility of CRISPR/Cas9 to gene edit iPSCs or 
iPSC-derived cells needed for skin tissue fabrication may be complicated by the need 
to modify multiple genes needed to revert skin disease phenotypes. Currently, a maxi-
mum of nine genomic loci have been simultaneously targeted in a particular cell using 
CRISPR/Cas9. The use of CRISPR/Cas9 to modify iPSCs for skin tissue fabrication 
will also require considering possible off-target effects, which may cause unintended 
changes in expression of genes that will need to be addressed through refinements of 
Cas9 delivery [90–95].
An important consideration in the construction of skin tissues is the reproducibility 
and standardization of tissue fabrication. Tissue standardization using self-renewing 
and disease-specific cells currently limits the widespread deployment of commercially 
viable 3-D skin tissue platforms for drug screening [1,15,96]. While it will be advan-
tageous to develop more tissue complexity by incorporating multiple cell types, this 
will require that these primary cells can be sourced in ways that consistently mimic the 
cells that they were initially derived from. iPSCs can serve as a replenishing, isogenic 
source of multiple cell types found in the human skin that are needed for skin tissue 
fabrication. Producing such isogenic cell types from a common source should ad-
vance the development and standardization of 3-D tissue fabrication for preclinical 
drug evaluation [15,16].
Differentiating well-standardized cells from iPSCs that can be used reproducibly 
for 3-D tissue fabrication has proved to be challenging. Reprogramming is a stochastic 
process, and individual reprogrammed iPSC clones may show great variability be-
tween them [7,21,75]. As a result, iPSC reprogramming and differentiation may not 
always establish a uniform source of skin cells that would improve upon existing het-
erogeneous sources of primary cells derived from adult skin. It is therefore important 
to establish criteria to assess this cellular heterogeneity in order to identify which 
iPSC clones can be used for differentiating skin cells for tissue fabrication. This will 
need to include analysis of molecular and functional benchmarks that are acquired 
by epithelial and stromal cells differentiated from iPSCs that reflect their capacity 
to support skin development in 3-D tissue models. As seen in Fig.  5, molecular 
benchmarks can be characterized by markers of sequential ectodermal specification 
(keratin 18) and by their subsequent keratinocyte commitment (p63 and keratin 14) 
and terminal differentiation of iPSC-derived epithelial cells (Fig. 5). In addition, 
 iPSC-derived fibroblasts can be characterized by markers of specification (Thy-1 and 
PDGFR-β) and commitment (type I/III collagen and fibronectin) to fibroblast lineage 
(Fig. 5). Functional benchmarks for stromal fibroblasts differentiated from iPSC may 
include production of growth factors (HGF, KGF, GM-CSF, and IL1-B) and CD sur-
face markers that can be detected in monolayer culture and indicate that iPSC-derived 
fibroblasts are likely to support skin tissue fabrication. Additional benchmarks for 
iPSC-derived fibroblast function that are important for 3-D skin tissue fabrication in-
clude the capacity to self-assemble an ECM stroma [12] and for that stroma to produce 
supportive growth factors needed for epithelial tissue maturation. Fabricating skin 
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tissues requires incorporation of keratinocyte progenitors that are enriched for cells 
that can proliferate extensively to generate fully stratified epithelium [29,40,97–100]. 
As a result, it is important to identify iPSC-derived cells that are enriched in highly rep-
licative progenitor cells that will be required for successful 3-D tissue fabrication. The 
developmental stage of progenitor cells differentiated from iPSCs is difficult to assess, 
as these cells are often heterogeneous in nature [68]. As a result, it will be important to 
develop strategies to identify keratinocyte progenitors with the elevated proliferative 
cell fraction needed for the growth, differentiation, and morphological development of 
skin-like tissues. Optimal keratinocyte progenitors derived from iPSCs can be identi-
fied by determining the colony-forming efficiencies of these cells to best predict their 
utility when incorporated into skin tissues (Fig. 5B). Establishing such standardized 
functional [15,17] benchmarks for the proliferation of iPSC-derived skin cells should 
also improve cell source uniformity needed for skin tissue fabrication. This is likely to 
improve the qualities of iPSC-derived skin cells when compared with heterogeneous, 
primary adult-derived cells currently used for skin tissue fabrication.
The development of skin tissues from iPSCs will provide a replenishing isogenic 
cell source that can ideally obviate the need for sourcing cells from different pri-
mary tissue donors to improve reproducibility and scalability of these tissues when 
applied to higher throughput, tissue-based platforms. In this light, developing reliable 
and reproducible sources of iPSC-derived cells for skin tissue fabrication will be an 
Fig. 5 Criteria to identify optimal iPSC-derived skin cells for tissue fabrication. Analysis 
of molecular benchmarks (A) will indicate the status of epithelial cells and fibroblasts 
through sequential stages of differentiation, specification, lineage commitment, and terminal 
differentiation following differentiation from iPSCs. Functional benchmarks (B) used to 
characterize epithelial and stromal cells differentiated from iPSCs are needed to show that 
these iPSC-derived cells have acquired the capacity to support skin development in 3-D tissue 
models. Benchmarks for stromal fibroblasts in 2-D culture include growth factor production 
and CD surface marker profiling, and 3-D skin tissues include the capacity to self-assemble 
an ECM stroma and production of supportive growth factors. iPSC-derived epithelial cell 
function can be characterized by monitoring expression of keratin protein lineage markers and 
clonogenic potential in 2-D culture and proliferation and barrier function in 3-D skin tissue.
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 important advancement over currently available monolayer tissue cultures, as their 
improved predictive value will greatly streamline preclinical decisions on the safety 
and efficacy of new drugs. Developing and optimizing iPSC-derived cells to generate 
disease-specific 3-D tissues will hopefully provide a renewable cell source that can 
produce all needed cell types in 3-D tissues and have the potential to revolutionize 
future scale-up and commercialization of disease- and patient-specific tissues for drug 
screening. In this way, iPSCs can streamline screening of drugs designed to improve 
treatment of skin diseases, so they can safely and efficiently enter human clinical tri-
als. Optimally developed 3-D skin tissues can mimic complex, organ-level functions 
and can identify unexpected or untoward side effects that may fail to be detected using 
conventional 2-D monolayer cultures commonly used for preclinical drug screening 
[15,16,101]. As a result, skin tissue models may enable more efficient, cost-effective 
ways of predicting drug failures before embarking on human clinical trials. In the con-
text of drug discovery, iPSC-derived skin tissues are likely to pave the way for novel 
preclinical drug screening models that may reveal molecular mechanisms of action, 
drug toxicities, and new biomarkers [2,10,15]. This holds potential to dramatically im-
prove our ability to identify effective and safe candidate compounds at an early stage 
of drug development that will move the field of preclinical drug screening scale-up 
and commercialization to better prioritize the selection of new drugs.
The goal of developing a more streamlined approach to drug screening is also be-
ing advanced by the development of human “organs-on-chips,” which are microflu-
idic cell culture devices harboring interconnected tissues to measure in  vitro drug 
responses within and across different 3-D tissue types [3]. By incorporating 3-D skin 
tissues into this on-chip design using iPSC-derived cells, skin tissues can be gener-
ated and integrated with other tissues fabricated from these iPSCs to create screening 
systems that can reconstitute “whole-body” physiology and disease conditions [102]. 
Using iPSC-derived cells in these formats for drug screening will provide information 
that is more highly predictive of multiple human tissue responses and would shorten 
the preclinical drug development timeline, save animal lives, reduce failure rates, in-
form regulatory decision-making, and accelerate the development of new and more 
effective therapeutics to treat skin disease [15,16].
6.  Conclusions
In conclusion, iPSCs offer a source of multiple patient-specific cell types necessary to 
fabricate 3-D skin tissues, including fibroblasts, keratinocytes, melanocytes, endothe-
lial cells, macrophages, and folliculogenic epithelial stem cells that give rise to skin 
appendages. Three-dimensional skin tissue models harboring iPSC-derived cells will 
enable better understanding of skin biology and differentiation processes into cells 
needed for skin fabrication. Future incorporation of other important skin iPSC-derived 
cell types, such as adipocytes and sensory neurons, will allow to create improved 3-D 
skin tissues models. The use of increasingly complex tissues in disease modeling and 
drug testing will be fostered by incorporating 3-D skin tissues with multiple other or-
gans in an organs-on-chips design. Even though challenges associated with 3-D skin 
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tissues incorporating iPSC-derived cells that need to be resolved remain, these tissues 
hold great promise for drug testing and regenerative therapies. Complex 3-D skin tis-
sues constructed with multiple iPSC-derived cells offer reliable, highly standardized, 
predictable models of human diseases and conditions that will allow to test efficacy 
and safety of drugs. Three-dimensional skin tissues constructed with iPSC-derived, 
patient-specific, isogenic cell types in combination with gene editing strategies will 
provide products to satisfy the needs of regenerative medicine at a large scale.
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1. Outline
This chapter will focus on the use of in vitro skin models for drug screening rather 
than at the automated production of the tissue constructs. The authors provide an over-
view concerning existing methods and approaches and crystallize the most demanding 
requirements for integration of human in vitro skin models in high-throughput screen-
ing (HTS) processes.
2.  Introduction
When considering the use of human skin models for HTS purposes, two essential 
questions arise:
(1) What is driving the demand for the use of such in vitro human skin equivalents?
(2) What are the requirements and obstacles preventing the routine implementation of HTS of 
skin equivalents today?
The aim of this article is to answer these questions and to identify actions that have 
to be taken to enable HTS of in vitro skin models. The article will also discuss the 
factors required in order to achieve relevant and robust data that are representative of 
the in vivo situation being studied. The automated cultivation or the large-scale pro-
duction of human skin models is not discussed here; the reader is referred to previous 
reviews on this subject [1-4]. Systems and processes have already been defined for the 
manufacture of cell- and matrix-based organotypic models and for models represent-
ing a disease phenotype [5]. There are companies that offer human skin models; these 
companies make use of robotic systems to guarantee a high and standardized quality 
of their products (e.g., EpiSkin, Mattek, and CellSystems). However, when it comes to 
the use of such skin models in the cosmetic or pharmaceutical industry or even in ac-
ademia, the process steps (drug application, cultivation, and analysis) are mainly con-
ducted manually, with only limited use of robotics. Another important issue of such 
models is to support scientific investigation of factors influencing skin biology [6].
These uses of in vitro skin models address the first question, that is, what is the 
impetus that drives the need for the development of such models. In particular, driven 
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by the demands of regulatory authorities and customers, the cosmetic industry has 
supported the establishment of human skin models to serve as predictive tools for 
safety assessment studies [7,8]. Ultimately, once such in vitro skin models have been 
validated and showed to faithfully reflect the action of compounds on the skin, then 
such a model could be used to screen the 10,000 compounds that have been profiled in 
the Tox21 screening program (https://www.epa.gov/chemical-research/toxicity-test-
ing-21st-century-tox21). Such a screening process would allow the correlation of 
compound structures and activity on a large scale, helping to improve in vitro toxicity 
testing and prediction.
In the cosmetic industry, reconstructed human epidermal models are routinely used 
nowadays to assess the risk of skin irritancy and corrosion by assessing relatively 
simple end points based on the metabolic status of the skin model and cytokine release 
[9-11]. However, as the number of new compounds to be assessed with such methods 
rarely exceeds 50 compounds per experiment, adaptation of the process for truly HTS 
has not been necessary. Besides evaluating any risk a compound may exhibit, more 
and more interest is currently arising concerning profiling and high-content analysis in 
order to scientifically support the product claims [12]. In the pharmaceutical industry, 
however, there is still a need for novel dermatologically acting drugs, and appropriate 
models have to be designed to enable target and hit validation in an HTS setup. Skin 
diseases such as psoriasis, atopic dermatitis, decubitus ulcer, eczema, acne, vitiligo, 
skin cancer, and abnormal scar formation after trauma remain illnesses requiring novel 
treatments [13-15]. However, the development of models suitable for greater under-
standing of such disorders and the validation of potential drug targets will require 
further assay development and validation.
Currently, there is a broad spectrum of models and ways to create 3-D skin rep-
licas, which represent different levels of biological complexity [16,17]. The first 
and the most thoroughly characterized models consist of only one cell type (recon-
structed human epidermis made of keratinocytes, RHE). Such models are routinely 
used for risk assessment of compounds [18]. Even so, more sophisticated models 
are needed when investigating subjects such as the efficacy, pharmacodynamics 
(PD), or pharmacokinetics (PK) of treatments for a particular disease. Such models 
may require the incorporation of multiple cell types (fibroblasts [5,19,20], melano-
cytes [21], stem cells [22,23], Langerhans cells [24], vascular structures [25], and 
adipocytes [26,27]). However, such models are more challenging to standardize 
due to the complexity of their creation and the readouts used to monitor activity, 
leading to greater assay variability. Parameters that contribute to increased variabil-
ity of the phenotypic outcome of an in vitro created skin model can be divided into 
three clusters: (I) cell types, (II) epigenetics, and (III) cultivation condition (arti-
ficial environment). (I) Primary human cell lines are usually isolated and pooled 
from different donors for the creation of skin equivalent models. Differences exist 
between individuals, but even cells from one individual vary, for example, differ-
ent subtypes of dermal fibroblasts that contribute to different responses in assays 
such as hypertrophic scar formation [28]. (II) Epigenetic modifiers can regulate 
epidermal differentiation processes, and diseases such as psoriasis and cancer ex-
hibit shifts in these epigenetic mechanisms, resulting in variations of proliferation 
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and differentiation [29]. (III) Cultivation of cells in the artificial environment of a 
cell culture plate, submerged with a mixture of undefined components like fetal 
bovine serum to achieve the phenotype of interest, has a crucial impact, and small 
changes can alter expression patterns significantly [30]. Consequently, to address 
the basic requirement for stable in  vitro tissue equivalents, the establishment of 
an unlimited cell source is critical. Reproducible sources of cells can be obtained 
by using human telomerase reverse transcriptase (hTERT) immortalized cells [31] 
or redifferentiated iPS cells [32-35]. In the case of hTERT immortalization, the 
overexpression of telomerase is not sufficient to circumvent senescence [36]. The 
usage of pluripotent stem cells as an appropriate source leads to the concern that 
epigenetic differences may have been created that will result in diversity of the 
organotypic skin models being generated. In order to obtain some insight into this 
issue, different methylation patterns of the gene encoding trichohyalin (an interme-
diate filament-associated protein associated with keratin intermediate of the granu-
lar layer of the epidermis), which is important for barrier maturation of the stratum 
corneum, were investigated regarding the phenotypic outcome of the barrier prop-
erties. The results supported the assumption that methylation patterns of this spe-
cific gene do not effect the differentiation of the in vitro tissue model [35,37]. In 
order to ensure that epigenetic factors for other critical genes are not modulating 
the function of the skin model, further studies have to be performed to pave the way 
for iPS cell-based skin models for routine use.
3.  Technical aspects
3.1  Automated platform for HTS lead discovery
Automation of cell-based assays for high-throughput lead discovery is well estab-
lished, and various vendors of liquid-handling platforms offer solutions for numerous 
applications [38] (Table 1).
While there are systems that automate the procedure of conventional cell culture 
and passaging of cells in flasks, it is much more common to manually culture cells. 
Cell-based models are often developed and miniaturized to fit the ANSI/SLAS format 
of microplates. Assays that are established in this format can be transferred to robotic 
liquid-handling platforms available on the market. Automated pipetting in microplates 
from 1 well to 1536 wells is standard and, depending on the type of culture or assay, 
can be performed not only by individual 8- or 12-channel pipettes but also by the 
use of multiple 96- or 384-channel pipetting heads. Depending on the type of assay, 
samples can be prepared by the liquid-handling arms present in the automated work 
station or off-line by hardware specifically designed for sample dispensing (such as 
the Labcyte Echo dispenser or Tecan D300e Digital Dispenser). Such automated set-
ups can be used in a broad range of different assay types, for example, viability assays 
or dose-response experiments, and in many different research areas, such as target and 
lead discovery or ADME. The assay itself is then performed on the same worksta-
tion including all liquid handling and robotic handling of the microplates to dedicated 
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Vendor System
Mammalian 
cell culture 
and HTS 
analysis 3-D tissues
Transwell 
systems
Handling of 
skin cells
Beckman 
Coulter, 
Inc.
Biomek FXP
Biomek NXP
Yes Yes Not 
specified
Not specified, 
2-D cell 
cultures and 
related assays 
feasible
CyBio 
AG
CyBi-Drop 
3D
Multiplexed 
viability, 
cytotoxicity, 
and 
apoptosis
Phenotypic 
screening 
[39]
Spheroid 
liver model 
[40]
Hanging 
drop array 
[41]
No Not specified, 
2-D cell 
cultures and 
related assays 
feasible
Hamilton Microlab 
STAR 
pipetting 
workstation
Cell 
counting, 
confluence, 
and viability; 
genomics and 
proteomics
Not 
specified
Standard 
and 
Transwell 
plates
Production 
of skin cell 
experi mental 
models [42]
Perkin-
Elmer 
Inc.
cell::explorer Yes 3-D 
spheriods
Not 
specified
Not specified, 
2-D cell 
cultures and 
related assays 
feasible
Sartorius 
Stedim 
Biotech
SelecT and 
CompacT 
SelecT
Cell culture 
only
2-D cell 
culture
Not 
specified
Not specified, 
2-D cell 
cultures and 
related assays 
feasible
Tecan 
 
 
 
 
 
 
 
 
 
 
Freedom 
EVO
Fluent 
 
 
 
 
 
 
 
 
Media 
exchange, 
cell plating, 
incubation, 
and assay 
preparation. 
Cell-based 
assays, cell 
counting, 
bright-field-
based cell 
imaging
Scaffold-
based or 
scaffold-free 
cultures 
 
 
 
 
 
 
 
Intestine 
models in 
Transwell 
 
 
 
 
 
 
 
 
Not specified, 
2-D cell 
cultures and 
skin models 
in Transwell 
system should 
be feasible 
 
 
 
 
Table 1 Vendors and systems of automated liquid-handling 
platforms experienced with cell and tissue cultures
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 positions for specific functions, such as shaking, incubation, plate washing, and finally 
insertion of the plate into the reader for data generation. The seamless integration of 
dedicated devices required for an assay and full automation are essential for HTSs, 
unless a workstation approach is taken where each step in the process is performed by 
a stand-alone workstation. Both approaches lead to increased productivity, leaving ad-
ditional time for laboratory personnel to perform other tasks, while the robotic system 
is performing the routine assays.
As shown in Table 1, there are multiple vendors around offering liquid- handling 
platforms for cell culture (including barcoding of the cell culture laboratory hardware, 
barcode readers, microplate centrifuges, plate readers and imagers, plate transport 
devices, shakers, plate washers, safety and biocontainment enclosures, temperature- 
controlled storage of liquids, and tube handling devices for capping/decapping).The 
cultivation and basic monitoring of the cells on robotic platforms are currently feasible, 
even for complex 3-D cultures. In particular, the use of spheroids has been described 
and used for multiple HTS approaches [43,44]. For such organoid 3-D models, there 
are examples where automation, data generation, and analysis have been shown to be 
possible, but this has not been widely applied for skin models. The only company that 
claims the production and handling of skin models on their platform is Hamilton [42]. 
Although rather designed for the production of standardized epithelial models than 
for the screening process, an adaptation might be conceivable. The liquid-handling 
platform Freedom EVO was used in the past to process another type of epithelium 
(intestine) and may be adaptable to skin models.
The formats for creating and cultivating of epithelial barrier models, which are used 
on automated systems, are typically grown in microplates: in a matrix (e.g., Matrigel), 
in hanging drops (e.g., GravityPLUS), or in round-bottom low-attachment plates (e.g., 
Corning) where the cells build spheroids or most commonly in Transwell plates where 
cells grow at the air-liquid interface on a membrane on the insert plate. The format that 
is chosen is highly dependent on the experimental question to investigate the interac-
tion between the organism and the environment.
One feature of using skin models in the context of drug application and drug test-
ing is that test compound can be lipophilic and yet has to be applied directly onto the 
dry stratum corneum. Such application of highly lipophilic fluids using automated 
liquid-handling systems requires optimization of the liquid-handling parameters to 
guarantee accurate dispensing of defined volumes evenly over the whole surface of 
the tissue microstructure.
3.2  Laboratory hardware adaptation
As stated above, truly HTS requires an automated assay platform, and so, the formats 
of the organotypic tissue models have to be adapted accordingly. As already men-
tioned, a commonly used system to grow human skin models in vitro is the Transwell 
system [5,45,46]. This system enables the cultivation of the cell culture at an air-liquid 
interface, which is important to trigger the differentiation of the keratinocytes and 
the maturation of the stratum corneum barrier. Transwell systems are available from 
different suppliers in formats ranging from 6 to 96 wells within the standard SBS plate 
dimensions (Table 2).
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HTS Transwell plates for robotic manipulation exist in a 96-well format with apical 
and basolateral access ports that allow for automated filling and sampling [47,48]. 
Assuming that the appropriate protocol for a suitable in vitro skin tissue exists, this 
setup allows for compound application and harvesting from the basolateral medium 
reservoir. The tissue constructs have to be removed from the Transwell insert to fa-
cilitate lysis or preparation for histological analysis, steps that have proved difficult 
to automate. Application of lysis buffer alone is not sufficient for full disruption of 
in vitro-derived skin models, and so, additional mechanical manipulation is required, 
again making full automation of the process challenging. The harvesting of tissue 
from Transwell inserts for standard immunohistological analysis is not trivial, espe-
cially in a HTS setup. However, customized solutions can be installed that enable the 
harvesting of the tissues for fixation and embedding [49] .
Alongside standard Transwell systems, human skin microtissues are also avail-
able from InSphero AG (Switzerland). Complementing a portfolio of human- derived 
in vitro 3-D model systems, skin microtissues were developed for applications that 
require larger throughput (e.g., dose- and time-dependent substance evaluation). 
Skin microtissues can be obtained with and without the keratinocyte layer, which 
allows direct comparison to the extent to which the epidermal barrier might impact 
tissue response. In contrast to Transwell skin models, which are used to test topi-
cally administered compounds (including final formulations or lipophilic actives), 
only soluble substances can be tested with skin microtissues. The tissues are grown 
to a size of 350–450 μm with a relative standard deviation below 10% and are com-
posed of primary human dermal fibroblasts (dermal microtissues) and keratinocytes 
(epidermal microtissues). They are maintained in serum-free, defined medium con-
ditions with an in vitro lifetime of at least 14 days. Similar to conventional 2-D cell 
culture, the application of microtissues in a 96-well format allows a multiparamet-
ric analysis of test compounds in a dose-dependent manner in an assay volume of 
50–70 μL. The spherical skin microtissues show the expression of dermal matrix 
and basal lamina proteins and cytokeratin and involucrin occurrence at distinct 
layers in the epidermis (Fig. 1). Further functional characterization of the tissues 
Table 2 List of common vendors selling Transwell plates
Company Web-based information
Merck Millipore http://www.merckmillipore.com/CH/de/product/Millicell-
Zellkulturplatten-mit-24--96-Wells,MM_NF-C10584?ReferrerURL=h
ttps%3A%2F%2Fwww.google.ch%2F&bd=1
Corning Inc. https://www.corning.com/worldwide/en/products/life-sciences/
products/permeable-supports/transwell-snapwell-netwell-falcon-
permeable-supports.html
Neuro Probe Inc. http://www.neuroprobe.com/product/chemo_tx/
Greiner Bio-one https://shop.gbo.com/en/germany/articles/catalogue/
article-groups/0110_0110_0090/
Essen BioScience http://www.essenbioscience.com/en/products/reagents-consumables/
incucyte-clearview-96-well-cell-migration-plate/
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with regard to epidermal barrier quality, metabolic competence, and response to 
different test substances shows the similarity of standard skin tissue equivalents to 
the native human skin. As skin microtissues are particularly developed for HTS, 
assay reproducibility and intraplate, interplate, and interbatch variations are basic 
parameters evaluated at the very beginning of model establishment, in contrast 
to most Transwell-based tissue systems. Multiple common end points have been 
established for use with microtissue models that apply also for the skin microtis-
sues, such as viability (CellTiter-Glo, Promega Corp.), histology, efficient RNA 
extraction, barrier function assays, high-content analysis, or genetic  engineering of 
distinct cell populations within the model (personal communication, InSphero AG).
Fig. 1 3D InSight Skin MTs loaded on the GravityTRAP microtissue platform acquired with 
Cell3iMager plate scanner imaging device (Dainippon Screen) (top). Histological analysis 
of dermal only microtissues (3D InSight Dermal MT) on H&E and collagen type 3 and skin 
microtissues (3D InSight Epidermal MT), H&E and Ki67. HCA confocal imaging of 3D 
InSight skin MT with Opera Phenix (PerkinElmer) at 40× confocal, plane 8–14 μm at distance 
2 μm (bottom) (provided by InSphero AG, Switzerland).
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4.  End points, read-out systems, and assay analysis
4.1  Requirements regarding target validation
Screening using phenotypic assays has been recognized as the major source of truly 
novel pharmaceutical treatments and an important tool for the identification of novel 
drug targets [50]. One of the major challenges (but also the greatest opportunity) is 
the identification of the efficacy target of any novel treatment [51]. Methods for target 
identification span the gamut from genetic to biochemical profiling methods, with no 
single method being applicable to all assay formats [52]. Compelling target identifi-
cation usually requires the agreement of numerous combinations of these methods in 
order to provide supporting evidence from multiple orthogonal assay methods [53] or 
as exemplified in Ref. [17].
For example, in the case of vitiligo, multiple models were created, and different 
studies were conducted to try and reveal the molecular cause of the disease [54,55]. 
Unfortunately, these studies were not coordinated, leading to only a fragmented pic-
ture of the overall situation. A full understanding can only be acquired if all data are 
put into context, taking account of the differences of data acquisition [56].
The requirement for any assay, monitoring the phenotype of interest, to be suitable 
for target deconvolution, is that it should be robust, that is, the assay should be repro-
ducible and specific. If the target of a congeneric series of compounds is being sought, 
then a series of related compounds showing a clearly structure-activity relationship 
(SAR), with active and inactive controls being present in the series, are of great help. 
Knowledge of the SAR for a given compound series is also helpful to identify sites on 
the compound suitable for labeling and attachment of affinity capture moieties [52].
4.2  Assay systems
HTS has become the predominant means by which novel drug leads are identified 
[57]. While there has been some controversy concerning the relative importance of 
target-based versus phenotypic-based drug discovery programs, in either case, screen-
ing remains the most efficient means by which as unbiased a set of treatment types as 
possible can be surveyed in order to identify the most promising lead.
The requirement for any assay system is that it accurately and reproducibly repli-
cates an aspect of biology, in a quantifiable manner, and that the assay can be scaled up 
to allow large-scale testing of potential treatments. For pharmaceutical research, the 
assay system should reflect, as closely as possible, the biology of the human subject 
and preferentially the patient for whom the treatment is being sought. These require-
ments have been summarized by researchers from Pfizer as the “phenotypic screen-
ing” rule of three [58] that states that phenotypic assays should be disease- relevant, 
should respond to the endogenous stimuli (or none if that is appropriate), and should 
monitor a readout relevant for the disease. Such requirements have driven two trends 
in pharmaceutical assay development in recent years. First, the establishment of as-
say systems using primary cells or cells is derived from iPS cells [59,60]. The sec-
ond trend that has developed in the last few years has been the development of 3-D 
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 organotypic models that hope to recapitulate the three-dimensional aspects of the or-
gan being studied [61,62]. Not only models of skin disease have to be able to replicate 
the 3-D structure of the organ with its temporal and structural structure, but also there 
is increasingly a recognition that the models should include a wide number of different 
cell types, from hair follicles to immune cells and melanocytes, as recently reviewed 
by Weitz and Ritchlin [63].
4.3  Standard analysis of in vitro skin models
Not only for skin tissue but also for all other three-dimensional tissue constructs, the 
spatial distributions of target markers and the morphology of these markers are of 
interest besides information concerning the distribution and metabolism of an applied 
compound. During drug development, a deep understanding of the pathways leading 
to drug action is advantageous and also facilitates the identification of biomarkers; 
immunohistochemical (IHC) analysis represents the state-of-the-art method for such 
objectives. This method is well established and belongs to a routine procedure in pa-
thology for evaluating human biopsies. But as immunohistological investigations re-
quire tissue fixation, dehydration using solvents, and demasking, these process steps 
may also disturb the applied substance and its impact leading to a false picture of its 
distribution and action. In cases where drug delivery processes are investigated, this 
may lead to biased conclusions. In order to adapt these histology methods to an auto-
mated high-content setting, the greatest challenge lies in the harvest of the tissues and 
the preparation of tissue sections. Further process steps of staining and automated im-
age analysis and quantification are reasonably well addressed by a number of different 
image analysis products [64].
The methods and challenges facing image analysis of standard tissue culture sys-
tems have recently been reviewed [65]. Unfortunately, this article (and others in the 
field) fails to address the specific challenges faced by image analysis of in vitro skin 
models. Driven by the need for fast and reliable analysis of tissue biopsies in oncology, 
advances in imaging technologies have recently occurred. Shinde et al. have demon-
strated the identification and quantification of two cancer markers using human skin 
biopsies. In an automated image analysis setup, they evaluated the outcome of an 
Aurora A inhibitor for mitotic and apoptotic indexes [66].
In addition to immunohistological characterization, the analysis of secreted cyto-
kines or metabolites of the applied drug can be assessed in the cell culture medium by 
many, well-established quantitative bioanalytical and chemical methods (e.g., ELISA, 
HPLC, and GC-MS).
4.4  High-content screening
Image-based descriptions of cellular tissue or organism’s phenotype (i.e., high- content 
screening (HCS)) have become an important approach for exploring biological  systems 
[67,68], as it allows the collection of many features of a biological sample. This has 
been highlighted by the observation that the majority of first-class drugs were discov-
ered by phenotypic screening, which is heavily reliant on image-based assays [69]. 
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Image-based assays now have a role in all aspects of drug discovery and development, 
from helping to identify novel targets or mechanisms of action [70] and screening for 
novel treatments to including aspects of safety assessment [71].
Image-based assays for monitoring different aspects of skin biology often measure 
features such as cell migration [72,73] or proliferation [74] that can be measured us-
ing relatively simple 2-D models of skin cells. Not only single cultures but also a co-
culture system of keratinocytes and melanocytes were adapted to be applicable in a 
high-throughput/HCS to screen 4000 compounds in respect to their ability to modulate 
pigmentation [75]. In order to visualize and evaluate certain tissue structures of 3-D 
models on histological sections, fluorescence microscopy is the most common method. 
In particular, confocal fluorescence microscopy is the state-of-the-art imaging technol-
ogy when it comes to the visual analysis of 3-D tissue constructs. This technique allows 
the localization and intensity of fluorescent-labeled markers to be followed. Optical 
sectioning of the tissue layers is achieved by the combination of point illumination and 
point detection. Recently, Li et al. (2016) summarized existing 3-D high-throughput 
imaging and high-content imaging systems [76]. In order to overcome the limitations of 
excitation beam penetration depth, two-photon excitation fluorescence [77] represents 
a valuable improvement but will remain unsuitable for high-throughput applications 
due to the length of time needed for acquisition and data analysis.
Although routinely used, fluorescent-based imaging does have a number of lim-
itations and constraints. Issues such as photobleaching, sensitivity, and autofluores-
cent properties of the tissue being investigated all serve to limit the sensitivity of this 
detection technique. Hence, the imaging methods needed to monitor more complex, 
3-D models of the skin require more sophisticated imaging techniques (such as 3-D re-
construction of confocal images), which consequently makes quantification and mea-
surement of the monitored phenotype more difficult. One such method for monitoring 
complex 3-D models is laser light sheet fluorescence microscopy that allows optical 
rather than physical sectioning of the specimen. As excitation and detection follow 
different paths and image acquisition does not require line scanning, this technology 
offers multiple advantages such as reduced time for image acquisition, low levels of 
photobleaching, and the decrease of phototoxic effects [78]. Many of the challenges 
facing the conversion of current 3-D image-based assays to a screening format have 
been reviewed recently [79]. Such complex models are currently not readily amena-
ble to HTS. Not only has the production and handling of the 3-D structures to be 
automated, but also depending on the system being studied, miniaturization may be 
limited by the numbers of a given cell type actually being present in the model. Then, 
the automation of treatment application may be a challenge, as discussed previously, 
especially if the treatment needs to be spread across the surface of the model. Once the 
assay has been run, monitoring the desired phenotype of the skin 3-D model may then 
be limited depending on the disease-relevant markers being monitored, and finally, not 
only the methods to quantify the amount of an analyte present but also any change in 
its location within the 3-D structure need to be developed.
Thus, the complexity of 3-D models currently makes truly HTS impossible, and 
so, one common strategy is to use simpler 2-D models first to identify compounds of 
interest and to then characterize these compounds further in skin models [80]. Hand 
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in hand with the complexity goes the heterogeneity of the individual organotypic skin 
models. In order to ensure unbiased conclusions based on the acquired data, all tech-
nical aspects in the assay protocols have to be carefully optimized to reduce well-to-
well and plate-to-plate variation. One key issue is certainly the choice of the source 
of keratinocytes, fibroblasts, and other cell types to be incorporated, as mentioned 
earlier. Concerning image acquisition for traditional insert-grown skin models, the 
presence of a supportive membrane (polycarbonate) makes image acquisition by an 
inverted microscope unfeasible. Even in the case of transparent membranes, light scat-
tering might remain an issue. The most striking aspect is the development of software 
packages that fulfill the technical requirements to analyze 3-D high-content images in 
respect to segmenting, tracking, visualizing, quantifying, and batch analyzing of the 
epithelial models. Although software and hardware systems exist for HCS, they have 
been optimized for 2-D cellular assays, while the transition to 3-D analysis is still 
ongoing. The field of skin tissue engineering is progressing dynamically in different 
directions (increase of model complexity, establishment of disease models, and stan-
dardization), but evaluation of equipment is lagging.
4.5  Emerging methods for HTS
A number of different mass spectrometry methods are being developed in differing 
fields that have the potential to be applied to models of skin. CyTOF has been devel-
oped primarily for immunologic applications, allowing the detailed characterization 
of subpopulations of cells and the response of such subpopulations to drugs [81,82]. 
This method though continues to be developed and has now been extended to allow 
the detection of antigens present in fixed cell samples [83,84].
In the attempt to analyze skin tissue models in a noninvasive manner, spectro-
scopic methods are having a greater impact. In order to gain deeper insight into the 
organization and composition of lipids in the stratum corneum, infrared spectroscopy 
(IR) can be used to deliver molecular information concerning the properties of the 
epidermal barrier [85]. Using this method, molecular conditions of psoriatic versus 
normal skin have been evaluated. The results from this study allowed the conclusion 
that an overall decrease of the structural organization occurs in psoriatic skin tissue, 
explaining the alteration of its barrier properties [86]. In the context of drug appli-
cation and the study of ADME, concentration profiles of applied substances can be 
determined by IR spectroscopy. This method also allows the interaction of the com-
pound with the different epidermal layers to be evaluated [87,88]. As IR spectroscopy 
exhibits a strong interference with water, it makes measurements in a liquid environ-
ment rather impractical [89]. A method that overcomes the limitations of IR spectros-
copy is Raman spectroscopy. Raman spectroscopy represents a label-free technique 
based on the scattering of laser light that enables the identification of chemicals due 
to their different Raman spectra. This can be used for the identification of patho-
logical alterations in the skin tissue [90], for example, in the case of cancer [91]. 
Moreover, it is feasible for Raman spectroscopy to identify the differences between 
in vivo and in vitro skin characteristics, revealing a significant difference concerning 
natural moisturizing factors [92]. In order to follow the distribution of an applied 
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drug through the different layers of the epidermis, this noninvasive technique allows 
the quantification of the substance into and across the skin [93,94]. A drawback of 
this very promising technique persists in the rather long acquisition times and in-
creases the risk of damaging the tissue by the laser [89].
Other methods that do not require novel labeling techniques are also being ap-
plied to gain further insight into the distribution of molecules over the surface of the 
skin [95]. One of the emerging methods in the context of drug delivery is electron 
paramagnetic resonance (EPR) spectroscopy. As most of the test systems of interest 
do not possess paramagnetic properties, reporter molecules have to be included [96]. 
Although EPR holds great promise in detecting the penetration pattern in a time- and 
cost-saving manner, it is restricted to the stratum corneum [96].
The advantage of such methods is that they may allow resolution of an analyst on 
a cell-by-cell basis, giving the potential for a detailed picture of different cell popu-
lations within an organ model noninvasively. However, this very detail offers chal-
lenges for the scientist in terms of representation and interpretation. Currently, very 
few methods have been reported for the analysis of populations of cells and their 
differing responses to environmental conditions, although efforts are being made in 
this regard [95].
4.6  Data analysis
Independent of the system and technique of image acquisition being used, the scien-
tists will be confronted with tremendous amounts of data that they have to consolidate 
to draw a conclusion for further decisions. HTS analysis of skin models will produce 
confusing quantities of data that cannot be processed manually. In order to meet the 
demand of software-aided data integration, some open-source platforms were estab-
lished, supporting 3-D image analysis (ImageJ, BioImageXD, Vaa3D, CellProfiler, 
and others). In addition to these image analysis packages, a number of open-source 
tools such as KNIME and Jenkins have been used to link such tools to allow their ap-
plication to truly high-throughput applications. These tools have even been extended 
to allow tracking and monitoring of live cells [97]. Moreover, vendors of acquisition 
hardware also supply software packages that may offer more features compared with 
the open-source platforms. Referring to 3-D analysis of the tissue constructs, the soft-
ware programs enable the measurement of shapes, volumes, and distances of the 3-D 
objects with precision. However, although much effort has been put in during the last 
decade, all these systems are not yet ready for high-throughput in combination with 
high-content analysis, which would be needed in the case of skin model evaluation in 
the context of drug development.
5.  Conclusions
This chapter has briefly outlined the requirements for the development of skin equiv-
alent models for research and safety assessment while also reviewing some of the 
developing assay methods that could be used in the future to further characterize these 
models.
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The application of skin models for HTS holds great potential for the identification of 
new active compounds treating dermal dysfunctions. As these models are well established 
and mimic important properties of in vivo skin, they have already shown their relevance 
in helping to describe some of the basic biological features of the skin. These organotypic 
tissue models are suitable for ADME and toxicology studies, as multiple approaches have 
shown. Nevertheless, although such assays are practical and could be transferred to an 
HTS platform, there are still a few practical issues that have not yet been resolved.
When looking at the individual issues we have identified that need to be addressed in 
order to bring skin tissue models on to HTS platforms, they seem to be dealt with quite 
well when considered as a stand-alone solution. For example, there are some disease 
models of the human skin that are already well defined and characterized [63,98–100]. 
Some automated liquid-handling and robotic platforms exist that are able to handle the 
different assay formats used for the production of skin models. Even the issues con-
cerning tissue analysis have recently begun to be addressed by the use of nondestructive 
methods to allow an unbiased picture of the cellular mechanisms and the temporal and 
spatial distribution of an applied substance across the epidermal layers.
However, there seems to be a break between the production and quality control of 
skin models and their application for the testing of the large numbers of samples. As the 
upstream process of commercially available in vitro skin models is performed by the 
incorporation of automated process steps, the downstream process of compound eval-
uation does not seem to have been transferred to robotic platforms in a comprehensive 
manner. During extensive investigation, two main bottlenecks in the process chain of 
drug evaluation have been identified, preventing the standardized application of in vitro 
skin models in HTS scenarios (Fig. 2). First, there is a necessity for community-wide 
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Fig. 2 Estimated attainment of identified requirements in the process chain of integration of 
in vitro skin tissue models to HTS.
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acceptance and agreement concerning the phenotypes and targets to be monitored by 
such skin models. Community-wide acceptance of these criteria for model valida-
tion would then facilitate and enable interbatch comparisons and assay performance. 
Second, techniques and algorithms for characterization and trusted data analysis of the 
tissue models, as well as monitoring the interaction of these biological models with 
applied substances, still have to be adapted for HTS readouts. Developments to address 
these needs will be a dynamic process and will be driven by the demands of the cos-
metic and pharmaceutical industries in order to meet the demands of the society.
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